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Steroid-resistant nephrotic syndrome (SRNS) is a heterogeneous condition with 
significant numbers of patients progressing to end-stage renal failure (ESRF) 
requiring transplantation.  After transplant, around half suffer disease recurrence, 
suggesting the existence of circulating pathogenic factors.  The aim of this study 
was to investigate the interplay of phenotype, genetics and potential biomarkers 
with response to treatment and long-term outcome.   
 
Detailed phenotyping of patients with SRNS, all of whom had had genetic testing, 
was used to examine for associations between baseline characteristics and 
outcomes.  Novel biomarkers were sought in plasma by using mass spectrometry-
based proteomics.  The effects of putative circulating factors were investigated by 
treating podocytes in vitro with plasma samples followed by phosphoproteomic 
analysis of cell extracts. 
 
This study found a genetic cause in 21.2% of patients with SRNS who underwent 
clinical genetic testing (n = 255) and in 27.8% who had whole exome sequencing 
(n = 187).  Those with genetic disease were significantly more likely to progress 
to ESRF but none suffered post-transplant recurrence.  Patients with secondary 
steroid resistance were highly unlikely to have a genetic cause and more 
frequently suffered recurrence.  Only approximately 25% of patients had a 
complete response to the first intensified immunosuppressive (IIS) agent.  Any 
response to first IIS was associated with a highly significantly lower risk of 
progression to ESRF compared with no response.  Plasma proteomics identified 
uteroglobin as a potential biomarker, being raised at the time of relapse versus 
remission, although further validation is necessary.  Phosphoproteomics suggested 
increased phosphorylation of palladin in podocytes after treatment with relapse 
plasma.  Given the role of palladin in actin cytoskeleton remodelling, this protein 
is worthy of further investigation. 
 
Stratification of patients with SRNS by genetics, pattern of steroid resistance and 
response to first IIS should be considered in future clinical trials and may help 





Firstly, I would like to thank my supervisors Dr Gavin Welsh and Professor 
Moin Saleem for giving me the opportunity to undertake this PhD and for their 
ongoing support and encouragement.  Gavin has always been on hand to advise 
about experimental design and analysis especially in the early stages on my return 
to laboratory research.  Moin has provided the clinical insight and helped me to 
appreciate the translational aspects of my research. 
I am grateful to all members of Bristol Renal especially Drs Carl May, 
Dan Henson, Abigail Lay, Jenny Hurcombe, Ruth Rollason, Yasuko Kobayashi 
and Mrs Lan Ni for teaching me laboratory techniques; Dr Agnieszka Bierzynska 
for helping me to understand whole exome sequencing and genetic variant 
analysis; Mark Graham for helpful discussions about proteomic analysis; and Drs 
Liz Colby and Maryam Afzal for their work managing the RaDaR SRNS and 
NephroS studies. 
Outside Bristol Renal, I would like to thank the team at Bristol Genetics 
Laboratory, in particular Mrs Maggie Williams and Dr Philip Dean with whom I 
collaborated in the study of clinical genetic testing in SRNS; Dr Kate Heesom at 
the University of Bristol Proteomics Facility for advice about sample preparation 
and analysis of proteomics data; and Dr Elizabeth Zuccala, formerly visiting PhD 
student at the University of Bristol, for advice about phosphoproteomics. 
I am very grateful to all patients and their families, clinicians and research 
nurses who are involved with the RaDaR SRNS and NephroS studies.  I also 
acknowledge the National Institute for Health Research Rare Diseases 
4 
 
Translational Research Collaboration (NIHR RD-TRC) for funding my Clinical 
Research Fellowship. 
I am grateful to Professor A.V. Ramanan for inspiring and encouraging me 
to pursue research and mentoring me throughout my clinical career.  I wish to 
thank my parents for their support of my education from a young age.  Finally, I 
owe a debt of gratitude to my wife, Rose, for her kindness, love and 
encouragement.  Our two young sons, Rohan and Theodore, were born during this 
period of research and without her patience and dedication none of this would 





I declare that the work in this dissertation was carried out in accordance with the 
requirements of the University's Regulations and Code of Practice for Research 
Degree Programmes and that it has not been submitted for any other academic 
award. Except where indicated by specific reference in the text, the work is the 
candidate's own work. Work done in collaboration with, or with the assistance of, 
others, is as follows.  
Chapter 2: Whole exome sequencing analysis was undertaken by Dr Agnieszka 
Bierzynska of Bristol Renal.  An earlier version of the data has been previously 
published in our co-authored article in Kidney International (Bierzynska et al. 
2017) [1].  Subsequently, further follow-up data were collected and an additional 
3 patients identified as having genetic disease.  The clinical data collection, 
analysis and all figures are the work of the author. 
Chapter 4: All genetic sequencing and analysis were undertaken by staff at Bristol 
Genetics Laboratory.  The text and data of this chapter were previously published 
in the Journal of Medical Genetics (Sen et al. 2017) [2].  Figure 4.3 showing 
NPHS1 and NPHS2 copy number variants is the work of Geoff Woodward at 
Bristol Genetics Laboratory. 
Chapters 5 & 7: TMT labelling of proteomic samples, phosphopeptide 
enrichment, LC-mass spectrometry and initial data processing were performed by 
Dr Kate Heesom and staff at the University of Bristol Proteomics Facility.  
Proteomic data relating to five patients with steroid-sensitive nephrotic syndrome 














Table of Contents 
Abstract ................................................................................................................... 2 
Acknowledgements ................................................................................................ 3 
Author’s declaration .............................................................................................. 5 
Table of Contents ................................................................................................... 7 
List of Tables ........................................................................................................ 14 
List of Figures ....................................................................................................... 17 
List of Abbreviations ........................................................................................... 20 
Chapter 1 Introduction .................................................................................. 23 
1.1 The Kidneys: Structure and Function ............................................. 24 
1.1.1 The glomerular filtration barrier ..................................................... 26 
1.1.1.1 Glomerular endothelial cells .............................................. 26 
1.1.1.2 Glomerular basement membrane ....................................... 27 
1.1.1.3 Podocytes ........................................................................... 28 
1.1.2 Kidney function and the glomerular filtration rate ......................... 30 
1.2 Nephrotic syndrome........................................................................ 32 
1.2.1 Diagnosis and Classification .......................................................... 32 
1.2.2 Epidemiology .................................................................................. 34 
1.2.3 Pathology ........................................................................................ 35 
1.2.3.1 Minimal change disease ..................................................... 35 
1.2.3.2 Focal segmental glomerulosclerosis .................................. 36 
1.2.4 Long term outcomes and complications ......................................... 38 
1.3 Genetics of Nephrotic Syndrome.................................................... 40 
1.3.1 Historical background ..................................................................... 40 
1.3.2 NPHS1 ............................................................................................ 41 
1.3.3 NPHS2 ............................................................................................ 42 
1.3.4 WT1 ................................................................................................. 43 
1.3.5 Collagen genes ................................................................................ 44 
1.3.6 Other genes ..................................................................................... 44 
1.4 The Circulating Factor Hypothesis ................................................. 56 
1.4.1 Evidence suggesting existence of circulating factors ..................... 56 
1.4.2 Role of the immune system ............................................................ 57 
1.4.3 Putative circulating factors ............................................................. 59 
1.4.4 Pathophysiology: VASP phosphorylation and podocyte 
cytoskeleton re-organisation ........................................................... 63 
8 
 
1.5 Treatments for Nephrotic Syndrome .............................................. 64 
1.5.1 Non-immunologic mechanisms of immunosuppressants in SRNS 71 
1.5.2 Plasmapheresis ................................................................................ 73 
1.5.3 Treatment outcomes in cohort studies of SRNS ............................. 74 
1.6 Biomarkers in Nephrotic Syndrome ............................................... 79 
1.6.1 Biomarkers and Stratified Medicine ............................................... 79 
1.6.2 Biomarkers in nephrotic syndrome ................................................. 79 
1.7 Aims and Hypotheses ..................................................................... 89 
Chapter 2 The UK SRNS Cohort .................................................................. 91 
2.1 Introduction..................................................................................... 91 
2.1.1 Whole exome sequencing ............................................................... 91 
2.2 Methods .......................................................................................... 95 
2.2.1 Patients ............................................................................................ 95 
2.2.1.1 The National Registry of Rare Kidney Diseases ................ 95 
2.2.1.2 The NephroS study ............................................................. 95 
2.2.1.3 Renal Patient View ............................................................. 95 
2.2.1.4 Inclusion and Exclusion criteria ........................................ 96 
2.2.2 Ethical permission .......................................................................... 97 
2.2.3 Whole exome sequencing ............................................................... 98 
2.2.4 Variant calling ................................................................................ 98 
2.2.5 Clinical data .................................................................................... 98 
2.2.6 Statistical analysis ........................................................................... 99 
2.3 Results .......................................................................................... 100 
2.3.1 Cohort characteristics ................................................................... 100 
2.3.2 Age of disease onset ..................................................................... 102 
2.3.3 Pattern of steroid resistance .......................................................... 103 
2.3.4 Incidence of genetic disease in relation to baseline clinical 
characteristics ............................................................................... 104 
2.3.5 Long-term outcomes in patients stratified by pattern of steroid 
resistance....................................................................................... 105 
2.3.6 Long-term outcomes in patients stratified by genetic disease ...... 107 
2.3.7 Genetic variants within the cohort ................................................ 109 
2.4 Discussion ..................................................................................... 112 
2.4.1 Findings of this study ................................................................... 112 
2.4.2 Comparison with other studies ..................................................... 114 
2.4.3 Limitations .................................................................................... 117 
2.4.4 Conclusions .................................................................................. 118 
9 
 
Chapter 3 Response to Immunosuppression in the UK SRNS Cohort .... 119 
3.1 Introduction................................................................................... 119 
3.2 Methods ........................................................................................ 120 
3.2.1 Patients .......................................................................................... 120 
3.2.2 Clinical data .................................................................................. 122 
3.2.3 Medication data ............................................................................ 122 
3.2.4 Management of missing medication data ..................................... 123 
3.2.5 Analysis of response to medication .............................................. 124 
3.2.6 Management of missing medication response data ...................... 125 
3.2.7 Data analysis ................................................................................. 126 
3.2.8 Statistical analysis ......................................................................... 126 
3.3 Results .......................................................................................... 127 
3.3.1 Patient characteristics in the two cohorts...................................... 127 
3.3.2 Medications administered and completeness of response data..... 130 
3.3.3 Response to immunosuppressive medications in the whole 
cohort ............................................................................................ 133 
3.3.4 Response to first immunosuppressive medications in the whole 
cohort ............................................................................................ 134 
3.3.5 Response to immunosuppressive medications stratified by 
genetic disease .............................................................................. 138 
3.3.6 Response to immunosuppressive medications stratified by 
pattern of steroid resistance .......................................................... 142 
3.3.7 Response to immunosuppressive medications stratified by first 
biopsy findings ............................................................................. 144 
3.3.8 Prior response to immunosuppressive medications in patients 
with post-transplant disease recurrence ........................................ 148 
3.3.9 Long term outcomes in patients with SRNS stratified by 
response to first immunosuppressive treatment ............................ 149 
3.3.10 Characteristics and outcomes in patients treated with rituximab . 151 
3.3.11 Response to ACEi and ARB in the whole cohort ......................... 155 
3.4 Discussion ..................................................................................... 157 
3.4.1 Findings of this study ................................................................... 157 
3.4.1.1 Genetic disease ................................................................. 158 
3.4.1.2 Pattern of steroid resistance ............................................ 160 
3.4.1.3 Biopsy findings ................................................................. 161 
3.4.1.4 Long term outcomes ......................................................... 161 
3.4.2 Comparison with other studies ..................................................... 164 
3.4.3 Limitations .................................................................................... 167 
3.4.4 Conclusion .................................................................................... 168 
10 
 
Chapter 4 Clinical Genetic Testing using an SRNS Gene Panel .............. 170 
4.1 Introduction................................................................................... 170 
4.2 Methods ........................................................................................ 175 
4.2.1 Patient Cohort ............................................................................... 175 
4.2.2 Assay Design, Target Enrichment and Sequencing ...................... 175 
4.2.3 Bioinformatic Analysis ................................................................. 176 
4.2.4 Variant Classification ................................................................... 176 
4.2.5 Variant Segregation Analysis ....................................................... 180 
4.2.6 Copy Number Analysis................................................................. 180 
4.3 Results .......................................................................................... 180 
4.3.1 Source of referrals......................................................................... 180 
4.3.2 Demographics ............................................................................... 181 
4.3.3 Data quality and gene panel performance .................................... 185 
4.3.4 Genetic variants ............................................................................ 185 
4.3.5 Variants of unknown significance (VUS)..................................... 188 
4.3.6 Novel variants ............................................................................... 192 
4.3.7 Single heterozygous variants in recessive NPHS1 and NPHS2 ... 195 
4.3.8 Likely pathogenic variants by age of disease onset ...................... 198 
4.3.9 Clinical impact of genetic testing ................................................. 199 
4.4 Discussion ..................................................................................... 200 
Chapter 5 Plasma Proteomics and Biomarker Discovery ......................... 205 
5.1 Introduction................................................................................... 205 
5.1.1 The Human Plasma Proteome ...................................................... 205 
5.1.2 Proteomics technology.................................................................. 207 
5.1.3 Plasma proteomics in SRNS ......................................................... 211 
5.2 Methods ........................................................................................ 212 
5.2.1 Patients .......................................................................................... 212 
5.2.2 Plasma sample processing and storage ......................................... 215 
5.2.3 Albumin depletion of plasma........................................................ 215 
5.2.4 Tissue culture of conditionally-immortalised human podocytes .. 216 
5.2.5 Treatment of podocytes with albumin-depleted plasma ............... 217 
5.2.6 Protein extraction and preparation ................................................ 218 
5.2.6.1 Solutions used for protein extraction ............................... 218 
5.2.6.2 Protein extraction method ................................................ 218 
5.2.7 Quantitative total proteomics ........................................................ 219 
5.2.8 Total Proteomics data analysis ..................................................... 219 
5.2.8.1 Geometric mean and t tests .............................................. 221 
11 
 
5.2.8.2 Empirical Bayes moderated t tests ................................... 221 
5.2.8.3 Fold change thresholds .................................................... 223 
5.2.9 Western blotting............................................................................ 223 
5.2.9.1 Solutions used for gel electrophoresis and Western 
blotting ............................................................................. 223 
5.2.9.2 Gel electrophoresis and Western blotting method ........... 224 
5.2.9.3 Quantification of Western blotting ................................... 226 
5.2.10 ELISA ........................................................................................... 227 
5.2.11 Statistical analysis ......................................................................... 228 
5.3 Results .......................................................................................... 229 
5.3.1 Patient characteristics ................................................................... 229 
5.3.2 VASP phosphorylation by albumin-depleted plasma samples ..... 235 
5.3.3 Proteomic analysis of albumin-depleted relapse and remission 
plasma samples from patients with SRNS .................................... 238 
5.3.3.1 Analysis using ordinary t tests ......................................... 238 
5.3.3.2 Analysis using empirical Bayes moderated t tests ........... 240 
5.3.3.3 Analysis using fold change thresholds ............................. 243 
5.3.4 Proteomic analysis of albumin-depleted relapse and remission 
plasma samples from patients with SRNS and SSNS .................. 247 
5.3.5 Biological characterisation of selected proteins ........................... 249 
5.3.6 Validation of mass spectrometry proteomics findings by Western 
blotting .......................................................................................... 253 
5.3.7 Validation of mass spectrometry proteomics findings for 
uteroglobin by ELISA................................................................... 260 
5.3.8 Validation of mass spectrometry proteomics findings for 
lumican by ELISA ........................................................................ 267 
5.4 Discussion ..................................................................................... 272 
5.4.1 Findings of this study ................................................................... 272 
5.4.2 Comparison of potential biomarkers from literature with 
proteomic data .............................................................................. 274 
5.4.3 Limitations .................................................................................... 282 
5.4.4 Conclusion .................................................................................... 283 
5.5 Appendix to Chapter 5 .................................................................. 285 
5.5.1 R code for empirical Bayes moderated t tests of quantitative 
mass spectrometry proteomics data .............................................. 285 
Chapter 6 Plasma Proteases and Protease Inhibitors ............................... 288 
6.1 Introduction................................................................................... 288 
6.2 Methods ........................................................................................ 288 
6.2.1 Patients .......................................................................................... 288 
12 
 
6.2.2 Human protease/protease inhibitor array ...................................... 288 
6.2.3 Statistical analysis ......................................................................... 290 
6.3 Results .......................................................................................... 290 
6.3.1 Patient characteristics ................................................................... 290 
6.3.2 Protease and Protease inhibitor assays ......................................... 290 
6.3.2.1 Protease assays ................................................................ 292 
6.3.2.2 Protease inhibitor assays ................................................. 298 
6.4 Discussion ..................................................................................... 303 
6.4.1 Findings of this study ................................................................... 303 
6.4.2 Comparison of potential biomarkers from literature with 
protease and protease inhibitor data ............................................. 304 
6.4.3 Limitations .................................................................................... 305 
6.4.4 Conclusion .................................................................................... 306 
Chapter 7 Phosphoproteomics of podocytes after SRNS plasma 
treatment ………………………………………………………………..307 
7.1 Introduction................................................................................... 307 
7.1.1 Conditionally immortalised human podocytes ............................. 307 
7.1.2 Phosphoproteomics ....................................................................... 308 
7.1.3 Phosphoproteomics of renal cells ................................................. 309 
7.2 Methods ........................................................................................ 310 
7.2.1 Patients .......................................................................................... 310 
7.2.2 Tissue culture of conditionally-immortalised human podocytes .. 311 
7.2.3 Treatment of podocytes with patient plasma ................................ 311 
7.2.4 Protein extraction and preparation ................................................ 311 
7.2.5 Quantitative total and phosphoproteomics ................................... 311 
7.2.6 Phosphoproteomics data analysis ................................................. 312 
7.2.7 Western blotting for phosphoproteins .......................................... 314 
7.2.8 Immunoprecipitation..................................................................... 314 
7.3 Results .......................................................................................... 316 
7.3.1 Patient characteristics ................................................................... 316 
7.3.2 Phosphoproteomic analysis of podocytes treated with relapse 
and remission plasma from patients with SRNS .......................... 316 
7.3.3 Validation of phospho-BAD findings using Western blotting ..... 327 
7.3.4 Validation of palladin findings using immunoprecipitation ......... 330 
7.4 Discussion ..................................................................................... 333 
7.4.1 Findings of this study and comparison with the literature ............ 333 
7.4.2 Limitations .................................................................................... 337 
7.4.3 Conclusion .................................................................................... 337 
13 
 
Chapter 8 Discussion .................................................................................... 339 
8.1 Findings of this study ................................................................... 339 
8.2 Limitations of this study ............................................................... 344 
8.3 Future studies ................................................................................ 346 
8.4 Conclusions .................................................................................. 347 
9 References ...................................................................................................... 349 
10 Appendices ..................................................................................................... 378 
10.1 Demographic and clinical features of 187 patients who had whole 
exome sequencing (Chapter 2) ........................................................................ 379 
10.2 Demographic and clinical features of 63 patients who had clinical 
genetic testing (Chapter 3) ............................................................................... 385 
10.3 Genotypes and phenotypes of patients with likely-pathogenic 
variants detected by clinical genetic testing (Chapter 4) ................................. 388 




List of Tables 
Table 1.1 Classification of CKD by stage ............................................................. 32 
Table 1.2 Definitions and Classification in Nephrotic Syndrome ......................... 33 
Table 1.3 Renal biopsy findings in children with SRNS ....................................... 37 
Table 1.4: Genes associated with SRNS ................................................................ 46 
Table 1.5: National and international studies genotyping patients with SRNS ..... 51 
Table 1.6: Putative causative circulating factors in SRNS .................................... 60 
Table 1.7: Recommendations for treatment of SRNS in children ......................... 65 
Table 1.8: Disease-modifying treatments in SRNS ............................................... 68 
Table 1.9: Response to treatment with ciclosporin in a German cohort study 
of patients with genetic and non-genetic CNS or SRNS...................... 76 
Table 1.10: Response to immunosuppressive treatment within the first year 
after disease onset in the PodoNet cohort of patients with SRNS ....... 77 
Table 1.11: Responses to specific immunosuppressive drugs treatment 
episodes within the first year after disease onset in the PodoNet 
cohort of patients with SRNS ............................................................... 78 
Table 1.12: Potential clinical markers and biomarkers in NS ............................... 82 
Table 1.13: Recent biomarker discovery studies in nephrotic syndrome .............. 85 
Table 2.1: Clinical characteristics of the cohort .................................................. 101 
Table 2.2: Long-term outcomes in the cohort stratified by pattern of steroid 
resistance ............................................................................................ 106 
Table 2.3: Long-term outcomes in the cohort stratified by genetic/non-
genetic aetiology ................................................................................ 108 
Table 2.4: Frequency of likely-pathogenic genetic variants stratified by age 
of disease onset .................................................................................. 110 
Table 3.1: Terms for free text search for medications ......................................... 122 
Table 3.2: Demographic characteristics of 63 patients who had clinical 
genetic testing ..................................................................................... 128 
Table 3.3: Number of treatments and availability of outcome response data 
in WES group of patients ................................................................... 130 
Table 3.4: Number of treatments and availability of outcome response data 
in CGT group of patients .................................................................... 131 
Table 3.5: Number of immunosuppressive treatments administered per 
patient ................................................................................................. 134 
Table 3.6: Characteristics and long-term outcomes of patients stratified by 
response to first immunosuppressive treatment ................................. 137 
Table 3.7: Patients with genetic disease who had complete response to 
immunosuppression............................................................................ 140 
Table 3.8: Patients with genetic disease who had partial response to first 
immunosuppression............................................................................ 141 
Table 3.9: First immunosuppressive treatments, characteristics and long-
term outcomes of patients stratified by first biopsy findings ............. 145 
Table 3.10: Characteristics and long-term outcomes of patients treated with 
rituximab stratified by response ......................................................... 152 
Table 3.11: Number of ACEi / ARB treatments administered and responses ..... 156 
Table 4.1: Genes included in the diagnostic 37-gene panel and coverage .......... 172 
Table 4.2: Variant classification criteria .............................................................. 178 
15 
 
Table 4.3: Clinical characteristics of the cohort .................................................. 183 
Table 4.4: Genes with likely-pathogenic variants in the steroid-resistant 
nephrotic syndrome group and haematuria / Alport syndrome 
group .................................................................................................. 187 
Table 4.5: Patients with variants of unknown significance ................................. 189 
Table 4.6: Genotypes and phenotypes of patients with single heterozygous 
variants in NPHS1 and NPHS2 .......................................................... 196 
Table 5.1: Solutions used for protein extraction from podocyte cultures ............ 218 
Table 5.2: Solutions used for gel electrophoresis and Western blotting ............. 224 
Table 5.3: Antibodies used in Western blotting .................................................. 226 
Table 5.4: ELISA kits used for protein quantification ......................................... 227 
Table 5.5: Demographic and clinical characteristics of patients included in 
plasma proteomic studies ................................................................... 231 
Table 5.6: Laboratory results associated with relapse and remission plasma 
samples used in plasma protein studies .............................................. 233 
Table 5.7: Number of proteins reaching relapse/remission fold change 
thresholds for patients SRNS1, SRNS2, SRNS3 and 419 ................. 243 
Table 5.8: Proteins identified by mass spectrometry with fold change > 2 or 
< 0.5 between relapse and remission plasma samples in 4 patients 
with SRNS .......................................................................................... 245 
Table 5.9: Clinical and laboratory data associated with relapse and 
remission plasma samples from patients with SSNS ......................... 247 
Table 5.10: Proteins consistently increased in relapse versus remission 
across 4 patients with SRNS and 5 patients with SSNS/MCD .......... 249 
Table 5.11: Biological characteristics of proteins selected for further 
investigation ....................................................................................... 250 
Table 5.12: Uteroglobin concentrations determined by ELISA in relapse and 
remission plasma samples from patients with SRNS ......................... 263 
Table 5.13: Plasma proteins significantly altered in relapse versus remission 
in study by Andersen et al (2012): comparison with proteomic 
data from 8 patients with SRNS ......................................................... 275 
Table 5.14: Plasma protein release/remission ratios for 8 patients with 
SRNS for proteins suggested as biomarkers in the published 
literature ............................................................................................. 278 
Table 6.1: Proteases consistently increased or decreased in relapse versus 
remission across 10 patients with nephrotic syndrome ...................... 296 
Table 6.2: Relapse/remission ratio of urokinase-type plasminogen activator 
in patients with nephrotic syndrome .................................................. 298 
Table 6.3: Protease inhibitors consistently increased or decreased in relapse 
versus remission across 10 patients with nephrotic syndrome ........... 302 
Table 6.4: Relapse/remission ratio of NGAL in patients with SRNS assayed 
using mass spectrometry and human protease array kit ..................... 305 
Table 7.1: Antibodies used in Western blotting .................................................. 314 
Table 7.2: Solutions used for immunoprecipitation ............................................. 314 
Table 7.3: Number of peptides in phospho-enriched podocyte extracts 
reaching fold-change thresholds after treatment with plasma 
versus serum-free media .................................................................... 317 
Table 7.4: Number of peptides in phospho-enriched podocyte extracts 
reaching relapse/remission fold-change thresholds and used for 
STRING pathway analysis ................................................................. 317 
16 
 
Table 7.5: Top 5 KEGG pathways most likely affected differentially by 
treatment with relapse or remission plasma from patients with 
SRNS .................................................................................................. 323 
Table 7.6: Phosphopeptides with relapse/remission fold change > 2 across 
four patients with SRNS..................................................................... 324 
Table 7.7: Relapse/remission fold change at level of total proteins 
corresponding to identified phosphopeptides..................................... 325 
Table 7.8: Biological characteristics of proteins identified from most 
consistently altered phosphopeptides ................................................. 325 
Table 10.1: Demographic and clinical features of 187 patients who had 
whole exome sequencing ................................................................... 379 
Table 10.2: Demographic and clinical features of 63 patients who had 
clinical genetic testing ........................................................................ 385 
Table 10.3: Genotypes and phenotypes of patients with likely-pathogenic 





List of Figures 
Figure 1.1: Schematic diagram of a nephron ......................................................... 25 
Figure 1.2: Schematic diagram of the glomerular filtration barrier ....................... 26 
Figure 1.3: Ultrastructure of the glomerular filtration barrier ............................... 29 
Figure 1.4: Incidence of nephrotic syndrome in Yorkshire, UK, stratified by 
age group and subtype .......................................................................... 34 
Figure 1.5: Potential mechanism by which circulating proteases lead to 
podocyte disruption and proteinuria..................................................... 64 
Figure 1.6: Schematic showing current and future approaches to treatment in 
SRNS .................................................................................................... 81 
Figure 2.1: Overview of steps in next-generation sequencing ............................... 93 
Figure 2.2: Frequency distribution of patients by age at onset of nephrotic 
syndrome stratified by genetic/non-genetic aetiology ....................... 102 
Figure 2.3: Frequency distribution of patients by pattern of steroid resistance 
stratified by genetic/non-genetic aetiology ........................................ 103 
Figure 2.4: Percentage of kidney survival stratified by pattern of steroid 
resistance ............................................................................................ 107 
Figure 2.5: Percentage of kidney survival stratified by genetic/non-genetic 
aetiology ............................................................................................. 109 
Figure 2.6: Flow chart summarising stratification of patients by pattern of 
steroid resistance and genetic testing ................................................. 113 
Figure 3.1: Flowchart of patients from the UK RaDaR Nephrotic Syndrome 
cohort showing those included in the analysis of response to 
immunosuppressive treatment ............................................................ 121 
Figure 3.2: Clinical characteristics of patients for whom medication and 
response data were known ................................................................. 132 
Figure 3.3: Response to intensified immunosuppressive (IIS) medications ........ 133 
Figure 3.4: Response to first-administered intensified immunosuppressive 
(IIS) medications ................................................................................ 135 
Figure 3.5: Response to intensified immunosuppressive (IIS) medications in 
patients with genetic or non-genetic disease ...................................... 139 
Figure 3.6: Response to intensified immunosuppressive (IIS) medications in 
patients with non-genetic presumed/primary steroid resistance 
and secondary steroid resistance ........................................................ 143 
Figure 3.7: Response to first intensified immunosuppressive (IIS) 
medications in patients stratified by first biopsy findings ................. 146 
Figure 3.8: Response to all intensified immunosuppressive (IIS) medications 
in patients stratified by first biopsy findings ...................................... 148 
Figure 3.9: Kidney survival analysed by response to first 
immunosuppressive treatment ............................................................ 150 
Figure 3.10: Response to rituximab in patients stratified by timing of 
treatment and pattern of steroid response ........................................... 154 
Figure 3.11: Response to first-administered ACEi and ARB .............................. 157 
Figure 3.12: Flow chart showing long term outcomes in patients stratified 
by pattern of steroid resistance, genetics and response to first-line 
intensified immunosuppressive treatment .......................................... 164 
Figure 4.1: Source of referrals for NGS gene panel testing ................................. 181 
18 
 
Figure 4.2: Flow chart of patients by phenotype at presentation, age and 
genetic diagnosis ................................................................................ 186 
Figure 4.3: NPHS1 and NPHS2 Copy number variants ....................................... 193 
Figure 4.4: Genetic diagnostic rates for patients with known age at disease 
onset ................................................................................................... 198 
Figure 5.1: Intersection of human kidney, urine and plasma proteomes 
determined by mass spectrometry ...................................................... 206 
Figure 5.2: Steps in mass spectrometry-based proteomic analysis ...................... 208 
Figure 5.3: Summary of sample processing, isobaric labelling and mass 
spectrometry for quantitative proteomic analysis .............................. 210 
Figure 5.4: Flow diagram showing patients included at different stages of 
the proteomic discovery and validation process ................................ 214 
Figure 5.5: Snapshot from Proteome Discoverer illustrating protein 
grouping ............................................................................................. 220 
Figure 5.6: Western blots showing VASP phosphorylation in podocytes 
treated with relapse and remission plasma with or without prior 
albumin depletion ............................................................................... 236 
Figure 5.7: Volcano plot of protein quantification data for relapse/remission 
plasma samples from patients SRNS1, SRNS2, SRNS3 and 419...... 238 
Figure 5.8: Volcano plot of protein quantification data for relapse/remission 
plasma samples from patients SRNS1, SRNS2 and SRNS3.............. 239 
Figure 5.9: Boxplot showing median normalised relative protein abundances 
in relapse and remission plasma samples from patients SRNS1, 
SRNS2, SRNS3 and 419 .................................................................... 241 
Figure 5.10: Volcano plot of protein quantification data showing ordinary 
and moderated p values for relapse/remission plasma samples 
from patients SRNS1, SRNS2, SRNS3 and 419 ................................ 242 
Figure 5.11: Western blotting and proteomic quantification of RANBP3 in 
paired relapse/remission plasma samples ........................................... 254 
Figure 5.12: Western blotting and proteomic quantification of Lumican in 
paired relapse/remission plasma samples ........................................... 256 
Figure 5.13: Western blotting and proteomic quantification of Nek3 in 
paired relapse/remission plasma samples ........................................... 258 
Figure 5.14: Western blotting for EphB4 in paired relapse/remission plasma 
samples ............................................................................................... 259 
Figure 5.15: Western blotting for Uteroglobin in paired relapse/remission 
plasma samples ................................................................................... 260 
Figure 5.16: ELISA standard curve of optical density against uteroglobin 
concentration with curve fitting using the 4-parameter logistic 
regression method .............................................................................. 261 
Figure 5.17: ELISA standard curve of uteroglobin concentration against 
optical density with curve fitting using the polynomial line of 
best fit ................................................................................................. 262 
Figure 5.18: ELISA and proteomic quantification of uteroglobin in paired 
relapse/remission plasma samples ...................................................... 264 
Figure 5.19: Relationship of uteroglobin concentration in plasma to uPCR 
for samples taken during relapse and remission in patients with 
SRNS and SSNS ................................................................................ 267 
Figure 5.20: ELISA standard curve of lumican concentration against 
absorbance with curve fitting using the polynomial line of best fit ... 268 
19 
 
Figure 5.21: ELISA and proteomic quantification of lumican in paired 
relapse/remission plasma samples ...................................................... 269 
Figure 5.22: Relationship of lumican concentration in plasma to uPCR for 
samples taken during relapse and remission in patients with 
SRNS and SSNS ................................................................................ 271 
Figure 6.1: Dot array output from the Human Protease/Protease Inhibitor 
Array Kit for patient 1291 .................................................................. 291 
Figure 6.2: Heat map of log2 (relapse/remission fold change) for proteases 
in plasma from patients with nephrotic syndrome ............................. 292 
Figure 6.3: Relationship between the geometric mean of relapse/remission 
fold change ratio for all proteases and the relapse/remission 
uPCR ratio .......................................................................................... 294 
Figure 6.4: Volcano plot of protease quantification data for 
relapse/remission plasma samples from patients with nephrotic 
syndrome ............................................................................................ 295 
Figure 6.5: Heat map of log2 (relapse/remission fold change) for protease 
inhibitors in plasma from patients with nephrotic syndrome ............. 299 
Figure 6.6: Relationship between the geometric mean of relapse/remission 
fold change ratio for all protease inhibitors and the 
relapse/remission uPCR ratio ............................................................. 300 
Figure 6.7: Volcano plot of protease inhibitor quantification data for 
relapse/remission plasma samples from patients with nephrotic 
syndrome ............................................................................................ 301 
Figure 7.1: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus 
remission plasma from patient SRNS1 .............................................. 319 
Figure 7.2: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus 
remission plasma from patient SRNS2 .............................................. 320 
Figure 7.3: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus 
remission plasma from patient SRNS3 .............................................. 321 
Figure 7.4: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus 
remission plasma from patient 419 .................................................... 322 
Figure 7.5: Western blotting and proteomic quantification of phospho-BAD 
in extracts from podocytes treated with paired relapse/remission 
plasma samples ................................................................................... 329 
Figure 7.6: Western blotting of total palladin in extracts from podocytes 
treated with paired relapse/remission plasma samples ....................... 330 
Figure 7.7: Immunoprecipitation of podocyte extracts with anti-palladin 
antibody and Western blotting for palladin and total 
phosphoserine ..................................................................................... 331 
Figure 7.8: Western blotting of total palladin and anti-phosphoserine in 
extracts from podocytes treated with paired relapse/remission 




List of Abbreviations 
ABB Albumin binding buffer 
ACEi Angiotensin converting enzyme inhibitor 
ACR Albumin:creatinine ratio 
AHSG Alpha-2-HS-glycoprotein, also known as Fetuin A 
APC Antigen-presenting cell 
ARB Angiotensin receptor blocker 
AS Alport syndrome 
BGL Bristol Genetics Laboratory 
CGT Clinical genetic testing 
ci-hPod Conditionally-immortalised human podocyte 
CKD Chronic kidney disease 
CNI Calcineurin inhibitor 
CNS Congenital nephrotic syndrome 
CNV Copy number variant 
CR Complete remission/response 
DDS Denys-Drash syndrome 
DMS Diffuse mesangial sclerosis 
ELISA Enzyme-linked immunosorbent assay 
EM Electron microscopy 
ESL Endothelial surface layer 
ESRF End-stage renal failure 
EVP NHLBI Exome Sequencing Project 
ExAC Exome Aggregation Consortium 
FAC Focal adhesion complex 
FAK Focal adhesion kinase 
FDR False discovery rate 
FP Foot process 
21 
 
FR-SSNS Frequently-relapsing steroid-sensitive nephrotic syndrome 
FS Frasier syndrome 
FSGS Focal segmental glomerulosclerosis 
GAG Glycosaminoglycan 
GBM Glomerular basement membrane 
GEnCs Glomerular endothelial cells 
GFB Glomerular filatration barrier 
GFR Glomerular filtration rate 
HUS Haemolytic uraemic syndrome 
IgG Immunoglobulin G 
IIS Intensified immunosuppressive 
INS Idiopathic nephrotic syndrome 
IQR Interquartile range 
IV Intravenous 
KDIGO Kidney Disease Improving Global Outcomes 
LC-MS/MS Liquid chromatography – tandem mass spectrometry 
LDL Low density lipoprotein 
LM Light microscopy 
LP Likely-pathogenic 
LPS Lipopolysaccharide 
MCD Minimal change disease 
MesPGN Mesangioproliferative glomerulonephritis 
MHc Mesangial hypercellularity 
MHC Major histocompatibility complex 
MMF Mycophenolate mofetil 
MN Membranous nephropathy 
MPGN Membranoproliferative glomerulonephritis 
MW Molecular weight 
NephroS National Study of Nephrotic Syndrome 
NFAT Nuclear factor of activated T cells 
22 
 
NGAL Neutrophil gelatinase-associated lipocalin 
NGPPSR Non-genetic presumed/primary steroid resistance 
NGS Next-generation sequencing 
NHS National Health Service 
NS Nephrotic syndrome 
PAR Protease activated receptor 
PEx Plasma exchange 
PR Partial remission/response 
PSR Primary steroid resistance 
RaDaR National Registry of Rare Kidney Diseases 
RCT Randomised controlled trial 
RRT Renal replacement therapy 
SD Slit diaphragm 
SDNS Steroid-dependent nephrotic syndrome 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SLE Systemic lupus erythematosus 
SNV Single nucleotide variant 
SR Steroid-resistance 
SRNS Steroid-resistant nephrotic syndrome 
SSNS Steroid-sensitive nephrotic syndrome 
SSR Secondary steroid resistance 
suPAR Soluble urokinase plasminogen activator receptor 
TBMN Thin basement membrane nephropathy 
TNF Tumour necrosis factor 
uPCR Urine protein:creatinine ratio 
VASP Vasodilator stimulated phosphoprotein 
VUS Variant of unknown significance 
WES Whole exome sequencing 




Chapter 1 Introduction 
Nephrotic syndrome (NS) is a rare condition, particularly affecting children, 
characterised by swelling of the face and other parts of the body due to loss of 
protein in the urine.  Around 80-90% of patients respond initially to the first-line 
treatment which is steroids.  For those who are steroid-resistant, there is a 
significant risk of progression to end-stage renal failure needing dialysis and 
transplantation.  Unfortunately, around half of the patients who are transplanted 
suffer recurrence of the disease.  Currently, our ability to predict the disease 
course for an individual patient, and therefore intervene with the most appropriate 
treatments to prevent progression, is limited.  It is clear that patients with NS are a 
heterogeneous group.  Research, particularly over the last decade, has helped to 
stratify patients into more similar subgroups which hopefully share a similar 
disease biology and thus open the door for more targeted therapies.  This study 
uses data and samples from cohorts of patients with steroid-resistant nephrotic 
syndrome (SRNS) to explore the associations between clinical presentations, 
genetics, potential circulating biological markers and outcomes.   
 The Introduction will first explain the structure and function of the kidney 
with particular focus on the key cell affected in NS: the podocyte.  Since the 
identification of the first genetic cause of NS in 1998, mutations in over 50 genes 
have been identified to be responsible for approximately 30% of cases of SRNS in 
childhood.  Many of these genes have a role in podocyte structure or function.  In 
the remaining 70% of patients, a “circulating factor”, possibly immune-mediated, 
has been hypothesised.  The evidence for this and some of the proposed 
candidates are discussed below.  Subsequent sections review the current disease-
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modifying treatments in SRNS, many of which have been used for decades.  
Some small studies of novel biologic treatments have been reported but results 
have generally been disappointing.  One explanation may be our incomplete 
understanding of the pathogenesis of SRNS and therefore inclusion of patients in 
studies with diverse biologies.  The way forward may be detailed phenotyping and 
genotyping of patients together with development of biomarkers which can be 
used together for stratification.  The use of relatively recent technologies, in 
particular whole exome sequencing and proteomics analysis for biomarker 
discovery in relation to SRNS will be explored. 
 
1.1 The Kidneys: Structure and Function 
The kidneys in humans are a pair of organs situated posterior to the abdominal 
cavity which function to filter and remove waste substances from the blood; 
maintain water, electrolyte and acid-base balance; control blood pressure and 
process hormones including vitamin D and erythropoietin [3].  Each kidney 
consists of approximately 1 million functioning units called nephrons.  Filtration 
occurs in the glomerulus with small molecules passing from the plasma into the 
Bowman’s capsule (Figure 1.1).  Reabsorption of most of the water and 
electrolytes occurs in the proximal convoluted tubule, loop of Henle and distal 





Figure 1.1: Schematic diagram of a nephron 
Adapted from: http://biologymayhem.blogspot.com/2011/01/on-kidneys_03.html 
 
Central to normal kidney function is the filtration of small substances and 
retention of cells and larger molecules by the glomerular filtration barrier (GFB).  
The selectivity of the barrier is dependent on both the size and charge of the 
solutes, being particularly restrictive to negatively charged proteins.  Moving from 
blood plasma to the Bowman’s capsule, the GFB consists of three layers: 
glomerular endothelial cells (GEnCs), the glomerular basement membrane (GBM) 





Figure 1.2: Schematic diagram of the glomerular filtration barrier 
GBM, glomerular basement membrane; rbc, red blood cell; SD, slit diaphragm. 
Adapted with permission of American Society for Clinical Investigation from 




1.1.1 The glomerular filtration barrier 
1.1.1.1 Glomerular endothelial cells 
Blood enters the glomerulus via the afferent arteriole which branches into a 
network of multiple capillaries.  These are lined by GEnCs which form a single 
cell layer punctuated by openings, 60-100 nm in diameter, called fenestrae, 
allowing rapid passage of water and solutes.  Although the fenestrae are larger 
than plasma proteins such as albumin, it has generally been thought that 
movement is prevented by repulsion from the negatively-charged glycocalyx 
which covers the GEnCs.  The glycocalyx is composed of glycoproteins, 
glycosaminoglycans and proteoglycans [5].  Adsorption of plasma components 
into the glycocalyx forms a thicker covering called the endothelial surface layer 
(ESL) which further narrows the fenestrae and restricts movement [6].  The 
importance of the ESL at preventing loss of protein into the urine (proteinuria) has 
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been demonstrated in animal models and humans by scenarios where the 
glycocalyx is lost.  Adriamycin-induced glycocalyx shedding in rat models led to 
significant proteinuria and diabetes-associated proteinuria is correlated with ESL 
damage in humans [7, 8]. 
 Normal development and function of GEnCs is dependent on cross-talk 
between these cells and podocytes.  Studies have highlighted the importance of 
vascular endothelial growth factor A (VEGFA) secreted by podocytes acting in a 
paracrine fashion on VEGF receptors on GEnCs [9].  Blockage of signalling using 
anti-VEGF antibodies resulted in GEnC abnormalities and proteinuria.  Both 
GEnCs and podocytes function together to produce the GBM. 
 
1.1.1.2 Glomerular basement membrane 
The GBM forms both a scaffold to support GEnCs and podocytes and a functional 
component of the filtration barrier.  It consists mainly of a lattice of proteins, 
principally collagens, laminins, heparin sulfate proteoglycans and nidogen-1 [10].  
Evidence for the importance of the GBM to the GFB selective filtration function 
derives from genetic disease in humans.  The predominant form of collagen in the 
mature GBM is type IV collagen, composed of trimers of α3, α4 and α5 subunits.  
Pathogenic variants in the respective genes (COL4A3, COL4A4 and COL4A5) 
cause Alport syndrome (AS) [11].  This is characterised by abnormal thinning of 
the GBM, passage of blood into the urine (haematuria) and sometimes proteinuria, 
in addition to extra-renal features such as deafness.  Laminins are also trimeric 
proteins which cross-link to the type IV collagen network.  The predominant form 
is laminin-521 (composed of α5, β2 and γ1 subunits).  Pathogenic variants in 
LAMB2, which encode laminin-β2, cause Pierson syndrome, an autosomal 
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recessive condition with congenital onset of proteinuria [12].  Laminins interact 
directly with podocytes, in particular with their actin cytoskeleton via other 
proteins such as integrins and dystroglycan, as discussed below. 
 
1.1.1.3 Podocytes 
Podocytes are highly specialised epithelial cells located on the urinary side of the 
GBM (Figure 1.3).  Extending from their cell bodies are branching primary 
processes and more distal foot processes (FPs) which interdigitate with those of 
adjacent cells [13].  Intercellular junctions, called slit diaphragms (SDs), form 
structural and functional links across the 30-50 nm-wide filtration slits between 
the FPs of different cells.  The SD is the final selective barrier to the passage of 
substances from the plasma before entering the urinary filtrate and its 
ultrastructure and molecular components have been extensively studied in recent 
years [3].  It has been suggested that the role of the SD is to keep FPs apart, like a 
“molecular spring”, rather than pull them together [14].  It is now recognised to be 
not purely a physical barrier but, perhaps more importantly, a focus of proteins 
essential for signalling between FPs and internally to the podocyte cytoskeleton 









Figure 1.3: Ultrastructure of the glomerular filtration barrier 
A: Scanning electron microscopy view of podocytes and their foot processes; B: 
Transmission electron microscopy view of the glomerular filtration barrier. 
CB, cell body; FP, foot process; GBM, glomerular basement membrane; MP, 
major process; SD, slit diaphragm. Republished with permission of Annual 
Reviews, Inc, from Greka, A. & Mundel, P. (2012) [15]; permission conveyed 
through Copyright Clearance Center, Inc. 
 
Maintenance of the FP structure is dependent on its actin cytoskeleton.  
Normally, actin is highly organised into parallel contractile bundles centrally 
within the FP and a network of cortical actin lies more peripherally adjacent to the 
plasma membrane [16, 17].  This allows the FPs to move and regulate the 
filtration slits between adjacent cells.  Any process, either intrinsic or extrinsic to 
the podocyte, which disrupts this can lead to flattening and fusion of the FPs 
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known as effacement.  This structural change alters the integrity of the slit 
diaphragm and causes proteinuria, a characteristic feature of NS as discussed later 
[15].  The SD separates the FP surface membrane into an apical domain which 
faces the urinary filtrate and a basolateral domain which contacts the GBM.  
Signalling via proteins in either domain and at the SD can modulate the actin 
cytoskeleton. 
One of the key proteins at the SD is nephrin, encoded by NPHS1.  It has a 
large extracellular domain which contacts with neighbouring nephrin molecules.  
The short intracellular domain can be phosphorylated and interacts with several 
adaptor proteins, including Nck, to regulate the actin cytoskeleton [18].  Many 
other proteins which interact with or regulate the cytoskeleton are critical for 
normal podocyte function, and are discussed in recent reviews [3, 19].  There is an 
increasing list of genes, some coding for these proteins, which when mutated 
cause nephrotic syndrome and these will be discussed subsequently in relation to 
the genetics of NS. 
 
1.1.2 Kidney function and the glomerular filtration rate 
As part of its normal function, an adult kidney filters approximately 180 litres of 
plasma each day.  This can be quantified by the glomerular filtration rate (GFR).  
In a human subject this can be measured formally by intravenous (IV) injection of 
a known quantity of inulin and measurement of its excretion into urine over a 
fixed period of time.  Inulin is an inert protein which is freely filtered in the 
kidneys and is neither synthesised nor metabolised in the body.  The GFR can 
then be calculated as volume per unit time (ml/minute).  Since the number of 
glomeruli, and therefore GFR, is dependent on body size, and more specifically 
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body surface area, the calculation is usually standardised to allow comparison 
between individuals by reporting GFR in ml/min/1.73m2.  In clinical care, 
injection of inulin is an invasive and impractical method of measurement of GFR 
on a routine basis.  The estimated GFR (eGFR) is, therefore, frequently used, 
which is calculated on the basis of creatinine clearance.  Creatinine is a by-
product of normal muscle metabolism and is generally released into plasma at a 
constant rate dependent on muscle bulk which is related to age, size and sex of the 
subject.  Creatinine concentration (in mg/dL or µmol/L) can be measured on 
routine blood tests and there are several formulae for the calculation of eGFR 
based on creatinine concentration.  A commonly-used method, and one used in 





Where Ht is height in centimetres, k is a constant (0.45 for infants 1 – 52 weeks 
old; 0.55 for children 1 – 13 years old; 0.55 for adolescent females 13-18 years 
old; and 0.7 for adolescent males 13-18 years old), and Crserum is serum creatinine 
in mg/dL.  The constant, k, was determined empirically by Schwartz and 
colleagues and varies with age and gender in order to account for the differing 
relationship between height and muscle mass in these groups.  A normal GFR is > 
130 ml/min/1.73m2.  The persistent loss of normal renal filtration function is, by 




Classification of CKD by stages is shown in Table 1.1.  
 
Table 1.1 Classification of CKD by stage  
CKD Stage Glomerular filtration rate 
(ml/min/1.73m2) 
Comments 
1 ≥ 90 Kidney damage with 
normal or increased GFR 
2 60-89 Kidney damage with mild 
reduction of GFR 
3 30-59 Moderate reduction of 
GFR 
4 15-29 Severe reduction of GFR 
5 < 15 (or dialysis) Kidney failure 
5Tx  Transplanted 
Adapted from Hogg et al. 2003 [21]   
Legend: CKD, chronic kidney disease; GFR, glomerular filtration rate 
 
A patient who remains persistently at CKD5 is in end-stage renal failure 
(ESRF) and, if untreated, the accumulation of urea and other waste substances, 
electrolyte disturbance and acid-base derangement would be incompatible with 
life.  At this point, renal replacement therapy (RRT), usually in the form of 
dialysis, or kidney transplantation is required. 
 
1.2 Nephrotic syndrome 
1.2.1 Diagnosis and Classification 
Nephrotic syndrome is diagnosed clinically by the triad of proteinuria (urine 
protein:creatinine ratio > 200mg/mmol or ≥ 3+ dipstick proteinuria), 
hypoalbuminaemia (plasma albumin < 25g/L) and oedema [22].  It is clear that 
NS is not a single disease but a common endpoint for various pathological 
processes.  NS may be secondary to other conditions such as hypertension, 
obesity, systemic lupus erythematosus (SLE) or infections such as human 
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immunodeficiency virus (HIV) [23].  More frequently, however, it is primary or 
idiopathic in which such diseases are not identified.    Currently the standard 
initial treatment for idiopathic nephrotic syndrome (INS) in childhood is oral 
steroids, usually prednisolone.  Responsiveness to steroids is an important method 
of classification of INS used in clinical practice (Table 1.2) [22].    The definition 
of steroid-resistance varies between studies and publications, being failure to 
respond to either 4 weeks or 8 weeks of oral high-dose prednisolone [23-25].  
Rarely, INS presents antenatally, at birth or within the first three months of life: 
this is called congenital nephrotic syndrome (CNS).   
 
Table 1.2 Definitions and Classification in Nephrotic Syndrome 
Type Description 
Remission uPCR < 200 mg/g (< 20 mg/mmol) or < 1+ dipstick 
protein for 3 consecutive days 
Relapse uPCR ≥ 2000 mg/g (≥ 200 mg/mmol) or ≥ 3+ dipstick 
protein for 3 consecutive days 
SSNS Remission achieved within 4 weeks of high-dose oral 
prednisolone, and subsequent relapses respond to 
steroids 
FR-SSNS ≥ 2 relapses within the first 6 months, or ≥ 4 relapses 
within any 12-month period  
SD-SSNS Relapse while on steroid therapy or within 2 weeks of 
discontinuation 
SRNS Failure to achieve remission within 4 weeks of high-
dose oral prednisolone 
Primary SR Failure to achieve remission within the initial 4 weeks of 
high-dose oral prednisolone 
Secondary SR Remission achieved within the initial 4 weeks but 
subsequent relapse (sometimes months or years later) 
not controlled by high-dose oral steroids 
Presumed SR Presentation is with CNS or NS associated with a 
syndrome or in established renal failure, therefore 
steroids presumed to be ineffective 
Adapted from [22].  
Legend: CNS, congenital nephrotic syndrome; FR, frequently-relapsing; SD, 
steroid dependent; SR, steroid resistance; SRNS, steroid resistant nephrotic 






INS affects children of all ages with an incidence of 1 - 7 per 100,000 
children/year [26].  A regional UK epidemiological study from 1987-1998 
calculated an age-sex standardised incidence of 2.3 per 100,000 children/year and 
male:female ratio of 1.6:1 [25].  Onset is most common in the 1-4 year age group 
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Figure 1.4: Incidence of nephrotic syndrome in Yorkshire, UK, stratified by 
age group and subtype 
Data from McKinney et al. (2001) [25] 
 
  SRNS represents 10-20% of cases with a UK incidence reported of 0.3 per 
100,000 children/year [25].  International studies have revealed variation of INS 
incidence with figures of 3.35/100,000 children/year in Paris, France, and 
6.49/100,000 children/year in Japan [27, 28].  Consistent with these findings, 
other reports examining ethnic differences identified higher incidence of INS in 
South and Southeast Asians compared with Europeans [29].  Furthermore, Afro-
Caribbean and Hispanic patients are more likely to have steroid-resistance, and 
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worse long-term outcomes, compared with White Caucasians [30].  There are 
suggestions that incidence of SRNS, and the most commonly-associated biopsy 
finding of focal segmental glomerulosclerosis (FSGS, see below), has increased 
over the past three decades [31-33].  Although changes in biopsy patterns may 
partly account for this, it is likely that the cohort of children with SRNS has 
grown in recent years. 
 
1.2.3 Pathology 
As part of the investigation of NS once steroid resistance is evident, the 
International Kidney Disease Improving Global Outcomes (KDIGO) Clinical 
Practice Guidelines for SRNS in Children recommend performing a renal biopsy 
and processing for light microscopy, immunofluorescence and electron 
microscopy [34].  NS is associated with various histopathological appearances on 
biopsy.   
 
1.2.3.1 Minimal change disease 
In SSNS, although biopsy is not routinely performed, the most common finding is 
minimal change disease (MCD) [35].  This is characterised by normal 
appearances on light microscopy with no immune complex deposits but electron 
microscopy (EM) reveals disruption of normal podocyte architecture with 
effacement and fusion of foot processes [36].  MCD is sometimes used 
synonymously with SSNS.  While it is assumed that all (unbiopsied) patients with 
SSNS have MCD, not all patients with MCD are steroid-sensitive.  In fact, 
between 3% and 35% of SRNS patients in different international studies have 
MCD on biopsy [37].  Historical studies, from the 1960s - 1970s in which all 
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patients with nephrotic syndrome underwent biopsy, showed that 95% of patients 
with MCD have a good outcome with no or infrequent relapses but up to 5% 
progress to ESRF or die earlier from complications [38]. 
 
1.2.3.2 Focal segmental glomerulosclerosis 
FSGS is the single commonest finding on renal biopsy in paediatric patients with 
SRNS identified in 38.7% to 70.6% of cases [37, 39-42].   This is characterised by 
changes visible on light microscopy of scarring of glomeruli which is focal (some 
but not all glomeruli) and segmental (only part of each affected glomerulus).  On 
EM, extensive foot process effacement is found but with no other abnormalities of 
the GBM.  Both MCD and FSGS are considered primary disorders of podocytes, 
or podocytopathies.   It is hypothesised that they lie on a pathologic spectrum with 
MCD sometimes progressing to FSGS.  Given that, by definition, FSGS is focal, a 
biopsy which includes only a few glomeruli may miss the affected areas: it has 
been suggested that biopsies with fewer than 15 glomeruli cannot confidently 
exclude FSGS [43]. 
Other histological patterns seen in SRNS are summarised in Table 1.3 and 
include diffuse mesangial sclerosis (DMS), mesangioproliferative 
glomerulonephritis (MesPGN) and “Finnish type” CNS characteristically seen in 
patients with pathological variants in NPHS1 (nephrin).  It is evident that there is 
not direct one-to-one correspondence between the clinical presentation (steroid 
sensitive versus steroid resistant) and underlying renal histology.  A small 
proportion of patients with FSGS are steroid-sensitive, although exact numbers 
are not clear since most SSNS patients are not biopsied.  Therefore, it is unclear to 
what extent histology predicts response to treatment or outcome. 
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Table 1.3 Renal biopsy findings in children with SRNS 




FSGS 56.0 Focal and segmental scarring, extensive foot process 
effacement on EM, absence of immune complex 
deposits 
MCD 21.1 Normal glomeruli on LM; foot process effacement on 
EM 
MesPGN 12.4 Mesangial cell proliferation and increased mesangial 
matrix on LM; mesangial IgM deposits on IF; granular 
deposits in mesangial matrix on EM 
DMS 2.9 Small condensed glomeruli, increased dense mesangial 
collagen on LM, widespread foot process effacement 
on EM 
MPGN 2.6 Endocapillary proliferation, double contours of GBM 
on silver stain on LM; IgG, C3 and C1q deposits along 
capillary wall or mesangium on IF; subendothelial and 
mesangial deposits, foot process effacement on EM 
GGS 1.3 Scarring of the whole of each affected glomerulus on 
LM; extensive foot process effacement on EM 
MN 0.8 Spikes/holes appearance of GBM on LM; IgG and C3 
capillary wall deposits on IF; subepithelial deposits 
and foot process effacement on EM 
CNS 0.6 Glomeruli may be normal or have variable mesangial 
and/or endocapillary hypercellularity on LM; complete 
foot process effacement on EM; absence of immune 
complex deposits 
Other 2.3  
* Frequency data from the European PodoNet Registry Cohort of childhood-onset 
SRNS, CNS and persistent sub-nephrotic proteinuria (n = 1368) [44]. Descriptions 
based on [36, 45-49]. 
Legend: CNS, Finnish-type congenital nephrotic syndrome; DMS, diffuse 
mesangial sclerosis; EM, electron microscopy; FSGS, focal segmental 
glomerulosclerosis; GBM, glomerular basement membrane; GGS, global 
glomerulosclerosis; IF, immunofluorescence; LM, light microscopy; MCD, 
minimal change disease; MesPGN, Mesangioproliferative glomerulonephritis; 




Performing a renal biopsy in children with SRNS is associated with inherent risks 
and costs [50, 51]: 




• Arteriovenous fistula 
• Pain 
• Inadequate or unrepresentative sample (no renal tissue or very few 
glomeruli) 
  
The key, linked questions for clinicians when considering a renal biopsy are: 
1. To what extent does knowing the histology help to predict response to 
treatment and outcome? 
2. Will the biopsy result change management? 
3. Do the benefits outweigh the risks? 
 
1.2.4 Long term outcomes and complications 
Nephrotic syndrome is associated with a variety of complications: in the short 
term these are associated with proteinuria and loss of functional proteins from the 
circulation; in the long term they mostly relate to development of CKD [23].  
Over a period of days, hypoalbuminaemia and reduced intravascular oncotic 
pressure result in fluid redistribution out of the circulation and into surrounding 
tissues (causing oedema) and “third spaces” such as the lungs (resulting in pleural 
effusions) and abdomen (leading to ascites).  Loss of specific plasma proteins also 
have more targeted effects:  
• Reduced levels of immunoglobulins predispose to infections 
• Falling low density lipoprotein (LDL) and changes in enzymes in the lipid 
biosynthesis pathway lead to hypercholesterolaemia and elevated 
triglycerides 




Long-term complications result both from the progression of the underlying 
disease and side effects of treatments used to control it.  Patients with SSNS who 
remain steroid-sensitive with infrequent relapses usually have minimal long-term 
sequelae and do not develop ESRF. Patients with FR-SSNS or SD-SSNS are at 
risk of side effects from chronic steroid exposure and non-steroid 
immunosuppression, which will be discussed below.  The greatest burden of long-
term complications, however, falls on patients with SRNS.  In a retrospective 
longitudinal study, 25% of children with SRNS progressed to ESRF within 5 
years and 42% within 10 years [52].   
For clinicians caring for patients with SRNS, some of the key questions are: 
1. Will this patient respond to non-steroid immunosuppression and, if so, 
which one? 
2. Will this patient progress to ESRF? 
3. If this patient reaches ESRF and requires a kidney transplant, should we 
consider live-related donation from a family member? 
4. Will this patient suffer post-transplantation disease recurrence and how 
best can this be treated (and, if possible, prevented)? 
Research endeavours into the genetic and immunological pathogenesis of 
SRNS over the past two decades are making some inroads towards answering 
these questions.  It is increasingly clear that patients with SRNS are a 
heterogeneous group.  Fundamental to improvement in outcomes is the 
subcategorisation, or stratification, of patients into more homogeneous subgroups.  
A scientific understanding about pathogenesis can then be translated from bench 
to bedside by the development of targeted therapies.  The following sections will 
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provide a review of our current understanding of pathogenesis, treatment and 
stratification in SRNS which forms the basis of this study. 
 
 
1.3 Genetics of Nephrotic Syndrome 
1.3.1 Historical background 
Since the early 20th Century, babies with in utero oedema had been reported and 
rarely survived beyond a few months of life.  In Finland in the 1950s, cohorts of 
babies were identified with characteristic changes on renal biopsy / post-mortem 
study which were described as congenital nephrotic syndrome of the Finnish type 
[53].  The antenatal onset of severe disease, together with the familial inheritance 
pattern in siblings (boys and girls) born to unaffected parents, strongly suggested 
an autosomal recessive pattern of genetic transmission.  The use of family studies 
with linkage disequilibrium analysis narrowed the search to genes on chromosome 
19 [54].  Subsequent positional cloning identified mutations in the gene later 
named NPHS1 (for “nephrotic syndrome 1”) as being the cause of disease in these 
children [55].  Two years later in 2000 the second gene, NPHS2, was also 
recognised as an autosomal recessive cause of SRNS [56].  The number of 
causative genes has rapidly expanded in the past 5 years and now numbers over 
50, most of which are structurally or functionally related to the podocyte.  These 
are summarised in Table 1.4 below. 
SRNS is a genetically heterogeneous disorder with dominant, recessive or 
sporadic inheritance with a single-gene cause reported in 29.5% of cases [57].  
There is a differing spectrum of genes and mutations associated with congenital 
and childhood-onset disease in comparison with adult disease.  Genetic mutations 
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may manifest as a renal-only phenotype or nephrotic disease as part of a wider 
syndrome [58].  The proportion of cases with an identified genetic cause is 
inversely related to the age of disease onset: 69.4% - 100% of patients with CNS 
have been reported as having a genetic condition [57, 59].  Genes with variants 
inherited in a recessive pattern include NPHS1 (nephrin) [55], NPHS2 (podocin) 
[56], LAMB2 (laminin subunit β2) [12] and PLCE1 (phospholipase C.ε1) [60].  
Those following a dominant pattern include INF2 (inverted formin-2)[61], TRPC6 
(transient receptor potential channel 6) [62], ACTN4 ( actinin-α4) [63], LMX1B 
(LIM homeobox transcription factor 1-β) [64] and WT1 (Wilms tumour) [65].  
Pathogenic variants in certain genes are associated with multisystem syndromes 
for example Pierson syndrome (LAMB2), Denys-Drash syndrome (WT1) and 
Charcot-Marie Tooth disease (INF2). 
The phenotypic spectrum is widening, both in terms of age of onset [66] 
and phenotypic variability, with novel phenotypes for individual genes emerging 
[67].  Recent evidence indicates that the phenotype of a mutation in an SRNS 
gene can be modified by a mutation in one of the collagen genes (COL4A3, 
COL4A4, COL4A5) [68] and potentially other SRNS genes.  The phenotype can 
also depend upon the location of the mutation within the gene/protein [69], and 
whether one or two mutations are present in a single gene.  
 
1.3.2 NPHS1 
NPHS1 codes for nephrin, which, as discussed previously, is a key protein at the 
podocyte slit diaphragm.   Mutations in this gene are the commonest cause for 
CNS, being responsible for 40-60% of cases.  In those of Finnish heritage, over 
90% of CNS results from two founder mutations which result in a premature stop 
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codon and absence of nephrin at the SD [70, 71].   Inheritance follows an 
autosomal recessive pattern and children usually present within the first 3 months 
of life, progressing to ESRF within the first few years.  Since first being identified 
in Finnish infants, causative mutations in NPHS1 have been detected in patients 
with onset in older childhood (5 months – 8 years) and in adulthood [57, 66, 72].  
Over 240 mutations in NPHS1 have been identified in international populations 
[73, 74] and the phenotypic spectrum is widening to include patients with 
homozygous mutations who respond to immunosuppressive therapy and do not 
progress to ESRF. 
 
1.3.3 NPHS2 
NPHS2 is the gene which is most-frequently implicated in genetic forms of SRNS 
and encodes the protein podocin [56].  One study identified it as the cause in 
39.1% of CNS and 35.3% of infantile onset NS [75].  Podocin is localised to the 
SD, in particular to lipid rafts which are functionally-important signalling 
microdomains in the plasma membrane [76].  It recruits and stabilises nephrin as 
well as increasing its activity.  Mutations in NPHS2 have been shown to disrupt 
the targeting of nephrin to the lipid raft microdomains [77].   Homozygous or 
compound heterozygous pathogenic variants cause onset of SRNS usually under 
the age of 6 years with FSGS found on renal biopsy.  Within European 
populations, the R138Q variant is the most common although over 125 different 
mutations have been identified.  The R229Q variant is recognised as a non-neutral 
polymorphism: in a homozygous state it does not cause disease however it is 
pathogenic when in compound heterozygosity with specific variants in exons 8 or 
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9 on the other allele [69].  Typically, children with podocin mutations progress 
rapidly to ESRF. 
 
1.3.4 WT1 
WT1 encodes Wilms tumour 1, a nuclear transcription factor which controls 
development of the kidney and urogenital tract and affects expression of several 
genes including NPHS1 [78, 79].  Unlike NPHS1 and NPHS2, WT1 mutations are 
inherited in an autosomal dominant fashion (mostly in exons 8 or 9 of WT1) and 
are often associated with syndromic presentation with extra-renal features.  
Denys-Drash syndrome (DDS) has features of infantile-onset SRNS with DMS on 
renal biopsy, ambiguous genitalia and Wilms tumour [80].  Frasier syndrome (FS) 
is notable for the association of SRNS with male pseudohermaphroditism.  These 
features highlight the importance of confirmation of karyotype (XX or XY) in 
patients with suspected or confirmed WT1 mutations.  In addition to the pattern of 
extra-renal features, the pattern of kidney disease (age of onset, progression to 
ESRF) appears to be associated with the specific location of the mutation within 
the gene (exons, introns, splice sites) [80, 81].  Although many patients with WT1 
mutations progress to ESRF, there have been reports of a small number of patients 
responding to intensified immunosuppressive (IIS) therapy with ciclosporin and 
IV steroids possibly via direct effects on podocytes rather than immune system 
modulation [82].  The non-immunologic mechanisms of action of 




1.3.5 Collagen genes 
As discussed earlier, collagen IV is a major structural component of the GBM and 
mutations in COL4A3, COL4A4 and COL4A5 cause classical Alport syndrome, 
with clinical features of haematuria and sensorineural hearing loss together with 
typical EM findings on renal biopsy of diffuse GBM lamellation.  However, 
several patients have been reported presenting with FSGS and no extra-renal 
features who are found to have probably pathogenic variants in collagen genes on 
subsequent testing [83, 84]. 
 
1.3.6 Other genes 
Over 50 genes have been identified which are thought to cause inherited forms of 
SRNS and are summarised in Table 1.4 and discussed further in several recent 
reviews [58, 85].    Within the group of patients with genetic SRNS there is great 
heterogeneity in terms of age of disease onset, potential response to medication 
and progression to ESRF.  Knowledge of which is the causative gene, and the 
specific mutation within that gene, will assist with stratification of patients as 
discussed further in Chapters 2 and 4.   
Large national and international studies have been completed in recent 
years which have undertaken parallel testing of between 8 and 28 SRNS/FSGS-
associated genes in almost 4000 patients (Table 1.5).  Each has identified a 
genetic cause in around 30% of the patients tested.  Although there are likely to be 
more pathogenic genes to be identified and some patients’ disease may be caused 
by combinatorial effects of two or more genes [68, 86], our current understanding 
is that the majority of patients with SRNS have a non-genetic aetiology. 
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 Chapter 2 will explore genotype-phenotype associations in a UK cohort of 
187 patients all of whom had genetic analysis by whole exome sequencing.  The 
real-world utility of clinical testing using a next-generation-sequencing gene panel 
will be examined in Chapter 4. 
46 
 
Table 1.4: Genes associated with SRNS 




NPHS1 Nephrin AR CNS / SRNS Kestilä 1998 [55] 
NPHS2 Podocin AR CNS / SRNS Boute 2000 [56] 
CD2AP CD2-associated protein AD/AR FSGS / SRNS Löwik 2007 [87] 
PLCE  Phospholipase Cε1 AR CNS / SRNS Hinkes 2006 [60] 
PTPRO 
Protein tyrosine phosphatase, 
receptor type O 
AR NS Ozaltin 2011 [88] 
TRPC6 
Transient receptor potential 
channel 6 
AD Familial and sporadic SRNS (mainly adults) Winn 2005 [62] 
MAGI-2 
Membrane associated 
guanylate kinase, WW and 
PDZ domain containing 2 
AR CNS/SRNS Bierzynska 2017 [89] 
CRB2 
Crumbs 2, cell polarity 
complex component 
AR FSGS/SRNS Ebarasi 2015 [90] 
Nuclear proteins 
WT1 Wilms’ tumour 1 AD 
Sporadic SRNS (children—may be associated with abnormal 
genitalia); Denys-Drash and Frasier syndrome 
Pelletier 1991 [65] 
SMARCAL1 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily A-Like 1 
AR Schimke immuno-osseous dysplasia Boerkoel 2002 [91] 
LMX1B 
Lim homeobox transcription 
factor 1β 
AD 
Nail patella syndrome; also, FSGS without extrarenal 
involvement 
Dreyer 1998 [64] 
E2F3 E2F transcription factor 3 AD FSGS + mental retardation (whole gene deletion) Izu 2011 [92] 
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Nuclear RNA export factor 5 X-linked 
recessive 
NS, cosegregating with heart block Esposito 2013 [93] 
PAX2 Paired Box 2 AR FSGS, CAKUT Barua 2014 [94] 
WDR73 WD repeat domain 73 AR Galloway-Mowat syndrome, microcephaly, SRNS Colin 2014 [95] 
NUP93 Nucleoporin 93 AR FSGS/SRNS, haematuria Braun 2016 [96] 
NUP107 Nucleoporin 107 AR FSGS/SRNS Miyake 2015 [97] 
NUP205 Nucleoporin 205 AR FSGS/SRNS Braun 2016 [96] 
XPO5 Exportin 5 AR FSGS/SRNS Braun 2016 [96] 
Actin cytoskeleton and Signalling 
ACTN4  α-Actinin-4 AD Familial and sporadic SRNS (usually adult) Kaplan 2000 [63] 
INF2 Inverted formin-2 AD 
Familial and sporadic SRNS, FSGS-associated Charcot-Marie-
Tooth disease 
Brown 2010 [61] 
MYH9 
Myosin heavy chain 9 AD, 
association 
MYH9-related disease; Epstein and Fechtner syndromes Kopp 2008 [98] 
SYNPO Synaptopodin Uncertain Adult-onset NS 
Asanuma 2005, Huber 
2006 [99, 100] 
APOL1 Apolipoprotein L1 Risk factor 
Increased susceptibility to FSGS in African Americans and those 
of African ancestry 
Genovese 2010 [101] 
MYO1E 
Myosin 1E 
AR Familial SRNS 
Mele 2011, Sanna-









AR CNS Gupta 2013 [105] 
MED28 Mediator complex subunit 28 AR NS Fang 2012 [106] 









Epithelial membrane protein 
2 
AR SSNS, SRNS Gee 2014 [108] 
CUBN Cubilin AR NS, Megaloblastic anaemia Ovunc 2011 [109] 




AR NS, FSGS, nephronophthisis, tubulointerstitial lesions 










AR CNS, hypogonadism, adrenal calcification 
Janecke 2017, Lovric 
2017 [113, 114] 
FAT1 FAT atypical cadherin 1 AR NS, haematuria, tubular ectasia, intellectual impairment Gee 2016 [115] 
CTLA4 
Cytotoxic T-lymphocyte 
associated protein 4 
Risk factor Sporadic NS, MCD Spink 2013 [116] 
Mitochondrial 
MTTL1 
Mitochondrial tRNA leucine 
1 
Mitochondrial SRNS / FSGS, MELAS, hearing loss, diabetes mellitus Löwik 2005 [117] 
COQ2 Coenzyme Q2 AR Mitochondrial disease, encephalopathy / isolated nephropathy 
Diomedi-Camassei 
2007 [118] 
COQ6 Coenzyme Q6 AR NS +/- sensorineural deafness; DMS Heeringa 2011 [119] 
COQ7 Coenzyme Q7, hydroxylase AR Mitochondrial disease, encephalopathy Freyer 2015 [120] 
COQ9 Coenzyme Q9 AR Mitochondrial disease, encephalopathy, renal tubulopathy Duncan 2009 [121] 
ZMPSTE24 Zinc metallopeptidase STE24 AR Mandibuloacral dysplasia with FSGS Agarwal 2006 [122] 
PDSS2 
Decaprenyl diphosphate 
synthase subunit 2 
AR Leigh syndrome López 2006 [123] 
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aarF domain containing 
kinase 4 
AR SRNS / FSGS Ashraf 2013 [124] 
CYP11B2 
Cytochrome P450 family 11 
subfamily B member 2 
Association 
Corticosterone methyloxidase deficiency, Familial 
hyperaldosteronism 
Bantis 2011 [125] 
Glomerular basement membrane 
LAMB2 Laminin subunit beta 2 AR Pierson syndrome Zenker 2004 [12] 
ITGA3 Integrin subunit alpha 3 AR Interstitial lung disease, CNS, and mild epidermolysis bullosa Has 2012 [126] 
ITGB4 Integrin subunit beta 4 AR  Epidermolysis bullosa and pyloric atresia, FSGS Kambham 2000 [127] 
GPC5 Glypican 5 Risk factor Increased risk of NS Okamoto 2011 [128] 
COL4A3 
Collagen type IV alpha 3 
chain 
AR Alport syndrome 
Malone 2014, Gast 
2016 [83, 129] 
COL4A4 
Collagen type IV alpha 4 
chain 
AR Alport syndrome 
Malone 2014, Gast 
2016 [83, 129] 
COL4A5 
Collagen type IV alpha 5 
chain 




NS, pretibial bullous skin lesions, neurosensory deafness, 
bilateral lacrimal duct stenosis, nail dystrophy, and thalassemia 
minor 







AR Congenital disorder of glycosylation Park 2016 [131] 
PMM2 Phosphomannomutase 2 AR Congenital disorder of glycosylation 
Van der Knapp 1996 
[132] 
Lysosomal 
SCARB2 / Lysosome membrane protein AR Action myoclonus-renal failure syndrome +/- hearing loss Berkovic 2008 [133] 
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ALMS1, centrosome and 
basal body associated protein 
AR 
Alström syndrome, retinitis pigmentosa, sensorineural hearing 
loss 
Marshall 2015 [134] 
Other 
DGKE Diacylglycerol kinase ε AR Atypical HUS, SRNS 
Bierzynska 2017, 






Lowe syndrome, Dent disease type 2 De Mutiis 2015 [136] 
 
Legend: AD, autosomal dominant; AR, autosomal recessive; CAKUT, congenital abnormalities of the kidney and urinary tract; CNS, congenital 
nephrotic syndrome; DMS, diffuse mesangial sclerosis;  FSGS, focal segmental glomerulosclerosis; HUS, haemolytic uremic syndrome; Kb, 
kilobases; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; NS, nephrotic syndrome; SDNS, steroid-




Table 1.5: National and international studies genotyping patients with SRNS 




















SRNS/FSGS SRNS/FSGS SRNS CNS, SRNS, 
persistent 
proteinuria 
CNS, SRNS SRNS/FSGS SRNS/FSGS, 
persistent 
proteinuria 





Germany Japan China 









26 genes 28 genes 





1655 231  
(219 families) 
24 110 (SRNS), 
10 
(proteinuria) 
Male (%)  n/a 16 (44.4) n/a 1067 (52.9) n/a 106 (45.9) 12 (50.0) 67 (55.8) 
Age at onset in 
years (%) 
0-0.25 15 (12.0) 5 (13.9) 5 (20.0) 253 families 
(14.2) 
98 (6.3) 62 (26.8) 1 (4.2) 12 (10.0) 
 0.25-1 8 (6.4) 1 (2.8) 4m-5y: 9 
(36.0) 
n/a 106 (6.9) n/a 0 (0) 18 (15.0) 
 1-12 37 (29.6) 26 (72.2) 6-12y: 3 
(12.0) 
n/a 1136 (73.6) n/a 23 (95.8) 88 (73.3) 
 13-18 9 (7.2) 4 (11.1) 0 (0) n/a 204 (13.2) n/a 0 (0) 2 (1.7) 






  Median 3.4y; 
range 0-63y 
Unknown: 111 Median 5.1y 
(IQR 2.7-8.6) 
in NG. Median 
3.5y (IQR 1.3-


























 39/125 (31.2) 10/36 (27.8) 11/25 (44.0) n/a 25.6% n/a 6/24 (25.0) 19/108 (17.6) 
Consanguinity 
/ number with 
data available 
(%) 
 7/125 (5.6) n/a 4 (16.0) 372 families 
(20.9)  





White n/a 22 (73.3) n/a n/a 1151 (90.3) n/a 0 (0) 0 (0) 




n/a 0 (0) n/a n/a 3 (0.2) n/a 0 (0) 0 (0) 
 Pakistani n/a 2 (6.7) n/a n/a  n/a 0 (0) 0 (0) 
 Hispanic n/a 0 (0) n/a n/a 93 (7.3) n/a 0 (0) 0 (0) 





n/a 0 (0) n/a n/a 2 (0.2) n/a 0 (0) 0 (0) 
 Chinese n/a 0 (0) n/a n/a  n/a 0 (0) 120 (100) 
 Mixed n/a 1 (3.3) n/a n/a 11 (0.9) n/a 0 (0) 0 (0) 
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 No ethnicity 
data 
available 
n/a 6 n/a n/a 381 n/a 0 0 
Biopsy 
findings (% of 
patients where 
data available) 
FSGS 108 (93.1) n/a n/a n/a 752 (56.0) 119 (58.9) 22 (100.0) 42 (53.2) 




0 (0) n/a n/a n/a 166 (12.4) 0 (0) 0 (0) 7 (8.9) 
DMS 3 (2.6) n/a n/a n/a 39 (2.9) 26 (12.9) 0 (0) 0 (0) 
Finnish type 3 (2.6) n/a n/a n/a 8 (0.6) 8 (4.0) 0 (0) 0 (0) 






9 n/a * * 287 29 0 41 
ESRD (% of 
patients where 
data available) 
 69 (55.2) 12 (34.3) n/a n/a 25.9% 125 (54.1) 16 (66.7) 16 (15.7) 
Age at ESRD 
in years (Mean 
± SD; Median; 
Range) 
 27.3 ± 19.1; 
24.0; 0.2-61.0 
7.0 ± 3.9; 6.3; 
2.0-13.5 










































131 (56.7) 8 (33.3) 34 (28.3) 
NPHS1  15 (13.6) 5 (13.9) 4 (16.0) 131 (7.4) 138/1088 
(12.7) 
35 0 (0) 7 (5.8) 
NPHS2  13 (11.8) 3 (8.3) 2 (8.0) 177 (9.9) 41/208 (19.7) 43 1 (4.2) 4 (3.3) 
WT1  5 (4.5) 0 (0) 1 (4.0) 85 (4.8) 48/902 (5.3) 33 2 (8.3) 7 (5.8) 
PLCE1  0 (0) 1 (2.8) 0 (0) 37 (2.1) 10/75 (13.3) 2 0 (0) 1 (0.8) 
LAMB2  - 0 (0) 0 (0) 20 (1.1) 5/84 (6.0) 3 1 (4.2) 1 (0.8) 
TRPC6  3 (2.7) 0 (0) 1 (4.0) 9 (0.5) 1/96 (1.0) 5 1 (4.2) 1 (0.8) 
INF2  1 (0.9) 0 (0) 1 (4.0) 9 (0.5) 4/112 (3.6) 3 1 (4.2) 0 (0) 
SMARCAL1  - 0 (0) 0 (0) 16 (0.9) 12/68 (17.6) - 0 (0) 1 (0.8) 
COQ6  - - 0 (0) 8 (0.4) 3/30 (10.0) 0 0 (0) 0 (0) 
IGTA3  - - 0 (0) 5 (0.3) - - - 0 (0) 
MYO1E  - 0 (0) 0 (0) 5 (0.3) 2/48 (4.2) - 0 (0) 0 (0) 
CUBN  - - 0 (0) 5 (0.3) - - - 2 (1.7) 
COQ2  - 1 (2.8) 0 (0) 4 (0.2) 1/56 (1.8) - 0 (0) 0 (0) 
LMX1B  - 0 (0) 0 (0) 4 (0.2) 1/27 (3.7) 2 0 (0) 2 (1.7) 
ADCK4  - - - 3 (0.2) 1/27 (3.7) - - 8 (6.7) 
DGKE1  - - - 2 (0.1) - - - 0 (0) 
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PDSS2  - 0 (0) - 2 (0.1) 0/56 (0) - 0 (0) 0 (0) 
ARHGAP24  - - 0 (0) 1 (0.06) - - 0 (0) 0 (0) 
ARHGDIA  - - - 1 (0.06) - 1 - 0 (0) 
CFH  - - 0 (0) 1 (0.06) - - - 0 (0) 
ITGB4  - - - 1 (0.06) - - 0 (0) 0 (0) 
PTPRO  - 0 (0) 0 (0) 0 (0) 6/45 (13.3) - 0 (0) 0 (0) 
ACTN4  0 (0) 0 (0) 0 (0) 0 (0) 0/59 (0) 1 0 (0) 0 (0) 
CD2AP  0 (0) 0 (0) 0 (0) 0 (0) 0/56 (0) 0 2 (8.3) 0 (0) 
COL4A3  - 0 (0) 0 (0) - - - - - 
COL4A4  - 1 (2.8) 0 (0) - - - - - 
COL4A5  - 0 (0) 0 (0) - - - - - 





Legend: G, genetic patients; n/a, not available; NG, non-genetic patients; –, gene not tested in the cohort 
* Biopsy data only available for patients found to have genetic disease 
† Some of the cases reported in Büscher et al. (2016) were also included in Trautmann et al. (2015).  Data from Büscher et al. (2010) [141] are 
not included in the above table due to the overlap of patients with the more recent study by the same authors. 





1.4 The Circulating Factor Hypothesis 
Based on recent large cohort studies (Table 1.5), approximately 70% of patients 
with SRNS have non-genetic disease.  In this group, the prevailing hypothesis has 
been that the disease is driven by (an) immune-mediated circulating factor(s).   
 
1.4.1 Evidence suggesting existence of circulating factors 
The potential of circulating factors as causative agents in some cases of SRNS has 
been considered since the 1970s.  There are several strands of evidence which 
support the hypothesis:  
1. In 30-50% of cases, the observation of recurrence of proteinuria within 
minutes to hours after transplantation of a healthy donor kidney into a 
patient with SRNS accompanied by typical biopsy findings of podocyte 
effacement [142].   
2. A case of rapid disease recurrence and histological changes in a kidney 
transplanted into a patient with SRNS but recovery of normal function and 
histology when removed and re-transplanted into a patient with CKD 
secondary to diabetes mellitus [143].   
3. The case of a neonate born to a mother with NS/FSGS who had nephrotic 
proteinuria at birth but which resolved over subsequent days [144].  This 
would suggest the factor(s) can cross the placenta and is not IgG which 
persists in an infant’s circulation for several months. 
4. The effectiveness of plasmapheresis in management of post-transplant 
recurrence, thought to be by removal of a putative permeability factor(s) 
[142].   
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5. The reduced risk of post-transplant recurrence by repeated plasmapheresis 
before transplantation [145]. 
6. Increased permeability to albumin in isolated rat glomeruli perfused with 
plasma from patients with FSGS but not with control plasma [146]. 
 
1.4.2 Role of the immune system 
Shalhoub originally proposed in 1974 that MCD was the result of T cell 
dysfunction producing a lymphocyte-derived permeability factor [147].  This was 
based on several observations: 
• Absence of immune complexes in glomeruli 
• Association of MCD with Hodgkin’s disease, in which adaptive immunity 
is impaired 
• Remission following measles infection, which modifies cell-mediated 
immunity 
• Rapid response to corticosteroids. 
 
The potential role of the immune system in the pathogenesis of SRNS has 
been supported by the fact that patients respond to various types of 
immunosuppressive treatment [147, 148].  Those with secondary SR, by 
definition, initially responded to corticosteroids and those with either primary or 
secondary SR can show resolution of proteinuria with drugs such as ciclosporin or 
tacrolimus.  However, more recent research has highlighted that steroids, 
ciclosporin and tacrolimus can have a direct effect on podocytes and the actin 
cytoskeleton [149, 150]. 
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If the immune system is involved in SRNS pathogenesis, it would seem to 
be by secretion of soluble factors and not by direct cellular infiltration of the 
glomerulus or antibody deposition at the filtration barrier.  This is evidenced by 
the absence of neutrophils/lymphocytes and immune complex deposits on light 
microscopy and immunofluorescence of renal biopsies in MCD and FSGS [36, 
45].  Early studies on lymphocytes from patients with MCD stimulated with 
concanavalin A (which acts as a T cell mitogen) showed that the supernatant 
contained a factor which modified vascular permeability [151].  Several T 
lymphocyte-derived cytokines, such as interleukin-13 (IL-13) and tumour necrosis 
factor alpha (TNFα) have been suggested as circulating factors in NS and are 
discussed below (Section 1.4.3). 
Mechanisms exist by which podocytes may interact directly with the 
immune system in pathogenesis of NS.  In order for T lymphocytes to be 
activated, they generally require antigen to be processed and presented by antigen-
presenting cells (APCs) in the major histocompatibility complex (MHC) 
alongside co-stimulation.  This co-stimulation is provided by direct cell-cell 
signalling via surface proteins.  CD80 and CD86 (also known as B7.1 and B7.2) 
and CD40 on APCs interact with CD28 and CD40 ligand (CD40L) respectively 
on T cells leading to their activation [152].  Interaction of CD80 and CD86 with 
CTLA4 (cytotoxic T-lymphocyte-associated protein 4) on T cells, in contrast, 
provides an inhibitory signal.  Several studies, in various disease models including 
MCD, have shown increased podocyte expression of CD80, increased urinary 
excretion of CD80 and proteinuria [153].  A report has suggested that podocytes 
may act as professional APC and have a more direct role in immune system 
function than was previously thought [154].  Further discussion of the podocyte-
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immune system interaction is beyond the scope of this project but has been 
recently reviewed [152, 153, 155]. 
 
1.4.3 Putative circulating factors 
Early studies separated FSGS plasma using fractionation columns, galactose 
affinity chromatography and mass spectrometry and tested for permeability-
inducing activity on rat glomeruli [146].  Savin et al. concluded that the 
circulating factor has a size of < 30 kDa and identified a potential circulating 
factor as cardiotrophin-like cytokine factor-1 (CLCF-1).  A second candidate 
intensively investigated by Reiser and colleagues is soluble urokinase 
plasminogen activator receptor (suPAR) [156].  Several studies have proposed 
that the factor is a protease, including activated hemopexin [157, 158].  Evidence 





Table 1.6: Putative causative circulating factors in SRNS 
Putative 
circulating factor 
In vitro evidence  In vivo evidence Human / Clinical evidence Concerns / evidence against 
suPAR  Activates podocyte αvβ3-integrin → 
cytoskeletal reorganisation [156] 
Suppresses WT1 → reduced 
nephrin expression [159] 
Administration causes 
albuminuria in uPAR-/- 
mice [156]  
High plasma concentrations in 
patients with FSGS [156] 
High plasma concentrations in 
post-transplant recurrence [156] 
Non-specific: raised levels in primary 
FSGS and other proteinuric diseases [160, 
161] 
Inversely correlated to eGFR in various 
disease groups [162] 
Podocyte αvβ3-integrin stimulation also 
seen in diabetic kidney disease [163] 
Non-standard mouse model: 
administration does not cause albuminuria 
in WT mice [164] 
Different suPAR isoforms not detected by 
current ELISA kits [165] 
CLCF-1 Increases permeability to albumin 
in isolated rat glomeruli, blocked by 
anti-CLCF-1 Ab [166] 
Decreases nephrin expression and 
disrupts podocyte cytoskeleton 
[166] 
Inhibitors of Jak/Stat3 block CLCF-
1 and FSGS sera effects [167] 
Binds to galactose columns; 
galactose blocks increase in 




and proteinuria in mice 
[167] 
Levels in FSGS patients > 100-
fold higher than controls [166] 
 
Difficult to measure – not yet tested in 




Blocks increase in permeability to 
albumin in isolated rat glomeruli 
caused by FSGS sera [168] 
  Conflicting results in clinical studies: 3/7 
patients in clinical study of galactose had 
50% reduction in proteinuria with stable 









suPAR → proteinuria in 
WT mice but not CD40-/- 
mice or WT mice given 
CD40-blocking Ab [171] 
Identified as strongest predictor 
of post-transplant recurrence in 
serum autoantibody panel [171] 
Injection into WT mice did not cause 
proteinuria (only with suPAR) 
Size ~ 150kDa (larger than 30-50kDa 
identified as active fraction of FSGS sera) 
[172] 
Hemopexin Causes nephrin-dependent actin 
cytoskeleton reorganisation in 
cultured human podocytes [173] 
Induces reversible 
proteinuria in rats [174] 
Increased hemopexin activity in 
plasma from MCD relapse 
patients vs MCD remission 
[158] 
 
TNFα Blocking TNFα pathway reverses 
activation of podocyte β3-integrin 
caused by plasma from patients 
with FSGS recurrence [175] 
Infusion → albuminuria in 
rats [176] 
Increase in PBMC mRNA 
expression in patients with 
MCD relapse [177] 
Remission of proteinuria after 
infliximab or adalimumab (anti-
TNF mAb) treatment in some 
patients [178, 179] 
Lack of consistent effect of anti-TNFs 
Interleukin-13  Over-expression in rats → 
MCD-like disease and 
nephrotic proteinuria [180] 
Increased CD4+ and CD8+ T 
lymphocyte mRNA expression 
in patients with MCD relapse 
[181] 
 
Other conditions associated with 
increased IL-13 (asthma, psoriasis, 
allergic dermatitis) not linked to 
proteinuria [153] 
 
Ab, antibody; CLCF-1, cardiotropin-like cytokine factor-1; FSGS, focal segmental glomerulosclerosis; Jak, Janus kinase; mAb, monoclonal 
antibody; PBMC, peripheral blood mononuclear cell; Stat, signal transducer and activator of transcription; suPAR, soluble urokinase type 
plasminogen activator receptor; TNFα, tumour necrosis factor alpha; WT, wild type 




Although research to identify the putative circulating factor(s) has been 
undertaken for decades and is ongoing, it remains elusive [152, 182].  It may be 
the presence of a factor(s) which causes recurrent podocyte effacement and 
proteinuria post-transplant but also possible is the absence of a factor(s) which 
normally prevent this process.  The absence of a protective factor could explain 
the observations discussed previously in Section 1.4.1 only if there was a 
permeability factor(s) which could be regulated by it.  Variation in the 
methodology used in different studies to define the characteristics of putative 
circulating factors may be one reason for some lack of cross-validation of results 
between research groups.  Furthermore, patients included in such studies may not 
be homogeneous and are likely receiving different medications [186].  Recently, 
the following criteria have been proposed to establish the causality of a putative 
circulating factor (quoted from Maas et al. 2014) [185]: 
• The permeability factor must have biological effects in vitro and in vivo, 
and be confirmed in validation studies 
• Identification of the permeability factor in well-phenotyped patients but 
not in appropriate controls and validation in independent patient cohorts 
• Temporal relation of the permeability factor with disease activity and 
remission 
• Specific removal or inhibition of the permeability factor in vivo blocks the 
biologic effect 
Much of the evidence for individual circulating factors (suPAR, CLCF-1, 
CD40 autoantibodies) derives from the work of single research groups and, thus 
far, none consistently fulfils all criteria proposed by Maas et al.  Given the 
heterogeneity of NS/SRNS, it may be that there is not a single permeability factor 
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but different factors causing disease in different non-genetic patients.  Research is 
ongoing with the aim of providing better understanding of disease pathogenesis.  
It is hoped that this will lead to improvement in targeted treatments and allow 
patient stratification by development of novel biomarkers as discussed in the next 
sections. 
 
1.4.4 Pathophysiology: VASP phosphorylation and podocyte 
cytoskeleton re-organisation 
If circulating factors are a cause of NS (MCD or FSGS), based on histological 
changes discussed earlier, the main effects appear to be on podocyte structure and, 
in particular, the actin cytoskeleton.  Mechanisms by which the factors may have 
this effect have been studied by several groups including at the University of 
Bristol.  Using a conditionally-immortalised human podocyte cell line (ci-hPod) 
[187], Harris et al. showed that vasodilator stimulated phosphoprotein (VASP) is 
phosphorylated consistently and cell migration increased in response to treatment 
with FSGS relapse plasma compared with the plasma from the same patients in 
remission [188].  The effect appeared specific, not being observed when using 
plasma exchange samples from patients with other non-kidney diseases.  The 
effect was blocked in the presence of inhibitors of plasma proteases.  Protease 
activated receptors (PARs), which respond to proteases, were previously known to 
activate the MAPK and NFκB pathways and signal to the actin cytoskeleton.  The 
group demonstrated that podocytes express PAR1-3 and treatment of ci-hPod with 
synthetic agonists of PAR1 and PAR2 led to VASP phosphorylation [188].  
Knockdown of PAR1 but not PAR2 significantly reduced the effect of relapse 
plasma on VASP phosphorylation.    Podocytes with a mutated form of podocin 
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(R138Q which is incorrectly localised) were also treated with FSGS relapse 
plasma but this did not lead to VASP phosphorylation [188].  This suggests that 
signalling via PAR-1 to VASP is dependent on correct localisation of podocin.  
The proposed mechanism by which a putative circulating protease leads to 













1.5 Treatments for Nephrotic Syndrome 
The management of nephrotic syndrome is multi-faceted: acutely involving the 
control of blood pressure, fluid balance and infection; chronically, when 
associated with CKD, involving renal replacement therapy, bone disease and 
anaemia.   These aspects will not be discussed further and have recently been 
reviewed [189].  The main focus here is on disease-modifying treatments 




Podocyte disruption and Proteinuria 
Circulating factor(s)  
? Proteases 
PAR1 Podocin 
Figure 1.5: Potential mechanism by which circulating proteases lead to 
podocyte disruption and proteinuria 
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The first-line treatment of nephrotic syndrome is steroids (glucocorticoids) 
namely prednisolone/prednisone or methylprednisolone.  Overall, 80-90% of 
children respond within the first 4 weeks of treatment.  In children who do not 
respond, and therefore classified as having SRNS, the KDIGO group published 
treatment recommendations in 2012 which are summarised in Table 1.7 [34]. 
 
Table 1.7: Recommendations for treatment of SRNS in children 
Recommendation / Suggestions Grade of 
evidence 
1. Use a CNI as initial therapy for children with SRNS 1B 
1.1 Continue CNI therapy for a minimum of 6 months and then stop if a 
partial or complete remission of proteinuria is not achieved 
2C 
1.2 Continue CNI therapy for a minimum of 12 months when at least a 
partial remission is achieved by 6 months 
2C 
1.3 Combine low-dose corticosteroid therapy with CNI 2D 
2.  Treat children with SRNS with ACEi or ARB 1B 
3. In children who fail to achieve complete or partial remission on CNIs 
and steroids: 
 
3.1 Consider high-dose corticosteroids, MMF or a combination of these 2D 
3.2 Suggest not giving cyclophosphamide 2B 
4.  In patients with relapse of NS after complete remission, restart therapy 
using any of the following: 
2C 
Oral corticosteroids 2D 
Return to previous successful immunosuppressive agent 2D 
Alternative immunosuppressive agent to minimise potential cumulative 
toxicity 
2D 
Legend: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.  
Grade of evidence: 1, “we recommend”; 2, “we suggest”; B, moderate quality of 
evidence; C, low quality of evidence; D, very low quality of evidence [190]. 
 
One study has compared the CNIs ciclosporin and tacrolimus directly 
which showed no significant difference in the control of proteinuria (80% vs 
85.7% respectively) and similar rates of side effects including hypertension, 
nephrotoxicity and diabetes mellitus [191].  Gum hyperplasia and hypertrichosis 
were more frequent in patients on ciclosporin.  Proteinuria generally decreased 
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within 4 weeks with median times to remission (either complete or partial) in the 
RCT being 8 and 12 weeks for tacrolimus and ciclosporin respectively. 
A Cochrane review from 2016 provides the most comprehensive analysis 
of treatments available for SRNS [192].  Studies included were RCTs of children 
3 months to 18 years with SRNS comparing immunosuppressive or non-
immunosuppressive treatments with each other, with placebo or corticosteroids.  
Nineteen, mostly small, RCTs with 773 evaluable children were included and of 
these 9 were published before 2000.  Overall, CNIs were associated with a greater 
rate of complete and partial remission compared with no treatment/placebo or 
cyclophosphamide.  One study (41 children) found no significant difference in 
complete remission between ciclosporin and tacrolimus.  The use of ACEi was 
found to reduce proteinuria significantly in two studies.  One of the 19 studies in 
the Cochrane review excluded patients if mutations had been detected in NPHS2 
or WT1 [193], one excluded patients with hereditary or syndromic disease [194], 
and in one study all patients had genetic testing for NPHS2  and WT1 exons 8 and 
9 but this was not used this to determine recruitment [191].   Although the 
criterion of being over 3 months likely excluded some patients with genetic 
disease, it is probable that most studies included a mixture of patients with genetic 
and non-genetic SRNS. 
 The failure of many therapeutic studies in FSGS/SRNS to phenotype 
patients adequately and only include a relatively homogeneous group, or at least 
stratify patients with adequate numbers in each subgroup to allow analysis, has 
been identified as a reason for inconclusive outcomes [195, 196].  The use of 
multiple parameters, such as genotyping, pattern of steroid resistance 
(primary/presumed vs secondary steroid resistance) and age of disease onset to 
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stratify patients with SRNS are examined in Chapters 2 and 3 and these are likely 
to be important in future clinical trials. 
As illustrated by the levels of evidence in Table 1.7 (mostly grade C or D), 
other than initial treatment with CNIs and ACEi/ARBs, subsequent management 
of SRNS has not be widely subjected to randomised controlled trials.  Most 
evidence derives from smaller, non-randomised cohort studies which, until 
recently, did not have comprehensive genotyping data to include in the analysis.  
The range of treatments used for NS together with related evidence is summarised 





Table 1.8: Disease-modifying treatments in SRNS 
Medication Mechanism of 
action 
Indication Typical dose and route Evidence / Clinical trials Key 
references 





New presentation of 
NS 
Relapses 
60mg/m2 or 2mg/kg daily 
for 4-6w then 40mg/m2 or 






Enalapril 0.2-0.6mg/kg/d Dose-related reduction in 
proteinuria (52% with enalapril 
0.6mg/kg). 
Fosinopril with prednisolone 
significantly reduces proteinuria 






Losartan 0.7mg/kg/d RCT in adults with FSGS: 
significant decrease in proteinuria 
and increase in plasma albumin at 6 
and 12m in losartan vs untreated 
control group  
[199] 





2-3mg/kg bd po Three RCTs in SRNS: n=49. CR 
31%, PR 38% within 6m vs 0-16% 
in control groups 
[34] 
Tacrolimus Calcineurin inhibitor; 
blocks T-cell 
proliferation 
SRNS 0.1-0.2mg/kg/d po in 2 
divided doses 
Tacrolimus vs Ciclosporin: no 











600mg/m2 bd po CR or PR: 65% in SSNS, 67% in 
SRNS 
CR or PR: 33% in MMF + oral 
dexamethasone arm of RCT (no 




Cyclophosphamide Cytotoxic alkylating 




Not recommended in 
SRNS 
2mg/kg/d po for 12w 
500mg/m2 IV monthly for 
6m 
Relapsing SSNS: decreased 
incidence of relapse at 6-12m vs 
prednisolone alone. 
FSGS: No evidence of benefit over 
pred alone. CR or PR: 50% vs 57% 
[202, 203] 
Levamisole Alters balance 
between type I and II 
cytokines. Direct 






2.5mg/kg po alternate days Significantly fewer relapses vs 
placebo, pred or no treatment 
[203] 
Azathioprine Purine nucleoside 
analogue, inhibits 
DNA replication 
Not recommended in 
SRNS 
 RCT in SRNS: No difference in CR 
or PR for azathioprine + pred vs 






Not recommended in 
SRNS 
375mg/m2 IV, 2 doses 2 
weeks apart 
SDNS & FR-SSNS: RCT rituximab 
vs placebo showed significantly 
longer relapse-free period (267d vs 
101d)  
SRNS: RCT showed no additional 
benefit of rituximab + ciclosporin + 
pred vs ciclosporin + pred.  Smaller 
non-controlled studies suggested 
some benefit in SRNS.  
[193, 206, 
207] 





300mg/1.73m2 IV, then 
2000mg/1.73m2 IV 6 
weekly for 5 doses 





Abatacept CTLA4-Ig fully 
human fusion 
protein, inhibits T 
cell co-stimulation 
via CD80 
Not recommended in 
SRNS 
10mg/kg IV repeated 2 
weeks later 
CR or PR in 5 patients with FSGS 
and CD80+ podocytes on renal 
biopsy. 
No improvement in 5 patients with 
post-transplant FSGS recurrence 
[210, 211] 
Adalimumab Anti-TNF, Fully 
human mAb 
Not recommended in 
SRNS 
24mg/m2 sc every 2 weeks More than 50% reduction in 
proteinuria in 4/10 patients with 
SRNS in phase I study 
RCT: no patients in adalimumab 
arm (n=7) reached primary outcome 
[169, 179] 
Galactose Inhibits putative 
circulating factor 
Possible adjunct in 
SRNS 
0.2g/kg bd Decrease in circulating factor 
activity but no effect on proteinuria 
[170] 
Summarised from [34, 192, 203, 212]. Legend: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; bd, twice 
daily; CR, complete remission; d, days; IV, intravenous; m, month; mAb, monoclonal antibody; MMF, mycophenolate mofetil; po, by mouth; 




1.5.1 Non-immunologic mechanisms of immunosuppressants in 
SRNS 
Many of the treatments used for SRNS are immunosuppressants which accords 
with our understanding that non-genetic disease involves an immune-mediated 
circulating factor.  With greater understanding of the pathogenesis of NS, several 
drugs are now thought to have direct actions on podocytes [213].  The first-line 
treatment, glucocorticoids, have widespread effects on the immune system but it 
has been recognised that they can stabilise the actin cytoskeleton and promote 
survival in podocytes [149, 214].  
Ciclosporin does have an immunosuppressive effect via inhibiting the 
activity of calcineurin and so nuclear factor of activated T cells (NFAT).  This 
prevents transcription of IL-2 and other cytokines and reduces activation of T 
cells.  This was thought to be its primary action in SRNS.  However, more recent 
studies have suggested a direct effect on the podocyte cytoskeleton by blocking 
the calcineurin-dependent dephosphorylation of synaptopodin [215].  If one 
mechanism of action is directly on stabilising the actin cytoskeleton, this may 
explain why ciclosporin does appear to have some effect in genetic forms of 
FSGS which is presumed to be non-immune mediated.  In one study, ciclosporin 
led to remission in 78% of patients with non-genetic disease compared with 19% 
of those with genetic disease [138]. 
 TNF inhibitors, including infliximab, adalimumab and etanercept, have 
been tried in patients with recurrent FSGS with some limited effect [178, 179].  In 
vitro studies using ci-hPod have shown that the cytoskeletal disruption caused by 
exposure to plasma from patients with relapsed FSGS was blocked in a dose-
dependent manner by anti-TNF antibodies [175].  By treatment of podocytes with 
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TNFα they found evidence that it activates β3 integrin which in vivo could impact 
on cell adhesion to the GBM. 
Rituximab is a chimeric mouse-human monoclonal antibody directed 
against CD20 which is expressed on B cells.  One mechanism of action is by 
reduction in B cell numbers so reducing autoantibody production and antigen 
presentation/co-stimulation of T cells.  In SRNS, another potential mechanism is 
by binding to sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) on 
podocytes which promotes stabilisation of the actin cytoskeleton [216]. 
 Abatacept is a CTLA-4 agonist and CD80 inhibitor which has its immune 
system effects by blocking the co-stimulation of T lymphocytes by CD28.  
Podocytes have been shown to express CD80 and it seems to have a role in actin 
cytoskeleton regulation.  In mouse and in vitro podocyte models, treatment with 
lipopolysaccharide (LPS) led to increased expression of CD80 in podocytes, actin 
reorganisation, effacement and nephrotic syndrome [217].  The effects were not 
seen in CD80-/- mice.  In a cohort of 5 patients with CD80-positive podocytes 
confirmed on renal biopsy, treatment with abatacept resulted in sustained 
remission of NS in all cases [210].  However, this response has not been 
confirmed in subsequent larger studies [218, 219]. 
 Taken together, knowledge of the direct effects of immunosuppressive 
drugs and improvements in understanding of SRNS pathogenesis highlight 
avenues for exploration in development of novel therapies targeting podocyte 
signalling and the actin cytoskeleton.  It will be important to test the drugs in well-





As discussed previously, post-transplant recurrence of proteinuria occurs in 30-
50% of cases.  Risk factors for this have been identified in a retrospective study 
[220]: 
• A short time period between disease onset and renal biopsy 
• Higher proteinuria at diagnosis 
• Lower serum albumin at diagnosis 
• Lower eGFR at diagnosis in relation to circulating factor disease 
 
Plasmapheresis, which is the procedure of separating plasma from blood and 
retaining it outside the body, has been used as a therapy for management of post-
transplant recurrence of NS.  In the management of SRNS, usually large volumes 
of plasma are removed (1-1.5 plasma volumes / several litres) which is replaced 
with an albumin-containing fluid: this is termed plasma exchange (PEx) [221].  
Blood is removed from a patient and, in the commonest method, subject to 
centrifugation which separates components by density.  Plasma moves closest to 
the axis of rotation while red blood cells are furthest away with white blood cells 
and platelets intermediate.  A single exchange session of 1-1.5 plasma volumes 
removes 60-70% of the circulating substances in the plasma.  This includes 
clotting factors, antibodies, medications and, presumably, the putative 
permeability factor(s) responsible for some cases of SRNS.  Complications of PEx 
are not infrequent (4-36%): some relate to central venous access, such as 
infections and pneumothorax; others due to large fluid shifts and loss of plasma 
proteins, such as hypotension and clotting problems [221]. 
 In post-transplant recurrence of SRNS, a protocol of 10 PEx sessions  over 
2 weeks followed by weekly sessions for 2 months has been described [222].  In 
74 
 
some cases PEx has been used alongside cyclophosphamide [142].  Adsorption of 
plasma proteins (mainly immunoglobulins) onto a protein A column as an 
alternative to PEx has been reported in a small number of cases but the effects on 
reducing proteinuria appeared temporary [142, 223].  A review, published in 
2010, of 12 studies reported that 49/70 (70%) children with post-transplant 
recurrence of FSGS and treated with PEx or immunoadsorption had partial or 
complete remission of proteinuria [224].  The effect was greatest with frequent 
PEx started early after recurrence.  However, the studies were generally small, 
without a comparator group and with variable long-term outcomes. 
 There are reports of use of PEx pre-transplant and immediately post-
transplant in attempts to prevent post-transplant recurrence.  A report of 10 
patients at high risk of recurrence, who had 8 peri-operative PEx sessions, found 
70% were recurrence-free at follow-up (238-1258 days) [145].  Five patients 
received kidneys from living donors with PEx starting 1 week prior to transplant, 
and the other five from deceased donors with the first PEx within 24 hours of 
transplant.  Other studies of prophylactic PEx have reported variable recurrence 
rates ranging from 0% in recipients of living donor grafts who had > 5 sessions of 
PEx pre-transplant, to 100% in deceased-donor recipients with a single pre-
transplant session [142, 225]. 
 
1.5.3 Treatment outcomes in cohort studies of SRNS 
In efforts to understand particularly the genetics of SRNS, national and 
international cohorts of patient with this rare disease have been established in 
recent years and were summarised earlier in Table 1.5.  Although the main focus 
was genotyping, in some cases treatments and responses were recorded.  These 
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data have mostly been published since the start of this research study in 2014.  In 
several reports, treatment information was provided only for some of the patients 
with a genetic cause for disease [57, 59].  However, data from a German cohort 
and from the PodoNet registry allow analysis of responses to treatment in SRNS 
patients with and without pathogenic variants [44, 138, 141, 226]. 
Responses to ciclosporin were reported in a cohort of 231 patients (< 20 
years at onset) with CNS or SRNS recruited at 6 centres in Germany.   
Complete remission (CR) was defined as:  
- proteinuria < 4 mg/m2/hour OR 
- urine protein to creatinine ratio (uPCR) < 30 mg/mmol OR 
- trace of protein on dipstick analysis AND 
- normalisation of serum albumin (> 3.5 g/dl).   
Partial remission (PR) was defined as:  
- proteinuria 4-40 mg/m2/hour AND 
- normalisation of serum albumin (> 3.5 g/dl).   
The results are shown in Table 1.9 stratified by genetic versus non-genetic cause 




Table 1.9: Response to treatment with ciclosporin in a German cohort study 
of patients with genetic and non-genetic CNS or SRNS 
 Non-genetic (n = 100) Genetic (n = 131) 
Number of 
patients 
CNS (n = 2) SRNS (n = 98) CNS (n = 60) SRNS (n = 71) 
Treated with 
ciclosporin, n / 
ninfo (%) 
0 82/96 (85.4) 9/56 (16.1) 32/68 (47.1) 
With response 
data 
- 81 9 32 
CR (%) - 49 (60.5) 1 (11.1) 1 (3.1) 
PR (%) - 15 (18.5) 0 (0) 5 (15.6) 
NR (%) - 17 (21.0) 8 (88.9) 26 (81.3) 
Legend: CR, complete remission; ninfo, number of patients with available 
information; NR, no response; PR, partial remission 
Data abstracted from: Büscher et al. (2016) [138] 
  
The use of ciclosporin was much higher in the non-genetic compared with 
genetic SRNS patients in this cohort.  The timing of genetic testing and 
availability of results in relation to disease onset was not reported so it is unclear 
whether clinicians had genetic information when deciding on ciclosporin 
treatment or whether based purely on clinical assessment.  There was some 
response (CR or PR) to ciclosporin in 79% of patients with non-genetic SRNS 
compared with 18.7% in genetic SRNS. 
The PodoNet registry included patients with CNS, primary SRNS and 
persistent subnephrotic proteinuria of likely genetic cause with age of onset ≤ 20 
years [226].  In the analysis of long-term outcomes and responses to treatments 
(published in 2017), patients with CNS and those lacking outcome data were 
excluded giving a cohort of 1354 children, of whom 1064 had genetic testing 
(Sanger sequencing of single genes in 607 children and next generation 
sequencing using a 30-gene panel in 457).  CR was defined as:  
- proteinuria reduction to < 100 mg/m2/24-hour protein excretion OR 
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- < 0.2 mg/mg uPCR in spot urine (if age < 2 years old: < 0.5 
mg/mg) OR 
- a negative dipstick reading OR  
- serum albumin > 30 g/L combined with dipstick trace.   
PR was defined as:  
- persistent non-nephrotic–range proteinuria with a 24-hour protein 
excretion 100-1000 mg/m2/day OR 
- uPCR 0.2–2 mg/mg (if age < 2 years old: 0.5–2 mg/mg) OR  
- dipstick 1+ in combination with serum albumin > 30 g/L OR 
- dipstick trace in combination with serum albumin < 30 g/L. 
The response to immunosuppressive treatment during the first year after diagnosis 
stratified by sporadic, familial or genetic disease is shown in Table 1.10. 
  
Table 1.10: Response to immunosuppressive treatment within the first year 
after disease onset in the PodoNet cohort of patients with SRNS 










Number of patients 713 290 139 212 
Number with first 
year treatment 
response available 
387 115 36 74 
CR (%) 92 (23.8) 45 (39.1) 11 (30.6) 2 (2.7) 
PR (%) 67 (17.3) 20 (17.4) 6 (16.7) 8 (10.8) 
NR (%) 228 (58.9) 50 (43.5) 19 (52.8) 64 (86.5) 
(n = 1354 total, 612 with treatment response data) 
Legend: CR, complete remission; NR, no response; PR, partial remission 
Data abstracted from Trautmann et al. (2017) [226] 
 
Taking the two studies together, in patients with confirmed genetic cause 
for SRNS, there was no response to ciclosporin or other immunosuppression in 
over 80% of cases.  Conversely, there were a few patients with genetic disease 
who did show CR or PR and, if these could be identified early after diagnosis, it 
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may be worthwhile pursuing medical treatments in these cases.  In the PodoNet 
cohort, of 423 patients with non-genetic disease and available treatment 
responses, 176 (41.6%) showed CR or PR in the first year.  This seems lower than 
the 79% combined CR or PR to ciclosporin in the German cohort, however this 
was not limited to the first year after disease onset.  The PodoNet cohort study did 
provide response rates to specific therapies as show in Table 1.11.   
 
Table 1.11: Responses to specific immunosuppressive drugs treatment 
episodes within the first year after disease onset in the PodoNet cohort of 
patients with SRNS 
Treatment CR PR NR Total 
CNI 129 (29.8) 82 (18.9) 222 (51.3) 433 
CPH 9 (9.2) 8 (8.2) 81 (82.7) 98 
MMF 2 (8.3) 2 (8.3) 20 (83.3) 24 
CNI + MMF 4 (11.8) 10 (29.4) 20 (58.8) 34 
IV Steroid 16 (6.8) 25 (10.6) 195 (82.6) 236 
IV Steroid + 
CNI 
4 (8.2) 5 (10.2) 40 (81.6) 49 
IV Steroid + 
other 
1 (5.9) 1 (5.9) 15 (88.2) 17 
IV CPH ± 
other 
1 (12.5) 1 (12.5) 6 (75.0) 8 
RTX ± other 2 (28.6) 0 (0) 5 (71.4) 7 
All 1st year 
treatments 




150 (24.5) 101 (16.5) 361 (59.0) 612 
n = 612 patients 
*  In patients who received more than one immunosuppressive drug in the first 
year, this reported the outcome of the most efficacious treatment  
Legend: CNI, calcineurin inhibitor; CPH, cyclophosphamide; CR, complete 
remission; MMF, mycophenolate mofetil; NR, no response; PR, partial remission; 
RTX, rituximab 
Data abstracted from Trautmann et al. (2017) [226] 
 
The CNIs had the highest frequency of CR at 29.8%, followed by 
rituximab at 28.6%.  However, the latter represented only 2 patients and the data 
were not stratified by genetic / non-genetic disease, therefore, comparisons 
between the different immunosuppressive regimens were difficult.  Furthermore, 
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in both cohorts, some patients were concomitantly treated with ACEi or ARB 
which potentially confounded interpretation of the response to 
immunosuppression. 
Treatment outcomes in the UK cohort of patients with childhood-onset 
SRNS will be discussed in Chapter 3. 
 
1.6 Biomarkers in Nephrotic Syndrome 
1.6.1 Biomarkers and Stratified Medicine 
Biomarkers have been defined as “objective indications of medical state observed 
from outside the patient which can be measured accurately and reproducibly” 
[227].    They can be used to help categorise disease subtypes (diagnostic 
biomarker), to guide treatment (predictive biomarker) or provide information 
about long-term outcomes (prognostic biomarker) [228]. 
Use of the combination of clinico-pathological features with molecular 
markers has been described as “precision medicine”.  This approach is most 
advanced in cancer medicine where genetic and molecular markers of the tumour 
are used as entry criteria for therapeutic trials where drugs have been designed to 
target specifically the key pathogenic pathway [229].  Biomarkers are also used to 
predict which patients are likely to suffer serious side effects from particular 
treatments and avoid this. 
 
1.6.2 Biomarkers in nephrotic syndrome 
Several key questions arise at first presentation or during follow-up when 
managing a patient with NS:   
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• Will the patient be steroid-sensitive or steroid-resistant? 
• If steroid-resistant, what will be the most effective second-line treatment? 
• Can progression to ESRF be prevented? 
• In a patient with ESRF awaiting a renal transplant, will there be disease 
recurrence post-transplant (and how can this be prevented)? 
 
As discussed previously, SRNS is a heterogeneous condition and better ways 
to stratify patients for therapeutic trials and clinical management are likely to 
improve outcomes and avoid giving medications to patients who are unlikely to 
respond but will be exposed to the side effects.  The lack of clear outcomes from 
RCTs in NS may partly be due to the mixed groups of patients in each arm of the 
trial [228].  Our current and potential future strategies for management of SRNS is 








Figure 1.6: Schematic showing current and future approaches to treatment 
in SRNS 
A: Current strategy. B. Future strategy. The colour of the figures corresponds to 
the treatment to which they will respond. 
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Using the term in the broadest sense, the biomarkers that could help 
stratify patients with SRNS are summarised in Table 1.12.  It is likely that some 
of the phenotypic features (age at disease onset, family history, consanguinity) are 
proxies for genetic disease. 
 
Table 1.12: Potential clinical markers and biomarkers in NS 
Phenotype Genotype Biochemical 
Sex Genetic analysis of >50 
genes associated with 
SRNS 
Albumin at disease onset 
Age at disease onset  uPCR at disease onset 
Family history  Plasma or serum 
circulating proteins 
Consanguinity  Urine proteins 
Pattern of steroid 
sensitivity 
  
Renal biopsy findings   
 
Detailed phenotypic information and genetics have been discussed 
previously and will be explored in Chapters 2-4 in relation to response to 
treatment and long-term outcomes.  Chapters 5 and 6 will examine potential 
plasma biomarkers and a review of the current status of circulating and urinary 
biomarkers is detailed below. 
The potential of laboratory-measured biomarkers, either in blood or urine, 
have been investigated in recent years.  The principles of biomarker discovery in 
NS are: 
1. Identification of cohorts with different characteristics (e.g. SS versus SR; 
MCD versus FSGS; response versus non-response to a particular 
treatment; recurrence versus no recurrence post-transplant) 
2. Collection of biological samples (usually blood or urine, with appropriate 
timing, processing and storage) 
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3. Analysis and quantification of all proteins in the samples from a 
“discovery cohort” of patients 
4. Validation of potential biomarkers in a “validation cohort”. 
 
As discussed earlier (Section 1.2.3), renal biopsy findings do have some 
prognostic value but are associated with risks, particularly in smaller children.  
One important study examined the potential of urine biomarkers to distinguish 
between causes of glomerular disease [230].  Urine samples were obtained from 
32 patients at the time of renal biopsy (8 with FSGS, 11 with lupus nephritis, 5 
with membranous nephropathy and 8 with diabetic nephropathy).   Samples from 
half the group were used in the discovery phase: urine was processed, and proteins 
separated by 2-dimensional gel electrophoresis, stained and imaged.  Protein 
abundances were compared between groups and the combination of protein spots 
which indicated the cause of glomerular disease with highest sensitivity were 
identified.  The abundance data for 21 spots were used to predict the diagnosis for 
the validation set, with a correct prediction in 10 out of 16 patients.  Mass 
spectrometry (MS) of the spots identified the following proteins: albumin, α-1 
antitrypsin, α-1 microglobulin, complement factor B Ba fragment, haptoglobin, 
hemopexin, orosomucoid, plasma retinol binding protein, transferrin, 
transthyretin, vitamin D binding protein and zinc α2 glycoprotein.  Some of these 
have been identified as possible biomarkers specifically in NS as summarised in 
Table 1.13 below. 
Several studies have sought non-invasive biomarkers, which can distinguish 
MCD from FSGS.  The most accessible sample used in the search for novel 
biomarkers has been urine [231, 232].  Knowing that podocyte expression of 
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CD80 is increased in nephrotic syndrome, one study used enzyme-linked 
immunosorbent assay (ELISA) to examine urinary soluble CD80 (sCD80) levels 
in MCD in relapse and remission compared with FSGS, other glomerular 
diseases, SLE and healthy controls [233].  They found urinary sCD80 levels 
significantly higher in MCD relapse than remission or other conditions, but no 
difference in serum sCD80 levels.  A similar increased urinary CD80 
concentration in active MCD was reported by another group [234].  The authors 
suggested that urinary sCD80 may be a useful biomarker to distinguish MCD (in 
relapse) from FSGS.  However, no large-scale clinical studies to validate this, or 
examine whether it could avoid renal biopsy, have been published. 
Some of the possible biomarkers in NS may be directly involved in 
pathogenesis, such as circulating factors discussed previously (suPAR, 
hemopexin, IL-13, anti-CD40 antibodies) [228, 231, 232, 235].  In other cases, 
particularly when potential biomarkers have been discovered using proteomic 
techniques, there may be no clear role of the protein in pathophysiology.  These 
more recent studies, which have taken an exploratory approach to identify 
proteins, metabolites and micro RNAs, are summarised in Table 1.13.  Proteomics 
methods and analysis will be discussed in more detail in Chapter 5. 
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Table 1.13: Recent biomarker discovery studies in nephrotic syndrome 
Aims / Target 
groups 
Number of patients in 
subgroups 
Samples Methodology Key findings Publication (first 
author, year, 
reference) 
MCD vs FSGS Discovery: 10 MCD, 11 
FSGS 
Validation: 14 MCD, 14 
FSGS 
Urine Proteomic (2D-PAGE, MS) 
Validation: ELISA 
AAT, TF, HTN-3, MRPL17 significantly higher 
in MCD. Decision tree using CALB2, MRPL17 
and HTN-3 distinguished MCD and FSGS. 
Pérez 2017 [236] 
MCD vs FSGS Discovery: 4 MCD, 4 
MN, 4 FSGS, 4 HC 
Validation: 13 MCD, 26 
MN, 5 FSGS, 9 IgAN, 8 
HC 
Urine Proteomic (MS) 
Validation: ELISA 
C9, CD14, SERPINA1 distinguished MCD from 
MN and FSGS 
Choi 2017 [237] 
MCD vs FSGS 10 MCD, 8 FSGS, 10 
controls 
Urine  Lipidomic (MS) Increased urinary FA and LPC and decreased PC 
in FSGS compared with MCD 
Erkan 2016 [238] 
MCD vs FSGS 5 MCD (clinically 




Micro RNA analysis (miR-
193a) 
Exosome miR-193a significantly higher in 
FSGS 
Huang 2017 [239] 





Micro RNA array 
Validation: qRT-PCR 
Several plasma and urine miRs significantly 




MCD vs FSGS vs 
MGN 
Discovery: 12 MCD, 12 
FSGS, 12 MGN, 12 HC 
Validation: 18 each 
MCD, FSGS, MGN 
Urine Metabolomic (MS) Multi-metabolite panels are able to distinguish 
MCD, FSGS and MGN from each other 
Lee 2016 [241] 
MCD vs FSGS vs 
MsPGN vs MN 
10 MCD, 10 FSGS, 10 
MsPGN, 10 MN, 16 
controls 
Serum Micro RNA expression using 
qRT-PCR for miR-181a, 
miR-483-5p, miR-557 
miR-181a significantly higher in all disease 
groups compared with controls. No significant 
difference between disease groups. 
Sui 2014 [242] 
86 
 
MCD vs FSGS vs 
MsPGN and 
others 
8 MCD, 4 FSGS, 22 
MsPGN and others 
(total n = 52) 
Renal 
biopsy 
Micro RNA expression using 
qRT-PCR for miR-191, miR-
151-3p, miR-150, miR-30a-
5p, miR-19b 
miR-191 significantly higher and miR-151-3p 
lower in all disease samples compared to 
controls. miR-150 significantly different 
between MCD and some other subtypes 
Lu 2015 [243] 
FSGS vs controls 11 FSGS, 6 IgAN, 8 
controls 
Urine Proteomic (MS) 77 proteins different between FSGS and healthy 
controls, most significantly CD59, CD44, IBP7, 
Robo4, DPEP1 
Nafar 2014 [244] 
FSGS vs MN 25 FSGS, 23 MN Serum Proteomic (SDS-PAGE) Protein of molecular weight 29 kDa found 
significantly more frequently in FSGS than MN 
Pant 2016 [245] 
SSNS vs SRNS Discovery: 15 SSNS, 12 
SRNS, 5 controls 
Validation: 40 SSNS, 
20 SRNS, 20 controls 
Urine Proteomics (MS) 
Validation: ELISA 
Apolipoprotein A1 differentiates SRNS from 
FRNS/SDNS.  Alpha-2 macroglobulin, 
orosomucoid 2 and retinol binding protein 4 can 
distinguish SRNS-MCD from SRNS-FSGS 
Suresh 2016 [246] 
SSNS vs SRNS 6 SSNS, 4 SRNS Urine Proteomics (MS) Apolipoprotein A1 most increased in SSNS 
compared with SRNS. Matrix remodelling-
associated protein 8 most decreased in SSNS 
compared with SRNS. 
Kalantari 2014 
[247] 
SSNS vs SRNS 25 SSNS, 27 SRNS, 18 
controls 
Urine Urine NGAL Urine NGAL significantly higher in SRNS than 
SSNS, optimal cut off 0.46 ng/mg creatinine 
Nickavar 2016 
[248] 
SSNS vs SRNS 47 SSNS, 23 SRNS Urine Urinary protein bound sialic 
acid 
UPBSA significantly higher in SRNS than 
SSNS, optimal cut off 2.71 μg/ml of protein 
Gopal 2016 [249] 
SSNS vs SRNS 28 SSNS, 24 SRNS, 5 
controls 
Urine Vitamin D binding protein 
ELISA 
Urine VDBP significantly higher in SRNS than 
SSNS or controls 
Bennett 2016 
[250] 
SSNS vs SRNS 20 SSNS, 16 SRNS Blood 
PBMCs 
Flow cytometry of P-
glycoprotein expression 
P-glycoprotein expression significantly higher in 
SRNS 
Badr 2016 [251] 
SSNS vs SRNS 56 SSNS, 10 SRNS DNA SXR rs3842689 
polymorphism analysis 
Del/Del polymorphism was risk factor for 
steroid resistance 
Turolo 2016 [252] 





PMBC TLR-3, TLR-4 and 
CD80 mRNA expression. 
Urine CD80 level 
Median TLR-3, TLR-4, CD80 mRNA levels 
higher in active SSNS than SRNS. Urine CD80 





SSNS vs SRNS 47 SSNS, 23 
SDNS/SRNS 
Urine Urine protein carbonyl 
content (UPCC) as marker of 
oxidative stress / free radicals 
UPCC significantly higher in SDNS/SRNS 
group. Threshold of 5.10 nmol/mg of protein 
Gopal 2017 [254] 
SSNS vs SRNS Discovery: 5 SSNS, 5 
SRNS 
Validation: 30 SSNS, 
20 SRNS 
Urine Proteomics (MS) 
Validation: ELISA/ 
immunonephelometry  
VDBP, prealbumin (transthyretin), NGAL, 
fetuin-A, AGP2 significantly higher in SRNS. 
Bennett 2017 
[255] 
SSNS vs SRNS 40 SSNS, 40 SRNS, 40 
controls 
Serum Nephronectin (NPNT) 
ELISA 
NPNT significantly higher in SSNS than SRNS 




Active NS vs 
remission 
Discovery: 4 pairs 
(relapse & remission) 
Validation: 14 pairs (3 





Plasma hemopexin significantly lower in active 
NS compared with remission. Urine E-cadherin 











 CD154+ CD4+ CD3+ T cells < 83.3%, IFNγ+ 
CD3+ T cells < 2.5%, IL-2+ CD3+ T cells < 0.3% 
are good predictors of rituximab response. 
Chan 2016 [258] 
Predication of 
response to LDL 
apheresis 
SRNS treated with 
apheresis: 4 responders, 




Proteomics (2D-PAGE, MS) 
of proteins from apheresis 
column 
ELISA on serum 
Among column-bound proteins and in serum, 







10 FSGS, 5 with eGFR 
< 60 and 5 with eGFR > 
60 ml/min/1.73m2 
Urine Proteomics (MS) 54 proteins significantly increased or decreased 
in patients with lower GFR compared with 




recurrence vs no 
recurrence 
14 FSGS with post-
transplant recurrence, 
61 FSGS without 
recurrence, 30 FSGS-
unrelated proteinuria, 
14 familial FSGS 
Urine Proteomics (2D-PAGE, MS) 
Validation: ApoA-I by WB 
Urine levels of ApoA-Ib increased in 92.9% 
patients with post-transplant recurrence vs 1.6% 
without recurrence, 3.3% with FSGS-unrelated 







recurrence vs no 
recurrence 
4 FSGS with post-
transplant recurrence, 9 
FSGS with no 
recurrence 
Urine ApoA-I WB ApoA-I positive before recurrence in 3/4; 
always negative in 8/9 with no recurrence. 
Sensitivity of 93.3% and specificity of 90.9% to 
diagnose FSGS relapses   
Puig-Gay 2018 
[262] 
Legend: 2D-PAGE, two-dimensional polyacrylamide gel electrophoresis; AAT, alpha-1 antitrypsin; AGP2, alpha-1 acid glycoprotein 2 
(orosomucoid 2); ApoA-Ib, apolipoprotein A-Ib; APOE, apolipoprotein E; C9, complement factor 9; CALB2, calretinin; DPEP1, Dipeptidase 1; 
FA, fatty acids; GFR, glomerular filtration rate; HTN-3, histatin-3; IBP7, insulin-like growth factor-binding protein 7; LPC, 
lysophosphatidylcholines; MRPL17, mitochondrial ribosomal protein L17; MS, mass spectrometry; MsPGN, Mesangioproliferative 
glomerulonephritis; NGAL, neutrophil gelatinase-associated lipocalin; PC, phosphotidylcholine; qRT-PCR, quantitative reverse transcription-
polymerase chain reaction; Robo4, roundabout homolog 4; SAP, serum amyloid P-component; SDS-PAGE, sodium dodecyl sulphate-
polyacrylamide gel electrophoresis; SXR, alternative name for nuclear receptor subfamily 1 group I member 2; TF, transferrin; VDBP, vitamin 




Many recent biomarker studies in NS have focused on diagnosis, either 
histological (MCD or FSGS) or clinical (SSNS or SRNS).  Relatively small 
numbers of patients have been included and validation in large prospective 
clinical cohorts has not yet been undertaken.  One study (Andersen et al. 2012) 
examined differences in urine and plasma proteins at time of relapse and 
remission, mostly in patients with SSNS [257].  They found that 11 proteins were 
significantly (p < 0.05) increased and 7 were significantly decreased in plasma at 
time of relapse versus remission.  In particular, they reported that plasma 
hemopexin was decreased at relapse and this MS finding was confirmed by 
ELISA.  Chapters 5 and 6 of the current study will investigate proteins which 
differ in relapse and remission in patients with SRNS particularly focussing on 
post-transplant recurrence.  This has the potential to identify biomarkers and 
possible circulating factors.  Chapter 7 will examine the effect of treatment of ci-
hPod with plasma from SRNS patients at time of relapse and remission, again as a 
method to identify biomarkers and for insights into pathophysiology. 
 
1.7 Aims and Hypotheses 
 
The overall aim of this study was to investigate the interplay of phenotype, 
genetics and potential biomarkers with response to treatment and long-term 
outcome in SRNS. 
The main aims were: 
To undertake deep phenotyping of a cohort of patients with SRNS and examine 
associations between baseline characteristics and long-term outcomes (Chapter 2) 
90 
 
To compare characteristics and outcomes in subgroups with and without genetic 
disease (Chapter 2) 
To examine response to disease-modifying treatments in subgroups with and 
without genetic disease (Chapter 3) 
To evaluate the performance of genetic testing of SRNS patients in real-world 
clinical practice (Chapter 4) 
To identify potential novel biomarkers in patients with SRNS at times of disease 
relapse and remission (Chapters 5, 6 and 7) 
 
It was hypothesised that in SRNS, specific genetic and phenotypic features would 
be able to stratify patients into subgroups with better response to disease-
modifying treatment and long-term outcome.  It was also envisaged that these 
features would identify patients with a poorer prognosis who would be unlikely to 
respond to medical management but may benefit from transplantation.  It was 
hypothesised that certain proteins in plasma (other than albumin and 
immunoglobulins) would be consistently different (either increased or decreased) 
at time of relapse compared with remission.  The protein(s) may be a marker of 
disease activity or may be involved with disease pathogenesis (for example a 
circulating factor).  If plasma contains a pathogenic factor, it was hypothesised 
that intracellular pathways in podocytes, the target cells for disease in SRNS, 
would be affected differently when exposed to relapse versus remission plasma.  
The effect may also be a marker of disease activity and give an insight into the 




Chapter 2 The UK SRNS Cohort 
2.1 Introduction 
As a rare condition, much of our deepest understanding of the causes, natural 
history and outcomes of SRNS has derived from studies of cohorts of patients at a 
national and international level.  One of the prime motivators has been to identify 
factors at diagnosis or early during the course of disease which may help to 
predict longer-term outcomes and response to treatment.  The latter will be the 
focus of Chapter 3.  This part of the study will examine demographic and clinical 
features, together with results of genetic analysis, and the association with long-
term outcomes in children with SRNS in the UK national cohort. 
 As discussed in Chapter 1 (Table 1.5), data from other national and 
international studies have been published during the course of the current 
research.  Some, such as the large international cohort reported by Sadowski et al. 
[57] included patients with adult-onset disease.  All had, as a primary focus, the 
genotyping of patients targeting a panel of between 8 and 28 genes previously 
shown to be associated with SRNS.  This study took the approach of whole exome 
sequencing (WES) which allows the identification of pathogenic variants in all the 
genes known to cause SRNS but also the potential to discover novel disease-
associated genes. 
 
2.1.1 Whole exome sequencing 
The human genome contains 3.1 billion DNA base pairs [263].  Approximately 
1% of this is coding sequence, called the exome, and is arranged into around 
20000 protein-coding genes [264].  Although likely an overestimate, it has been 
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thought that the exome contains 85% of all pathogenic mutations associated with 
Mendelian diseases [265].  The Human Genome Project completed sequencing of 
the first human genome in 2001 using Sanger sequencing.  In this process, single-
stranded DNA, up to 1000 bases in length, acts as a template.  A targeted primer 
binds to the complementary sequence.  It is extended by DNA polymerase in the 
presence of the four normal deoxynucleotides (dNTPs) and four chain-terminating 
dideoxynucleotides (ddNTPs) labelled with different fluorescent colours.  
Separation of the reaction products on a gel allows the base letter code to be 
“read” from the shortest to longest.  Over the past decade, massively parallel 
sequencing, or “next-generation sequencing” (NGS), has allowed rapid 
sequencing of the whole genome (WGS) or whole exome (WES) within a matter 
of days and at greatly reduced cost [266].  A summary of the steps in NGS using 





Figure 2.1: Overview of steps in next-generation sequencing 
A: Patient DNA is fragmented randomly in < 1000 base pair lengths. Known 
adaptor sequences are ligated to fragments. B: Bait probes bind only to DNA from 
exons which are captured allowing intronic fragments to be washed away. C: 
DNA fragments bind to primers attached to a glass slide via the adaptor 
sequences.  The fragments are clonally amplified by polymerase chain reaction to 
generate fragment clusters.  Four fluorescently-labelled nucleotides are added to 
the slide and compete to be incorporated to the growing chains.  In each cycle, the 
clusters are excited by laser and the emitted fluorescence is recorded allowing the 
base sequence to be “read” over time.  D: Multiple overlapping DNA segments 
(reads) are aligned to the reference genome.  The number of overlaps at a 
particular position is called the coverage.   
Reproduced from Archives of Disease in Childhood, Schnekenberg RP & Németh 




Sequencing of the DNA code is now relatively straightforward and the main 
challenge currently is in bioinformatic analysis to identify likely disease-causing 
variants among the vast amount of data generated [268].  In the first stage, the 
patient’s sequence is aligned with the reference genome (Figure 2.1D) so that 
each nucleotide can be assigned to a particular position within a known gene.  The 
nucleotide at each position in the patient can be compared with the nucleotide(s) 
seen at the same position in population databases (containing only “healthy” 
subjects or those known not to have the disease of interest).  Such databases 
include the NHLBI Exome Sequencing Project (EVP), 1000 Genomes Project, 
dbSNP and the Exome Aggregation Consortium (ExAC).  Ideally, the patient’s 
sequence would be compared with data from a population of the same ethnicity 
(or genetic ancestry).  However, this is more challenging for non-Caucasians who 
are under-represented in the population databases.  Any difference between the 
patient’s and the reference sequence is called a variant and typically 20000 – 
50000 variants are identified per exome.  If a variant has a clinical effect it is 
known as a pathogenic variant, and if it has no effect it is called a benign variant 
or polymorphism.  If the effect is unknown, it is defined as a variant of unknown 
significance (VUS).  The variant analysis process has been recently reviewed 







2.2.1.1 The National Registry of Rare Kidney Diseases 
The National Registry of Rare Kidney Diseases (RaDaR) was established under 
the governance of the Renal Association of Great Britain following a 2008 
initiative of the Medical Research Council to develop cohorts of patients with rare 
diseases for translational research [270].  RaDaR established an infrastructure for 
collection of generic and disease-specific clinical data relating to diagnosis and 
follow-up.  The Rare Disease Group to investigate childhood SRNS was one of 
the first to be established.  Data were collected retrospectively and prospectively 
via an online portal from the time of diagnosis with nephrotic syndrome and 
includes demographics, family history, consanguinity, pattern of steroid 
resistance, medications, transplantation and subsequent recurrence. 
 
2.2.1.2 The NephroS study 
The National Study of Nephrotic Syndrome (NephroS) operated within RaDaR 
and permited collection of biological samples including blood (EDTA) for DNA 
extraction and genetic testing, blood (lithium heparin) for plasma and plasma 
exchange effluent.  Further details are available online [271].  Samples were 
collected with the written consent of parent(s)/guardian(s) and assent/consent of 
children depending on age. 
 
2.2.1.3 Renal Patient View 
Renal Patient View (PV) was a secure online portal for use by patients and 
clinicians which provides individuals with access to their laboratory results, letters 
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and medications together with generic advice about renal diseases and treatments 
[272].  When fully activated, the system automatically pulled laboratory results 
and medication data from their electronic patient records held by the NHS hospital 
trust or GP practice.  Since 2015, for some patients at certain NHS hospital trusts, 
PV was directly linked to RaDaR, therefore provided a complete and current set 
of laboratory and medication data.  For those patients without this link, data were 
entered manually by local clinicians and research nurses on an approximately 6-
monthly basis. 
 
2.2.1.4 Inclusion and Exclusion criteria 
From its inception in 2011, the RaDaR cohort included children (< 19 years at 
disease onset) with SRNS.  Inclusion and exclusion criteria were as follows. 
Inclusion: 
• < 19 years at age of onset 
• Idiopathic nephrotic syndrome (nephrotic range proteinuria and 
hypoalbuminaemia) with no response to 4 weeks of high-dose oral 
prednisolone, including 
o Congenital nephrotic syndrome (presumed steroid resistance) 
o SRNS with primary steroid resistance 
o SRNS with secondary steroid resistance 
o NS as part of a syndrome, for example Nail-Patella syndrome or 
Denys-Drash syndrome 
o NS with FSGS on biopsy 
Exclusion: 
• ≥ 19 years at age of onset 
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• Nephrotic syndrome secondary to any other condition, including 
o IgA nephropathy 
o MPGN / C3 glomerulopathy 
o MN 
o Vasculitis 
o Systemic lupus erythematosus 
o Hypertension 
o Obesity 
o Diabetes mellitus 
 
Following an amendment to the study protocol in December 2015, 
inclusion criteria were broadened to encompass patients with onset of disease at 
any age and all forms of idiopathic nephrotic syndrome, including SSNS, FR-
SSNS and SDNS. 
 
2.2.2 Ethical permission 
Both RaDaR and NephroS (formerly the National Study of Steroid Resistant 
Nephrotic Syndrome in Childhood) received favourable opinions from the 
relevant Research Ethics Committees.  For children < 16 years, parents or 
guardians provided written informed consent for participation with children being 
offered the ability to give assent.  All adult patients provided written informed 
consent for participation.  Patients/parents/guardians could choose to participate in 





2.2.3 Whole exome sequencing 
Anticoagulated (EDTA) blood samples were posted at ambient temperature from 
recruiting centres to Bristol Renal, University of Bristol.  DNA was extracted at 
Bristol Genetics Laboratory, Southmead Hospital, Bristol, using QIAmp DNA 
Blood Mini Kit or Gentra Puregene Blood Kit (Qiagen, Hilden, Germany).  
Exome sequencing was performed in the Genomics Core Facility of the 
Biomedical Research Centre at Guy’s and St Thomas’ Hospitals and King’s 
College, London.   
 
2.2.4 Variant calling   
Bioinformatic analysis of exome data was performed by Dr Agnieszka Bierzynska 
in the Bristol Renal research group.  Detailed methods of variant analysis have 
been published in our co-authored paper [1]. 
 
2.2.5 Clinical data 
Detailed phenotypic data were extracted from the RaDaR database including 
baseline demographics, family history, consanguinity, pattern of steroid 
resistance, extra-renal or syndromic features, first and subsequent biopsy findings, 
progression of CKD, date of ESRF, details of RRT, transplantation and post-
transplant disease recurrence.  These data were identified from both the relevant 
fields within the database and from searches of free text information copied from 
clinic letters.  The time to ESRF and total duration of follow-up were calculated.   
The date of ESRF was determined as follows: 
i. The date of ESRF as entered in RaDaR by the local research team; 
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ii. If (i) was not available, the eGFR was calculated using the Schwartz 
formula from the plasma creatinine and patient height.  The start of ESRF 
was taken as the first date with eGFR persistently < 15 ml/min/1.73m2 or 
the start of RRT, whichever was earlier. 
The duration of follow-up was calculated between the date of diagnosis and 
the most recent data available in RaDaR.  The most recent complete download of 
the database was in March 2017 and, for some patients, data continued to be 
entered to this point.  For some patients, particularly those who moved from 
Paediatric to Adult care, follow-up data were available only to around age 18 
years.  Local research teams were approached regarding any missing data items to 
maximise completeness. 
 
2.2.6 Statistical analysis 
Data were analysed using Microsoft Excel 2013 (Microsoft Corporation, WA, 
USA) and GraphPad Prism 7 (GraphPad Software, Inc., CA, USA).  Demographic 
and clinical features were described with frequencies and percentages and central 
tendency by median (inter-quartile range).  The population was stratified by 
genetic / non-genetic status and by primary or presumed SR / secondary SR 
pattern.  Analysis of 2 × 2 contingency tables used Fisher’s exact test.  
Comparisons in larger contingency tables used the chi-squared test.  Groups were 
pooled if any expected frequencies were < 5.  Progression to ESRF in different 
subgroups was assessed using the Kaplan-Meier survival method.  Analysis of 
differences between survival curves was by the log-rank (Mantel-Cox) test.  All 






The results of this study have been previously published in a co-authored paper 
[1].  At the point of submission, follow-up data were available until June 2015 and 
of 187 included patients, 49 were identified as having genetic disease.  
Subsequent analysis confirmed that a further 3 patients had a genetic cause of 
their condition and follow-up data were available in many cases to March 2017.  
This chapter, therefore, presents results of the more recent analysis. 
 
2.3.1 Cohort characteristics 
The cohort included the first 187 patients recruited into the RaDaR SRNS 
database from inception in 2011 until 2015 who had had WES and variant 
analysis completed.  They were recruited from 12 Paediatric Nephrology units 
across England, Scotland and Wales.  The demographic features are shown in 
Table 2.1.  There was an approximately-equal gender balance with almost 70% 
White / Caucasian and the majority (55.7%) having FSGS on their first biopsy.  
Data relating to family history and consanguinity were available for most patients 
and showed 11.8% with a positive family history and 7.2% consanguinity.  Forty-
five patients had some form of extra-renal features most commonly neuro-
developmental delay in 16.  One patient each had recognised Frasier syndrome, 
Pierson syndrome and Aarskog syndrome.  Complete details of the whole cohort 
are given in Table 10.1 in the Appendices.  
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Table 2.1: Clinical characteristics of the cohort 













 187 135 (72.2) 52 (27.8)  






 22 / 186 
(11.8) 
8 / 134 
(6.0) 







 13 / 181 
(7.2) 
5 / 130 
(3.8) 
8 / 51 
(15.7) 
0.0096 
Ethnicity (% of 
patients where 
data available) 
White 130 (69.5) 91 (67.4) 39 (75.0) 0.18* 




9 (4.8) 8 (5.9) 1 (1.9) 
 Pakistani 16 (8.6) 9 (6.7) 7 (13.5) 
 Bangladeshi 2 (1.1) 2 (1.5) 0 (0) 
 Asian 6 (3.2) 6 (4.4) 0 (0) 
 Mixed 10 (5.3) 9 (6.7) 1 (1.9) 
 Other 5 (2.7) 3 (2.2) 2 (3.8) 
First biopsy 
findings (% of 
patients where 
data available) 
FSGS 98 (55.7) 80 (61.1) 18 (40.0) < 
0.0001† 
 MCD 43 (24.4) 34 (25.9) 9 (20.0) 
 MHc 10 (5.7) 8 (6.1) 2 (4.4) 
 Finnish type 5 (2.8) 0 (0) 5 (11.1) 
 DMS 3 (1.7) 2 (1.5) 1 (2.2) 
 ESRF 3 (1.7) 0 (0) 3 (6.7) 
 Alport 1 (0.6) 0 (0) 1 (2.2) 
 TBMN 1 (0.6) 1 (0.8) 0 (0) 
 Other 12 (6.8) 6 (4.6) 6 (13.3) 




11 4 7  
Percentages are calculated for column totals. p values are for the comparison 
between genetic and non-genetic disease.  
* For chi-squared analysis, “Bangladeshi”, “Asian”, “Mixed and “Other” were 
combined into one group, as shown by the square bracket 
† For chi-squared analysis, “Finnish type”, “DMS” and “ESRF” were combined 
into one group; “Alport”, “TBMN” and “Other” were combined into another 
group, as shown by the square brackets 
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Legend: DMS, diffuse mesangial sclerosis; FSGS, focal segmental 
glomerulosclerosis; MCD, minimal change disease; MHc, mesangial 




2.3.2 Age of disease onset 
The age at disease onset ranged from birth (CNS) to 16 years with a median of 4.0 
years (IQR 2.1-8.9 years).  The distribution of patients by age group is shown in 
Figure 2.2.  The most frequent period of onset was 1-3 years with 51 patients 
diagnosed at this age.  The highest proportion of patients with genetic mutations 
was found in the 0-0.25 year group (13/15, 86.7%).  When all patients were 
included, there was a significant association between age of onset and genetic 
disease (p < 0.0001, chi-squared, 9 df).  However, there was no significant 
association when only patients with onset ≥ 1 year were considered (p = 0.39, chi-
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Figure 2.2: Frequency distribution of patients by age at onset of nephrotic 
syndrome stratified by genetic/non-genetic aetiology 
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2.3.3 Pattern of steroid resistance 
Of 187 patients, the large majority (182, 97.3%) had SRNS.  Four patients had 
SSNS (two with FR-SSNS) with FSGS on biopsy in three and mesangial 
proliferative change in one.  One patient had asymptomatic persistent proteinuria 
with FSGS on biopsy and was not treated with steroids.  The number of patients 
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Figure 2.3: Frequency distribution of patients by pattern of steroid resistance 
stratified by genetic/non-genetic aetiology 
 
Presumed steroid resistance was seen in 25 patients, of whom 16 had 
disease onset under 1 year of age, including all 13 with CNS.  The other 9 older 
patients had ESRF at presentation (n = 4), a family history of genetic SRNS/FSGS 
(n = 4) and prominent hypertension with advanced FSGS on biopsy (n = 1).   As 
might be expected on this basis, the frequency of genetic disease in those with 
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presumed steroid resistance was particularly high at 84% (21/25).  Among 
patients with primary steroid resistance, 23.1% had genetic disease compared with 
none of those with secondary steroid resistance.  The association of genetic 
disease with different patterns of steroid resistance was highly significant (p < 
0.0001, chi-squared, 3df).  One patient with FR-SSNS was found to have genetic 
disease and this case will be discussed in further detail in Section 2.3.7 below. 
 
2.3.4 Incidence of genetic disease in relation to baseline clinical 
characteristics 
A probable genetic cause was identified in 52 (27.8%) of patients (see Table 2.1 
above).  This did not appear to be associated with gender or ethnicity.  As might 
be expected, there was a significantly higher frequency of a positive family 
history (26.9%) in the patients with genetic disease.  In patients with a positive 
family history, the frequency of genetic disease was 63.3% (14 / 22) compared 
with 23.2% (38 / 164) in those with a negative family history (p = 0.0002, Fisher’s 
exact test, two-sided).  The cohort included two sets of siblings: two sisters with 
compound heterozygous NPHS2 variants and a brother and two sisters with likely 
pathogenic NUP107 variants.  If families are considered rather than individuals 
[57], the frequency of genetic disease was 57.9% (11/19 families) in those with a 
positive family history.   
 There was a significantly higher frequency of consanguinity (15.7%) in 
the parents of patients with genetic disease.  61.5% (8/13) of children from 
consanguineous relationships had genetic disease compared with 25.6% (43/168) 
of children who were not from such relationships (p = 0.0096, Fisher’s exact test, 
two-sided).  Seven of eight children from consanguineous relationships with 
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genetic disease were homozygous for variants typically inherited with an 
autosomal recessive pattern (four children with variants in NUP107, two in 
NPHS1, one in MYO1E).   
 Genetic disease was significantly associated with biopsy findings when all 
patients were considered (p < 0.0001, chi-squared test with groups combined, 4 
df).  In all cases with a first biopsy showing CNS of the Finnish type, ESRF and 
Alport syndrome a genetic cause of disease was identified; however, these 
represent only small numbers within the cohort (9 patients in total).  When 
considering only the most frequent biopsy findings, of 98 patients with FSGS, 18 
(18.4%) had genetic disease compared with 9 (20.1%) of 43 patients with MCD (p 
= 0.82, Fisher’s exact test, 2-sided).  Of the 43 patients with MCD initially, 12 
(32.6%) had FSGS on the most recent biopsy, 7 had persistent MCD, 2 had other 
findings and 22 had not been re-biopsied. 
 
2.3.5 Long-term outcomes in patients stratified by pattern of steroid 
resistance 
Data from RaDaR to March 2017 were used to examine long-term outcomes in 
the cohort.  Sixty-six patients had reached the age of 18 years by this date and, for 
some, follow-up data were not available after transition from Paediatric to Adult 
care.  The total follow-up time for the cohort was 1485 patient-years with a 
median follow-up of 4.0 years, (range 1.0-21.7 years, IQR 2.1-8.9 years).   
 In the whole cohort of 187 patients, 40.6% progressed to ESRF and 31.6% 
were transplanted (Table 2.2).  Of 59 transplanted patients, 18 (30.5%) suffered 
disease recurrence.  As would be expected, no patient who remained responsive to 
steroids progressed to ESRF.  Among those with SRNS, patients with presumed 
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steroid resistance were significantly more likely to reach ESRF (76.0%) than 
either those with primary SR (36.9%, p = 0.0004, Fisher’s exact test) or with 
secondary SR (33.3%, p = 0.0025, Fisher’s exact test).  There was no significant 
difference in the proportions reaching ESRF between primary and secondary SR 
(p = 0.83, Fisher’s exact test).   
 
Table 2.2: Long-term outcomes in the cohort stratified by pattern of steroid 
resistance 


































14 (56.0) - - - 












0 (0) - - - 
Legend: FR, frequently-relapsing; PSR, primary steroid resistance; SSR, 
secondary steroid resistance; SSNS, steroid-sensitive nephrotic syndrome 
 
The percentage of kidney survival over time for the different patterns of steroid 
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Figure 2.4: Percentage of kidney survival stratified by pattern of steroid 
resistance 
 
The median time to ESRF for patients with presumed SR was 2.0 years 
compared with 9.9 years for patients with primary SR and 9.7 years for those with 
secondary SR.  The differences between the curves were highly significant (p < 
0.0001, log-rank test, 2df). 
 No patient with presumed SR suffered a post-transplant recurrence 
compared with 35.9% of those with primary SR (p = 0.011, Fisher’s exact test) 
and 66.7% in those with secondary SR (p = 0.0031, Fisher’s exact test).  Although 
the difference between post-transplant recurrence frequency in patients with 
primary SR and those with secondary SR appears large, this is not statistically 
significant (p = 0.20, Fisher’s exact test) most likely due to the small numbers of 
patients with secondary SR who were transplanted. 
 
2.3.6 Long-term outcomes in patients stratified by genetic disease 
The long-term outcomes in patients with or without genetic disease are 
summarised in Table 2.3 and time to ESRF in the Kaplan-Meier survival curves 
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(Figure 2.5).  Patients with genetic disease were significantly more likely to 
progress to ESRF in a median of 3.3 years and none suffered post-transplant 
recurrence. 
 
Table 2.3: Long-term outcomes in the cohort stratified by genetic/non-genetic 
aetiology 
 Total Non-genetic Genetic p value 
Number of 
patients 




76 (40.6) 42 (31.1) 34 (65.4) < 0.0001 
Median time to 
ESRF (years) 
9.4 n/a* 3.3 < 0.0001 
Number (%) 
transplanted 
59 (31.6) 32 (23.7) 27 (51.9) 0.0004 






18 (30.5) 18 (56.3) 0 (0) < 0.0001 
p values for proportions calculated using Fisher’s exact test (two-sided). p value 
for median time to ESRF calculated by log-rank (Mantel-Cox) test of Kaplan-
Meier survival curves. *The median time to ESRF for non-genetic patients is not 
available because less than 50% of the cohort reached ESRF.  For the 42 non-
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Figure 2.5: Percentage of kidney survival stratified by genetic/non-genetic 
aetiology 
 
2.3.7 Genetic variants within the cohort 
Whole exome sequencing identified 52 patients (27.8%) with likely-causative 
mutations.  The genes harbouring these variants are detailed in Table 2.4 stratified 
by the age of disease onset.  The details of the variants in 49 of the patients have 
been published [1].  Subsequent work by Bierzynska et al. confirmed novel 
variants in MAGI2 to be the likely cause of disease in two patients [89] and 














0-0.25 0.25-1 1-5  5-13 13-17 Total 
Total number 
of patients 
15 7 86 64 15 187 
NPHS1 11  2 1  14 
NPHS2   6 4 2 12 
WT1 1  3   4 
NUP107   1 2 1 4 
MAGI2  2    2 
TRPC6   1 1  2 
LMX1B     2 2 
LAMB2 1     1 
COL4A5  1*    1 
CRB2  1    1 
MYO1E  1    1 
DGKE   1   1 
COL4A3    1  1 
NUP93    1  1 
ADCK4    1  1 
APOL1    1  1 
ACTN4    1  1 
OCRL    1  1 
PODXL     1 1 














Zeros are omitted for clarity.  * This patient also had two different homozygous 
missense variants in MYO1E 
 
NPHS1 variants were the most common cause for CNS, being responsible 
for 11 of 13 cases.  Interestingly, one of these patients (patient 353), with onset at 
age 2 months, was steroid sensitive with frequent relapses and remained steroid 
sensitive with no progression to CKD during 17 years of follow-up.  Although 
mostly causing early-onset disease, the oldest child (patient 414) with NPHS1 
pathogenic variants had onset at 5.7 years.  Of 14 patients with NPHS1 mutations, 
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11 progressed to ESRF within 0.5-4.6 years and were subsequently transplanted 
with no disease recurrence. 
 NPHS2 was the cause of presumed or primary steroid-resistant SRNS in 
12 children with median age of onset of 4.9 years.  Nine (75%) have progressed to 








2.4.1 Findings of this study 
The data presented here from a UK cohort of 187 patients with childhood-
onset SRNS showed that baseline demographic and clinical characteristics were 
differentially associated with genetic versus non-genetic disease.  Children with 
disease onset under 1 year of age, with a positive family history or with 
consanguinity were significantly more likely to have genetic aetiology.  The 
pattern of steroid resistance strongly predicted non-genetic disease: none of 27 
patients with secondary steroid resistance was found to have a likely-pathogenic 
variant.  In contrast, the histology findings of the first renal biopsy, excluding the 
9 patients with CNS of the Finnish type, ESRF and Alport syndrome, did not help 
to differentiate between patients with genetic versus non-genetic disease.  
Approximately 20% of patients with FSGS or MCD were found to have likely-
pathogenic variants. 
Regarding long-term outcomes, both the presence of genetic disease and 
presumed steroid resistance (of which group 84% were genetic) were strong 
predictors of progression to ESRF but none of these patients suffered post-
transplantation recurrence.  In comparison, patients with secondary steroid 
resistance were significantly less likely to require a transplant but had a higher 
risk of recurrence. 
A flow chart summarising patient stratification including data from this 
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by KDIGO guidelines) 
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Figure 2.6: Flow chart summarising stratification of patients by pattern of 
steroid resistance and genetic testing 
*Four patients with SSNS and one with persistent proteinuria not treated with 
steroids were omitted from the original 187 for this analysis. 
Legend: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; ESRF, end-stage renal failure; IS, immunosuppression; 













Five patients from the original cohort of 187 were omitted from the 
analysis.  Although they met criteria for inclusion in the RaDaR study as defined 
previously (Section 2.2.1.4), they did not have steroid resistance.  They were, 
therefore, excluded from Figure 2.6 so that more homogeneous groups were 
shown in this analysis. 
The overall genetic detection rate in this cohort using WES was 27.8%, 
with likely-pathogenic variants found in 19 different genes.  Although in some 
cases the clinical presentation could reasonably predict the affected gene (with 
85% of children with CNS having NPHS1 variants), some patients had variants in 
genes less frequently involved in childhood onset disease as previously published 
[1].  It is possible that not all pathogenic variants were detected by this study.  
Causative mutations in regulatory sequences within introns would not be 
sequenced by WES.  Furthermore, as bioinformatic databases expand and 
functional studies are performed in future, variants which have been considered of 
unknown significance may be reclassified as likely-pathogenic. 
 
2.4.2 Comparison with other studies 
The current study was the first to use whole exome sequencing in all patients with 
SRNS included in the cohort.  This enabled pathogenic variants to be detected not 
only in genes previously known to be associated with SRNS but also novel genes 
to be identified.  As discussed previously in Chapter 1, other national and 
international cohort studies genotyping patients with SRNS tested panels of 
between 8 and 28 genes (see Table 1.5).  Furthermore, in two studies including 
patients in the PodoNet cohort and German CNS/SRNS follow-up study, the 
number of genes and exactly which genes were screened varied depending on the 
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recruiting centre or on an algorithm based on patient age, renal histopathology 
and/or syndromic features [44, 138].  As discussed previously and in our co-
authored paper [1], the range of clinical phenotypes associated with variants in a 
specific gene is broadening, therefore selecting which genes to test based on the 
clinical presentation risks incorrectly labelling patients as having non-genetic 
disease. 
 This study comprised patients recruited from 12 centres in a single 
country.  While the number of patients who underwent WES and were included in 
analysis is felt to be large enough to draw reasonable conclusions, it is smaller 
than published international studies by Sadowski et al. (2014) which included 
2016 patients and Trautmann et al. (2015) with 1655 patients  [44, 57].  
Compared with that of Trautmann et al., the current study had a lower frequency 
of a positive family history (11.8% vs. 25.6%) and consanguinity (7.2% vs. 
28.6%) likely as a result of the former including patients from Turkey and the 
Middle East.  Despite this, genetic disease was identified in 23.6% of 1174 
patients tested compared with 27.8% in this study.  One could speculate that this 
relatively higher detection rate in a population with a lower prior probability of 
genetic disease was the result of the WES approach.  The cohort of Sadowski et 
al. reported consanguinity in 20.9% of the 1783 included families.  The frequency 
of a positive family history was not reported.  The overall rate of genetic disease 
was 30.5%, possibly reflecting a standardised NGS strategy for a panel of 27 
genes tested in all included patients. 
 The studies of Sadowski et al. and Trautmann et al. did not stratify 
patients by pattern of steroid resistance, therefore, a direct comparison of the 
subgroups is not possible.  A previous study from our group at the University of 
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Bristol together with collaborators from France examined outcomes in a cohort of 
150 patients with SRNS who had been transplanted and stratified data by pattern 
of steroid resistance.  Of 28 patients with secondary steroid resistance, 9 had 
genetic testing and none was found to have likely-pathogenic variants, consistent 
with the findings of the current study.  Among the same 28 patients, the 
recurrence rate post-transplantation was 92.9%.  In this study, among the 6 
patients with secondary steroid resistance, the recurrence rate post-transplantation 
was 66.7%.  Although this appears lower, the small numbers limit interpretation 
of whether this is a significant difference. 
Regarding long-term outcomes, this study had a median follow-up time for 
the cohort of 4.0 years (IQR 2.1 -8.9 years, range 1.0-21.7 years) while the 
median time to ESRF was 9.4 years (based on Kaplan-Meier survival curve 
analysis).  Overall, 5-year renal survival was 65.1%.  The follow-up time was 
comparable to the median 3.6 years (IQR 1.5-6.8 years, maximum 15 years) 
reported by Trautmann et al.(2017) in a long-term follow-up analysis of the 
PodoNet cohort (n = 1354) and 5-year renal survival was 74% [226].  They, 
however, reported median time to ESRF of 2.8 years. Although the authors stated 
that they used the Kaplan-Meier analysis to determine the median time to ESRF, 
clearly over 50% of the cohort had not reached ESRF by 5 years.  Their 10-year 
and 15-year renal survival rates were 58% and 48% respectively suggesting that 
the actual median time to ESRF was some point after 10 years and, therefore, 
longer than in the present study.  Their analysed cohort did not include patients 
with CNS (onset < 3 months of age) and only 15.7% had proven genetic disease 
(290 of 1354 did not have genetic testing) which may explain the relatively better 
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outcomes in the PodoNet study.  They reported outcomes stratified by response to 
immunosuppressive treatment and this will be a focus of Chapter 3. 
 
2.4.3 Limitations 
Recruitment of patients to the RaDaR SRNS study was conducted by 
Paediatric Nephrologists across Great Britain.  Although any children meeting the 
inclusion criteria were eligible, because the study offered WES on a research 
basis, there is the potential for bias leading to increased recruitment of patients 
with suspected genetic disease or those without a diagnosis based on local clinical 
genetic testing.  However, comparison of the overall genetic rate of 27.8% in this 
study with data from other cohorts (as detailed in Table 1.5) shows the figure is 
broadly in line at around 30%. 
 Clinical phenotyping data were provided by local Paediatric Nephrology 
research teams and inputted into the online RaDaR database.  Although more 
recent follow-up information was collected prospectively, data relating to baseline 
and original diagnosis were retrospective.  After initial data download, as part of 
this research, all centres were contacted individually with requests for specific 
data to maximise completeness.  Despite this, information about consanguinity, 
ethnicity and initial biopsy findings were not available for all patients, particularly 
in a few cases where they were first diagnosed in a different centre or country. 
 Regarding long-term outcomes, data were available until the most recent 
RaDaR download in March 2017.  Some patients who were destined to reach 
ESRF may not yet have reached that stage or been transplanted by that point.  In 
addition, patients who reached the age of 18 years and transferred to Adult 
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Nephrology clinics were in some cases lost to follow-up.  Both these factors could 
lower the apparent rate of progression to ESRF.   
 
2.4.4 Conclusions 
Secondary steroid resistance was associated in all cases in this study with non-
genetic disease.  This raises the question of whether, in clinical practice, genetic 
testing should be conducted only for patients with primary or presumed steroid 
resistance.  Genetic testing in a clinical context using a National Health Service 
(NHS)-approved gene panel will be examined in detail in Chapter 4.  Secondary 
steroid resistance also predicted a higher rate of post-transplant recurrence 
pointing to the presence of putative circulating factors.  Analysis of the plasma 
proteome in some patients with such recurrence will be the focus of Chapter 5.  
This chapter has examined long-term outcomes in relation to non-modifiable, 
baseline patient factors (genetics, age at disease onset, pattern of steroid 
responsiveness and renal histology).  Chapter 3 will investigate in more detail the 




Chapter 3 Response to Immunosuppression in 
the UK SRNS Cohort 
3.1 Introduction 
Chapter 2 showed that certain baseline demographic and clinical characteristics in 
patients with SRNS are associated with genetic disease and that both genotype 
and phenotype can predict, to some extent, long-term outcomes.  The optimum 
immunosuppressive treatment strategies for patients with SRNS are not known 
since large, well-controlled clinical trials comparing therapies in stratified groups 
of patients have not been conducted [195, 196].  In the absence of prospective 
trials, retrospective cohort studies have been used to investigate whether baseline 
characteristics affect response to treatment and the effects of immunosuppressive 
drugs on long-term outcomes. 
 As discussed in Chapter 1, data from a German cohort of 231 patients with 
CNS or SRNS were published in 2016 [138] and from the PodoNet cohort of 1354 
in 2017 [226].  Overall, a minority (< 20%) of cases with confirmed genetic cause 
for SRNS responded to immunosuppression compared with over 40% of patients 
with non-genetic disease achieving complete or partial remission on treatment 
(see Table 1.9 and Table 1.10). 
 The aim of this study was to examine the response to immunosuppressive 
treatment in the UK cohort of patients with childhood-onset SRNS stratified by 






The RaDaR cohort of patients with NS was used as the source of cases as 
described in Chapter 2.  At March 2017, a total of 1785 patients had been 
recruited.  Two groups of patients were included for analysis of response to 
treatment.  The first group was the same 187 patients who had had genetic 
analysis by WES and were described in Chapter 2 and previously published [1].  
In order to expand the cohort and include patients with comparable clinical 
features, the RaDaR cohort of 1785 was filtered by age of onset < 18 years and 
then by diagnosis of SRNS (Figure 3.1).  The 187 patients already identified were 
excluded leaving 181 patients.  The “gene test” sections and free text entries 
within the RaDaR database were searched to discover those who had had clinical 
genetic testing with results available.  RaDaR consent permitted access to 
participants’ medical records, therefore the results of genetic testing undertaken 
by Bristol Genetics Laboratory (BGL) at Southmead Hospital were checked for 
the 181 patients.  BGL offered clinical genetic testing through the NHS using an 
NGS panel of 37 genes associated with SRNS.  This will be the focus of Chapter 
4.  By these means, an additional 63 patients with genetic test results were 







































RaDaR Nephrotic Syndrome cohort at 
March 2017  
n = 1785 
< 18 years at onset 
n = 713 
SRNS 
n = 366  
SSNS included in 
187 WES cohort 
n = 2 
WES cohort previously 
published 
n = 187 
 
Non – WES cohort 
n = 181 
Genetic  
n = 52 
Clinical genetic testing 
results available 
n = 63 
Genetic 
n = 21 
Non-genetic  
n = 135 
Non-genetic 
n = 42 
Figure 3.1: Flowchart of patients from the UK RaDaR Nephrotic Syndrome 




3.2.2 Clinical data 
Demographic, clinical and long-term outcome data were extracted from the 
RaDaR database as previously described in Section 2.2.5. 
 
3.2.3 Medication data 
The RaDaR database current to March 2017 was downloaded into Microsoft 
Excel and filtered on the 250 patients included in this part of the study.  The 
medication fields including the name of the drug, and start and stop dates, were 
extracted.  In order to avoid missing treatments which had not been entered in the 
correct sections of the registry, a search was conducted on free text sections of the 
database which in many cases included anonymised copies of patient clinic letters. 
The text search terms are summarised in Table 3.1. 
 
Table 3.1: Terms for free text search for medications 











The search also used the associated medication proprietary names, common 
abbreviations (e.g. MMF) and alternative spellings (e.g. cyclosporin).   
 Since the aim of this study was to examine the disease-modifying anti-
proteinuric effect of the medications, they were filtered to include only those with 
a start date prior to the date of onset of ESRF.  For each patient, the medications 
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were sorted by chronological order of start date.  For IIS drugs, only the first 
course of each drug was included for analysis.  Therefore, for a particular 
medication, each treatment course corresponded one-to-one with a different 
patient.  This enabled valid analysis on the basis of the number of treatment 
episodes (which was equivalent to the number of independent patients).   
Since the evaluation of response (discussed below) used a window of 6 
months after the start date, in the case of rituximab this may include several 
intravenous doses.  For ACEi and ARB, individual drugs were considered by class 
and only the first course within each class was included for analysis.  For 
example, in a patient who first received enalapril and was later changed to 
lisinopril, only the response to enalapril would be evaluated. 
 
3.2.4 Management of missing medication data 
The list of all patients receiving at least one ACEi/ARB or IIS prior to ESRF was 
compared with the total list of 250 patients.  The RaDaR data for those appearing 
not to be receiving any of these medications were reviewed in detail.  In some 
cases, a reason for the lack of medication became evident including: 
• CNS 
• The patient already being in CKD or ESRF at presentation 
• SRNS as part of a syndromic or familial pattern 
• SSNS (who were included in the 187 WES cohort). 
If no explanation became obvious, the research teams at local recruiting centres 




3.2.5 Analysis of response to medication 
The primary outcome was defined using the change in plasma albumin and 
proteinuria before and within 6 months after starting the medication.   
Complete response (CR) was defined as: 
• Urine protein:creatinine ratio (uPCR) < 20 mg/mmol or negative/trace 
dipstick proteinuria within 6 months of starting therapy. 
Partial response (PR) was defined as: 
• uPCR > 20 mg/mmol or dipstick ≥ 1+ but plasma albumin > 25 g/L within 
6 months of starting therapy. 
In cases where the plasma albumin was already > 25 g/L prior to starting 
treatment but remained above this in the following 6 months and proteinuria did 
not reach the threshold for CR, this was classed as PR. 
 The following laboratory data were extracted from the RaDaR database for 
all patients who received the medications under investigation: 
• Plasma albumin 
• uPCR 
• Urine dipstick protein 
• Urine albumin:creatinine ratio (ACR) 
If all measures of proteinuria were available, preference was given to uPCR.  If 
only urine ACR was available, a value < 3.0 mg/mmol was considered equivalent 
to uPCR < 20 mg/mmol. 
In the cases where the RaDaR record was electronically linked to 
laboratory data via Renal PV, complete results were available.  In some cases, 
however, only limited laboratory data were available which had been entered 
manually by the research teams.  The data closest to, and prior, to the medication 
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start date were taken as the baseline.  Where complete results were available, the 
lowest uPCR and highest plasma albumin achieved together were used to judge 
against the criteria for CR and PR. In some cases, only single results were 
available during the time frame.   
If a medication was stopped within 6 months of starting, only laboratory 
data while receiving the medication were used to judge response, except in the 
cases of rituximab and IV cyclophosphamide which were given as intermittent 
doses rather than daily.  If two medications were started simultaneously or within 
1 month of each other, the same response outcome was assigned to both although 
it was not possible to determine which of the two, or the combination, was 
responsible for any improvement. 
 
3.2.6 Management of missing medication response data 
After completion of the above analysis, the medications for which a response 
could not be assigned were identified.  In all cases this was due to incomplete 
laboratory data.  Research teams at recruiting centres were approached to provide 
the relevant missing laboratory results.  In addition, they were given an option to 
complete a spreadsheet listing their patients and ACEi/ARB and IIS medications 
which they were invited to complete to indicate which medications they had 
received and the response using the same criteria for CR and PR as above.   
 In order to maximise medication response completeness, free text entries 
in RaDaR in the period after the start date were reviewed both for laboratory 
results and the clinician opinion.   If laboratory data alone, sought in a variety of 
ways, were insufficient to make a judgement on medication response, the overall 
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clinician opinion and statements such as “absence of proteinuria” or “in 
remission” were used to assign a response. 
 
3.2.7 Data analysis 
The proportions of patients achieving CR and PR for each medication were 
calculated for the cohort as a whole and stratified by genetic/non-genetic disease 
and by pattern of steroid resistance.  As discussed in Chapter 1, patients with non-
genetic disease who suffer post-transplant recurrence represent those most likely 
to have a pathogenic circulating factor.  The response to IIS medications was 
examined particularly in this subgroup. Since clinicians often use IS drugs in a 
particular sequence, some drugs were used more often only after failure of others 
in patients who are then considered more “resistant”.  To attempt to avoid this 
bias, outcomes for only the first IIS drug used per patient were analysed.   
  
3.2.8 Statistical analysis 
Data were analysed using Microsoft Excel 2013 and GraphPad Prism 7.  
Comparisons for proportions between cohorts and groups with data in 2 × 2 
contingency tables used Fisher’s exact test.   Other analysis was conducted as 





3.3.1 Patient characteristics in the two cohorts 
The demographic features of the 187 patients who underwent WES have been 
described in Chapter 2.  The characteristics of the additional 63 patients who had 





Table 3.2: Demographic characteristics of 63 patients who had clinical 
genetic testing 















63 42 (66.7) 21 (33.3)  
Male (%)  31 (49.2) 23 (54.8) 8 (38.1) 0.29 
Age at onset 
(years) – 
number (% of 
column total) 
0-0.25 19 (30.2) 6 (14.3) 13 (61.9) 
 
0.25-1 2 (3.2) 2 (4.8) 0 (0) 
1-5 22 (34.9) 19 (45.2) 3 (14.3) 
6-12 14 (22.2) 9 (21.4) 5 (23.8) 







13 / 49 
(26.5) 
8 / 36 
(22.2) 








11 / 50 
(22.0) 
5 / 36 
(13.9) 
6 / 14 
(42.9) 
0.052 
Ethnicity (% of 
patients where 
data available) 
White 38 (73.1) 28 (75.7) 10 (66.7) 
0.61* 
Asian 10 (19.2) 7 (18.9) 3 (20.0) 
Black African / 
Caribbean 
3 (5.8) 1 (2.7) 2 (13.3) 
Other 1 (1.9) 1 (2.7) 0 (0) 
No ethnicity 
data available 
11 5 6  
First biopsy 
findings (% of 
patients where 
data available) 
FSGS 26 (59.1) 23 (69.7) 3 (27.3) 
0.015† 
MCD 5 (11.4) 4 (12.1) 1 (9.1) 
MHc 4 (9.1) 1 (3.0) 3 (27.3) 
ESRF 2 (4.5) 0 (0) 2 (18.2) 
FGGS 2 (4.5) 1 (3.0) 1 (9.1) 
DMS 1 (2.3) 0 (0) 1 (9.1) 
Collapsing 
glomerulopathy 
1 (2.3) 1 (3.0) 0 (0) 
Other 3 (6.8) 3 (9.1) 0 (0) 
No biopsy data 
available / Not 
biopsied 




Presumed 23 (36.5) 7 (16.7) 16 (76.2) 
 
Primary 34 (54.0) 29 (69.1) 5 (23.8) 
Secondary 4 (6.4) 4 (9.5) 0 (0) 
Not tried 2 (3.2) 2 (4.8) 0 (0) 
Percentages are calculated for column totals. p values are for the comparison 
between genetic and non-genetic disease.  
* For chi-squared analysis, “Black African / Caribbean” and “Other” were 
combined into one group  
† For chi-squared analysis, “MHc”, “ESRF”, “FGGS”, “DMS”, “Collapsing 
glomerulopathy” and “Other” were combined into one group 
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Legend: DMS, diffuse mesangial sclerosis; FSGS, focal segmental 
glomerulosclerosis; MCD, minimal change disease; MHc, mesangial 
hypercellularity; TBMN, thin basement membrane nephropathy 
 
 
For patients with available data, the group of 63 patients with CGT results 
had a significantly higher frequency of positive family history (26.5% vs 11.8%, p 
= 0.022, Fisher’s exact test) and consanguinity (22.0% vs 7.2%, p = 0.0066, 
Fisher’s exact test) compared with the 187 WES group.  There was also a higher 
frequency of CNS (19/63 [30.2%] vs 15/187 [8.0%]) and presumed steroid 
resistance (36.5% vs 13.5%, p = 0.0002, chi-squared, 2df for the comparison of 
presumed, primary and secondary steroid resistance between the two cohorts).   
Despite these contrasts there was no statistically significant difference in rates of 
genetic disease (33.3% of 63 vs 27.8% of 187, p = 0.43, Fisher’s exact test).  The 
difference in clinical characteristics may partly be due to clinicians referring 
patients for CGT where there was a perceived higher prior probability of genetic 
disease.  It is also likely that WES had a higher detection rate than single gene or 
gene panel testing.   
 For analysis of ethnicity, “Indian”, “Pakistani”, “Bangladeshi” and 
“Asian” were combined into one group, and “Mixed” and “Other” into a second 
group.  There was no significant difference in ethnic groups between the 187 
WES and 63 CGT cohorts (p = 0.48, chi-squared, 3df).  For analysis of initial 
biopsy findings, four groups were used: FSGS, MCD, MHc and Other.  There was 




3.3.2 Medications administered and completeness of response data 
The number of treatments received by patients in the WES group is shown in 
Table 3.3 and by patients in the CGT group in Table 3.4.   
 
Table 3.3: Number of treatments and availability of outcome response data in 




























or IIS (%) 
Total 
29 / 187 
(15.5) 









8 - - - 
Syndromic 3 - - - 
Steroid-
sensitive 
1 - - - 










or IIS 158 / 187 
(84.5) 
407 
152 / 158 
(96.2) 








19 / 158 
(12.0) 
- - - 
IIS only 64 /158 
(40.5) 
- - - 
ACEi/ARB 
and IIS 
75 / 158 
(47.5) 






94 / 158 
(59.5) 
113 / 407 
(27.8) 
79 / 94 
(84.0) 
95 / 113 
(84.1) 
All IIS 139 / 158 
(88.0) 
294 / 407 
(72.2) 
135 / 139 
(97.1) 





Table 3.4: Number of treatments and availability of outcome response data in 
CGT group of patients 


















Total cohort  63 - - - 
Not receiving 
ACEi/ARB or 
IIS (% of 63 
patients) 
Total 
19 / 63 
(30.2) 
- - - 
Reason for no 
ACEi/ARB or 
IIS 








3 - - - 
Total receiving 
treatments (% 





44 / 63 
(69.8) 
95 
38 / 44 
(86.4) 






12 / 44 
(27.3) 
- - - 
IIS only 14 / 44 
(31.8) 
- - - 
ACEi/ARB 
and IIS 
18 / 44 
(40.9) 





30 / 44 
(68.2) 
35 / 95 
(36.8) 
25 / 30 
(83.3) 
28 / 35 
(80.0) 
All IIS 32 / 44 
(72.7) 
60 / 95 
(63.2) 
31 / 32 
(96.9) 




The proportion of patients not receiving ACEi/ARB or IIS in the CGT 
group was higher than in the WES group (30.2% vs 15.5%) broadly as a result of 
the higher number of patients with CNS in the former cohort.  In both groups, of 
all patients receiving any medication the majority were given at least one IIS drug 
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(88.0% and 72.7%).  On average, each patient received 2 different IIS treatments.  
Almost half (47.5% and 40.9%) received both ACEi/ARB and IIS at some stage.   
For all treatments that were administered, the completeness of response 
outcomes was above 85% in both cohorts.  The 371 treatments with known 
outcomes were given to 152 patients in the WES group and the 81 treatments 
were given to 38 patients in the CGT group.  The clinical profiles of these patients 

















































































































W E S  c o h o r t (n  = 1 5 2 )
C G T  c o h o rt (n  =  3 8 )
 
Figure 3.2: Clinical characteristics of patients for whom medication and 
response data were known 
ESRF/transplant status were unknown for 3 patients in the CGT cohort.  All other 
data in both cohorts were complete. 
 
In general, the characteristics of patients in the two cohorts were similar, 
although there was a higher frequency of CNS and presumed steroid resistance in 
the CGT cohort.  The apparent higher proportion of post-transplant recurrence in 
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this group (57.1%) in fact represented 4 of 7 patients and was not significantly 
different from 41.7% in the WES group (p = 0.68, Fisher’s exact test). 
 In the subsequent assessment of responses to individual medications, data 
from all 190 patients from both cohorts were pooled and analysed together. 
 
3.3.3 Response to immunosuppressive medications in the whole 
cohort 
Of the 190 patients, 166 were given a total of 329 IIS treatments for which 
outcome data were available.  The numbers of drug treatments and response rates 







































































































































C o m p le te  re s p o n s e
P a rtia l re s p o n s e
 
Figure 3.3: Response to intensified immunosuppressive (IIS) medications 





Around 50% of patients achieved either CR or PR when treated with each 
of ciclosporin, tacrolimus, MMF or rituximab.  However, the proportion of 
patients achieving either CR or PR was lower at 31.8% for cyclophosphamide and 
only 11.4% achieved CR.    
 
3.3.4 Response to first immunosuppressive medications in the whole 
cohort 
Although the average number of IIS treatments for which outcome data were 
known was 2.0 per patient, the actual number of treatments administered varied 
between 1 and 5 and the distribution is shown in Table 3.5. 
 
Table 3.5: Number of immunosuppressive treatments administered per 
patient 













Since the second or subsequent IIS treatments may have been used in 
patients who had already failed the first therapy, the analysis of response rate may 
be confounded by the sequence in which clinicians chose to administer the 
medications.  In order to avoid this potential bias, response rates to only the first 
treatment were examined. 
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 Ciclosporin was the first treatment in 76 patients (45.8%), tacrolimus in 39 
(23.5%) and cyclophosphamide in 33 (19.9%) with the other medications being 
used in fewer than 10 patients each.  While MMF and rituximab were relatively 
frequently used in the entire cohort, they represented only a relatively small 
proportion of first-line IIS therapy.  The responses to all initial treatments are 





































































































































C o m p le te  re s p o n s e
P a rtia l re s p o n s e
 
Figure 3.4: Response to first-administered intensified immunosuppressive 
(IIS) medications 
 
Of the three most frequently-used first-line treatments, ciclosporin and 
tacrolimus appeared to have similar levels of response (CR in 26.3% and 25.6% 
of patients respectively).  Both had a higher response than cyclophosphamide 
(9.1% of patients achieved CR), although not statistically significant in the case of 
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tacrolimus (p = 0.045 for cyclophosphamide versus ciclosporin; p = 0.12 for 
cyclophosphamide versus tacrolimus). 
 Other patient characteristics and long-term outcomes grouped by response 
to first IIS treatment are shown in Table 3.6.   
137 
 
Table 3.6: Characteristics and long-term outcomes of patients stratified by 
response to first immunosuppressive treatment 
  Total 
with 
outcomes 




166 37 38 91 5 
First-line IIS 
treatment 
Ciclosporin 76 20 19 37 3 
Tacrolimus 39 10 8 21 0 
MMF 8 2 1 5 0 
Cyclo-
phosphamide 
33 3 7 23 2 
Rituximab 5 1 1 3 0 
Levamisole 4 1 2 1 0 
Azathioprine 1 0 0 1 0 
Age at onset 
(years) – 
number (% of 
column total) 
















































































































50 / 164 
(30.5) 
2 / 36 
(5.6) 
4 / 38 
(10.5) 
44 / 90 
(48.9) 




 35 / 164 
(21.3) 
1 / 36 
(2.8) 
3 / 38 
(7.9) 
31 / 90 
(34.4) 









19 / 35 
(54.3) 
1 / 1 
(100) 
0 / 3 
(0) 
18 / 31 
(58.1) 
2 / 3 
(66.6) 
Legend: ESRF, end stage renal failure; IIS, intensified immunosuppressive; 





As might be expected, only a small number of patients with CNS or 
infantile-onset were given IIS treatment.  More detailed analysis of responses for 
patients stratified by genetic disease will be discussed in Section 3.3.5, stratified 
by pattern of steroid resistance in Section 3.3.6, stratified by first biopsy findings 
in Section 3.3.7 and the long-term outcomes in Section 3.3.9. 
 
3.3.5 Response to immunosuppressive medications stratified by 
genetic disease 
Of 166 patients who were treated with IIS medications and with outcome data 
available, 24 (14.5%) had genetic disease.  When only first-line ISS treatments 
were considered (Table 3.6), CR was seen in 4.2% of patients and PR in 37.5% of 
patients.  These were significantly different from the corresponding responses for 
patients with non-genetic disease (25.4% achieved CR and 20.4% achieved PR, p 
= 0.033, chi-squared, 2df).  However, the proportion of patients achieving either 
CR or PR was not significantly different between patients with genetic versus 
non-genetic disease (41.7% versus 45.8% respectively, p = 0.83, Fisher’s exact 
test). 
In total, 40 IIS medications were administered to the 24 patients with 
genetic disease (1.7 medications/patient) and 289 were given to 142 patients with 
non-genetic disease (2.0 medications/patient).  The numbers of drug treatments 































































































































































N o n -g e n e tic : c o m p le te  re s p o n s e
N o n -g e n e tic : p a r tia l re s p o n s e
G e n e tic : c o m p le te  re s p o n s e
G e n e tic : p a rtia l re s p o n s e
 
Figure 3.5: Response to intensified immunosuppressive (IIS) medications in 
patients with genetic or non-genetic disease 
Details in brackets are the total number of treatments given to patients with 
genetic (G) or non-genetic (NG) disease 
 
When considering all IIS treatments, 26.6% of patients with non-genetic 
disease had CR and 24.2% of patients had PR.  12.5% of patients with genetic 
disease had CR and 32.5% of patients had PR.  There was no significant 
difference in the number of patients achieving complete or partial remission 
between the two groups (p = 0.50, Fisher’s exact test); nor was there a difference 
in the number of patients achieving complete remission alone (p = 0.053). 
When considering each drug separately, there was no significant 
difference between patients with genetic disease and those with non-genetic 
disease in relation to the number achieving CR or PR when treated with 
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ciclosporin (35.7% vs 55.2%, p = 0.25), tacrolimus (75.0% vs 57.0, p = 0.46), 
MMF (50.0% vs 48.7%, p > 0.99), cyclophosphamide (16.7% vs 34.2%, p = 0.65) 
or rituximab (25.0% vs 47.4%, p = 0.61).  In general, the number of patients with 
genetic disease receiving IIS medications was small and the numbers given 
levamisole and azathioprine were too small for analysis. 
Two patients with genetic disease appeared to achieve CR with IIS 
medications.  The details of these patients are shown in Table 3.7 with full clinical 
information available in Table 10.1 and Table 10.2 in the Appendices. 
 
Table 3.7: Patients with genetic disease who had complete response to 
immunosuppression 



















there was a 
complete 
response 
















According to RaDaR data, patient 7656 was not on ACEi or ARB but was 
started on MMF and tacrolimus concomitantly which was confirmed by the local 
research team.  Patient 353 was treated initially with ciclosporin, started MMF 
over 3 years later and was given rituximab 4 years after that.  Unusually this 
patient had a congenital onset of disease but was steroid-sensitive and was found 
to have compound heterozygous possibly-pathogenic variants in NPHS1 
(c.1747G>A:p.Glu583Lys; c.2734G>A:p.Ala912Thr).  The c.1747G>A variant 
had a frequency in EXaC of 0.0001065 and the other variant was not reported in 
that database.  Neither had been reported previously in patients and in the absence 
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of parental samples from patient 353, it was not possible to confirm that the 
variants were in trans (personal communication, Dr Agnieszka Bierzynska). 
 Nine patients with genetic disease appeared to show PR to the first-
administered IIS.  These patients are detailed in Table 3.8 with complete clinical 
and outcome information in the tables at the Appendices. None has progressed to 
ESRF, although follow-up for three patients was under 2 years.   
 
Table 3.8: Patients with genetic disease who had partial response to first 
immunosuppression 


























Other 1 No 17.7 Levamisole 




M 7.1 primary FSGS 1 No 0.4 Ciclosporin 
687 CRB2 F 0.8 presumed MCD 1 No 4.0 Levamisole 
729 NPHS2 M 7.9 primary Other 2 Asthma 2.8 Tacrolimus 








770 COL4A3 F 7.9 primary FSGS 1 No 2.5 Ciclosporin 












In 2 patients (495 and 900) the response was based on the opinion of the 
treating clinician.  In the remaining 7, plasma albumin was ≥ 30g/L and for the 6 
with proteinuria data, uPCR or dipstick proteinuria decreased from > 200 
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mg/mmol to < 80 mg/mmol or 2+ within the period following the start of IIS 
therapy.  Based on RaDaR data, one patient (514) started enalapril shortly after 
ciclosporin and the observed partial response may, therefore, have been due to the 
combination of treatment rather than IIS alone. 
 Three of the patients (353, 687, 731) had congenital or infantile-onset 
disease and may not have been expected to respond to IIS drugs.  Two of these 
were subsequently found to have likely-pathogenic variants in genes that were 
novel or rarely associated with childhood SRNS (MAGI2 in 731 and CRB2 in 
687).  The other patients’ disease was caused by a range of different genes and 
showed response to various immunosuppressive drugs and it is, therefore, difficult 
to draw any broader conclusions. 
 
3.3.6 Response to immunosuppressive medications stratified by 
pattern of steroid resistance 
 
Of the 166 patients who were given IIS medications and with treatment responses 
available for analysis, 4 had presumed, 133 had primary and 26 had secondary 
steroid resistance.  The remaining 3 had SSNS and were not included in the 
subsequent analysis. 
 As discussed in Chapter 2, patients with non-genetic disease and 
presumed/primary steroid resistance (NGPPSR, 114 patients) may represent a 
subgroup distinct from those with secondary steroid resistance (SSR, 26 patients), 
therefore the responses of these groups to IIS were compared.  When considering 
only first-line IIS medications (Table 3.6), CR was achieved in 25 patients with 
NGPPSR (21.9%), and PR in 23 patients with NGPPSR (20.2%) compared with 
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10 patients with SSR who achieved CR (38.5%) and 6 patients with SSR who 
achieved PR (23.1%) (p = 0.14, chi-squared, 2df).  There was no significant 
difference in the number of patients who achieved CR or PR between the two 
groups (p = 0.08, Fisher’s exact test). 
In total, 140 patients received 285 IIS medications.  The numbers and 
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Figure 3.6: Response to intensified immunosuppressive (IIS) medications in 
patients with non-genetic presumed/primary steroid resistance and 
secondary steroid resistance 
Details in brackets are the total number of treatments given to patients with non-





Overall, when considering all 285 IIS treatment episodes, the frequency of 
CR was 21.8% and PR was 25.5% for patients with NGPPSR compared with 
41.5% and 20.0% respectively for patients with SSR.  In patients with SSR, the 
number of treatment episodes leading to CR was significantly higher than in 
patients with NGPPSR (p = 0.0022, Fisher’s exact test).  Likewise, the number of 
treatment episodes leading to CR or PR was higher in patients with SSR 
compared with those with NGPPSR (p = 0.049).  Analysis of individual 
medications showed that rituximab led to CR in 66.7% of patients with SSR 
compared with 19.2% of patients with NGPPSR (p = 0.0086).  Likewise, 
rituximab led to CR or PR in 75.0% of patients with SSR compared with 34.6% of 
patients with NGPPSR (p = 0.035).  There was no significant difference in 
responses between the groups to ciclosporin, tacrolimus, MMF or 
cyclophosphamide. 
 
3.3.7 Response to immunosuppressive medications stratified by first 
biopsy findings 
Of 166 patients who were given IIS medication and with treatment responses 
available, 162 had biopsies performed with results for analysis.  FSGS was seen in 
96 (59.3%) first biopsies, MCD in 41 (25.3%), MHc in 11 (6.8%) and other 
findings in 14 (8.6%).  The treatments given and clinical characteristics of the 





Table 3.9: First immunosuppressive treatments, characteristics and long-
term outcomes of patients stratified by first biopsy findings 








164 96 41 11 14 
First-line IIS 
treatment 
Ciclosporin 75 47 15 7 6 
Tacrolimus 37 22 9 1 5 
MMF 7 2 4 0 1 
Cyclo-
phosphamide 
33 20 10 2 1 
Rituximab 5 3 1 1 0 
Levamisole 4 1 2 0 1 
Azathioprine 1 1 0 0 0 
Age at onset 
(years) – 
number (% of 
column total) 
















































































































50 / 161 
(31.1) 
34 / 95 
(35.8) 
11 / 41 
(26.8) 
3 / 11 
(27.3) 




 35 / 161 
(21.7) 
26 / 95 
(27.4) 
7 / 41 
(17.1) 
1 / 11 
(9.1) 









19 / 35 
(54.3) 
11 / 26 
(42.3) 
6 / 7 
(85.7) 
1 / 1 
(100) 






Considering only the groups with FSGS and MCD, there was no 
significant difference between the specific first IIS medication administered (p = 
0.26, chi-squared, 4df, with rituximab, levamisole and azathioprine combined into 
one group); no difference in age at onset (p = 0.41 chi-squared, 2 df with 0-5 years 
as one group); no difference in presumed/primary versus secondary steroid 
resistance (p = 0.068, Fisher’s exact test); no difference in frequency of genetic 
disease (p > 0.99, Fisher’s exact test) and no difference in the proportion reaching 
ESRF (p = 0.33, Fisher’s exact test).  There was also no difference in the 
proportion who were transplanted (p = 0.28, Fisher’s exact test) or in post-
transplant recurrence (p = 0.085, Fisher’s exact test). 
The responses to first-line IIS treatment based on first biopsy findings are 
shown in Figure 3.7. 
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Figure 3.7: Response to first intensified immunosuppressive (IIS) 
medications in patients stratified by first biopsy findings 





Overall, there was no significant difference in response to first-line IIS 
between the groups based on first biopsy findings (p = 0.19, chi-squared, 6df). Of 
the group with “other” biopsy findings 21.4% of patients achieved CR and 50% of 
patients achieved PR.  These proportions were significantly different when 
compared with the responses of the other three groups (FSGS + MCD + MHc) 
combined (p = 0.032, chi-squared, 2df).  “Other” findings included four with 
mesangial proliferation, two with focal global glomerulosclerosis, two with C1q 
nephropathy, one each with DMS, collapsing glomerulopathy, Alport’s, thin 
membrane disease, IgA nephropathy, and one unspecified. 
 When considering only the two most prevalent histology findings (FSGS 
and MCD), there were no significant differences in patients achieving CR (21.9% 
in patients with FSGS versus 24.4% in those with MCD, p = 0.82, Fisher’s exact 
test) or in those who achieved either CR or PR (44.8% in patients with FSGS 
versus 41.5% in patients with MCD, p = 0.85, Fisher’s exact test). 
 In total, the 162 patients with reported biopsy results were given 320 ISS 
medications.  The numbers and responses to all IIS treatments stratified by biopsy 
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Figure 3.8: Response to all intensified immunosuppressive (IIS) medications 
in patients stratified by first biopsy findings 
Details in brackets are the total number of treatments received by patients with 
each of the biopsy findings 
 
When considering the response in patients to all IIS treatments, there was 
no significant difference between groups with different biopsy findings (p = 0.50, 
chi-squared, 6df).  In this analysis, patients with “other” findings on biopsy had no 
difference in response compared with the other groups (p = 0.15, chi-squared, 
2df).  There were no differences in either the numbers achieving CR or the 
numbers achieving either CR or PR between patients with FSGS and those with 
MCD (p = 0.55 and p = 0.80 respectively, Fisher’s exact test). 
 
3.3.8 Prior response to immunosuppressive medications in patients 
with post-transplant disease recurrence 
Although post-transplant disease recurrence cannot be used as a predictive marker 
for direct management in clinical practice, as discussed previously, it can give an 
insight into disease biology and indicate patients likely to have a circulating factor 




Of the 166 patients in the current analysis, 35 received a transplant and 
recurrence occurred in 19 (54.3%).  These included 17 with primary steroid 
resistance (none genetic) and 2 with secondary steroid resistance.  This group of 
19 patients received 43 IIS treatments.  The 16 who did not suffer post-transplant 
recurrence included 14 with primary steroid resistance (7 genetic) and 2 with 
secondary steroid resistance.  Excluding patients with genetic disease, the 9 
patients received 13 IIS treatments. 
The numbers of patients receiving individual medications were too small 
for statistical analysis.  Of the 43 treatment episodes relating to 19 patients who 
were later treated for post-transplant disease recurrence, CR was achieved in 4.7% 
of treatment episodes and PR in 4.7% of treatment episodes.  Among the 13 
treatments given to 16 patients with no post-transplant recurrence, the CR 
response rate was 0% and the PR rate was 23.1% of treatment episodes.  None of 
the latter patients who achieved PR concurrently started treatment with ACEi or 
ARB. 
 
3.3.9 Long term outcomes in patients with SRNS stratified by 
response to first immunosuppressive treatment 
The response to initial immunosuppression is sometimes used by clinicians when 
offering prognostic information to patients.  The responses to first-line IIS 
treatments were discussed earlier in Section 3.3.4.    The long-term outcomes 
including progression to ESRF, transplantation and post-transplant recurrence 
were detailed above in Table 3.6. 
 Among the 166 patients treated with IIS drugs and with known outcomes, 
the CKD status at most recent follow-up was known for 164.  For these, the total 
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follow-up time was 844.4 patient-years with median 4.3 years (IQR 2.2-7.5, range 
0.1-17.8 years).  
 The frequency of progression to ESRF clearly increased from 5.6% in 
those with CR, to 10.5% in those with PR and to 48.9% in those with no response 
to first IIS treatments (p < 0.0001, chi-squared, 2df).  The frequency of 
transplantation was also significantly higher in patients failing to respond to the 
first treatment (p < 0.0001, chi-squared, 2df).   
Patients with no response to first IIS therapy had significantly more rapid 
progression to ESRF as shown in the Kaplan-Meier survival curves with p < 
0.0001 by log-rank (Mantel-Cox) test (Figure 3.9).  The five-year ESRF-free 
survival rates were 93.8%, 90.3% and 60.0% for patients with CR, PR and no 
response respectively.  The corresponding 10-year rates were 93.8%, 81.3% and 
25.7%. 




























C o m p le te  re s p o n s e
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36 31 19 11 5 3 2 0  Complete response 
38 28 20 15 9 2 2 2  Partial response 
90 60 32 15 6 1 1 0  No response 
 
Figure 3.9: Kidney survival analysed by response to first immunosuppressive 
treatment 




Post-transplantation disease recurrence occurred in 25% (1/4 patients) who 
achieved either CR or PR versus 58.1% (18/31 patients) who did not respond to 
IIS, although this difference was not statistically significant (p = 0.31, Fisher’s 
exact test).  As discussed in Chapter 2 (Section 2.3.6), genetic disease is a strong 
predictor of not developing disease recurrence post-transplant.  In the subgroup 
without genetic disease, recurrence occurred in 25% (1/4 patients) who achieved 
either CR or PR versus 75% (18/24 patients) who did not respond to IIS (p = 
0.084, Fisher’s exact test).  
  
 
3.3.10 Characteristics and outcomes in patients treated with 
rituximab 
Of all IIS treatments, whether analysed collectively or individually, and however 
the patients were stratified, CR was generally seen in below 30% of patients.  The 
most notable exception, as noted in Section 3.3.6, was rituximab used in patients 
with SSR where the frequency of CR was 66.7% (8 of 12 patients).  By definition, 
patients with SSR were at one point steroid-sensitive and it may be that rituximab 
was being used to manage SDNS or FR-SSNS.  In order to understand the 
implications of these findings, patients treated with rituximab were studied in 





Table 3.10: Characteristics and long-term outcomes of patients treated with 
rituximab stratified by response 
  Total 
with 
outcomes 












Age at onset 
(years) – 
number 
0-0.25 1 1 0 0 0 
0.25-1 0 0 0 0 0 
1-5 25 10 3 12 2 
6-12 10 3 0 7 1 




































































































14 / 42 
(31.1) 
1 / 14 
(7.1) 
1 / 5 
(20.0) 






 7 / 42 
(16.7) 
0 / 14 
(0) 
0 / 5 
(0) 











5 / 42 
(11.9) 
- - 
5 / 7 
(71.4) 
- 
Legend: N/A, patients treated with rituximab but for whom outcome data were not 
available. The numbers in brackets are the percentages of the column totals 




Of all patients treated with rituximab, CR was seen in 33.3% and PR in 
11.9%.  CR was observed most frequently in patients with SSR and those with 
MCD.  One patient with genetic disease appeared to have CR to rituximab (patient 
353), but the clinical presentation in this case was of FR-SSNS and they were 
discussed in more detail previously in Section 3.3.5.  Complete or partial response 
to rituximab was associated with a significantly lower frequency of progression to 
ESRF (10.5% versus 52.2%, p = 0.008) and no patients had been transplanted at 
most recent follow-up.  One patient with CR to rituximab (patient 615) progressed 
to ESRF.  Further review of clinical information revealed that the patient 
remained steroid-sensitive at the time of rituximab treatment but became steroid-
resistant 9 months later before progressing to ESRF over the subsequent 4 
months. 
 The timing of starting rituximab after diagnosis of nephrotic syndrome is 





















































































































P S R : c o m p le te  re s p o n s e
P S R : p a rtia l re s p o n s e
S S R : c o m p le te  re s p o n s e
S S R : p a rtia l re s p o n s e
T im e  (y e a rs )  fro m  d ia g n o s is  o f n e p h ro tic
s y n d ro m e  to  s ta r t  o f  r itu x im a b  tre a tm e n t
 
Figure 3.10: Response to rituximab in patients stratified by timing of 
treatment and pattern of steroid response 
Legend: PSR, primary steroid resistance; SSR, secondary steroid resistance  
The exact time between diagnosis and start of rituximab treatment was not known 
for 5 patients with PSR and so are not shown in this figure.   
 
Thirteen patients with PSR were treated with rituximab within the first 
year of diagnosis but only 1 (7.7%) showed CR.  None of the 4 patients with PSR 
with treatment onset after 3 years since diagnosis showed any response.  Overall, 
patients with PSR who had complete or partial response had a younger median 
age at disease onset (2.6 versus 6.0 years, p = 0.39, Mann-Whitney test) and 
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shorter disease duration at time of treatment (0.6 versus 1.4 years, p = 0.19, 
Mann-Whitney test) but the differences were not significant. 
All patients with SSR started rituximab more than 1 year after diagnosis.  
Nine (75%) had CR or PR.  Among patients with SSR, there was no significant 
difference between patients achieving either CR or PR compared with those who 
did not respond to IIS in terms of median age of disease onset (4.0 versus 4.7 
years, p = 0.86, Mann-Whitney test) or median time between diagnosis and 
treatment (3.3 versus 6.4 years, p = 0.28, Mann-Whitney test). 
The responses of patients with SSR to rituximab were examined in greater 
detail.  Of 12 patients treated, 8 had CR and one had PR.  Using data available in 
RaDaR, among the former group of 8 patients it appeared that 3 (patients 413, 
567, 615) had FR-SSNS or SDNS at the time they received rituximab treatment.  
The other 5 patients (457, 469, 475, 505, 552) had been classed as steroid-
resistant (with failure to achieve complete remission of proteinuria on > 4 weeks 
of steroid treatment) prior to receiving rituximab but documented information 
suggested that there was still some responsiveness to steroids.  The patient with 
PR (patient 427) was initially steroid-sensitive but became resistant by 3 months 
after diagnosis and was treated with rituximab 2.5 years later.  The three patients 
with SSR who had no response to rituximab were treated 4 months, 1 year and 10 
years respectively after becoming steroid-resistant and had received 2, 5 and 2 IIS 
drugs previously since original diagnosis with NS.  
 
3.3.11 Response to ACEi and ARB in the whole cohort 
In the whole cohort of 250 patients, based on data available in RaDaR, 124 
patients received ACEi and/or ARB.  A total of 148 drugs in these classes were 
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administered. As highlighted in the Methods, only the earliest-prescribed drug for 
each patient in each of the two classes were considered for analysis.  Response 
data were available for 123 (83.1%) of these treatments which were given to 104 
patients.  Nineteen patients received both ACEi and ARB, 11 patients had ARB 
only and 74 had ACEi only.  The number of treatments and responses are detailed 
in Table 3.11 and shown in Figure 3.11. 
 
Table 3.11: Number of ACEi / ARB treatments administered and responses 
  Total 
with 
outcomes 




123 19 29 75 25 
First ACEi 
All ACEi 93 15 22 56 17 
Captopril 8 1 0 7 0 
Enalapril 42 9 12 21 12 
Lisinopril 13 2 3 8 1 
Ramipril 4 0 0 4 2 
Not specified 26 3 7 16 2 
First ARB 
All ARB 30 4 7 19 8 
Irebesartan 1 0 0 1 1 
Losartan 22 4 5 13 6 
Valsartan 1 0 1 0 0 
Not specified 6 0 1 5 1 
Legend: N/A, patients who received ACEi / ARB but for whom outcome data 
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Figure 3.11: Response to first-administered ACEi and ARB 
Figures in brackets are the total number of treatments 
 
For all ACEi as a class, there were no significant differences in CR between 
patients with genetic versus non-genetic disease, with NGPPSR versus SSR, or 
with FSGS versus MCD.  Considering ARB, there were no differences in CR 
between patients with genetic versus non-genetic disease, or with FSGS versus 




3.4.1 Findings of this study 
The data presented here, from a UK cohort of 166 patients with SRNS/FSGS 
treated with IIS and with genetic testing results available, revealed that the most-
frequent first-line medications were ciclosporin, tacrolimus and 
158 
 
cyclophosphamide with MMF and rituximab also given frequently as second-line 
or subsequent agents.  Overall, the efficacy of the treatments was limited, with 
some response (either CR or PR) in approximately 50% of patients treated with 
ciclosporin, tacrolimus, MMF or rituximab.  The response was lower at 31.8% for 
patients treated with cyclophosphamide. 
 An aim of this study was to ascertain whether stratification of patients by 
baseline characteristics could identify subgroups who were more responsive to IIS 
treatment.  This chapter has examined genetics, pattern of steroid resistance and 
first biopsy findings in particular.   
 
3.4.1.1 Genetic disease 
In patients with genetic disease, confirmed by WES or CGT, there was a 
statistically significantly lower probability of achieving CR to first IIS compared 
with those without genetic disease (4.2% versus 25.4%).  The differences were 
not significant, however, when comparing patients with or without genetic disease 
experiencing any response (either CR or PR) to IIS or when comparing responses 
to all IIS treatment episodes (as opposed to the first-administered).  The PR rates 
in patients with genetic disease were comparatively high (37.5% for first-line IIS 
treatments and 32.5% for all treatment episodes).  The definition of PR was 
ongoing proteinuria (uPCR > 20 mg/mmol or dipstick ≥ 1+) but plasma albumin > 
25 g/L within 6 months of starting therapy.  If plasma albumin was already > 25 
g/L prior to starting treatment but remained above this in the following 6 months 
and proteinuria did not reach the threshold for CR, this was also classed as PR.  
Defined in this way, PR may have been relatively easy to achieve.  However, as 
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the same criteria were applied to all patients, this would not explain differences 
between genetic and non-genetic patients.   
 As a retrospective cohort study, the decisions about which treatments to 
use, and when, were made by the treating clinicians.  The majority of treatments 
examined in this analysis were started prior to 2014, whereas results for WES and 
CGT were becoming available after this time.  Therefore, it is likely that most 
therapy decisions were being made without definite knowledge of genetic status.  
Of 166 patients included who received IIS, 24 (14.5%) had an identified genetic 
aetiology compared with 73 (29.2%) of the original cohort of 250 who had had 
genetic testing (see Figure 3.1).  The response to IIS in patients with genetic 
disease in this study is, therefore, not representative of all inherited forms of 
SRNS.  It is likely that clinicians selected patients to receive IIS based on clinical 
features which they associated with a higher chance of response to that treatment.  
For example, clinicians did not give IIS or ACEi/ARB to 22 patients with CNS 
(see Table 3.3 and Table 3.4) of whom 17 (77.3%) were confirmed to have 
genetic disease. 
 Of the cohort of 166 patients treated with IIS, 10 with genetic disease 
showed CR or PR.  These patients had likely-pathogenic variants in 8 different 
genes and variously showed response to ciclosporin, tacrolimus, MMF, rituximab 
and levamisole.  With such small patient numbers and diverse treatments, it is not 
possible to determine whether any specific treatment may be more effective in 




3.4.1.2 Pattern of steroid resistance 
Patients with genetic disease were excluded from the analysis of response to IIS 
stratified by pattern of steroid resistance.  This study has shown that patients with 
SSR treated with IIS had a significantly higher rate of response compared with 
those with NGPPSR.  When responses to individual IIS medications were 
analysed, this significant difference held for rituximab but not others.   
 Further examination of patients with SSR given rituximab suggested that 
those who showed response generally had some degree of steroid sensitivity at the 
time they received treatment.  A previous double-blind, randomised, placebo-
controlled trial in children with FR-SSNS and SDNS has shown a significantly 
longer relapse-free period after treatment with rituximab compared with placebo 
[206].  Evidence of efficacy of rituximab in these groups of patients with steroid-
responsiveness has also derived from several retrospective cohort studies and case 
series [207].  In contrast, in 31 patients with steroid-resistant and calcineurin 
inhibitor-resistant nephrotic syndrome, an open-label randomised trial of addition 
of rituximab did not show reduction in proteinuria at 3 months [193].  The authors 
did, however, report a non-significant reduction in proteinuria by 48% through 
addition of rituximab in a subgroup of patients with “delayed resistance” defined 
as development of resistance to steroids and calcineurin inhibitors months or years 
after initial diagnosis with NS.  A systematic review of rituximab treatment for 
childhood SRNS included 8 studies and 226 patients [273].    Limited genetic 
testing was performed in 42 patients and 5 were found to have pathogenic variants 
in NPHS2 or WT1.  The systematic review reported complete or partial remission 
in 42% of 100 patients with initial steroid-resistant NS and 53.8% of 65 patients 
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with late steroid-resistant NS. The current study found some response (either CR 
or PR) in 34.6% of patients with NGPPSR and in 75.0% with SSR. 
 As discussed in Chapter 2 and previously published [274], SSR was 
associated with a higher risk of post-transplant disease recurrence and may be a 
marker of (a) pathogenic circulating factor(s).  The efficacy of rituximab in this 
group of patients may be via an indirect effect on this factor or its downstream 
mechanisms.  It is known that rituximab targets CD20 on B cells and reduces their 
number and antibody production in addition to affecting T cell proliferation and 
modulating T-cell subsets [275].   
   
3.4.1.3 Biopsy findings 
For the 162 patients who received IIS and with biopsy results available, this study 
found no significant difference in response to first treatment or all treatments 
based on initial histology.  This suggests that biopsy findings are unlikely to be 
helpful in making a clinical decision about specific IIS medications.   
 
3.4.1.4 Long term outcomes 
This study has shown that the type of response to first IIS treatment is highly 
significantly associated with progression to ESRF and need for transplantation.  
The five-year ESRF-free survival rates were 93.8%, 90.3% and 60.0% for patients 
with CR, PR and no response respectively.  These findings suggest that “response 
to first IIS treatment” has the potential to be used to stratify patients into 
prognostic groups and may help clinicians decide about subsequent treatments.   
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 Figure 3.12 shows a flow chart which builds on stratification of patients by 
pattern of steroid resistance and genetics as discussed in Chapter 2 (Figure 2.6) 





RaDaR SRNS Cohort < 18 
years at onset with genetic 
testing results 
n = 250 
Received IIS treatments with outcomes available 

































































































No treatment given (n = 41: 22 CNS; 
11 CKD at presentation; 4 SSNS; 3 
syndromic; 1 familial) 
ACEi/ARB given but no IIS (n = 31) 
No treatment data available (n = 10) 




Figure 3.12: Flow chart showing long term outcomes in patients stratified by 
pattern of steroid resistance, genetics and response to first-line intensified 
immunosuppressive treatment 
Legend: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CNS, congenital nephrotic syndrome; CKD, chronic kidney 
disease; ESRF, end-stage renal failure; IIS, intensified immunosuppressive 
treatment; NR, no response; R, complete or partial response; Recur, post-
transplant disease recurrence; SRNS, steroid-resistant nephrotic syndrome; SSNS, 
steroid-sensitive nephrotic syndrome; Tx, transplanted 
 
 
Figure 3.12 illustrates that in all cases, some response to first IIS was 
associated with a lower rate of progression to ESRF compared with patients who 
showed no response.  This was also the case in patients with a likely-genetic cause 
for disease: none of the 9 patients who showed some response to IIS had reached 
ESRF (see Table 3.7 and Table 3.8 for further patient details).  It should be noted, 
however, that for this subgroup of patients the median duration of follow-up was 
2.5 years, therefore renal survival at 5 and 10 years is not yet known.  At the most 
recent follow-up, 1 patient was at CKD stage 4, 2 patients at stage 2 and the 
remaining 6 at stage 1. 
 Response to first IIS also has potential to help predict post-transplantation 
recurrence.  In the subgroup of patients with non-genetic disease, recurrence 
occurred in 25% of patients with any response versus 75% with no response, 
although this difference was not statistically significant (p = 0.084).  This was 
probably due to the small numbers of patients who did respond to first IIS that 
needed transplantation (n = 4). 
 
3.4.2 Comparison with other studies 
The current study was the first to have examined response to IIS and long-
term outcomes in a cohort of children with SRNS, all of whom had had genetic 
165 
 
testing with WES or an extensive gene panel.  The most comparable studies were 
the German cohort of 231 patients published in 2016 [138] and the PodoNet 
cohort of 1354 patients from 2017 [226].  Each had slightly differing definitions 
of CR and PR as detailed in Chapter 1 (Section 1.5.3).  The German cohort study 
focused only on response to ciclosporin and reported CR, PR and no response 
rates of 60.5%, 18.5% and 21.0% respectively in patients with non-genetic 
disease, and 3.1%, 15.6% and 81.3% respectively in patients with genetic disease.  
The comparable figures for the current study were 29.9% for CR, 25.3% for PR 
and 44.8% for no response in patients with non-genetic disease, and 7.1%, 28.6% 
and 64.3% respectively in those with genetic disease.  Although the figures 
differed, the studies indicated that around 20% or more patients with genetic 
disease showed some response to ciclosporin.  This may have been via its non-
immunomodulatory effects directly on the podocyte cytoskeleton [276, 277].  The 
PodoNet cohort study reported transient CR in 2.7% and PR in 11% of 74 
children with genetic disease.  Most of these were receiving ciclosporin either 
alone or in combination with methylprednisolone or ACEi/ARB.  Bensimhon et 
al. collated data from 12 studies to identify patients with genetic SRNS who 
responded to ciclosporin [276].  They reported 10 patients achieving CR and 27 
PR.  The patients with CR had pathogenic variants in WT1 (4 patients), ACTN4 
(2), NPHS1 (2), NPHS2 (1) and PLCE1 (1).   Those with PR had variants in 
NPHS2 (15), WT1 (10), COQ6 (1) and EMP2 (1).  These findings together with 
data from this study suggest that patients with genetic disease with variants in a 
wide range of genes can respond to IIS.  Further study will be required to 
understand at a functional level how specific pathogenic variants may render the 
disease responsive to IIS treatments.  In the future, if genetic testing was 
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undertaken at the point of diagnosis of SRNS with results available in a relatively 
short time-frame, clinicians may be able to use knowledge of specific variants to 
decide on treatments.  The use of clinical genetic testing in SRNS will be the 
focus of Chapter 4. 
Looking at the response to IIS other than ciclosporin, this study showed a 
significantly lower response rate to cyclophosphamide.  This was in keeping with 
other large cohort studies [226] and a systematic review of treatments for SRNS 
[192] supporting the recommendation that cyclophosphamide should not be used.  
The present study showed no difference in response between ciclosporin and 
tacrolimus.  Similar results were seen in an RCT with follow-up to 12 months 
[191].  However, another prospective comparative study reported that the 
estimated renal survival at 5 years was significantly better for those treated with 
tacrolimus (79% versus 33%) with fewer side effects [278].     
In the current study, rituximab was associated with CR in 33.3% overall 
and 66.7% in the subgroup with SSR.  Although an open-label RCT showed no 
benefit of addition of rituximab to prednisolone and a calcineurin inhibitor [193], 
several smaller studies have suggested benefit.  A systematic review including 
226 patients with SRNS treated with rituximab reported remission in 40.8% of 
patients with initial steroid-resistance and 52.8% with late steroid-resistance 
[273].  The higher apparent CR rate in the SSR subgroup reported here may have 
been related to some of the patients having a degree of steroid -responsiveness at 
the time they received rituximab. 
Regarding long-term progression to ESRF, findings of this study were 
generally in agreement with those previously published.  Ten-year renal survival 
rates in this cohort were 93.8%, 81.3% and 25.7% for patients achieving CR, PR 
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and no response respectively.  The equivalent figure for the PodoNet cohort were 
94%, 72% and 43% [226].  Ten-year outcomes were not reported in the German 
cohort study but maintenance of normal renal function at most-recent follow-up 
(median 94 months) was seen in 98% of patients with CR to ciclosporin, 67% 
with PR and 47% with no response [138].   
 
3.4.3 Limitations 
As a retrospective, non-controlled study, various factors should be considered in 
the interpretation of the findings.  Many patients likely received concomitant 
treatments alongside IIS.  In some cases, IIS were given simultaneously, 
ACEi/ARB were used with IIS or albumin infusions administered.  When two IIS 
were started in parallel, the outcome during the next 6 months was assigned to 
both drugs. The use of other therapies alongside IIS were likely to inflate the 
numbers appearing to show response, particularly for PR defined as an increase in 
plasma albumin > 25 g/L.  Due to the nature of a retrospective study where 
treatment decisions were made by local clinicians, the direct effects attributable to 
IIS could not be known with certainty. 
 All efforts were made to obtain complete data with direct requests for 
specific data items missing from RaDaR sent to the local teams.  Despite this, 
some patients had no record of medications administered and in other cases the 
laboratory data available was insufficient to be certain of response to treatment.  
In the latter case, free text entries, which included anonymised copies of clinic 
letters, were reviewed and clinicians contacted directly to provide an opinion on 
the response to treatment using the same definitions of CR and PR. 
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 The outcome data relating to patients with genetic disease were 
representative only of the subset of patients to whom clinicians decided to give 
IIS.  In most cases it was unlikely that genetic testing results were available when 
decisions were made about starting the first IIS, therefore baseline clinical 
characteristics, such as age of onset < 3 months or associated syndromic features, 
would have influenced that decision.  A prospective study with genetic testing at 
presentation and results available within weeks together with standardised follow-
up data would help in the understanding of which patients with genetic disease 
may benefit. 
 The analyses using data from all IIS treatments during the course of 
patients’ disease may have been subject to bias resulting from the sequence in 
which clinicians tend to prescribe the drugs.  Those used more frequently as 
second- or third-line IIS were more likely to be administered to patients with a 
“drug-resistant” phenotype and so may appear less effective.  In order to avoid 




This study has demonstrated a similar efficacy of tacrolimus and ciclosporin when 
used a first-line IIS, and significantly higher than cyclophosphamide, but with CR 
in only around 25%.   Rituximab was associated with a better response in patients 
with SSR compared with those with NGPPSR.  Complete response to first IIS was 
significantly lower in patients with genetic compared with non-genetic disease.  
However, several patients with a likely-genetic cause for disease did show at least 
partial response.  Irrespective of the genetic aetiology, complete or partial 
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response to the first-line IIS was associated with better long-term outcomes and 
kidney survival at 5 and 10 years. 
 This study focused on a UK cohort, many of whom had genetic analysis 
by WES on a research basis.  Chapter 4 will examine the utility and outcomes of 




Chapter 4 Clinical Genetic Testing using an 
SRNS Gene Panel 
4.1 Introduction 
As discussed in earlier chapters, genetic analysis of patients with SRNS 
has the potential to stratify patients and help decisions regarding treatments and 
prognosis.  Pathogenic variants in single genes affecting podocyte function are a 
common cause of SRNS, reported in up to 29.5% of a predominantly childhood 
cohort [57].  There is a differing spectrum of disease genes and pathogenic 
variants associated with congenital and childhood-onset disease in comparison 
with adult disease, and genes may present a renal-only phenotype or NS as part of 
a wider syndrome.  Alport syndrome (AS) is associated with pathogenic variants 
in COL4A3, COL4A4 or COL4A5 and may present with proteinuria (some with 
FSGS on biopsy), and more commonly haematuria [279].  The renal histology is 
characterised by an alteration of the glomerular basement membrane.  Variants in 
COL4A3 and COL4A4 have been identified in association with FSGS together 
with thin basement membrane nephropathy but without the extra-renal features of 
AS [280]. 
The proportion of single gene cases identified inversely correlates with the 
age of onset with 69.4% - 100% of congenital-onset disease reported as having a 
genetic aetiology [57, 59].  Over 53 genes, with pathological variants inherited in 
both recessive and dominant patterns, have been implicated in SRNS [1, 85].   
Timely genetic testing can considerably alter patient management, and 
facilitate a greater understanding of the genetic complexity of the condition [281].  
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Recent studies report a multiple-gene testing approach using next generation 
sequencing (NGS) [57, 68, 137, 282].  Only a single NGS study has reported copy 
number variation in NS genes,[1] hence the contribution of this mechanism to 
SRNS is currently largely unknown, although evidence has been provided for this 
as a mechanism [283, 284].   Several studies report patients with a typical 
phenotype and only a single recessive pathogenic variant [285, 286].  This 
suggests there may be as-yet uncharacterised variants and that a comprehensive 
NGS assay with the ability to detect copy number variants (CNVs) would be of 
increased value.   
Collaboration between the University of Bristol and Bristol Genetics 
Laboratory led to the development of a clinically-approved gene panel test for 37 
SRNS and collagen-related genes (Table 4.1) using a targeted amplicon based 
NGS assay and bespoke bioinformatics analysis that detects both single nucleotide 
variants (SNVs) and CNVs in batches of 12-16 patients.   Importantly, the panel 
has the flexibility to be extended according to discovery of new genes.  An 
enlarged panel of 70 renal-associated genes has been offered since March 2017 
for new referrals including novel genes recently reported associated with SRNS 
such as NUP93, NUP107, NUP205, KANK1, KANK4, MAGI2, EMP2 and ANLN 
[89, 96, 107, 108, 112].  
The aim of this study was to examine the utility and detection rate of 





Table 4.1: Genes included in the diagnostic 37-gene panel and coverage 







Accession no Disease association Key reference 
ACTN4 * 19 21 4.2, 99.8% AD NM_004924 
Familial and sporadic SRNS (usually 
adult) 
[63] 
ALG1 16 13 2.0, 90.5% AR NM_019109 Congenital disorder of glycosylation [131] 
ALMS1 2 23 13.7, 98.9% AR NM_015120 
Alström syndrome, retinitis pigmentosa, 
sensorineural hearing loss 
[134] 
APOL1 * 
2 7 1.9, 97.9% 
Risk factor NM_145343 
Increased susceptibility to FSGS in 





4 10 2.9, 99.2% 
AD NM_001025616 FSGS 
[104] 
ARHGDIA 17 6 1.4, 100% AR NM_001185077 CNS [105] 
CD151 
11 9 1.1, 100% 
AR NM_004357 
NS, pretibial bullous skin lesions, 
neurosensory deafness, bilateral lacrimal 
duct stenosis, nail dystrophy, and 
thalassemia minor 
[130] 
CD2AP * 6 18 2.8, 99.9% AD/AR NM_012120 FSGS / SRNS [87] 
COL4A3 2 52 8.3, 98.4% AR NM_000091 Alport syndrome [83, 287] 
COL4A4 2 48 7.5, 99.8% AR NM_000092 Alport syndrome [83, 287] 
COL4A5 X 53 7.9, 99.1% X-linked NM_033380 Alport syndrome [287] 
COQ2 * 4 7 1.7, 100% AR NM_015697 
Mitochondrial disease, encephalopathy / 
isolated nephropathy 
[118] 
COQ6 * 14 12 2.3, 100% AR NM_182476 NS +/- sensorineural deafness; DMS [119] 
COQ7 16 6 1.1, 100% AR NM_016138 Mitochondrial disease, encephalopathy [120] 
COQ9 16 9 1.5, 99.8% AR NM_020312 
Mitochondrial disease, encephalopathy, 
renal tubulopathy 
[121] 
CYP11B2 8 9 2.0, 97.0% Association NM_000498 
Corticosterone methyloxidase 




E2F3 6 7 1.8, 99.5% AD NM_001949 
FSGS + mental retardation (whole gene 
deletion) 
[92] 
INF2 * 14 23 5.2, 97.8% AD NM_022489 
Familial and sporadic SRNS, FSGS-
associated Charcot-Marie-Tooth disease 
[61] 
ITGA3 17 26 4.8, 98.6% AR NM_002204 
Interstitial lung disease, CNS, and mild 
epidermolysis bullosa 
[126] 
ITGB4 17 40 7.8, 99.4% AR NM_000213 
 Epidermolysis bullosa and pyloric 
atresia, FSGS 
[127] 
KANK2 19 11 3.1, 100% AR NM_015493 SSNS/SDNS +/- haematuria [112] 
LAMB2 * 3 32 7.0, 100% AR NM_002292 Pierson syndrome [12] 
LMX1B * 9 8 1.6, 99.4% AD NM_002316 
Nail patella syndrome; also FSGS 
without extrarenal involvement 
[64] 
MED28 4 4 0.8, 100% AR NM_025205 NS [106] 
MYH9 
22 41 8.2, 100% AD, 
association 
NM_002473 
MYH9-related disease; Epstein and 
Fechtner syndromes 
[98] 
MYO1E * 15 28 5.0, 99.9% AR NM_004998 Familial SRNS [102, 103] 
NPHS1 * 19 29 5.2, 99.9% AR NM_004646 CNS / SRNS [55] 
NPHS2 * 1 8 1.6, 100% AR NM_014625 CNS / SRNS [56] 
PDSS2 6 8 1.9, 99.4% AR NM_020381 Leigh syndrome [123] 
PLCE1 * 10 33 8.9, 99.7% AR NM_016341 CNS / SRNS [60] 
PMM2 16 8 1.4, 100% AR NM_000303 Congenital disorder of glycosylation [132] 
PTPRO * 12 27 5.0, 99.7% AR NM_030667 NS [88] 
SCARB2 4 12 2.1, 100% AR NM_005506 
Action myoclonus-renal failure 
syndrome +/- hearing loss 
[133] 
SMARCAL1 2 18 3.8, 99.9% AR NM_014140 Schimke immuno-osseous dysplasia [91] 
TRPC6 * 11 13 3.4, 98.8% AD NM_004621 








Sporadic SRNS (children—may be 
associated with abnormal genitalia); 
Denys-Drash and Frasier syndrome 
[65] 
ZMPSTE24 1 10 1.9, 100% AR NM_005857 Mandibuloacral dysplasia with FSGS [122] 
* indicates genes included in the initial 16 gene panel 
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Legend: AD, autosomal dominant; AR, autosomal recessive; CNS, congenital nephrotic syndrome; DMS, diffuse mesangial sclerosis; FSGS, 
focal segmental glomerulosclerosis; Kb, kilobases; NS, nephrotic syndrome; SDNS, steroid-dependent nephrotic syndrome; SRNS, steroid-






4.2.1 Patient Cohort 
302 patients were referred with informed consent for diagnostic gene panel 
analysis via Consultant Nephrologists and Consultant Clinical Geneticists over a 
26-month period with clinical data supplied by clinical proforma.  The diagnostic 
test has been formally assessed for validity, and socio-legal/ethical implications 
by the UK Genetic Testing Network and UK NHS commissioners through the 
gene dossier process, and was undertaken in an accredited UK NHS Laboratory.  
Data presented pertains only to anonymised auditing of routine diagnostic testing; 
therefore, this study was not subject to ethical approval. 
 
4.2.2 Assay Design, Target Enrichment and Sequencing 
All genetic sequencing and analysis were undertaken by staff at Bristol Genetics 
Laboratory.  A custom HaloPlex Target Enrichment System (Agilent) was 
designed to target 37 genes (exons and 25bp of flanking intron) associated with 
SRNS.  DNA was prepared from venous blood samples using an Autopure Gentra 
system (Qiagen) or referred as DNA from external laboratories.  Genomic DNA 
(225ng) was processed for each sample according to the manufacturer’s protocol.  
Library QC was performed using an Agilent TapeStation 2200. Samples were 
pooled in typical batches of 12-16 and sequenced using 2x150bp paired end 
sequencing on a MiSeq (Illumina) analyser following manufacturer’s protocol. 
Twenty-two patients were sequenced on an earlier version of the panel comprising 
16 genes as indicated in Table 4.1.  After initial analysis, gap filling by Sanger 
sequencing was undertaken on the rare occasions where a gap in coverage was 
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found in a clinically-relevant gene or where a single LP variant was detected in a 
recessive gene. 
 
4.2.3 Bioinformatic Analysis 
Analysis was performed using a bespoke pipeline based on the Broad Institute’s 
Best Practice guidelines [288, 289]. FASTQs were hard trimmed to remove 
HaloPlex adapter sequences and read through, the trimmed reads were then 
mapped to UCSC GRCh37/hg19 FASTA reference using BWA-MEM. GATK 
(version 1.6) unified genotyper was used for indel realignment and variant calling, 
with quality, capture and alignment metrics generated using Picard. Pindel was 
used for additional long insertion/deletion and structural variant detection. 
Variants were annotated and stratified for analysis using Geneticist Assistant 
(SoftGenetics Version 1.1.5 Release Build 189 Revision 6848). 
 
4.2.4 Variant Classification 
Variants were classified according to the Association for Clinical Genetic Science 
best practice guidelines for the evaluation of pathogenicity and reporting of 
sequence variants: Class 1 - clearly not pathogenic, Class 2 - unlikely to be 
pathogenic, Class 3 - unknown significance, Class 4 - likely to be pathogenic and 
Class 5 - clearly pathogenic [290]. Variants were assessed using Alamut software 
v2.3.1 (Interactive Biosoftware, Rouen, France). Classification considered 
literature evidence, disease mechanism and phenotype, evolutionary conservation 
including relevant functional domains and population frequency (NHLBI Exome 
Variant Server, dbSNP and ExAC [total allele frequency]) (Table 4.2). Variants 
with a frequency >1% in any population were excluded from further investigation 
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(with the exception of the NPHS2 p.(Arg229Gln) variant). In addition, web-based 
prediction tools PolyPhen-2, Align GVGD and SIFT were used for the assessment 
of missense variants and splice site variants were investigated with prediction 
programs SpliceSiteFinder, MaxEntScan, Human Splice Finder, NNSPLICE and 
GeneSplicer.  Class 3, 4 and 5 variants were confirmed by Sanger sequencing 




Table 4.2: Variant classification criteria 
Class 5: 
Pathogenic 
Reported in the literature as pathogenic supported by functional evidence OR segregation studies OR 
multiple independent case reports AND 
 
Consistent with phenotype of patient, inheritance and disease mechanism  
Class 4:  
Likely pathogenic 
Minor Allele Frequency (MAF) <1%* AND 
 
Not reported or literature evidence sparse, with no segregation studies or functional analysis available 
AND  
 
Consistent with phenotype of patient, inheritance and disease mechanism AND 
 
- Missense variant in functional domain with high conservation and supporting in silico results 
OR 
- Nonsense or frame shift variant OR 
- Invariant splice site (+/-2) variant or highly conserved synonymous variant with >3/5 in silico 
splice prediction tools returning a >10% difference in splice site prediction value between 
reference sequence and variant. 
Class 3:  
Unknown Significance 
(VUS) 
MAF <1% AND 
 
- Inconclusive or conflicting in silico results, not reported in the literature, but consistent with 
phenotype, inheritance and disease mechanism OR 
- In silico predictions class the variant as Class 4, but not consistent with phenotype of patient 
Class 2:  
Likely Benign 
MAF <1% AND 
 
- In silico results indicate weak amino acid conservation and a benign impact on protein OR 




- Inconclusive or conflicting in silico results, not reported in the literature, not consistent with 
phenotype of patient, inheritance, or disease mechanism OR 
- Sparse literature evidence indicating benign status OR 
- Limited segregation studies not supporting pathogenicity 
Class 1:  Benign MAF >1% OR 
MAF<1% and proven as non-pathogenic in published literature 





4.2.5 Variant Segregation Analysis 
Analysis of parental samples and those from other available affected/unaffected 
relatives was undertaken where possible using Sanger sequencing to determine 
phase (cis or trans) and to gather evidence supporting pathogenicity by 
genotype/phenotype concordance in the family. 
 
4.2.6 Copy Number Analysis  
Copy number variants (CNVs) were identified by CONTRA using log-ratios of 
GC corrected, library balanced, binned and interpolated read depth data [291]. 
CNVs were confirmed using Multiplex Ligation-dependent Probe Amplification 
(MLPA) with custom designed probes and the MRC-Holland P200-A1 Human 




4.3.1 Source of referrals 





Figure 4.1: Source of referrals for NGS gene panel testing 
 
4.3.2 Demographics 
The majority of patients had a clinical diagnosis of idiopathic nephrotic syndrome, 
mostly SRNS, but 12 were steroid sensitive (SSNS) either frequently-relapsing or 
steroid-dependent.  Thirty-five patients were referred with features suggestive of 
AS including haematuria, a family history, hearing loss or thin basement 
membrane on biopsy.  For clinical analyses, the cohort was, therefore, separated 
into SRNS, SSNS and Alport groups.  The timing of disease onset was known for 
196 patients: 32 (16.3%) were congenital (< 3 months), 16 (8.2%) infantile (3-12 
months), 101 (51.5%) childhood (1-12 years), 17 (8.7%) juvenile (13-18 years) 
and 30 (15.3%) adult (>18 years).  Of 255 patients with SRNS, a biopsy report 
was available in 133 which showed FSGS in 109 (82.0%) and minimal change 
disease in 8 (6.0%).  In 9 of 12 SSNS patients with a biopsy report, 3 (33.3%) had 
FSGS and 3 (33.3%) had MCD.  In patients with SRNS, 35 (23.8%) of 147 with 
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data available had a family history of renal disease.  Among 132 SRNS patients 
where data on age of onset and family history were available, 52.6% (10/19) of 
adults compared with 12.4% (14/113) of patients <18 years had a positive family 
history.  This may represent differing referral patterns in clinicians caring for 
adult patients with NS such that they were less likely to request genetic testing for 
adults without a family history.  Among 35 patients in the Alport group, 78.6% of 
28 patients with data had a family history of a similar disease.  Other demographic 
data are shown in Table 4.3.  
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Table 4.3: Clinical characteristics of the cohort 
  Total cohort Steroid-resistant 






Total patients  302 255 12 35 
Male (%)  165 (54.6) 138 (54.1) 10 (83.3) 17 (48.6) 
Age at onset / testing* in 
years (%) 
0-0.25 32 (10.6) 31 (12.2) 1 (8.3) 0 (0) 
 0.25-1 16 (5.3) 13 (5.1) 0 (0) 3 (8.6) 
 1-12 147 (48.7) 125 (49.0) 9 (75) 13 (37.1) 
 13-18 45 (14.9) 40 (15.7) 1 (8.3) 4 (11.4) 
 > 18 62 (20.5) 46 (18.0) 1 (8.3) 15 (42.9) 
Family history positive / 
number with data 
available (%) 
 58 / 183 (31.7) 35 / 147 (23.8) 1 / 8 (12.5) 22 / 28 (78.6) 
Consanguinity / number 
with data available (%) 
 17 / 141 (12.1) 13 / 117 (11.1) 3 / 9 (33.3) 1 / 15 (6.7) 
Ethnicity (% of patients 
where data available) 
White 99 (65.8)  83 (66.4) 3 (37.5) 13 (76.5) 
 Indian 14 (9.4) 12 (9.6) 2 (25) 0 
 Black African / 
Caribbean 
7 (4.7) 5 (4.0) 1 (12.5) 1 (5.9) 
 Pakistani 6 (4.0) 3 (2.4) 2 (25) 1 (5.9) 
 Bangladeshi 2 (1.3) 2 (1.6) 0 (0) 0 (0) 
 Asian 2 (1.3) 2 (1.6) 0 (0) 0 (0) 
 Middle Eastern 2 (1.3) 2 (1.6) 0 (0) 0 (0) 
 Arabic 2 (1.3) 2 (1.6) 0 (0) 0 (0) 
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 Mixed 3 (2.0) 3 (2.4) 0 (0) 0 (0) 
 Other 13 (8.7) 11 (8.8) 0 (0) 2 (11.8) 
 No ethnicity data 
available 
152 130 4 18 
Biopsy findings (% of 
patients where data 
available); number (%) 
with genetic diagnosis 
FSGS 115 (71.9); 27 
(23.5) 
109 (82.0); 26 (23.9) 3 (33.3); 0 (0) 3 (16.7); 1 (33.3) 
 MCD 11 (6.9); 0 (0) 8 (6.0); 0 (0) 3 (33.3); 0 (0) 0 (0) 
 Mesangioproliferative 
GN 
3 (1.9); 0 (0) 3 (2.3); 0 (0) 0 (0) 0 (0) 
 DMS 5 (3.1); 2 (40.0) 4 (3.0); 2 (50.0) 1 (11.1); 0 (0) 0 (0) 
 Finnish type 2 (1.3); 2 (100) 2 (1.5); 2 (100) 0 (0) 0 (0) 
 Alport 8 (5.0); 7 (87.5) 0 (0) 0 (0) 8 (44.4); 7 (87.5) 
 TBMN 4 (2.5); 1 (25.0) 0 (0) 0 (0) 4 (22.2); 1 (25.0) 
 Other 12 (7.5); 3 (25.0) 8 (6.0); 3 (37.5) 2 (22.2); 0 (0) 3 (16.7); 0 (0) 
 No biopsy data 
available / Not 
biopsied 
142 122 3 17 
Total with likely-
pathogenic variants (%) 
 71 (23.5) 54 (21.2) 0 (0) 17 (48.6) 
 
* For patients where no data were available for age at disease onset, the age at genetic testing was used. 
Legend: DMS, diffuse mesangial sclerosis; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; MCD, minimal change disease; 
TBMN, thin basement membrane nephropathy 
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4.3.3 Data quality and gene panel performance 
An average gene coverage of 99.26% coding sequence at a minimum read depth 
of 30x was achieved on a typical 12-patient run. The per gene coverage is shown 
in Table 4.1.  The ACGS reporting time guideline for large panel tests is 112 
calendar days [292].  The median time from receipt of samples to issue of a report 
was 74 days (interquartile range: 49-106 days).  With clinically urgent referrals, it 
was possible to reduce substantially the turnaround time with complete genetic 
panel reports provided for 17 patients within 4 weeks and the fastest positive case 
report (NPHS2 compound heterozygote) being issued in 22 calendar days.  
 
4.3.4 Genetic variants 
Targeted gene panel testing of all 302 patients identified 71 (23.5%) with a likely 
genetic cause for disease.  The genetic diagnostic rate among the group with 
SRNS was 21.2%, including 44/209 (21.1%) paediatric and 10/46 (21.7%) adult 
nephrotic cases (Figure 4.2).  In SRNS patients where family history was known, 
the genetic diagnostic rate was 11/35 (31.4%) in those with a positive family 
history and 30/112 (26.8%) in those with negative family history.  In SRNS 
patients where family history was known and with age of onset over 18 years, the 
genetic diagnostic rate was 2/10 (20.0%) in those with a positive family history 
and 3/9 (33.3%) in those with negative family history.  The rate in those with 
parental consanguinity was 5/13 (38.5%) compared with 28/104 (26.9%) in those 
without.  In all the 12 SSNS patients, no pathogenic variants were found in any of 




Figure 4.2: Flow chart of patients by phenotype at presentation, age and genetic 
diagnosis 
“Age” refers to age at diagnosis or, if not available, age at genetic testing. “Genetic” 
refers to the number of cases with likely-pathogenic variants.  SRNS, steroid-resistant 
nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome. 
 
The spectrum of pathogenic variants is summarised in Table 4.4.  Detailed phenotypic 
and variant data for the 71 patients with genetic disease are shown in Table 10.3 in the 
Appendices.   
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Steroid-resistant nephrotic syndrome 
(number of patients) 
Haematuria / Alport syndrome 
(number of patients) 
Age group * ≤ 18 years 
(n = 209) 
> 18 years 
(n = 46) 
Total  
(n = 255) 
≤ 18 years 
(n = 20) 
> 18 years 
(n = 15) 
Total  
(n = 35) 
NPHS1 12 0 12 0 0 0 
WT1 9 2 11 0 0 0 
NPHS2 7 0 7 0 0 0 
LMX1B 4 0 4 0 0 0 
INF2 0 3 3 0 0 0 
LAMB2 3 0 3 0 0 0 
MYH9 2 0 2 0 0 0 
PLCE1 2 0 2 0 0 0 
ACTN4 1 0 1 0 0 0 
SCARB2 0 1 1 0 0 0 
SMARCAL1 1 0 1 0 0 0 
TRPC6 0 1 1 0 0 0 
COL4A3 0 1 1 3 2 5 
COL4A4 1 1† 2 0 2 2 
COL4A5 2 1 3 5 5 10 
Total 44 10 54 8 9 17 
* For patients where no data were available for age at disease onset, the age at genetic testing was used.  None of the 12 patients with steroid-
sensitive nephrotic syndrome had likely-pathogenic variants and so are not shown in this table.  † This patient was referred with hypertensive 
nephrosclerosis and a family history of renal disease. 
188 
 
The most frequently-detected LP variants in the SRNS group (n = 255) 
were in NPHS1, WT1 and NPHS2 in 12 (4.7%), 11 (4.3%) and 7 (2.7%) patients 
respectively.  In the Alport group, the variants were all in collagen genes: 
COL4A3, COL4A4 and COL4A5 in 5 (14.3%), 2 (5.7%) and 10 (28.6%) patients 
respectively.  Of note, 5 SRNS/FSGS patients had LP variants in COL4A3, 
COL4A4 and COL4A5 (1, 1 and 3 patients respectively) including a single novel 
LP COL4A3 variant, c.698G>A, p.(Gly233Glu), in a patient with a dominant 
family history of FSGS (patient 4) which tracked with disease in an affected 
brother.  Among patients with SRNS/FSGS who were found to have genetic 
disease (excluding those with collagen variants), there was an autosomal 
dominant mode of inheritance in 16/41 (36.6%) of those with disease onset ≤ 18 
years compared with 6/7 (85.7%) of those > 18 years. 
 
4.3.5 Variants of unknown significance (VUS) 
In addition to the patients with LP variants, a further 40 patients had one or more 
VUS (Table 4.5). Among the 52 VUS in these patients, the most frequently-
involved genes were: 28.9% in collagen genes; 7.7% each in NPHS1 and NPHS2; 
and 5.8% each in INF2, MYH9, PLCE1 and PTPRO.  Of the 71 patients with 
likely-genetic disease, 11 cases had 12 VUS in genes other than the one thought to 
be causative in that patient.  In these cases, 41.7% of VUS were in collagen genes 
and 16.7% in WT1.  Overall, of the 64 recorded VUS, 31.3% were in collagen 
genes, 6.3% in NPHS2, 6.3% in NPHS1 and 6.3% in MYH9.  
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Table 4.5: Patients with variants of unknown significance 
Patient 
number 
Sex Age at 
onset 
(years) 
Presentation Ethnicity; FH; 
Consanguinity 
Biopsy Clinical impact Gene Nucleotide; segregation AA 
72 F 53* SRNS ND; ND; ND ND ND ACTN4 c.2084G>A p.(Arg695His) 
73 M 2 SRNS In; N; N MCD No change ACTN4 c.2629G>A p.(Glu877Lys) 
       PTPRO c.2117G>A p.(Cys706Tyr) 
74 M 13* Haematuria, familial 
microscopic haematuria 
ND; Y; ND ND ND ALG1 c.1127C>T p.(Pro376Leu) 
       ALG1 c.1187+13C>A p.(?) 
75 M 13 NS, SCD ND; ND; ND ND ND CD2AP c.1637C>T p.(Ser546Phe) 
76 F 44* SRNS ND; Y; ND FSGS ND COL4A3 c.1855G>A p.(Gly619Arg) 
77 M 30 SRNS W; N; N FSGS No change COL4A3 c.2155T>C p.(Ser719Pro) 
       COL4A3 c.4664C>T p.(Ala1555Val) 
78 M 19 Alport, FH haematuria and 
hearing loss 
W; Y; N Other ND COL4A3 c.2313_2330del; mat; 
unaffected 
p.(Leu775_Gly780del) 
79 M 15* SRNS ND; ND; ND ND ND COL4A4 c.136C>A p.(Pro46Thr) 
80 M 8* SRNS ND; ND; ND ND ND COL4A4 c.809G>A p.(Gly270Glu) 
81 M 17* Haematuria and proteinuria W; Y; ND Alport ND COL4A4 c.4291C>T p.(Arg1431Cys) 
82 M 49 SRNS Iraqi; Y; N FSGS, 
laminopathy 
Imm not started COL4A4 c.4576A>G p.(Asn1526Asp) 
       COL4A4 c.4810-15_4810-
14delTT 
p.(?) 
83 F 53* Haematuria W; Y; N TBMN Imm not started COL4A5 c.466-3T>A p.(?) 
       COL4A5 c.3285T>C p.(=) 
84 M 32* SRNS ND; Y; Y ND ND COL4A5 c.2017A>G p.(Arg673Gly) 
       MYO1E c.3236A>G p.(Asp1079Gly) 
85 M 24 SRNS W; Y; N FSGS Cessation COL4A5 c.2326G>A; mat, tracks 





86 F 2 Steroid dependent NS Pa; N; Y MCD ND COL4A5 c.3691C>T p.(Pro1231Ser) 
87 M 18* SRNS ND; ND; ND ND ND COQ2 c.286C>T p.(Pro96Ser) 
88 F 50 SRNS W; Y; N FSGS ND INF2 c.763G>T; also in son 
with proteinuria, absent 
in unaffected daughter 
p.(Asp255Tyr)  
       LMX1B c.115C>A; absent in son 
with proteinuria, in 
unaffected mother 
p.(Pro39Thr)  
89 M 1 SRNS ND; ND; ND ND ND PTPRO c.1300G>A p.(Glu434Lys) 
90 F 14* SRNS W; Y; ND Not done Possibly change imm INF2 c.2942G>C p.(Arg981Thr) 
91 F 9* Haematuria ND; Y; ND ND ND LAMB2 c.1156T>C p.(Cys386Arg) 
92 M 62* SRNS ND; ND; ND MPGN ND LAMB2 c.3533G>A p.(Arg1178His) 
93 M 2 SRNS ND; Y; N ND ND MYH9 c.1784A>G  p.(Asn595Ser) 
94 F 9 SRNS, single kidney W; Y; N Not done Imm not started MYH9 c.3215C>T; also in 
affected sister 
p.(Ala1072Val) 
95 F 5.5 SRNS Ar; N; N Not done Variant found was not 
classified as likely-
pathogenic therefore not 
influenced treatment strategy 
MYH9 c.3838G>A p.(Val1280Met) 
96 F 3* SRNS ND; ND; ND FSGS ND MYO1E c.1547A>G p.(Asp516Gly) 
97 F 2 SRNS W; N; N FSGS ND NPHS1 c.2746G>T; pat p.(Ala916Ser) 
98 F 17* NS, short stature ND; ND; ND ND ND NPHS1 c.2746G>T p.(Ala916Ser) 
99 M 23 SRNS Pa; Y; N FSGS ND NPHS1 c.3027C>G p.(Tyr1009*) 
100 M 42* Haematuria, hearing loss W; Y; N TBMN ND NPHS2 c.156delG p.(Thr53Profs*46)  
101 M 22* SRNS W; N; N MPGN ND NPHS1 c.2591G>A p.(Arg864His) 
102 ND 0 SRNS ND; ND; ND ND ND NPHS2 c.860A>G p.(Gln287Arg) 
103 F 12* SRNS Samoan; N; N ND ND NPHS2 c.1064A>G p.(Asn355Ser) 
       NPHS2 c.138G>A p.(=) 
       PLCE1 c.3580G>A p.(Gly1194Arg) 
       ARHGAP24 c.1057_1058delinsAA p.(Ala353Asn) 
       COL4A5 c.4309C>G p.(Gln437Glu) 
104 F 11* SRNS ND; ND; ND FSGS ND PLCe1 c.1478G>A p.(Arg493Gln) 
105 M 18* SRNS ND; ND; ND FSGS ND PLCe1 c.2032A>G p.(Met678Val) 
106 M 7 SRNS W; Y; N ND ND PMM2 c.24_delC p.(Cys9Alafs*27),  
107 M 3.5 SRNS W; N; N FSGS Increase PMM2 c.691G>A; pat p.(Val231Met) 
108 F 19* SRNS ND; ND; ND FSGS ND PTPRO c.1631C>T p.(Thr544Met) 
109 M 14 SRNS ND; ND; ND ND ND TRPC6 c.1A>G p.(Met1?)  
       INF2 c.395G>A p.(Ser120Asn)  
110 F 8* NS ND; ND; ND ND ND TRPC6 c.2392G>C p.(Asp798His) 
111 M 4 SRNS W; N; N Membranous ND WT1 c.844T>C p.(Cys282Arg) 
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* Denotes age at genetic testing where age at disease onset was not available 
Segregation analysis to clarify pathogenicity is ongoing in 15 of these patients with VUS. 
Legend: 
AA, amino acid; Ar, Arabic; CKD, chronic kidney disease; ESRF, end stage renal failure; FH, family history; FSGS, focal segmental 
glomerulosclerosis; Imm, immunosuppression; In, Indian; mat, maternal; MPGN, membranoproliferative glomerulonephritis; N, no; n/a, not 
available; ND, not done/no data; NS, nephrotic syndrome; Pa, Pakistani; pat, paternal; SCD, sickle cell disease; SRNS, steroid resistant 




4.3.6 Novel variants 
Among the 71 patients with a genetic cause for disease, 32 had variants without a 
previous disease association including 26 with one or more novel variants absent 
from population databases.  Two patients had gene deletions of one or more exons 
detected by CNV analysis (Figure 4.3).  Patient 44 (see Table 10.3 in the 
Appendices) presented with congenital nephrotic syndrome (CNS) and had a 
maternally-inherited truncating deletion of NPHS1 exons 23-29 together with a 
paternally-inherited previously-reported nonsense variant c.866G>A p.(Trp289*) 
[74].  Patient 55 also presented with CNS and genetic testing revealed a 
maternally-inherited frame shift deletion of NPHS2 exon 2 in combination with a 
paternally-inherited c.1032delT variant. The c.1032delT variant has been 
previously reported as the most frequent pathogenic variant in NPHS2 in Poland 
(Kashubian region) [286].  Both parents of patient 55 are of Polish extraction.  In 
addition to these two patients, a further 30 had variants without a previous disease 
association in the following genes: ACTN4 (1 patient), COL4A3 (2), COL4A4 (1), 
COL4A5 (10), INF2 (2), LAMB2 (2), NPHS1 (5), NPHS2 (2), SMARCAL1 (1), 




Figure 4.3: NPHS1 and NPHS2 Copy number variants 
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Figure 4.3: A. NPHS1 deletion of Exon 23-29  B. NPHS2 deletion of Exon 2. 
NGS read depth analysis (top) with results confirmed by MLPA (below). NGS 
fold change in copy number (Log2 ratio) is shown across the locus (ORF scale) 
and averaged for each exon (exon scale). MLPA shows patient peaks in dark grey 
and normal control peaks in light grey. The patient/normal ratios are shown with 
deletions having ratio < 0.75. 
 
 
Novel INF2 LP variants were detected in two adult-onset NS patients: 
p.(Tyr50Asp) (patient 25) and p.(Leu165Arg) (patient 26).  Both were missense 
variants affecting highly-conserved residues within the diaphanous inhibitory 
domain (DID) of the INF2 protein consistent with the previously-reported 
spectrum of disease-causing variants.  Segregation supports pathogenicity, 
p.(Tyr50Asp) co-segregating with disease in 5 affected family members and 
p.(Leu165Arg) present in one affected family member and absent in 2 unaffected 
family members.  An additional sensory neuropathy phenotype previously 
reported in 12.5% of INF2 cases [293] was also seen in affected family members 
with the p.(Tyr50Asp) variant.  
Two novel missense WT1 variants were identified in the known hotspot 
region (exons 6-9) [81] in patients with atypical presentation and no recorded 
extra-renal manifestations.  p.(His339Arg) in exon 7 (patient 61) co-segregated 
with disease in 6 affected family members with a variable phenotype ranging from 
childhood-onset nephrotic-range proteinuria to mild proteinuria presenting in 
adulthood.  The p.(Arg390Gln) variant in WT1 exon 8 (patient 65) was associated 
with age of onset of 30 years and was inherited from an affected father who was 
diagnosed in his 30s.  Although |WT1 is normally associated with childhood-onset 
disease, these findings are consistent with a previously-described biphasic 




4.3.7 Single heterozygous variants in recessive NPHS1 and NPHS2 
In six clinically-affected SRNS cases (patients 112-117 in Table 4.6), full coding 
sequence analysis detected a single heterozygous pathogenic variant in NPHS1 or 
NPHS2 that has been previously published as disease-causing.  No CNVs were 
identified.  The finding of these variants may be incidental.  However, given the 
low incidence of SRNS, the young age of onset (below 5 years, two with CNS) 
and the low frequency/absence of the variants in databases of subjects without 
known renal disease it is possible that there are additional NPHS1/NPHS2 variants 
in unsequenced intronic or promoter regions which may act in combination to 
cause the phenotype in these patients.  These findings were reported as compatible 




Table 4.6: Genotypes and phenotypes of patients with single heterozygous variants in NPHS1 and NPHS2 
Patient 
number 
Sex Age at 
onset 
(years) 














112 M 4 SRNS W; N; N MCD LP NPHS1 c.313G>A p.(Asp10
5Asn) 
[294]    
113 M 3* SRNS ND; ND; ND ND LP NPHS1 c.895C>T p.(Arg29
9Cys) 
[74]    
114 F 0 CNS, 
clinodactyly 
2nd toe 
Jordanian; N; Y FSGS LP NPHS1 c.1138C>T p.(Gln38
0*) 
[295]    
115 M 0.3 CNS W; N; N Not done LP NPHS2 c.413G>A; pat p.(Arg13
8Gln) 
[296]    
      NNP NPHS2 c.686G>A; mat p.(Arg22
9Gln) 
[69, 297]    
116 F 4* SRNS ND; ND; ND FSGS LP NPHS2 c.467dupT p.(Leu15
6Phefs*1
1) 
[298]   
      NNP NPHS2 c.686G>A p.(Arg22
9Gln) 
[69]    
117 F 1.4 SRNS In; ND; ND Not done LP NPHS2 c.872G>A p.(Arg29
1Gln) 
[299]    
      LP NPHS1 c.2512C>A p.(Pro83
8Thr) 
PS Del; 1.00 NL; NL; NL 
* Denotes age at genetic testing where age at disease onset was not available.  
Legend: 
AA, amino acid; CNS, congenital nephrotic syndrome; FH, family history; FSGS, focal segmental glomerulosclerosis; In, Indian; LP, likely-
pathogenic; mat, maternal; N, no; ND, not done/no data; NL, not listed; NNP, non-neutral polymorphism; pat, paternal; PS, present study; 




Three of these patients (112, 113 and 114) with early-onset SRNS were 
heterozygous for previously-reported rare pathogenic variants in NPHS1.  Patient 
112 developed SRNS under the age of 4 years with a heterozygous 
p.(Asp105Asn) variant previously reported in a Japanese CNS patient where a 
second variant was not detected [294].  Patient 113 had a heterozygous 
p.(Arg299Cys) variant.  Patient 114, from a Jordanian consanguineous family, 
who presented with CNS and FSGS on biopsy had a c.1138C>T, p.(Gln380*) 
nonsense variant but, in common with the other cases, no other likely-pathogenic 
variants in NPHS1 or other genes in the panel.  Patient 117 had a single 
heterozygous missense variant in NPHS2: c.872G>A, p.(Arg291Gln) previously 
reported as pathogenic in the homozygous/compound heterozygous state. Patient 
117 also had a novel single heterozygous variant in NPHS1: c.2512C>A, 
p.(Pro838Thr) which is not reported in population databases and prediction tools 
suggest is deleterious. 
Two further patients (115 and 116) presenting with classical NS had single 
previously-reported pathogenic variants in NPHS2 p.(Arg138Gln) (exon 3) and 
p.(Leu156Phefs*11) (exon 4) in a compound heterozygous state with the NPHS2 
non-neutral polymorphism p.(Arg229Gln). Tory et al. (2014) previously 
demonstrated that p.(Arg229Gln)  is only pathogenic in combination with variants 
in exons 7 or 8 and, therefore, should not be pathogenic with p.(Arg138Gln) or 
p.(Leu156Phefs*11) [69].  It is possible that a third intronic or promotor variant in 




4.3.8 Likely pathogenic variants by age of disease onset 
The age of disease onset was known with certainty for 164 (64.3%) of 255 
patients referred with a clinical presentation of SRNS and Figure 4.4 illustrates 
the genetic diagnostic rates by age group. In patients with CNS the diagnostic rate 
was 58.1% (18/31) with LP variants in the following genes: NPHS1 (12 patients), 
LAMB2 (3 patients), NPHS2 (2 patients) and WT1 (1 patient).  For cases of SRNS 
with known age of onset over 18 years the rate was 28.6% (6/21) with LP variants 




Figure 4.4: Genetic diagnostic rates for patients with known age at disease 
onset 
Figures above each bar indicate: number with genetic disease / total number of 
patients in each group. None of the 12 patients with steroid-sensitive nephrotic 




4.3.9 Clinical impact of genetic testing 
Physicians were asked whether the results of genetic testing would alter 
immunosuppressive management in patients with SRNS.  Responses were 
obtained in relation to 71 (27.8%) of these patients.  The response rate was not 
high enough to make definitive conclusions, but broadly clinicians reported that 
results would influence decisions to reduce or stop immunosuppression and one 
physician indicated that treatment decisions would be made after the gene panel 
results were known.   The diagnostic test result from 67 patients resulted in the 
subsequent testing of 148 family members including 2 prenatal tests for LAMB2 
and NPHS2 pathogenic variants.  At least 9 family tests are known to have helped 
inform suitability for donor transplant treatment.  Other familial testing has 
provided diagnoses for relatives and aided in clarifying variant pathogenicity. 





Gene panel testing is becoming more and more relevant for screening rare 
diseases, with greatly increased cost/benefit. The knowledge of the genetic basis 
of SRNS has expanded considerably over the past 5 years with several national 
and international cohorts recently published [1, 44, 57]  where genetic analysis 
was undertaken either as part of a research study or on a limited number of genes 
dependent on the country or institution where the patient was seen.  This study 
reported on large gene panel testing available on a clinical diagnostic basis within 
the National Health Service in the United Kingdom.  Analysis was performed at a 
single accredited centre, with technological and bioinformatics expertise 
developed over several years in collaboration with academic research institutes.  
Although the majority of referrals were received from UK clinicians, 41% of 
referrals were from outside the UK.   
 The frequency of likely-pathogenic variants among patients with SRNS 
was 21.2%.  This was marginally lower than 24-34% reported in other studies 
which included predominantly subjects with childhood-onset disease [44, 57, 59, 
282].  The cohort reported here included patients referred for genetic testing by 
clinicians in routine practice and was, therefore, more heterogeneous than those 
included in international registries of SRNS.  The cohort was also not restricted to 
patients with childhood-onset disease with 30 patients having known onset in 
adulthood.  As illustrated in Figure 4.4, the genetic diagnostic rate decreased with 
increasing age of onset from congenital to childhood, similar to that reported in 
another international cohort [57].  However, there was an increased diagnostic 
rate in the juvenile and adult subgroups.  It is likely that the adults referred by 
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clinicians for gene panel testing were a filtered population of cases as suggested 
by the higher frequency of a positive family history of 52.6%.   
Twelve patients with SSNS were referred for genetic testing and none had 
a potentially pathogenic variant.  Thus far, no inherited causes for SSNS have 
been identified [300].  Associations between SSNS and variants in EMP2, KANK1 
and KANK2 have been described in family studies but evaluation in larger cohorts 
did not identify additional patients with pathogenic variants [108, 112].  KANK2 
was included in the gene panel reported here and no likely pathogenic variants 
were identified. The updated version of the panel includes EMP2, KANK1 and 
KANK4.  Our current recommendation for clinicians is not to use the NGS gene 
panel test for patients with persistently steroid-sensitive NS unless there are 
specific reasons to suspect a genetic aetiology.   
In this study, 100% of LP variants identified by NGS meeting diagnostic 
variant-calling quality parameters have subsequently been confirmed as being 
present on Sanger sequencing. Sanger confirmation of NGS LP variants is 
currently in line with best practice ACGS guidance.  It also provides a 
confirmation of sample identity following pooling of samples during the NGS 
process and establishes a familial test for relatives.  As further evidence is 
collected, confirmatory testing may become redundant. 
 The use of gene panel testing supersedes stepwise screening protocols [59] 
and avoids phenotype selection bias, allowing detection of pathogenic variants in 
genes that would not necessarily be expected from the clinical presentation such 
as the two adult cases with a WT1 variant without any manifesting extra-renal 
features.  In addition, variants in secondary genes which may potentially 
contribute to the phenotype of the patient can be identified by a panel approach.   
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Gene panel screening identified 32 likely-pathogenic variants without a 
previous disease association. Absence or rarity in population data is used as 
evidence to support pathogenicity, however it is acknowledged that some 
ethnicities in this global cohort were either not known or may currently be 
insufficiently represented in population databases. Where possible, segregation 
analysis was performed to provide additional evidence to support pathogenicity, 
however family members were not always available for testing, reflecting the use 
of this panel in a clinical setting. 
The interpretation of variants of unknown significance in a global cohort is 
also a challenge of panel testing.  As well as segregation analysis, future 
expansion of population databases will allow improved filtering of population 
specific variants and functional work may also aid the interpretation of variants. 
This study has demonstrated two cases of CNVs present in NS genes, 
therefore CNV analysis of NGS data should be routinely undertaken as part of the 
variant analysis pipeline together with confirmation using a second method such 
as MLPA.  It is also apparent that there are a number of clinically typical cases 
with only a single known NPHS1 or NPHS2 pathogenic variant detected, 
suggesting deep intronic or regulatory variants if they are truly inherited in a 
recessive pattern.  Future whole genome sequencing in these patients may help to 
elucidate a genetic pathogenesis. 
 The timing of testing in relation to disease onset and the speed of genetic 
reporting are important for clinical utility.  It is potentially possible to generate 
results within 1-2 weeks thereby avoiding diagnostic biopsy in some cases.  In 
certain contexts, earlier testing and more rapid turnaround are important because 
results may have direct consequences for prenatal testing and patient treatment.  
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Pathogenic variants in COQ2, COQ6, or PDSS2, coding for proteins the 
coenzyme Q10 pathway, may indicate the potential for benefit from treatment with 
this enzyme [119, 301].  Identification of a causative variant may lead to 
clinicians stopping or avoiding intensification of immunosuppressive treatment.  
There has, however, been a report of a patient with NS, diffuse mesangial 
sclerosis and PLCE1 variants who responded to treatment with steroids and 
ciclosporin [60].  Cases of unaffected older children and adults with the same 
homozygous PLCE1 variants as their affected relatives suggest a more complex 
genotype-phenotype interplay and raise the possibility of spontaneous 
improvement rather than a true response to medication [302, 303].  Some patients 
with WT1 variants have responded to steroids and immunosuppression [82].  
Certain pathogenic variants, such as in WT1, should prompt search for other 
features of an associated syndrome, such as Frasier syndrome and risk of 
gonadoblastoma [80]. 
 The presence of a causative variant in SRNS is associated with a lower 
risk of post-transplantation recurrence of disease, occurring in 25.8% of patients 
testing negative for genetic disease compared with 4.5% of those with an 
identified variant in a European cohort [44] and 0% in a published UK cohort [1].  
Availability of results supporting a genetic diagnosis may prompt more rapid 
progression to potentially definitive treatment with transplantation rather than 
persisting with partially-effective medical therapies.  Targeted sequencing of 
family members resulting from gene panel testing has been used prior to 
transplantation, particularly in cases with autosomal dominant gene variants. 
 This study has shown that NGS gene panel testing with bioinformatics 
analysis for pathological SNVs and CNVs at an early stage after diagnosis of 
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SRNS or suspected Alport syndrome with results in a clinically relevant timescale 
has the potential to improve patient stratification and the care pathway. 
 The studies reported thus far have used baseline clinical characteristics and 
genetics to examine association with long-term outcomes and response to 
treatment.  Subsequent chapters will discuss the investigation of circulating 
plasma factors, which may have a potential role as biomarkers or involvement in 




Chapter 5 Plasma Proteomics and Biomarker 
Discovery 
5.1 Introduction 
5.1.1 The Human Plasma Proteome 
Developments in technology over the past decade have allowed researchers to 
identify and quantify not just one or a few proteins within a complex mixture but 
essentially all the proteins using techniques such as mass spectrometry (MS).  The 
analysis can be applied to cell culture extracts, tissue or body fluids.  Blood 
plasma is one of the most complex human-derived proteomes [304].  It includes 
not only the typical “true plasma proteins” such as albumin, globulins and 
hormones, which perform their function in the plasma or by circulating to a target 
organ.  It also contains leakage products from damaged cells and aberrant 
secretions from diseased tissues which have significant potential as biomarkers. 
There is a very large dynamic range in protein concentrations in plasma 
over 10 orders of magnitude. The 22 most abundant proteins, including albumin, 
represent 99% of the total plasma protein by mass [305, 306].  On the other hand, 
the least abundant proteins may have important functions including cytokines 
such as interleukin-6 with a concentration of 0-5 pg/mL.  It is within the latter 
group that proteins with the potential to act as biomarkers are often found. 
 The Human Proteome Organisation’s (HUPO) Plasma Proteome Project, 
had identified 15710 protein/peptide sequences by 2005, rising to 27351 in the 
Proteomics IDEntifications Database (PRIDE) by 2011 [307].  By analysis of the 
MS peptide data, the PeptideAtlas group of researchers generated a non-
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redundant, high-confidence list of 1929 proteins in human plasma in the same 
year [308].  The same group have combined MS data from multiple proteomic 
experiments to derive lists of the human kidney proteome (n = 5515 proteins), 
urine proteome (n = 3175 proteins) and plasma proteome (n = 4098 proteins) with 
the ability to identify proteins which are shared or unique to each [309]. 
 
 
Figure 5.1: Intersection of human kidney, urine and plasma proteomes 
determined by mass spectrometry 
Nonredundant Swiss-Prot protein identifier set for Kidney proteome intersected 
with the complete mappings for Urine proteome and Plasma proteome. Each 
Swiss-Prot identifier counted at most once even if multiple distinct splice variants 
were observed.  Reprinted with permission from Farrah et al. J Proteome Res. 






 Processing of plasma samples prior to MS is important for enabling the 
greatest utility of data derived from this analysis.  The orders of magnitude 
problem is partially alleviated by depletion of the highly-abundant proteins on the 
assumption that it is those at lower concentrations that have more potential as 
biomarkers [310, 311].  Although the depletion step does improve detection and 
analysis of potential biomarkers, it introduces an additional variable factor which 
may affect reproducibility [312].  Depletion of albumin and immunoglobulins 
may lead to loss of proteins bound to them and inevitably there is some variation 
in effectiveness of depletion from one batch to another.  Although the technology 
for analysis of the whole plasma proteome by MS has been in place for over a 
decade, the identification and validation of novel biomarkers which have clinical 
applicability has been limited thus far [305].  
 
5.1.2 Proteomics technology 





Figure 5.2: Steps in mass spectrometry-based proteomic analysis 
Legend: LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem 
mass spectrometry. 
Reproduced with permission from The Royal Society of Chemistry, from Angel 
TE et al. Chem Soc Rev. 2012;41:3912-28.[313] 
 
Typically, an initial method is used to separate the complex mixture of 
proteins into fractions before analysis by MS, usually two-dimensional gel 
electrophoresis or liquid chromatography (LC).  A wide range of technologies are 




First, in the case of complex protein mixtures such as plasma, high 
abundance proteins including albumin and immunoglobulins are removed to 
facilitate later analysis of the low concentration, and potentially more interesting, 
proteins. Equal quantities of protein from each of several samples are prepared. 
The proteins are digested by trypsin which cleaves on the carboxyl terminal side 
of arginine and lysine residues except when followed by proline [315].  This 
typically produces peptides 700 to 1500 Daltons which are the appropriate size for 
subsequent MS.  A key step in multiplex proteomics processing is isobaric 
labelling.  This allows several samples to be mixed and processed together so 
reducing variability but with the ability to assign the identified proteins to the 
correct original sample during the data analysis stage.  The tandem mass tag 
(TMT) method allows 10 samples to be processed in parallel using different 
markers all with same mass which, therefore, do not affect the physical properties 





Figure 5.3: Summary of sample processing, isobaric labelling and mass 
spectrometry for quantitative proteomic analysis 
Reprinted by permission from Springer Nature: Relative Protein Quantification 
Using Tandem Mass Tag Mass Spectrometry by Zhang, L & Elias, JE. [316]  
Copyright (2017).  
 
 
After separating the proteins by LC based on mass and charge, the proteins 
are analysed by MS.  At a fundamental level, a mass spectrometer ionises 
molecules, accelerates them along a curved cylinder and alters their flight path by 
adjusting the electromagnetic forces.  Typically in proteomics, peptides are 
positively charged and are repelled and accelerated away from the positively-
charged cathode.  By gradually increasing the AC frequency in the ion trap, 
peptides of increasing mass to charge (m/z) ratio are emitted and subsequently 
detected.  Within the Orbitrap mass spectrometer, the oscillation of ions within an 
electromagnetic field is transformed into a mass spectrum which is unique to the 
m/z ratio of the ion [314].  The experimental spectra are compared, using 
algorithms such as SEQUEST, against a library of theoretical spectra generated by 
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in silico trypsin digestion of all human proteins (derived by translation of the 
genome) [307].  Due to the high stringency of matching criteria, 70% or more of 
the spectra remain unidentified.  Those spectra that are matched enable 
identification of the peptides and thereby the likely parent proteins.  The 
fragmented TMTs give characteristic peaks on the spectra and thereby allow 
assignment of peptides and proteins back to the original samples. 
 
5.1.3 Plasma proteomics in SRNS 
As discussed in Chapter 1 (Table 1.13), biomarker discovery studies in patients 
with nephrotic syndrome have been conducted mainly using urine samples and 
comparing subjects with SSNS and SRNS [317].  In different studies, a variety of 
analytical techniques were used including MS, SDS-PAGE and ELISA.  Two 
studies have used serum samples to compare FSGS versus MN [245], and SSNS 
versus SRNS [256] but neither employed MS analysis and therefore the ability to 
identify novel proteins as potential biomarkers has been limited.   
As highlighted in Chapter 1 (Section 1.4.1), several strands of evidence 
point to the role of circulating factors within plasma as being pathogenic in non-
genetic SRNS.  Patients with post-transplant recurrence, ipso facto, are considered 
to have circulating factor disease.  It can be hypothesised that plasma from such 
patients at the time of more active disease differs in protein composition, 
including levels of circulating factors, from plasma at the time of less active 
disease or remission.  Therefore, relative quantification of proteins in plasma 
using MS and comparison between times of disease relapse and remission has the 
potential to identify biomarkers associated with these states, some of which may 
have a role in pathogenesis. 
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The aim of this study was to compare proteins within plasma at times of 






Patients were selected for investigation from the cohort generated by the NephroS 
study and subjects recruited historically before NephroS was established.  Patients 
were included in the discovery phase if they had a diagnosis of SRNS and if their 
plasma samples (either derived from blood or plasma exchange) were available at 
the time of disease relapse and remission.  Relapse was defined as uPCR > 200 
mg/mmol.  Partial remission was defined as uPCR < 200 mg/mmol or plasma 
albumin > 25.  Complete remission was defined as uPCR < 20 mg/mmol.  Some 
patients did not achieve these thresholds but were judged by their treating 
clinician to have shown relative remission.   
In order to reduce variability between patients, all those in the initial discovery 
group had FSGS on most-recent native kidney biopsy, had progressed to end stage 
renal failure, received a transplant and suffered disease recurrence in the 
transplanted kidney.  In these cases, samples were derived from plasma exchange.  
Our group has previously shown that when conditionally-immortalised human 
podocytes are treated in vitro with plasma, vasodilator-stimulated phosphoprotein 
(VASP) was phosphorylated in response to relapse, but not remission, plasma 
[188].  Samples from patients in the initial discovery group had previously been 
tested by collaborators within the group demonstrating consistent differential 
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phosphorylation of VASP after podocyte treatment with relapse and remission 
pairs of plasma (D. Henson, personal communication).   
Collaboration with Dr Yasuko Kobayashi, also in the Bristol Renal group 
(now in the Department of Paediatrics, Gunma University Graduate School of 
Medicine, Gunma, Japan), provided access to plasma proteomics data at times of 
relapse and remission for 5 patients with SSNS/MCD.  These data were used 
together with results from patients with SRNS in exploratory biomarker analysis 
as discussed below. 
In the validation and further exploratory phases of the study, which involved 
the use of enzyme-linked immunosorbent assay (ELISA) discussed in Section 
5.2.10 below, a more diverse range of patients was included.  These comprised 
patients with: 
• SRNS and relapse/remission pairs derived from either plasma exchange or 
blood plasma 
• SRNS and paired plasma samples derived from either plasma exchange or 
blood plasma but both at times of remission 




  Patients with SRNS 
 
SRNS1, SRNS2, SRNS3, 419 
Patients with SSNS/MCD 
 
SSNS1, SSNS2, SSNS3, 
SSNS4, SSNS5 
Proteomic analysis by nano-LC MS/MS 
Proteins shortlisted for further validation 
Validation using Western blotting of 
samples from patients with SRNS 
 
SRNS1, SRNS2, SRNS3, 419 
 
560, 641, 1202, 1715 
(also by nano-LC MS/MS) 
Validation using ELISA of samples 
from patients with SRNS and SSNS 
 
Wider range of patients as detailed in 
Results 
Figure 5.4: Flow diagram showing patients included at different stages of 
the proteomic discovery and validation process 
Legend: ELISA, enzyme-linked immunosorbent assay; MCD, minimal change 
disease; nano-LC MS/MS, nano-liquid chromatography tandem mass 
spectrometry; SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid 




5.2.2 Plasma sample processing and storage 
Plasma exchange samples were stored at the local centre at 4°C before being 
couriered in cool bags with ice packs to the central centre.  On arrival they were 
aliquoted for long term storage at -80°C.    Blood was collected at local centres 
into lithium heparin tubes and posted to the central centre at ambient temperature.  
On arrival they were centrifuged at 3800 rpm at 4°C for 20 minutes.  Plasma was 
removed and aliquoted for long term storage at -80°C.  Samples were used where 
possible after one, but no more than three, freeze-thaw cycles. 
 
5.2.3 Albumin depletion of plasma 
Patient plasma samples were retrieved from storage at -80°C and thawed on ice.  
Albumin & IgG Depletion SpinTrap columns (GE Healthcare Life Sciences, Little 
Chalfont, UK; #28-9480-20) were prepared and used following the 
manufacturer’s instructions.  Briefly, after shaking the columns they were placed 
in 2 ml microcentrifuge tubes, centrifuged for 30 s at 100 × g and the collected 
liquid discarded.  The columns were equilibrated with binding buffer (15.5 
mmol/L Na2HPO4, 4.5 mmol/L NaH2PO4, 150 mmol/L NaCl, pH 7.4) by adding 
400 µL, centrifuging for 30 s at 800 × g and discarding collected liquid.  This step 
was repeated once.  The columns were placed in a new 2 mL microcentrifuge 
tube.  50 µL plasma was mixed with 50 µL binding buffer, applied to each column 
and incubated for 5 minutes without mixing.  Columns were centrifuged for 30 s 
at 800 × g and the eluate collected.  A further 100 µL binding buffer was added to 
each column and centrifuged for 30 s at 800 × g.  This step was repeated once to 
give a final volume of 300 μL.  The total protein concentration was determined 
using the bicinchoninic acid (BCA) assay following the manufacturer’s 
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instructions (Pierce®, Thermo Fisher Scientific, Boston, MA, USA; #23225) and 
100 μg protein sent on ice to the Bristol Proteomics Facility for total proteomic 
analysis.  Remaining albumin-depleted plasma was stored at -80°C for later 
analysis. 
 
5.2.4 Tissue culture of conditionally-immortalised human podocytes 
Conditionally-immortalised human podocytes were derived from normal patient 
samples using the processes described previously [187].  Frozen stocks of 
podocytes were thawed from -80°C and transferred to a T75 vented flask before 
adding standard medium (RMPI 1640 [Sigma-Aldrich, Poole, UK; #R8758] 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) [Thermo 
Fisher Scientific; #10500-064] and 1% insulin-transferrin-selenium (ITS) 
[Thermo Fisher Scientific; #41400-045]).  Medium was changed three times per 
week and cells kept at 33°C in 5% CO2 until above 80% confluence.  Cells in the 
stock flask were released with 0.5 mL trypsin-EDTA (Sigma-Aldrich; #T4049), 
suspended in 10 mL standard medium and centrifuged at 1200 rpm for 5 minutes. 
The cell pellet was resuspended in 8-10 mL.  In the case of T75 flasks, 1 
mL was aliquoted to the flasks before adding 9 mL standard medium and 
returning to 33°C.  For 6-well plates, the cells suspension was diluted 1:12.5 with 
medium and 2 mL aliquoted to each well of the plate.  When the cells reached 70-
80% confluence they were thermoswitched to 37°C to promote terminal 





5.2.5 Treatment of podocytes with albumin-depleted plasma 
On the day of treatment, standard medium was removed and replaced with RMPI 
1640 lacking FBS and ITS.  Podocytes were incubated for 2 hours in serum-free 
medium (SFM) before treatment started.  Albumin-depleted plasma was diluted in 
serum-free RPMI 1640 to a final concentration of 10%.  Paired relapse and 
remission samples were used. A final volume of 4 ml per T75 flask and 0.5 mL 
per well of a 6-well plate was used.  Treatments and controls were as follows: 
1. SFM 
2. Albumin binding buffer (ABB, as detailed in Section 5.2.3) 60% : SFM 
40% 
3. Flufenamic acid (Sigma-Aldrich; #F9005) 200 mmol/L in dimethyl 
sulfoxide (DMSO, Sigma-Aldrich; # D2650) diluted to 200 µmol/L in 
SFM 
4. Control patient plasma (C1) 10% : ABB 50% : SFM 40% 
5. Albumin-depleted (AD) or non-AD relapse patient plasma 10% : ABB 
50% : SFM 40% 
6. AD or non-AD remission patient plasma 10% : ABB 50% : SFM 40% 
Flufenamic acid (FFA) has been shown to activate the cation channel TRPC6 
leading to intracellular calcium signalling in culture podocytes [318].  This results 
in VASP phosphorylation hence FFA treatment acts as a positive control in these 
experiments.   
After applying the treatments as listed above, podocytes were returned to 




5.2.6 Protein extraction and preparation 
5.2.6.1 Solutions used for protein extraction 
The solutions used for protein extraction from podocyte cultures are detailed in 
Table 5.1. 
 
Table 5.1: Solutions used for protein extraction from podocyte cultures 
1 × Phosphate buffered saline 
(PBS) 
135 mmol/L NaCl 
3 mmol/L KCl 
1 mmol/L Na2HPO4 
1.75 mmol/L KH2PO4 
pH 7.4 
1% Triton extraction buffer 
150 mmol/L NaCl 
20 mmol/L Tris base 
10% (v/v) Glycerol 
1% (v/v) Triton® X-100 
Supplements added to 1% 
Triton buffer just prior to use 
1% (v/v) Protease inhibitor cocktail 
(Sigma-Aldrich; #P8340) 
1% (v/v) Phosphatase inhibitor cocktail 3 
(Sigma-Aldrich; #P0044) 
400 µmol/L Phenylmethane sulfonyl 
fluoride (PMSF) 
 
5.2.6.2 Protein extraction method 
Flasks of treated podocytes were removed from the 37°C incubator and placed 
immediately on ice.  The cells were washed twice with ice-cold PBS and all fluid 
removed before adding 300 μL per flask or 100 µL per well of 1% Triton 
extraction buffer with supplements.  Cells were scraped from the base of the tissue 
culture flask and centrifuged at 13200 rpm at 4°C for 5 minutes to remove cellular 




5.2.7 Quantitative total proteomics 
Quantitative total proteomics of albumin- and IgG-depleted plasma was 
performed at the University of Bristol Proteomics Facility under the direction of 
Dr Kate Heesom as previously described [319].  Briefly, 10 samples were 
digested with trypsin overnight, labelled with Tandem Mass Tag (TMT) 10-plex 
reagents and pooled together.  For total proteomics, the pooled samples were 
fractionated by high-pH reversed-phase chromatography.  The fractions were 
analysed by nano-liquid chromatography tandem mass spectrometry (nano-LC 
MS/MS) using an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher 
Scientific).  Data files were processed and analysed with Proteome Discoverer 
software (v1.4, Thermo Fisher Scientific) and searched against the Uniprot 
Human database (134169 sequences) using the SEQUEST algorithm. The search 
was performed with full tryptic digestion allowing a maximum of one missed 
cleavage.  The false discovery rate (FDR) was set at 5% for all peptide data using 
the reverse database search option. 
 
5.2.8 Total Proteomics data analysis 
Quantitative proteomic data were analysed using Proteome Discoverer software 
(v4.1, Thermo Scientific) and Excel (v2007, Microsoft).  During the processing of 
mass spectra in Proteome Discoverer, the algorithms sometimes assigned different 
(protein) accession numbers to peptides from the same or highly related proteins 
(for example protein fragments or different isoforms).  Figure 5.5 shows a 





Within one dataset, one protein from the group of related proteins was 
designated by the software as the master protein and the protein group was 
labelled using the accession number of this master protein (in this case Q59H90).  
However, in a second dataset, a different master protein/accession number may be 
used to label the same protein group, and, therefore, the associated quantitative 
data.  When it was necessary to combine results from different proteomic runs, 
data were first matched using the accession numbers in Excel.  Any rows 
remaining unmatched were compared with the second dataset using the full 
protein name and/or the gene name.  For any rows still remaining unmatched, the 
protein was identified manually in Proteome Discoverer and the linked accession 
numbers within the protein group used to search in the second dataset.  The aim 
was to maximise the number of proteins with complete quantitative data for 
further analysis. 
Relative fold change in protein quantification was calculated in Proteome 
Discoverer using the Ratio Reporting function as the ratio of quantity in the 
“relapse” sample to quantity in “remission” for the same patient.  Data were 
analysed in three ways.   
 
Figure 5.5: Snapshot from Proteome Discoverer illustrating protein grouping 
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5.2.8.1 Geometric mean and t tests 
The first method aimed to determine both the magnitude and statistical 
significance of differences in protein quantity between relapse and remission 
across all patients.  The geometric mean of the relapse/remission fold change was 
calculated for each protein.  A paired-sample two-tailed t-test of the log2 
transformed quantification was used to compare the SRNS patient relapse/control 
with the SRNS patient remission/control data.  In order to visualise both 
magnitude of fold change and statistical significance, (-log10 t-test probability) 
was plotted against (log2 geometric mean fold change) to generate a volcano plot 
[320].  To account for multiple comparisons, the Bonferroni correction was 
applied (threshold p = 0.05 / number of proteins).  An alternative adjustment for 
multiple comparisons was also used to control the FDR using the Benjamini-
Hochberg (BH) procedure [321].  The FDR is the proportion of “discoveries” (test 
positives) that are actually false positives.  The BH procedure involves sorting all 
p values from smallest to largest and allocating each a rank, i, with the smallest 
being 1.  The Benjamini-Hochberg critical value is calculated as (i/m) × Q, where 
i is the rank, m is the total number of tests and Q is the chosen FDR.  The largest p 
value for which p < (i/m) × Q is the cut-off for significance and all p values less 
than this are also significant. 
 
5.2.8.2 Empirical Bayes moderated t tests 
A second method of analysis employed a technique recently described by 
Kammers et al. which used empirical Bayes moderated t tests in contrast to the 
standard t tests described above [320].   This develops on techniques used for 
gene expression analysis such as LIMMA (Linear Models for Microarray Data).  
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Given the small number of samples (4 pairs in this case), proteins showing a large 
fold change may be declared non-significant using standard statistics due to large 
sample variance.  The empirical Bayes procedure uses the whole dataset to reduce 
the sample variances towards a pooled estimate giving greater ability to identify 
statistically significant differences.   
The data file was opened in Proteome Discoverer with peptide confidence 
set to “medium” (FDR 5%).  The quantification method was set to ratio reporting 
for the relevant relapse/remission pairs.  The experimental bias was set to 
“Normalize on Protein Median” with a minimum protein count of 20. This 
mirrored the normalisation step as described by Kammers et al [320].  In the 
normalisation process, each protein relative abundance was divided by the median 
of all relative protein abundances within a sample resulting in all samples having 
a median of one.  This compensated for any loading/pipetting errors when setting 
up samples for MS.  In Results filters / Peptide grouping, the option to “Show 
peptide groups” was unselected.  In Edit quantification method / Ratio calculation, 
the option to “Show the Raw Quan values” was selected.  These last two steps 
allowed the quantification data for all individual peptides to be used in subsequent 
analysis. 
The above steps generated a list of 49144 peptides with raw quantification 
data for each of the two conditions (relapse and remission) for the 4 patients.  
These data were exported to Microsoft Excel and then filtered to include only 
peptides used for protein quantification and only peptides with quantification data 
available for all 8 samples.  This reduced the peptide list to 21680. 
The data were analysed using the R statistics programme (R version 3.3.2) 
[322].  The method used software and code developed by Kammers et al. and 
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freely available at http://www.biostat.jhsph.edu/~kkammers/software/eupa/ [320].  
The data were imported from Excel and processed in R with full code given at the 
end of this chapter (Section 5.5.1).   
 
5.2.8.3 Fold change thresholds 
In a third method of analysis, the protein quantification ratios for 
relapse/remission samples were determined in Proteome Discoverer with 5% FDR 
and without median normalisation.  The data were exported to Excel and fold-
change thresholds were initially set at > 2 and < 0.5.  Proteins were filtered using 
these thresholds to maximise consistency across patients with paired 
relapse/remission samples.  Less stringent thresholds of > 1.5 and < 0.67, and > 
1.3 and < 0.77 were subsequently used to identify more proteins of potential 
relevance, reaching the threshold across a greater number of patient pairs.  Fold 
change thresholds alone do not take into account the variability of the data [323] 
but have been widely used previously in proteomics studies related to nephrotic 
syndrome and other fields of biomedical research [246, 257]. 
 
5.2.9 Western blotting 








Table 5.2: Solutions used for gel electrophoresis and Western blotting 
Sample buffer 
60 mmol/L Tris HCl pH 6.8 
10% (v/v) Glycerol 
2% sodium dodecyl sulphate (SDS) 
0.005% bromophenol blue 
2.5% (v/v) 2-mercaptoethanol (added just 
prior to use) 
10% or 15% Resolving gel 
10% or 15% (v/v) acrylamide / 
bisacrylamide 
375 mmol/L Tris pH 8.8 
0.1% (v/v) SDS 
5 mg/mL ammonium persulphate (APS) 
0.05% (v/v) N,N,N',N'-Tetramethyl 
ethylenediamine (TEMED) 
3.75% Stacking gel 
3.75% (v/v) acrylamide / bisacrylamide 
125 mmol/L Tris pH 6.8 
5 mg/mL APS 
0.05% (v/v) TEMED 
Running buffer 
192 mmol/L glycine 
25 mmol/L Tris pH 8.3 
0.1% SDS 
Transfer buffer 
192 mmol/L glycine 
25 mmol/L Tris pH 8.3 
10% (v/v) Methanol 
Tris-buffered saline with 
Tween (TBS-T) 
137 mmol/L NaCl 
20 mmol/L Tris pH 7.6 
0.1% (v/v) Tween-20®  
Blocking buffer 
5% bovine serum albumin (BSA, Sigma-
Aldrich; #A9647) in TBS-T 
 
5.2.9.2 Gel electrophoresis and Western blotting method 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were 
used to confirm findings from total proteomics and to analyse proteins in 
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podocyte extracts.  Albumin-depleted plasma was thawed on ice.  Using the total 
protein concentration determined previously by the BCA assay, ABB was added 
to the samples to give a final protein concentration of 0.5 µg/mL in a total volume 
of 100 µL.  These were mixed 4:1 with 5× sample buffer.  Samples were heated at 
95°C for 5 minutes in order to denature and reduce proteins.  10%-15% SDS-
polyacrylamide gels were prepared depending on the size of proteins to be 
separated.  25 μL (10 µg) protein samples were loaded in each lane of the gel with 
molecular weight marker (BLUeye Prestained Protein Ladder, Geneflow, 
Lichfield, UK; #S6-0024,) at each end.  For plasma samples, the same total 
quantity of protein was loaded per lane based on the BCA assay.  For podocyte 
extracts, 25 µL were loaded per lane without prior protein quantification; instead I 
used an internal loading control (GAPDH).  Gels were immersed in running 
buffer and a direct current applied at 150 V for 60-75 minutes until the 
bromophenol blue dye front reached the bottom of the gel and there was adequate 
separation of the protein sizes of interest.  Proteins were transferred onto 
polyvinylidene fluoride (PVDF, Immobilon-P membrane, 0.45 µm, Merck 
Millipore, Billerica, MA, USA; #IPVH00010) membranes in transfer buffer at 
4°C and 250 mA for 60 minutes.  Membranes were blocked in blocking buffer for 
1 hour at room temperature.  Primary antibodies were prepared in 5% BSA / TBS-
T.  The antibodies used, and dilutions, are shown in Table 5.3.  Membranes were 
incubated overnight on a rocking platform at 4°C with primary antibodies.  The 
following day, antibodies were stored for re-use at 4°C and membranes rinsed 
twice in TBS-T before 5 × 5-minute washes.  Secondary antibodies were prepared 
at 1:10,000 dilution in TBS-T and applied for 1 hour at room temperature.  
Membranes were rinsed and washed as above before application of Clarity 
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Western ECL substrate (BioRad, Hercules, CA, USA; #170-5061) and imaging 
with chemiluminescence settings on an Amersham Imager 600 (GE Healthcare 
Life Sciences).  
 





Manufacturer Species Dilution 
pVASP 
(Ser157) 
50 3111 Cell Signaling 
Technology (CST), 







Lumican 38, 50, 
60 
ab98067 Abcam, Cambridge, 
UK 
Rabbit 1:1000 
Uteroglobin 10 ab40873 Abcam Rabbit 1:5000 







DAG1 97 GTX105038 GeneTex, Irvine, 
CA, USA 
Rabbit 1:1000 
EphB4 135 14960 CST Rabbit 1:1000 








- A9044 Sigma-Aldrich Rabbit 1:10000 
 
 
5.2.9.3 Quantification of Western blotting 
Images of membranes were analysed using ImageJ (U. S. National Institutes of 
Health, Bethesda, Maryland, USA) [324].  Tif images were converted to grey 
scale (8-bit) and the rectangular selection tool used to place rectangles around 
each lane.  The “Plot lanes” function was used to create profile plots and 
horizontal lines drawn across the base of each peak to enclose an area and exclude 
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background.  Vertical lines were drawn to bisect the peaks and the area of the 
same half of each peak quantified using the “Wand” tool.   
 
5.2.10 ELISA 
ELISA was used for quantification and validation of proteins identified by total 
proteomics of plasma as differentially present in relapse and remission.  The 
following kits were used (Table 5.4): 
Table 5.4: ELISA kits used for protein quantification 
Target Product code Manufacturer 
Uteroglobin RD191022200 Biovendor, Brno, Czech 
Republic 
Lumican E-EL-H0198 Elabscience, Wuhan, China 
Lumican SEB496Hu Cloud Clone Corp, Katy, TX, 
USA 
 
The manufacturers’ protocol was followed with single wells used for the 
standard curve and test samples in duplicate for trial kits (24 wells) and all 
standards and samples in duplicate for 96-well plates. 
 For uteroglobin ELISA analysis, the manufacturer recommended 4-
parameter logistic regression (4PL) fitting for the standard curve.  This was 
implemented using freely available software online at 
http://www.elisaanalysis.com.  The 4PL method produced a curve of best fit for 
the standards assuming an (approximate) symmetrical S-shape on logarithmic 
axes with upper and lower detection limits [325, 326].  The regression equation 




where y is the measured optical density (OD), x is the uteroglobin concentration 
and a to d are the four parameters.  A separate curve was generated using the 
standards for each ELISA plate.  The 4PL curves were visualised and compared 
with the polynomial (third, fourth or fifth order) lines of best fit for the standards 
in Microsoft Excel to confirm that the interpolated concentrations for the test 
samples appeared reasonable. 
 Product literature accompanying the uteroglobin ELISA (Biovendor) 
reported a mean serum concentration of uteroglobin of 6.4 ng/mL (SD 1.9, range 
3.7-9.4, n = 18) for healthy men aged 20-39 years and mean 7.3 ng/mL (SD 2.3, 
range 3.6-11.1, n = 12) for healthy women of the same age.  The equivalent data 
were not available for plasma, however the mean lithium heparin plasma / serum 
concentration for a different set of subjects was 98.3%.  No results were provided 
for children. 
 
5.2.11 Statistical analysis 
Data were analysed using Microsoft Excel 2016 and GraphPad Prism 7.  The 
geometric mean was used to summarise fold change data across multiple patients.  
Statistical analysis was undertaken on the log2 transformed values. The paired t 
test (with two tails) was used to compare protein quantification data at the time of 
relapse and remission.  The Bonferroni correction and Benjamini-Hochberg 
procedures were used to account for multiple comparisons as described 
previously.  The association between variables was determined using Spearman’s 
rank correlation where bivariate normal distributions could not be assumed.  The 






5.3.1 Patient characteristics 
Investigations using patient plasma samples during this study started in September 
2014.  During the course of the project, more patients were recruited to RaDaR 
and NephroS and additional samples became available for testing.  Table 5.5 
details the characteristics of patients included at one or more stages of the 
investigation of plasma proteins as biomarkers in nephrotic syndrome. 
 Patients C1 and C2 were control subjects, both of whom had PEx for 
indications other than SRNS.  C1 had cryoglobulinaemia, an immune-complex-
mediated systemic vasculitis, without any renal involvement.  C2 had 
granulomatosis with polyangiitis (Wegener’s granulomatosis), an anti-neutrophil 
cytoplasmic antibody (ANCA)-associated small vessel vasculitis, with renal 
involvement [327].  These disease processes may alter the plasma proteome but 
would not affect the analyses in this study based on comparing relapse and 
remission plasma samples from the same patient with SRNS. 
 As discussed below, plasma samples from two sets of four patients were 
analysed on separate occasions by MS.  The first group was SRNS1, SRNS2, 
SRNS3 and 419.   The second group, whose samples were received later in the 
study, comprised 560, 641, 1202 and 1715.  All patients had a diagnosis of SRNS, 
had progressed to ESRF and been transplanted, and suffered post-transplant 
recurrence.   Among patients who had had genetic testing, none had a genetic 
cause for disease identified.  The timing and laboratory results associated with the 
plasma samples are detailed in Table 5.6.  All samples were derived from plasma 
exchange except in the case of 1202 where only a blood sample was received at 
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the time of partial remission.  Samples were sent from two patients (REL-1 and 
REL-2 from 419 and REL from 560) at times when the treating clinical team 
judged the patients to be in relapse.  The plasma was used as “relapse” samples in 
subsequent experiments.  However, when full clinical details and laboratory 
results became available and were analysed retrospectively, these samples were 
not at a time when the patients uPCR was greater than 200 mg/mmol. 
 A wider range of patients was included in subsequent experiments using 
ELISA to validate proteomics findings.  These included 5 patients with SRNS 
(middle section of Table 5.5 and Table 5.6) and 10 patients with SSNS (lower 
section of Table 5.5 and Table 5.6)  
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Table 5.5: Demographic and clinical characteristics of patients included in plasma proteomic studies 






















C1 N/A ND ND ND ND ND 
Cryoglobulin-
aemia 
ND ND ND ND ND ND 
C2 N/A ND ND ND ND ND GPA ND ND ND ND ND ND 
SRNS 1 ND M W ND 7 ND SSR FSGS 5Tx 11 Yes Yes 15 
SRNS 2 ND F W S 26 No PSR MCD 5Tx 10.7 Yes Yes 21 
SRNS 3 ND M W ND 7 ND SSR MCD 5Tx 9 Yes Yes 12 
419 No M W S 8.0 No PSR MCD 5Tx 5.2 Yes Yes 8.7 
560 No F I S 12.1 No PSR FSGS 5Tx 1.9 Yes Yes 5.2 
641 No F P S 7.8 ND PSR MCD 5Tx 1.8 Yes Yes 4.2 
1202 No M W Fam 13.6 No SSR FSGS 5Tx 0.9 Yes Yes 5.0 
1715 No M W S 11.0 No PSR 
Collapsing 
glomerulopathy 
5Tx 0.3 Yes Yes 2.1 
252 ND F W Fam 6.0 No PSR FSGS 5Tx 1.6 Yes Yes 7.5 
291 No F W S 9.5 No PSR FSGS 5Tx 5.5 Yes Yes 12.9 
1291 No F W S 12.4 No PSR FSGS 5Tx 1.3 Yes Yes 3.0 
5618 ND M W ND 6.4 ND PSR ND 5Tx 3.7 Yes Yes 6.7 
7030 ND M W ND 1.2 ND SSR FSGS 5Tx 16 Yes Yes 18.5 
2375 ND F W S 4 No FR-SSNS FSGS 1 N/A No N/A 11 
2703 ND F W S 5.2 No FR-SSNS ND 1 N/A No N/A 4.2 
2704 ND F W + As S 5.8 No FR-SSNS ND 1 N/A No N/A 1.4 
3496 ND M As S 21.5 No SSNS MCD 1 N/A No N/A 2.1 
3752 ND M As ND 3.3 ND SDNS ND 1 N/A No N/A 1.0 
3889 ND M As S 10.0 No SDNS MCD 1 N/A No N/A 30.6 
6690 ND M W S 4 No FR-SSNS MCD 2 N/A No N/A 40.4 
7025 ND M W S 6.8 No FR-SSNS ND 1 N/A No N/A 6.7 
7944 ND M Other S 33.4 No SSNS MCD 1 N/A No N/A 9.9 
9995 ND M As ND 4.6 ND SSNS ND 1 N/A No N/A 0.6 
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The top group of 10 patients (C1-1715) were included in plasma proteomic analyses using mass spectrometry as an initial discovery cohort.  The 
middle group of 5 patients (252-7030) all had SRNS and the bottom group of 10 patients (2375-9995) all had SSNS.  Plasma samples from these 
patients were included in exploratory and validation ELISA studies. 
Legend: As, Asian; F, female; Fam, familial; FR, frequently-relapsing; FSGS, focal segmental glomerulosclerosis; GPA, granulomatosis with 
polyangiitis; I, Indian; M, male; MCD, minimal change disease; N/A, not available; ND, not done / no data; P, Pakistani; PSR, primary steroid 
resistance; S, sporadic; SDNS, steroid-dependent nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome; SSR, secondary steroid 

















Date of uPCR or 
dipstick‡ 
uPCR (mg/mmol) or 
dipstick 
SRNS1 SSR 03/01/2011 
REL PEx 10/01/2011 10/01/2011 22 10/01/2011 2190 
P-REM PEx 07/02/2011 07/02/2011 32 07/02/2011 316 
SRNS2 PSR 07/2007 
REL PEx 28/09/2007 24/09/2007 27 24/09/2007 641.7 
P-REM PEx 16/10/2007 16/10/2007 37 16/10/2007 923.8 
SRNS3 SSR 16/04/2005 
REL PEx 14/08/2001 N/A N/A N/A N/A 
REM PEx 21/11/2005 N/A N/A N/A N/A 
419 PSR 21/04/2014 
REL-1* PEx 17/11/2014 17/11/2014 40 17/11/2014 24 
REL-2* PEx 13/07/2015 13/07/2015 37 13/07/2015 81 
REM PEx 24/11/2014 24/11/2014 41 24/11/2014 13 
560 PSR 23/01/2015 
REL* PEx 11/04/2016 13/04/2016 38 13/04/2016 8 
REM PEx 20/04/2016 20/04/2016 38 22/04/2016 4 (uACR) 
641 PSR 22/11/2015 
REL PEx 22/11/2015 22/11/2015 20 22/11/2015 7797 
P-REM PEx 21/12/2015 21/12/2015 35 21/12/2015 4348 
1202 SSR 29/03/2014 
REL PEx 27/04/2014 26/04/2014 33 26/04/2014 739 
P-REM Blood 27/05/2014 27/05/2014 32 27/05/2014 159 
1715 PSR 23/05/2016 
REL PEx 30/05/2016 30/05/2016 38 30/05/2016 583 
P-REM PEx 20/06/2016 20/06/2016 51 20/06/2016 42 
252 PSR 02/12/2011 
REL PEx 04/12/2011 04/12/2011 26 04/12/2011 1295 
P-REM PEx 15/12/2011 15/12/2011 32 15/12/2011 529 
291 PSR 30/06/2010 
REL PEx 05/07/2010 05/07/2010 14 05/07/2010 500 
P-REM Blood 05/09/2014 N/A N/A 05/09/2014 188 
1291 PSR 26/05/2016 
REL PEx 29/05/2016 29/05/2016 25 29/05/2016 609 
P-REM PEx 31/05/2016 31/05/2016 33 31/05/2016 243 
234 
 
5618 PSR 23/03/2017 
REL PEx 30/03/2017 30/03/2017 21 30/03/2017 2915 
REM PEx 10/04/2017 09/04/2017 34 09/04/2017 9.1 
7030 SSR 28/05/2016 
REL PEx 27/06/2016 27/06/2016 41 28/06/2016 360 (uACR) 
P-REM PEx 03/07/2016 03/07/2016 46 03/07/2016 165 (uACR) 
2375 FR-SSNS N/A 
REL Blood 10/03/2015 15/03/2015 20 15/03/2015 2899 
REM Blood 21/07/2016 21/07/2016 37 21/07/2016 9.9 
2703 FR-SSNS N/A 
REL Blood 23/11/2015 23/11/2015 25 23/11/2015 453 
P-REM Blood 23/02/2015 23/02/2015 32 23/02/2015 155 
2704 FR-SSNS N/A 
REL Blood 06/01/2016 06/01/2016 28 05/01/2016 704 
REM Blood 29/06/2015 29/06/2015 41 N/A N/A 
3496 SSNS N/A 
REL Blood 17/01/2017 10/01/2017 18 10/01/2017 1988 
REM Blood 12/04/2016 12/04/2016 44 12/04/2016 0 (dip) 
3752 SDNS N/A 
REL Blood 08/01/2016 08/01/2016 27 08/01/2016 3073 
P-REM Blood 02/11/2015 27/10/2015 28 14/10/2015 293 
3889 SDNS N/A 
REL Blood 23/08/2016 23/08/2016 14 23/08/2016 1043 
REM Blood 17/05/2016 17/05/2016 40 17/05/2016 11 
6690 FR-SSNS N/A 
REL Blood 06/12/2016 06/12/2016 24 06/12/2016 565 
REM Blood 07/06/2016 07/06/2016 35 07/06/2016 11 
7025 FR-SSNS N/A 
REL Blood 03/02/2017 03/02/2017 25 03/02/2017 232 
REM Blood 24/06/2016 N/A N/A 25/06/2016 15 
7944 SSNS N/A 
REL Blood 30/08/2016 30/08/2016 31 30/08/2016 891 
P-REM Blood 16/08/2016 16/08/2016 36 16/08/2016 127 
9995 SSNS N/A 
REL* Blood 19/12/2016 19/12/2016 31 19/12/2016 0 (dip) 
REM Blood 21/11/2016 21/11/2016 35 21/11/2016 0 (dip) 
†Due to the need for paired samples for this study, plasma at the time of partial remission had to be used for some patients where no others were 
available.  *These samples were taken at a time when the clinical team judged the patient to be in relapse (and were labelled as such).  When full 
data were available and analysed retrospectively the samples were not at relapse defined as uPCR > 200 mg/mmol. ‡The date of plasma albumin 
and proteinuria results were as close as possible to the sample date – in most cases this was on the same day. 
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Table 5.6 Legend: FR-SSNS, frequently-relapsing steroid-sensitive nephrotic 
syndrome; P-REM, partial remission; PSR, primary steroid resistance; REL, 
relapse; REM, remission; SSNS, steroid-sensitive nephrotic syndrome; SSR, 
secondary steroid resistance; uACR, urine albumin:creatinine ratio 
 
 
5.3.2 VASP phosphorylation by albumin-depleted plasma samples 
Human plasma contains a complex mixture of thousands of proteins.  In order to 
improve detection of low-abundance proteins by MS, it is common practice to 
deplete samples of albumin and IgG prior to analysis as discussed in Section 
5.1.1.   Studies performed by the Bristol Renal group have previously 
demonstrated that treatment of ci-hPod with plasma from patients with SRNS at 
time of relapse is associated with VASP phosphorylation [188].  In order to assess 
whether albumin-depletion affected this, podocytes were treated with albumin-
depleted and non-albumin-depleted plasma. 
Immunoblotting of paired relapse and remission samples both with and 
without albumin-depletion confirmed that there was no loss of VASP 











Figure 5.6: Western blots showing VASP phosphorylation in podocytes 













































































































Podocytes were treated for 30 minutes with plasma at a final concentration of 
10%. Phospho-VASP (Ser 157) quantification is shown relative to GAPDH and 
normalised to serum free control.  A: Patient 291. B: Patient SRNS2. C: Patient 
419 
Legend: SF, serum free media; ABB, albumin binding buffer; FFA, flufenamic 
acid 200 µmol/L; C1, control patient plasma; REL, relapse plasma; REM, 
remission plasma; AD, albumin depletion. 
 
 
For each of the three patients, although the final plasma concentration was 
the same in all cases (10%) it appeared that VASP phosphorylation was relatively 
greater with albumin-depleted compared with non-albumin-depleted samples. 
Albumin-depleted remission plasma from patient 291 (A in Figure 5.6) was 
associated with relatively higher VASP phosphorylation than albumin-depleted 
relapse plasma which was not expected from other work in the group.  Plasma 
from 291 had shown inconsistency in previous experiments (D. Henson, personal 
communication and data not shown) and therefore was not selected for further 
analysis at this stage.  Western blotting of albumin-depleted plasma from patients 
SRNS1 and SRNS3 confirmed that there was no loss of VASP phosphorylation 
activity (data not shown).  Samples from patients SRNS1, SRNS2, SRNS3 and 
419, which all showed the expected pattern of VASP phosphorylation after 
treatment of podocytes and with no loss after albumin depletion, were taken 






5.3.3 Proteomic analysis of albumin-depleted relapse and remission 
plasma samples from patients with SRNS 
5.3.3.1 Analysis using ordinary t tests 
  
Proteomic analysis of plasma from controls C1 and C2, and paired relapse 
and remission samples from SRNS1, SRNS2, SRNS3 and 419 identified, in total, 
11118 peptides corresponding to 2397 proteins with FDR 5%.  Only proteins for 
which there was complete quantification data for C1 and all patient samples were 
taken forward for further analysis.  This reduced the set to 1926 proteins. 
The range of fold change and t-test p values for all proteins are shown in 
the volcano plot (Figure 5.7).      
 




























Figure 5.7: Volcano plot of protein quantification data for relapse/remission 
plasma samples from patients SRNS1, SRNS2, SRNS3 and 419 
The horizontal line shows the Bonferroni-corrected significance threshold for 
1926 proteins with α = 0.05 
 
Among 1926 proteins, 261 (13.5%) achieved nominal significance at the 5% 
level, however this does not consider the multiple comparisons.  The horizontal 
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line represents the Bonferroni-corrected threshold of 0.05/1926 and it is evident 
that no proteins reached this level of significance.  The three proteins with the 
most significant fold change were: ribonuclease pancreatic (gene: RNASE1, p = 
8.3 × 10-5), dermokine (gene: DMKN, p = 5.0 × 10-4), and coiled-coil domain-
containing protein 66 (gene: CCDC66, p = 8.6 × 10-4).  No proteins reached the 
threshold for statistical significance after the Benjamini-Hochberg procedure for 
multiple comparisons with FDR 10%.   There were multiple proteins with Log2 
(geometric mean of relapse/remission fold change) less than -1 or greater than +1 
(corresponding to fold change of < 0.5 or > 2 respectively). 
 As discussed above, the REL-1 sample from patient 419 which was 
included in the proteomic analysis was taken at a time when the patient was not 
significantly proteinuric.  Patient 419 was therefore excluded, and the same fold 
change and t test analysis conducted on the remaining 3 patients.  The volcano 
plot representing a total of 1941 proteins is shown in Figure 5.8. 
 




























Figure 5.8: Volcano plot of protein quantification data for relapse/remission 
plasma samples from patients SRNS1, SRNS2 and SRNS3 
The horizontal line shows the Bonferroni-corrected significance threshold for 
1941 proteins with α = 0.05 
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The three proteins with the most significant fold change were: fetuin B (gene: 
FETUB, p = 1.4 × 10-4), ElaC ribonuclease Z 2 (gene: ELAC2, p = 4.2 × 10-4), and 
matrix extracellular phosphoglycoprotein (gene: MEPE, p = 5.6 × 10-4).  Again, 
no proteins reached the Bonferroni-corrected significance threshold or the 
threshold after the Benjamini-Hochberg procedure. 
 
5.3.3.2 Analysis using empirical Bayes moderated t tests 
As discussed above, with small numbers of samples the variance may be large and 
cause proteins with high fold change to appear non-significant.  Moderated t tests 
were used on median-normalised raw quantification data.  Figure 5.9 illustrates 
the pre-processed normalised protein quantification data for the 8 patient samples.  
As previously, proteins which could not be quantified due to missing peptide 
quantification data for some samples were excluded.  The analysis used more 
stringent criteria, namely setting isolation interference < 30% and excluding any 
proteins only identified by a single peptide.  This reduced the total number of 
















The median-normalised quantification data were analysed in R and volcano plots 
were generated using ordinary p values and moderated p values (Figure 5.10).  
Comparison of the plots illustrates that the Bayes moderated t tests generally 
increased the significance of proteins with large fold change values (and larger 
variance) and decreased the significance of those with small fold change values 
(and smaller variance) as was expected [320].  The result was that using 
moderated statistics, 33 proteins reached nominal significance at a 5% level 
compared with 27 with ordinary statistics.  No proteins reached statistical 
significance after Bonferroni correction (p < 9.2 × 10-5 corresponding to –log10 p 
value of 4.04) or the threshold after the Benjamini-Hochberg procedure with FDR 
10%.  
Figure 5.9: Boxplot showing median normalised relative protein 
abundances in relapse and remission plasma samples from patients 















































Figure 5.10: Volcano plot of protein quantification data showing 
ordinary and moderated p values for relapse/remission plasma 
samples from patients SRNS1, SRNS2, SRNS3 and 419 
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5.3.3.3 Analysis using fold change thresholds 
One of the explanations for the failure of any protein to reach statistical 
significance was likely to be variability between the small number of samples.  In 
addition, the use of the geometric mean was susceptible to distortion by extreme 
outliers in one of the patients.  As this was an exploratory analysis, it was decided 
to use fold change thresholds to identify proteins differentially present in relapse 
and remission.  The threshold was initially set to 2 and 0.5, followed by 1.5 and 
0.66, and then 1.3 and 0.77 with the aim of identifying proteins consistently 
changed above or below these values across all four patients.  It was considered 
that fold changes > 1.3 or < 0.77 would be biologically significant.  The numbers 
of proteins reaching the thresholds are shown in Table 5.7 below. 
 
Table 5.7: Number of proteins reaching relapse/remission fold change 













> 2 4 11 2 143 
> 1.5 4 37 7 459 
> 1.3 4 126 39 745 
< 0.5 3* 13 1 42 
< 0.66 4 3 0 111 
< 0.77 4 14 0 211 
*No proteins met the < 0.5-fold change threshold across all 4 patients, therefore 
the table displays data for proteins meeting the threshold across at least 3 patients 
 
 
As shown in the table, when a fold change threshold of > 2 was used, 143 
proteins reached this based on the geometric mean (that is to the right of the line 
log2 geometric mean = 1 in the volcano plots above).  However, when the 
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criterion of consistency across all 4 patients was applied by manual analysis in 
Excel, this number reduced to 11.  The list of proteins reaching threshold in three 
or four patients was compared with the proteins listed in the human plasma 
proteome database [328, 329].  Comparatively few of the proteins were found in 
this database.  However, this includes samples only from healthy individuals and 
proteins were, therefore, not excluded on the basis of not being listed. 
A bioinformatic search was conducted using Uniprot [330, 331], STRING 
[332], NCBI Gene [333] and GeneCards [334]  for the proteins reaching the 
thresholds in 3 or 4 patients as detailed in Table 5.7.  The proteins with fold 
change > 2 or < 0.5 are shown in Table 5.8 giving details of the associated genes 
and possible protein function.  A search for any associations between these 
proteins and nephrotic syndrome revealed no links.  A review of the proteins’ 
functions and subcellular localisation suggested that they were intracellular or 
membrane bound.  Although hypothetically they could be released into the plasma 





Table 5.8: Proteins identified by mass spectrometry with fold change > 2 or < 0.5 between relapse and remission plasma samples in 4 































P78540 Arginase-2, mitochondrial ARG2 Possible role in regulation of extra-urea 
cycle arginine metabolism 
5.32 7.12 18.23 2.87 6.67 
F8WB87 Coiled-coil domain-containing protein 
66 
CCDC66 Retinal rod cell development 5.62 5.22 9.41 5.69 6.29 
A0A087X128 Protein turtle homolog A IGSF9 Protein binding involved in cell-cell 
adhesion, regulation of synapse 
organization 
5.18 5.95 10.14 4.12 5.99 
F5H176 Nucleosome-remodelling factor subunit 
BPTF (Fragment) 
BPTF Sequence-specific DNA binding, 
transcription factor binding 
3.03 6.44 8.90 4.47 5.28 
B3KR25 cDNA FLJ33522 fis, clone 
BRAMY2006375, highly similar to PIAS-
like protein Zimp7 
ZIMZ2 Zinc ion binding 2.15 6.17 13.79 3.35 4.98 
E5RIZ8 Calbindin (Fragment) CALB1 Calcium ion binding 2.50 3.95 13.83 2.16 4.14 
K7EN45 Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 (Fragment) 
PIN1 Peptidyl-prolyl cis-trans isomerase activity 3.89 2.67 5.64 2.92 3.62 
A0A087X203 Serine/threonine-protein kinase Nek3 NEK3 ATP binding 2.78 3.95 5.87 2.16 3.43 
B2RA91 cDNA, FLJ94773, highly similar to Homo 
sapiens splicing factor, arginine/serine-
rich 2, interacting protein (SFRS2IP), 
mRNA 
SCAF11 Role in pre-mRNA alternative splicing by 
regulating spliceosome assembly 
3.35 2.32 3.27 2.62 2.86 
A0A0G2JMM2 Protein LOC105369239 LOC105369239 Multidrug Resistance-Associated Protein 6 2.06 2.60 4.72 2.30 2.76 
Q9UG22 GTPase IMAP family member 2 GIMAP2 Heterodimer formed by GIMAP2 and 
GIMAP7 has GTPase activity 
2.34 3.60 2.17 2.64 2.64 
Q1RLN5 ARHGAP12 protein ARHGAP12 GTPase activator activity; signal 
transduction 
0.43 4.21 0.17 0.19 0.49 
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H7C4E5 Cytochrome c oxidase copper 
chaperone (Fragment) 
COX17 Copper chaperone activity 0.45 0.38 0.35 0.86 0.48 
A0A0A6YY96 Iron-responsive element-binding 
protein 2 
IREB2 Translation repressor activity 0.29 1.94 0.22 0.38 0.47 
Q5T0J7 Testis-expressed sequence 35 protein TEX35 Microtubule cytoskeleton 0.47 0.59 0.35 0.45 0.45 
O60503 Adenylate cyclase type 9 ADCY9 Catalyses formation of signalling molecule 
cAMP in response to activation of G 
protein-coupled receptors 
0.41 1.51 0.17 0.19 0.37 
Q59GK2 N-deacetylase/N-sulfotransferase 
(Heparan glucosaminyl) 1 variant 
(Fragment) 
NDST1 Heparan sulfate-glucosamine N-
sulfotransferase activity 
0.33 1.86 0.19 0.15 0.36 
B4E205 cDNA FLJ61651, highly similar to 
Protein transport protein Sec24A 
SEC24A Intracellular protein transport 0.04 1.87 0.46 0.45 0.36 
A0A024R943 Torsin family 3, member A, isoform 
CRA_b 
TOR3A ATP binding 0.36 1.43 0.10 0.23 0.33 
B2RCH7 cDNA, FLJ96082, highly similar to Homo 
sapiens cervical cancer 1 
protooncogene (HCCR1), mRNA 
N/A N/A 0.35 0.21 0.24 0.56 0.31 
Q5STZ8 ATP-binding cassette sub-family F 
member 1 (Fragment) 
ABCF1 Member of superfamily of ATP-binding 
cassette (ABC) transporters, lacks 
transmembrane domains characteristic of 
most ABC transporters 
0.39 1.09 0.09 0.21 0.30 
Q59HA5 Cyclin G-associated kinase variant 
(Fragment) 
GAK Protein kinase activity, involved in the 
uncoating of clathrin-coated vesicles by 
Hsc70 in non-neuronal cells 
1.06 0.26 0.13 0.10 0.24 
E5RGB1 F-BAR and double SH3 domains protein 
1 
FCHSD1 Neuromuscular synaptic transmission N/A 0.08 0.27 0.43 0.21 
A0A087WW74 SAM and SH3 domain-containing 
protein 1 
SASH1 Scaffold protein involved in the TLR4 
signalling pathway 
N/A 0.08 0.32 0.35 0.21 
Legend: FC, fold change; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; N/A, not available; PSR, primary steroid 




5.3.4 Proteomic analysis of albumin-depleted relapse and remission 
plasma samples from patients with SRNS and SSNS 
 
Patients SRNS1, SRNS2, SRNS3 and 419 were known to have had recurrence of 
proteinuria post-transplant suggesting involvement of the putative circulating 
factor(s) in disease pathogenesis.  As discussed in the Chapter 1, MCD is also 
considered a circulating factor disease[146].  A collaboration with Dr Yasuko 
Kobayashi, formerly in the Bristol Renal group, provided quantitative proteomic 
data for relapse and remission plasma samples from 5 patients with SSNS/MCD.  
All were Japanese with childhood-onset of non-familial SSNS.  Three of the five 
had had biopsies confirming MCD.  Clinical and laboratory data relating to the 
patients are shown in Table 5.9. 
 
Table 5.9: Clinical and laboratory data associated with relapse and remission 
plasma samples from patients with SSNS 








SSNS1 M 12.7 ND 
REL 41 102 
REM 46 7 
SSNS2 M 10.5 MCD 
REL 35 1198 
REM 31 0 
SSNS3 M 10.5 MCD 
REL* 26 10 
REM 46 3 
SSNS4 M 1.3 ND 
REL 36 283 
REM 35 2 
SSNS5 F 3.2 MCD 
REL 37 647 
REM 34 11 
All plasma samples were from blood.  Laboratory results were from the same day 
as sampling. *This sample was taken at the end of a relapse when proteinuria was 
improving. 
Legend: F, female; M, male; MCD, minimal change disease; ND, not done; REL, 




It was hypothesised that analysis of the plasma proteome at time of relapse 
and remission in the four patients with SRNS likely caused by circulating factor 
disease and the five patients with SSNS may identify a small number of proteins 
with potential as biomarkers for further investigation.  The paired 
relapse/remission fold-change results from the two datasets were combined in a 
single spreadsheet using the processes described in Section 5.2.8 to maximise 
matching of proteins.  This resulted in a list of 890 proteins for which there was 
paired relapse/remission quantitative data for all nine patients. 
  There were no proteins identified meeting thresholds of (> 2 or < 0.5) or 
of (> 1.5 or < 0.67) across all nine patients.  A compromise needed to be achieved 
between using a higher fold-change threshold and maximising consistency across 
the patients.  For example, using a fold-change threshold of 2 identified proteins 
reaching this level in a maximum of four patients and a threshold of 1.5 in a 
maximum of seven.  A fold-change threshold of > 1.3 highlighted 14 proteins 
which were consistent across seven, eight or all nine patients.  These 14 proteins 
were ranked by geometric mean fold change and, following review of biological 
information in online databases [331, 333, 334], six of the top seven were chosen 





Table 5.10: Proteins consistently increased in relapse versus remission across 
4 patients with SRNS and 5 patients with SSNS/MCD 
 Patient SSNS1 SSNS2 SSNS3 SSNS4 SSNS5 SRNS1 SRNS2 SRNS3 419 




1.69 0.57 1.52 1.59 1.96 2.89 1.41 5.74 1.65 




1.39 0.94 1.48 1.85 1.40 2.78 3.95 5.87 2.16 
Ran-binding 
protein 3 
1.86 0.70 1.89 1.33 0.77 1.68 1.90 3.44 1.96 
Uteroglobin 1.35 0.49 1.37 1.10 1.48 2.19 2.03 5.41 1.99 
Red highlights fold change > 1.3 and blue < 0.77. 
 
 
5.3.5 Biological characterisation of selected proteins 




Table 5.11: Biological characteristics of proteins selected for further 
investigation 




Dystroglycan 1 DAG1 97 
Involved in a number of processes including laminin and 
basement membrane assembly, sarcolemmal stability, 
cell survival, peripheral nerve myelination, nodal 





Contact-dependent bidirectional signalling into 
neighbouring cells; role in heart morphogenesis and 
angiogenesis through regulation of cell adhesion and 
cell migration 
Lumican LUM 38 
Member of the small leucine-rich proteoglycan (SLRP) 
family; keratan sulfate proteoglycan distributed in 





Member of the NimA (never in mitosis A) family of 
serine/threonine protein kinases; activated by prolactin 
stimulation, leading to phosphorylation of VAV2 guanine 
nucleotide exchange factor, paxillin, and activation of 





Role in nuclear export as part of a heteromeric complex; 
cytoskeletal signalling and MAP kinase signalling; 
negative regulator of TGF-beta signalling through 
interaction with the R-SMAD proteins, SMAD2 and 
SMAD3, and mediating their nuclear export 
Uteroglobin SCGB1A1 10 
Member of the secretoglobin family of small secreted 
proteins; functions including anti-inflammation, 
inhibition of phospholipase A2 and the sequestering of 
hydrophobic ligands. 
Data extracted from UniProt and GeneCards.  Legend: MW, molecular weight 
 
All proteins had previously been identified in human plasma by MS and 
were recorded in the Plasma Proteome Database.  A search of PubMed was 
conducted for any associations between the kidneys and/or nephrotic syndrome 
and the selected proteins. 
 Dystroglycan has been identified in isolated human glomeruli by 
immunoblotting and localised to the basal membrane of podocyte foot processes 
by immunoelectron microscopy [335].  Using kidney biopsy specimens, the study 
suggested that α- and β-dystroglycan chains were significantly reduced in MCD 
but not in FSGS.  The relative intensity of staining was restored to normal levels 
after steroid treatment in MCD.  More recent studies have indicated that 
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dystroglycan is expressed by podocytes and has an important, although not 
critical, role in adhesion [336]. 
 EphB4 is a receptor tyrosine kinase localised to the venous endothelium 
with a role in angiogenesis.  Together with its ligand EphrinB2, it has been 
identified in human kidney sections and found to be more highly expressed in 
urogenital tract tumours [337].  EphB4 has been shown to be expressed in healthy 
podocytes in rats and appeared to be upregulated in a model of nephritis [338]. 
Inhibition of EphB4 phosphorylation was associated with podocyte damage and 
increased albuminuria. 
 Lumican is one of a family of small leucine-rich proteoglycans which also 
includes decorin, biglycan and fibromodulin.  They generally have 
glycosaminoglycan (GAG) side chains and have a structural role in the extra-
cellular matrix [339].  A study of healthy human kidney tissue localised lumican 
to the glomerular capillary endothelium, particularly in the endothelial cell coat 
attached to the glycocalyx [340].  Glomerular deposition of lumican has been seen 
in areas of fibrosis in diabetic nephropathy.  Human plasma proteomic studies 
have previously suggested lumican as a potential biomarker in pancreatic cancer 
[341] and acute aortic dissection [342, 343]. 
 Nek3 is a member of a family of serine/threonine protein kinases which 
have a role in microtubule dynamics in cilia and at mitosis [344].  One study has 
suggested it may function in regulation of cytoskeletal dynamics in neurones.  
Although NEK3 gene expression has been reported in microarray studies of 
normal and diseased kidneys in the Renal Gene Expression Database [345] no 
specific research has examined the function of the protein in these organs.   
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 RAN binding protein 3 has a role in nuclear export as a cofactor in a 
heteromeric complex.  In lung cell culture studies it has been shown to be 
activated by phosphorylation in influenza infection and may have a role in viral 
ribonucleoprotein export [346].  Another report has suggested a regulatory 
function in nuclear export in melanoma [347] but no studies have examined a role 
in the kidneys. 
 Uteroglobin (also known as Secretoglobin family 1A member 1, Club cell 
protein 16 or Clara cell 10kDa protein) is a steroid-inducible, secretory protein 
with immunomodulatory and anti-inflammatory properties acting by blocking 
soluble phospholipase A2 [348, 349].  It was originally discovered in rabbit uterus 
but has widespread expression in humans in mucosal epithelia of organs with 
connections to the external environment as well as being detected in blood, urine 
and other body fluids.  It appears to be involved in development of allergic and 
inflammatory airways diseases.  One study, which measured blood plasma levels 
using ELISA in patients with pulmonary contusion, has proposed uteroglobin as a 
biomarker of the severity of injury [350].  An MS-based biomarker discovery 
study using urine from patients with diabetic nephropathy (n = 6) identified 
uteroglobin in samples from those with low GFR but not in those with high GFR 
or healthy controls [351].  Other studies have found higher levels of urinary 
uteroglobin in patients with proximal tubular dysfunction in CKD and following 
renal transplant compared with controls [352, 353].  Recent work has suggested 
that a uteroglobin gene polymorphism (G38A) may be a risk factor for 
development of idiopathic NS [354].  The AA genotype was associated with a 




5.3.6 Validation of mass spectrometry proteomics findings by 
Western blotting 
 
Western blotting was used to validate findings from proteomics focusing initially 
on the six proteins discussed above in plasma from patients SRNS1, SRNS2, 
SRNS3 and 419.  The same albumin-depleted plasma samples were tested as were 
used for proteomics.  Equal amounts of total protein in the same volume were 
loaded per lane of the gel.  Albumin-depleted plasma relapse/remission pairs from 
a second cohort of SNRS patients (560, 641, 1202, 1715) were tested in parallel, 
although the MS plasma proteomic data for them had not yet been analysed at that 
stage.  Figure 5.11 to Figure 5.13 show blots and quantification data for RANBP3, 
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1.68 1.90 3.44 1.96 N/A N/A 1.31 1.16 
 
Figure 5.11: Western blotting and proteomic quantification of RANBP3 in 
paired relapse/remission plasma samples 
A: Western blot of control (C1, C2) and paired relapse and remission plasma 
samples. B: Mean (SD) of log2 transformed relapse/remission fold change 
quantification from densitometry of blots (n = 2) and MS proteomics. C: 
Relapse/remission fold change ratios determined from Western blotting and MS 






In the case of RANBP3 (Figure 5.11), MS proteomics suggested increased levels 
in relapse versus remission in the first four patients analysed.  When data were 
later available for the second set, although higher in relapse the fold change was 
less marked.  In two patients’ samples (560 and 641), MS was unable to detect 
RANBP3.  In the other cases it was identified by a single peptide.   
Western blotting detected a single clear band at the expected molecular 
weight of 70 kDa (according to antibody product literature, Bethyl Laboratories).  
No consistent difference between relapse and remission samples was evident 
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1.71 1.36 1.80 1.42 0.99 2.26 1.40 0.74 
 
Figure 5.12: Western blotting and proteomic quantification of Lumican in 
paired relapse/remission plasma samples 
A: Western blot of control (C1, C2) and paired relapse and remission plasma 
samples. B: Log2 transformed relapse/remission fold change quantification from 
densitometry of blots (n = 1) and MS proteomics. C: Relapse/remission fold 
change ratios determined from Western blotting and MS (densitometry ratio not 







Figure 5.12 shows the results for lumican.  MS quantification showed that 
for two patients in the second set (641 and 1202) the relapse/remission ratio was > 
1.3-fold.  However, for the other two it was no different or lower in relapse.  
Western blotting initially followed by detection using an anti-lumican antibody 
from Abnova (#H00004060-D01P) identified multiple bands at approximately 45, 
60, 65 and 75 kDa (data not shown).  These bands were persistent in repeat 
experiments despite changing the blocking agent from 5% BSA to 5% dry milk 
and additional washes.  Figure 5.12A shows a single band at approximately 
70kDa identified with a different anti-lumican antibody (Abcam, #ab98067).  The 
predicted molecular weight of lumican based on amino acid sequence was 38 kDa 
Product literature for the human anti-lumican antibody has reported detection of 
bands at 50 and 60kDa (Abcam, #ab98067) and 60-85kDa (R&D Systems, 
#AF2846).  These are likely to represent glycosylated forms which have 
previously been reported [355].  Western blotting showed inconsistency in the 
relapse/remission ratio for lumican and did not corroborate the MS findings.  Due 
to technical difficulties, ELISA was used as an alternative method for quantifying 
lumican as discussed below in Section 5.3.8. 
 Quantification data for Nek3 are shown in Figure 5.13.  It was not detected 
by MS in any of the samples from the second set of patients and was identified by 
a single peptide in the first set.  No, or inconsistent, bands were visible on 
repeated Western blot experiments and Figure 5.13A shows one result where 
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2.78 3.95 5.87 2.16 N/A N/A N/A N/A 
 
Figure 5.13: Western blotting and proteomic quantification of Nek3 in paired 
relapse/remission plasma samples 
A: Western blot of control (C1, C2) and paired relapse and remission plasma 
samples. B: Log2 transformed relapse/remission fold change quantification from 
densitometry of blots (n = 1) and MS proteomics. C: Relapse/remission fold 
change ratios determined from Western blotting and MS (no MS quantification 







Figure 5.14: Western blotting for EphB4 in paired relapse/remission plasma 
samples 
As was the case for Nek3, EphB4 was not detected by MS in any of the 
samples from the second set of patients.  Western blotting on several occasions 
detected multiple non-specific bands, none of which could be confidently 









Western blot of control (C1, C2) and paired relapse and remission plasma 
samples.  The expected position for the EphB4 band was 135 kDa. 
 
 
Dystroglycan 1 was increased in relapse versus remission plasma > 1.5-
fold in patients 560 and 1202 but decreased < 0.77 in the other two.  Western 
blotting did not provide interpretable data. 
The relapse/remission ratio for uteroglobin was > 1.3 for patients 560, 641 
and 1202 and 0.91 for 1715.  Considering all patients together, based on MS 
quantification, uteroglobin was increased > 1.3-fold in relapse in 7 (88%) of 8 
patients with SRNS and 3 (60%) of 5 patients with SSNS.  Given the small size of 
uteroglobin (10 kDa), plasma samples were run on 15% polyacrylamide gel.  On 
several replicates a prominent band was seen at approximately 25 kDa (Figure 
5.15) which was still present when blocking with 5% dry milk in place of 5% 
BSA but absent from lanes treated in the same way but lacking primary antibody 
in the overnight incubation solution.  The band at 25 kDa probably represents 




Western blot of control (C1, C2) and paired relapse and remission plasma 
samples.  The expected position for the uteroglobin band was 10 kDa. 
 
Given the consistency noted in the relapse/remission fold change for 
uteroglobin based on MS proteomics and published literature suggesting potential 
as a biomarker in other conditions, it was decided to use ELISA as an alternative 
to Western blotting for uteroglobin quantification. 
 
5.3.7 Validation of mass spectrometry proteomics findings for 
uteroglobin by ELISA 
A Uteroglobin ELISA was identified which had EU approval for in vitro clinical 
diagnostic use (Biovendor, #RD191022200) therefore suggesting a high level of 
quality control and with prior data from testing samples from healthy subjects.  It 
was first trialled with four paired patient samples.   Albumin-depleted plasma 
samples from patients SRNS1, SRNS2 and SRNS3 were included for consistency 
with the MS proteomics and Western blotting experiments above.  In standard 
clinical practice, the ELISA does not require the additional steps of albumin- or 
IgG-depletion and has been used with unmodified plasma samples.  Therefore, 




non-albumin-depleted plasma from SRNS3 was included for comparison in the 
initial trial with a view to higher-throughput and larger-scale patient testing. 
The standard curve for known concentrations of uteroglobin 0-50 ng/mL 
determined by the 4PL method (Figure 5.16) and polynomial line of best fit 
(Figure 5.17) are shown below.  Both curves showed a good fit to the measured 
standards and similar calculated values for the concentration of uteroglobin in the 





Figure 5.16: ELISA standard curve of optical density against uteroglobin 
concentration with curve fitting using the 4-parameter logistic regression 
method 
Absorbance was measured at 450 nm with the reference wavelength set to 630 
nm.  The concentration (ng/mL) is shown on a logarithmic scale.  The measured 
standards (in duplicate) are shown in grey with the line of best fit (blue).  The 
95% upper (green) and lower (red) confidence bounds are also shown.  The 
coefficient of determination (R2) = 0.998. The curves were generated using 








Figure 5.17: ELISA standard curve of uteroglobin concentration against 
optical density with curve fitting using the polynomial line of best fit 
The equation of the line of best fit is shown. R2 = 0.999.  The curve was generated 
in Microsoft Excel. 
 
The high and low quality control samples provided by the manufacturer 
had expected concentrations of 16.6 (11.6-21.6) and 4.85 (3.40-6.31) ng/mL 
respectively.  The concentrations obtained using the 4PL method were 15.0 and 
3.96 respectively.  The equivalent values for the polynomial line of best fit were 
14.7 and 3.88.   
The albumin-depleted plamsa samples were tested in duplicate.  The 
absorbance of one of the remission samples from SRNS3 was considerably lower 
than the replicate and all other plasma samaples, and was similar to the 0 ng/mL 
control.  This was considered an outlier and was excluded from further analysis.  
Single wells were used for the non-albumin-depleted plasma samples due to 
limited space on the initial ELISA plate. 
 






























Absorbance at 450nm (Reference 630nm)
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Table 5.12 shows a comparison of the relative quantification of 
uteroglobin in paired relapse and remission samples by ELISA and proteomics.   
 
 
Table 5.12: Uteroglobin concentrations determined by ELISA in relapse and 










SRNS1 Rel AD 1.31 
1.47 2.19 
SRNS1 Rem AD 0.89 
SRNS2 Rel AD 3.42 
0.82 2.03 
SRNS2 Rem AD 4.15 
SRNS3 Rel AD 3.81 
8.20 5.41 
SRNS3 Rem AD 0.47 
SRNS3 Rel not AD 49.0 
7.94  
SRNS3 Rem not AD 6.17 
The concentrations were determined using the 4PL method. 
Legend: AD, albumin-depleted; Rel, relapse; Rem, remission. 
 
 
For patients SRNS1 and SRNS3, uteroglobin was higher in relapse than 
remission, consistent with proteomic findings.  To allow direct comparison with 
proteomic results, plasma samples tested by ELISA were also albumin-depleted.  
The non-albumin-depleted plasma samples from SRNS3 had higher absolute 
concentrations of uteroglobin than the corresponding albumin-depleted samples.  
Importantly, however, the relapse/remission ratio was similar.  On this basis, in 
the larger discovery cohort discussed below, plasma was not albumin-depleted 
prior to ELISA. 
 The uteroglobin concentrations in plasma samples from control subjects 
and paired relapse/remission samples from patients with NS are shown in Figure 
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Patient SRNS1 SRNS2 SRNS3 419 560 641 1202 1715 
ELISA Rel/Rem 
fold change 




2.19 2.03 5.41 1.99 1.56 1.39 2.49 0.90 
Figure 5.18: ELISA and proteomic quantification of uteroglobin in paired 
relapse/remission plasma samples 
A: Uteroglobin concentration in control (C1, C2) and paired relapse and remission 
plasma samples determined by ELISA.  B: Log2 transformed relapse/remission 
fold change ELISA quantification and MS proteomics. C: Relapse/remission fold 







Figure 5.18A shows the absolute concentration of uteroglobin in each of 
the samples tested.  The results are data from two 96-well ELISA plates.  The 
relapse sample for patient 291 had absorbance measurements similar to the 0 
ng/mL control.  This was considered to be an outlier and the patient excluded 
from further calculations.  Although the 4PL method provided concentrations for 
all other samples tested, the validated range for the ELISA was 0-50 ng/mL, 
therefore results above 50 ng/mL should be treated with caution.  Ideally these 
would be repeated at ½ dilution. 
In this study it was evident that uteroglobin was present at relatively high 
concentrations in both control subjects C1 and C2 who had diseases other than 
SRNS (Figure 5.18A).  The samples tested were both from PEx.  As discussed 
previously (Section 5.3.5), uteroglobin is an immunomodulatory secretory protein 
which has been detected in a variety of body fluids and is increased in several 
conditions and, therefore, was not expected to be specific for NS.  The absolute 
concentration of uteroglobin was variable in both relapse and remission within the 
group with SRNS (patients SRNS1-7030, in the left part of Figure 5.18A) and 
with SSNS (patients 2375-9995, in the right part of Figure 5.18A).  However, 
across all 21 patients with SRNS or SSNS, the mean concentration of uteroglobin 
in relapse samples (18.9 ng/mL) was significantly higher than the mean 
concentration in remission samples (11.4 ng/mL, p = 0.011, paired t test, two 
tailed).  For the 12 patients with SRNS, the concentrations were 19.5 ng/mL in 
relapse and 13.1 ng/mL in remission (p = 0.084, paired t test).  The corresponding 
values for the 9 patients with SSNS were 13.1 ng/mL and 9.2 ng/mL respectively 
(p = 0.084, paired t test). 
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As shown in Figure 5.18B, the relapse/remission ratio was > 1.3 (> 0.38 
on log2 scale) in 11 (52.4%) patients and < 0.77 (< -0.38 on log2 scale) in 3 
(14.3%) patients.  Comparison of findings by ELISA and MS proteomics showed 
close agreement for 3 patients in the first cohort (SRNS1, SRNS3 and 419) and 
fold changes in the same direction for 3 others (560, 641 and 1715).  There were 
discordant results for SRNS2 and 1202.  The remission plasma from the latter was 
derived from a blood sample whereas all other samples used in MS were from 
PEx. This lack of consistency may make comparison with the other patients more 
difficult but since the same samples were used for both ELISA and MS, this does 
would not directly explain the discordance. 
The existence of any relationship between plasma uteroglobin 
concentration and degree of proteinuria was examined.  A uPCR measurement 
was available on the same day (or within a few days) of the tested plasma sample 
for 18 patients (34 samples, 19 at time of “relapse” and 15 at time of “remission”).  
Samples for which there were no uPCR data (including those with only urine 
dipstick or ACR) were excluded.  Figure 5.19 shows uteroglobin concentration 
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Figure 5.19: Relationship of uteroglobin concentration in plasma to uPCR 




There was no significant correlation between the two for relapse samples 
(Spearman r = 0.19, p = 0.44) or for remission samples (Spearman r = 0.26, p = 
0.34).   When all 34 samples were considered together there was also no 
significant correlation between uteroglobin and log10 uPCR (Spearman r = 0.26, p 
= 0.13). 
 
5.3.8 Validation of mass spectrometry proteomics findings for 
lumican by ELISA 
 
ELISA was used to quantify lumican in patient plasma as an alternative assay to 
Western blotting as discussed above (Section 5.3.6).  Literature was reviewed to 
determine the normal concentration of lumican in plasma of healthy subjects 
which was reported as 4000 ng/mL or 7881 ng/mL [329, 341].  On this basis, 
268 
 
samples were diluted to the working range of the ELISA (0.313-20 ng/mL, 
Elabscience, E-EL-H0198).  However, this resulted in quantities below the limit 
of detection.  Importantly, the reports of plasma lumican concentrations over 4000 
ng/mL were based on MS quantification data.  A subsequent and more detailed 
literature search identified a study which had used ELISA to measure plasma 
lumican concentrations and reported 0.85 ± 0.53 ng/mL as the mean ± SEM in 
normal healthy controls [342]. 
 Non-albumin-depleted plasma samples were used for the lumican ELISA 
after confirming a similar relapse/remission ratio for albumin-depleted samples 
for SRNS3 as previously seen for uteroglobin.  The polynomial line of best fit was 
used for the standard curve as recommended by the ELISA manufacturer (Figure 
5.20).  
 
Figure 5.20: ELISA standard curve of lumican concentration against 
absorbance with curve fitting using the polynomial line of best fit 
The equation of the line of best fit is shown. R2 = 0.999.  The curve was generated 
in Microsoft Excel. 
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E L IS A
P ro te o m ic s
 
Patient SRNS1 SRNS2 SRNS3 419 560 641 1202 1715 
ELISA Rel/Rem 
fold change 




1.71 1.36 1.80 1.42 0.99 2.26 1.40 0.74 
Figure 5.21: ELISA and proteomic quantification of lumican in paired 
relapse/remission plasma samples 
A: Lumican concentration in control (C1, C2) and paired relapse and remission 
plasma samples determined by ELISA.  B: Log2 transformed relapse/remission 
fold change ELISA quantification and MS proteomics. C: Relapse/remission fold 
change ratios determined from ELISA and MS.  N/A: data not available because 







Figure 5.21A shows the absolute concentration of lumican in each of the 
samples tested.  The minimum concentration detectable by the ELISA according 
to manufacturer’s instructions was 0.188 ng/mL.  All samples had a concentration 
at the lower end of the detectable range below 1.4 ng/mL.  The following samples 
had a calculated lumican concentration below the minimal detectable by the 
assay: both samples from patients SRNS2, 641 and 1291; relapse samples from 
1202 and 5618; and the remission sample from 2375.  These 6 patients were 
therefore excluded, leaving 13 in the subsequent analysis.   
 Both control subjects C1 and C2 had similar lumican concentrations of 
0.47 and 0.50 ng/mL respectively.  Across the 13 patients with SRNS or SSNS, 
the concentration of lumican in relapse samples (mean 0.66, SD 0.41 ng/mL) was 
higher than in remission samples (mean 0.48, SD 0.23 ng/mL) although this was 
not statistically significant (p = 0.055, paired t test).  For the 6 patients with 
SRNS, the concentrations were 0.38 ng/mL (SD 0.20) in relapse and 0.37 ng/mL 
(SD 0.17) in remission (p = 0.87, paired t test).  Among the 7 patients with SSNS, 
the lumican concentration was significantly higher in relapse (mean 0.91 ng/mL, 
SD 0.39) than in remission (mean 0.57 ng/mL, SD 0.25, p = 0.045, paired t test). 
 Figure 5.21B illustrates that for patients with SSNS (2703-7944, in the 
right part of the figure), the relapse/remission ratio was > 1.3 (> 0.38 on log2 
scale) in 4 (57.1%) of 7 patients.  There were no consistent findings for the 
patients with SRNS (SRNS1-252, in the left part of the figure) and moderate 
agreement between ELISA and MS proteomics for only two of the patients 
(Figure 5.21C).   
 The existence of any relationship between the plasma lumican 
concentration and degree of proteinuria was examined.  As for the uteroglobin 
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analysis, only samples for which an associated uPCR was available were 
included.  Figure 5.22 shows the lumican concentration plotted against log10 
uPCR. 
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Figure 5.22: Relationship of lumican concentration in plasma to uPCR for 
samples taken during relapse and remission in patients with SRNS and SSNS 
 
There was no significant correlation between the lumican concentration and 
uPCR for relapse samples (Spearman r = 0.028, p = 0.94) and a weak, non-
significant, negative correlation for the remission samples (Spearman r = -0.33, p 
= 0.39).  When all 21 samples were considered together there was no significant 







5.4.1 Findings of this study 
This study set out to identify proteins which were differentially present in plasma 
of patients with NS at times of relapse and remission.   
 Analysis of MS quantification ratios using ordinary t tests identified no 
proteins which were significantly different in relapse versus remission plasma 
after correction for multiple comparisons (using either the Bonferroni correction 
or BH procedure).  This was likely due to the large variance in the data with a 
small number of samples (4 patient pairs in the initial analysis) [356].  The 
application of Bayes moderated t tests, which are potentially more suited to 
analysis of proteomic data with small numbers of samples, also did not identify 
proteins with a statistically significant difference [320].    It is recognised that the 
Bonferroni correction, in particular, is very conservative and while minimising 
false positives also leads to false negatives; therefore, it may not be appropriate at 
the discovery phase of proteomic data analysis [357].  The use of fold-change 
thresholds and maximising consistency across subjects was employed as the main 
method for identifying potential biomarkers for further validation.  Although this 
did not provide a measure of statistical significance for differences in proteins 
between relapse and remission, by using a minimum threshold of 1.3-fold it was 
felt that this would represent biological significance [358]. 
 Using this methodology, with paired relapse and remission samples from 4 
patients with SRNS and 5 patients with SSNS, identified 14 proteins with fold 
change > 1.3 and consistent across ≥ 7 patients.  The top 6 proteins taken forward 
for further analysis were: Dystroglycan 1, EphB4, Lumican, Nek3, RAN binding 
protein 3 and uteroglobin.  Although these were potentially promising candidates, 
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none could be validated convincingly using Western blotting.  There was also a 
lack of consistency in the MS relative quantification data for the first set of 4 
patients (the initial discovery cohort) and the second set of 4.  Although all 8 
patients had SRNS, had been transplanted and suffered post-transplant recurrence, 
it is not clear whether differences were biological or related to batch effects from 
being processed and run on the mass spectrometer at different times. 
 Based on biological information about the 6 proteins originally identified 
in the discovery cohort and published data of potential as biomarkers in other 
conditions, lumican and uteroglobin were taken forward for further analysis by 
ELISA.  For lumican, 2 of the second cohort of 4 patients (641 and 1202) showed 
consistency on MS proteomics with fold-change > 1.3.  The findings were not, 
however, corroborated on ELISA for the 8 patients with MS data.  There was 
closer agreement between fold-change data from ELISA and MS proteomics for 
uteroglobin and across all 21 patients tested the concentration in relapse samples 
was significantly higher than in remission. 
 Taking MS and ELISA data together highlights uteroglobin as a potential 
biomarker worthy of further investigation in a larger cohort of patients.  It is 
known that the protein is steroid-inducible [349], therefore the apparently higher 
concentration in relapse samples in this study may be the result of treatments 
patients were receiving.  A future, prospective and longitudinal study would 
ideally obtain initial samples before any treatment is started, then subsequently on 
treatment at times of relapse and remission.  This would help to address the 
question of whether uteroglobin is predictive of relapse or post-transplant 




5.4.2  Comparison of potential biomarkers from literature with 
proteomic data 
As discussed in Chapter 1, previous studies have quantified and compared protein 
levels in subgroups of patients with NS to assess their potential as biomarkers.  
The most frequently-tested biological sample has been urine and comparisons 
made between MCD versus FSGS and SSNS versus SRNS (see Table 1.13 in 
Chapter 1).  Only one recent publication, by Andersen et al.[257], has undertaken 
proteomic analysis of plasma samples and compared at times of NS relapse and 
remission, and is, therefore, more directly comparable with the current study.  
They did, however, use plasma derived from centrifugation of blood rather than 
plasma exchange samples, and only 3 of the patients had SRNS whereas the other 
11 had SSNS.  They identified 11 proteins which were significantly increased in 
plasma at the time of active disease and 6 proteins (excluding albumin) which 
were decreased.  The comparison with proteomic data for 8 patients with SRNS in 
this study is shown in Table 5.13. 
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Table 5.13: Plasma proteins significantly altered in relapse versus remission in study by Andersen et al (2012): comparison with 








SRNS1 SRNS2 SRNS3 419 560 641 1202 1715 n > 1.3 n < 0.77 
Haptoglobin-related  
protein 
HPR 3.3 1.12 0.77 0.89 1.10 1.02 1.93 0.60 0.82 1 1 
Apolipoprotein B-100 APOB 3.2 1.82 0.61 1.22 1.11 0.89 1.35 0.93 0.71 2 2 
Haptoglobin HP 2.9 0.82 1.26 0.25 1.25 0.98 1.47 0.98 1.47 2 1 
Inter-alpha-trypsin heavy 
chain H3 
ITIH3 2.5 1.12 0.80 1.48 1.22 0.95 1.74 0.94 1.04 2 0 
Alpha-2-macroglobulin A2M 2.3 1.66 1.16 3.62 1.22 1.38 2.87 0.65 0.89 4 1 
Fibrinogen beta chain FGB 2.2 0.90 0.64 1.20 1.40 1.13 1.42 11.64† 0.62 3 2 
Protein AMBP AMBP 2.2 1.72 1.49 1.90 1.21 1.25 0.98 1.46 0.98 4 0 
Fibrinogen gamma chain FGG 2.1 0.83 0.82 1.34 1.30 1.14 1.21 8.28† 0.62 2 1 
Fibrinogen alpha chain FGA 2.0 0.85 0.65 1.27 1.41 1.11 1.37 8.53† 0.57 3 2 
Pregnancy zone protein PZP 2.0 2.03 0.72 1.00 1.19 0.73 1.33 0.55 0.56 2 4 
Immunoglobulin J chain IGJ 1.6 1.41 1.23 2.45 1.18 1.23 2.75 0.91 0.87 3 0 
Alpha-1-acid glycoprotein 1 ORM1 0.6 0.73 0.88 0.24 1.20 0.76 0.66 0.96 1.32 1 4 
Ig gamma-4 chain C region IGHG4 0.5 No data   
Hemopexin HPX 0.5 0.91 1.01 0.46 1.17 0.70 0.48 0.89 1.20 0 3 
Ig gamma-3 chain C region IGHG3 0.4 2.67 1.05 0.77 0.52 0.82 4.37 1.59 1.29 3 2 
Serotransferrin TF 0.4 1.47 1.12 0.93 1.29 0.37 No data 0.42 0.64 1 3 
Ig gamma-1 chain C region IGHG1 0.4 1.50 0.77 1.07 1.11 No data 1 1 
Red highlights fold change > 1.3 and blue < 0.77. * Data from Andersen et al.[257] †Relapse sample from PEx, remission sample from blood 
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Overall, there was not strong consistency between the current study 
patients and the published relapse/remission ratios.  Among the 11 proteins which 
were increased in active disease, in only a maximum of 4 patients was the 
relapse/remission ratio > 1.3, namely for protein AMBP and alpha-2-
macroglobulin.  The latter, however, appeared to be decreased in relapse (<0.77) 
in one patient.  Protein AMBP, also known as Alpha-1-Microglobulin/Bikunin 
Precursor, is cleaved into alpha-1-microglobulin, inter-alpha-trypsin inhibitor 
light chain and trypstatin and functions include serine protease inhibitor activity 
[334].  As discussed in Chapter 1 (Section 1.4.3), proteases or protease inhibitors 
may have a role in SRNS pathogenesis but protein AMBP has not been associated 
with this disease in the published literature.   
 Looking at proteins which were decreased in plasma in active disease 
according to the study by Andersen et al., there were no quantification data 
available from the proteomic analysis of samples from some patients, particularly 
for immunoglobulins which had been depleted from the plasma as part of the 
preparation process.  Where data were available, the greatest consistency in fold 
change was seen for alpha-1-acid glycoprotein 1 (AGP1) and hemopexin.  The 
former, also known as orosomucoid-1, is an acute phase plasma protein which is 
increased in inflammation [334].  It is thought to have inflammatory and 
immunomodulatory functions with plasma levels altered in a wide range of 
diseases [359].  In a different study, which undertook proteomic analysis of urine 
comparing patients with SSNS versus SRNS, initial exploratory analysis 
suggested AGP1 was significantly increased in urine of subjects with SRNS but 
this difference was not significant in the larger validation cohort [255]. 
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Hemopexin was decreased < 0.77-fold in relapse plasma in 3 patients in 
this study and in no patients was it increased > 1.3-fold.  Other research by 
Bakker et al. found that hemopexin was reduced in plasma of patients with MCD 
at relapse compared with remission (0.21±0.14 mg/ml vs 0.44±0.06 mg/ml; p 
<0.01) [158].  The same group, using kidney tissue in vitro, showed increased 
protease activity of hemopexin in MCD relapse plasma compared with remission.  
Previous work at the University of Bristol examined the effect of hemopexin on 
conditionally-immortalised human podocytes in vitro [173].  This demonstrated 
that treatment of the cells with hemopexin led to actin cytoskeletal reorganisation 
and that the effect was dependent on nephrin and reduced by pre-incubation with 
normal human plasma.   
 A number of recent biomarker discovery studies in NS have used urine 
samples to identify proteins which are significantly different between disease 
subgroups.  Although the methodologies and results are not directly comparable 
with the current study, the highlighted proteins were used in an exploratory 
analysis of the proteomic data from the 8 patients with SRNS at relapse and 
remission.  The 22 proteins with corresponding relapse/remission ratios from this 























MCD vs FSGS 
Alpha-1 antitrypsin 
(AAT) 
SERPINA1 0.64 0.98 0.65 1.19 0.83 0.94 1.06 1.30 1 2 
Pérez 2017 
[236] 
MCD vs FSGS Serotransferrin TF 1.47 1.12 0.93 1.29 0.37 
No 
data 
0.42 0.64 1 3 
Pérez 2017 
[236] 
MCD vs FSGS Histatin-3 HTN-3 No data 
Pérez 2017 
[236] 




MRPL17 No data 
Choi 2017 
[237] 
MCD vs FSGS 
Complement 
component 9 
C9 0.60 0.71 0.48 1.31 0.87 0.86 0.57 1.08 1 4 
Choi 2017 
[237] 




































Dipeptidase 1 DPEP1 No data 
Suresh 
2016 [246] 






















RBP4 1.58 1.31 0.90 1.01 0.99 0.71 1.44 0.79 3 1 
Kalantari 
2014 [247] 



















SSNS vs SRNS 
Vitamin D-binding 
protein 





SSNS vs SRNS 
Transthyretin 
(Prealbumin) 
TTR 1.66 1.26 0.79 1.25 0.76 0.35 1.82 1.29 2 2 
Bennett 
2017 [255] 




AHSG 0.59 0.56 0.56 1.04 0.68 1.04 0.52 0.57 0 6 
Watany 
2018 [256] 
SSNS vs SRNS Nephronectin NPNT No data 
Andersen 
2012 [257] 
Active NS vs 
remission 





Four proteins were not detected or were not quantifiable in plasma in this 
study, therefore had no data for analysis.  Among the rest, there was variability in 
the relapse/remission ratio between the patients but the protein showing the most 
consistent increase in plasma greater than 1.3-fold in relapse was neutrophil 
gelatinase-associated lipocalin (NGAL).  It was above this threshold in 7 of the 8 
patients studied and increased above 2-fold in 4 of them.   
NGAL is an iron-binding protein with roles in multiple processes 
including regulation of apoptosis, innate immunity and nephrogenesis [360].  Two 
recent publications measuring urinary NGAL in patients with NS found it was 
significantly higher in those with SRNS compared with SSNS [248, 255].  A 
growing body of evidence suggests that both plasma and urinary NGAL are 
clinically-useful biomarkers of early acute kidney injury in adults and children 
[360-362].  The wide range of clinical contexts associated with elevated NGAL, 
including sepsis, post-cardiac surgery, haemolytic uraemic syndrome and urinary 
tract infection, indicates that it is not specific for disease relapse in SRNS.  It may 
be a protein worthy of further study longitudinally in the context of children with 
SRNS before and after transplantation. 
 Of the proteins identified in the literature as possible biomarkers, the one 
most consistently decreased under 0.77-fold in relapse in this proteomic study was  
alpha-2-HS-glycoprotein (AHSG), also known as fetuin A.  It was reduced in 
relapse below the threshold in 6 of the 8 patients.  AHSG is mainly synthesised by 
the liver and has diverse roles including anti-inflammatory properties, regulation 
of calcium metabolism and bone remodelling, and insulin resistance [363, 364].  
Bennett et al. showed that urinary AHSG was significantly higher in patients with 
SRNS compared with SSNS [255].  Two other studies suggested that AHSG was 
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lower in the plasma of patients with NS in relapse compared with those in 
remission or controls [365, 366].  The level of AHSG correlated with serum 
albumin and negatively correlated with proteinuria suggesting that the reduction 
in relapse may be simply due to loss in urine.  Whether AHSG offers any 
advantages as a biomarker over measurement of plasma albumin and uPCR would 
require prospective longitudinal study in a larger cohort of patients with SRNS. 
 
5.4.3 Limitations 
This study has several limitations.  As is often the case with MS proteomic 
investigations, the sample size in the initial discovery cohort was relatively small 
[320].  As the research progressed, additional paired relapse and remission 
samples were received as part of the NephroS study which were used in the 
subsequent validation cohort.  Attempts were made to select an initial group of 
patients who were as similar as possible: all with SRNS and post-transplant 
recurrence of disease suggesting a circulating factor pathogenesis.  Despite this, 
the pattern of initial steroid resistance and first biopsy findings differed within the 
4 patients in the discovery cohort.  Whether the same circulating factor(s) were 
involved in pathogenesis in these or subsequent patients is unknown.  The degree 
of proteinuria associated with samples labelled as “relapse” varied between 
patients, and comparator samples from some were only available at times of 
partial remission since full remission was never achieved.  The drug treatments 
received are likely to have varied between patients and within the same patient at 
different times depending on disease status: this has the potential to confound 




 Differences in sample handling may have contributed to variability in 
relapse/remission ratios between patients.  Plasma exchange fluid was stored at 
local centres at 4°C, sometimes for several days, before transport to the central 
centre in cool bags with ice packs and aliquoted on the day of arrival for storage at 
-80°C.  Blood samples (taken at remission for patient 1202 and other patients in 
the wider validation cohort) were transported at ambient temperature by standard 
post often arriving for processing > 24 hours after leaving the patient.  It is 
possible that some alteration or degradation of proteins within the samples would 
have taken place potentially affecting results of this study.   
 In addition to patient and sample factors, some variability in the protein 
quantification may have resulted from the sample preparation and MS process.  
Although the same process of albumin and Ig depletion, TMT labelling and nano-
LC-MS/MS were performed for all samples, there is natural variation in the 
efficacy of depletion and labelling which may depend on the biophysical 
properties of different plasma samples and so cannot be completely controlled.  
Also, due to the number and complexity of peptides in a sample, only a subset of 
all proteins is identified in a single MS experiment [367].  The use of TMT 
labelling and multiplexing in this study should have reduced some of the 
experimental variability in the MS quantification process. 
 
5.4.4 Conclusion 
This study has identified uteroglobin as a protein which is increased in relapse 
compared with remission in patients with SRNS.  It has also indicated that 
hemopexin, NGAL and AHSG, which have previously been suggested as 
potential biomarkers in other studies, are differentially present in relapse and 
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remission plasma.  Further analysis of these proteins in a larger cohort of patients 
with longitudinal sampling would help to determine their value as predictive 
indicators of disease. 
 The approach used in this study involved a non-targeted analysis of the 
whole plasma proteome using MS in a discovery cohort of patients followed by 
validation in a larger group using Western blotting and ELISA.  A second 
approach specifically examining proteases and protease inhibitors, which may 
have a direct pathogenic role in NS, will be discussed in Chapter 6.
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5.5 Appendix to Chapter 5  
5.5.1 R code for empirical Bayes moderated t tests of quantitative 
mass spectrometry proteomics data 
 
Modified from Kammers et al. [320] and publicly available to download from: 
http://www.biostat.jhsph.edu/~kkammers/software/eupa/ 
 
Install R from CRAN and the basic Bioconductor packages by typing the following 
code in your R command window 
source("http://bioconductor.org/biocLite.R") 
biocLite() 
Now install additional Bioconductor packages. These packages are necessary for the 




Load the following packages by typing in your R command window 
library(limma) 
library(qvalue) 
# read artificial iTRAQ data set 
dat <- read.csv("F:/Results/Proteomics results/PLAS_Total round 1/
Median normalised/Pooled 1-15 5FDR Exp bias Median normalised Pept
ide ungrouped raw quant data for R.csv")  
dim(dat) 
str(dat) 
cha <- c("X127C", "X128C", "X129C", "X130C", "X128N", "X129N", "X1
30N", "X131") 
# data preprocessing, load all functions 
source("http://www.biostat.jhsph.edu/~kkammers/software/eupa/sourc
e.functions.r") 
dat <- read.peptides(dat, cha)  
dim(dat)  
dat <- quantify.proteins(dat, cha) 
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dat.onehit <- subset(dat, dat$n.peptides == 1)  
dim(dat.onehit) 
# eliminate "one-hit wonders" 
dat <- subset(dat, dat$n.peptides != 1) 
dim(dat) 
par(mfrow=c(1,1), font.lab=2, cex.lab=1.2, font.axis=2, cex.axis=1
.2) 
boxplot(dat[, 1:length(cha)],  ylim = c(-3, 3), main="Boxplot norm
alized Intensities") 
tr <- c("X127C", "X128C", "X129C", "X130C") 
ct <- c("X128N", "X129N", "X130N", "X131") 
design <- model.matrix(~factor(c(2,2,2,2,1,1,1,1))) 
design 
colnames(design) <- c("Intercept", "Diff") 
res.eb <- eb.fit(dat[, c(tr,ct)], design) 
head(res.eb) 
# volcano plots for ordinary and moderated p-values 
rx <- c(-1, 1)*max(abs(res.eb$logFC))*1.1 
ry <- c(0, ceiling(max(-log10(res.eb$p.ord), -log10(res.eb$p.mod))
)) 
 
par(mfrow=c(1,2), font.lab=2, cex.lab=1.2, font.axis=2, cex.axis=1
.2) 
par(las=1, xaxs="i", yaxs="i") 
 
plot(res.eb$logFC, -log10(res.eb$p.ord), pch=21, bg="lightgrey", c
ex=0.9,  
     xlim=rx, ylim=ry, xaxt="n", 
     xlab="fold change", ylab="-log10  p-value") 
abline(v=seq(-2,2,1), col="lightgray", lty="dotted") 
abline(h=seq(0,ry[2],1), col="lightgray", lty="dotted") 
axis(1, seq(-2,2,1), paste(c("1/4","1/2","1/1","2/1","4/1"))) 
title("volcano plot of ordinary p-values") 
 
plot(res.eb$logFC, -log10(res.eb$p.mod), pch=21, bg="lightgrey", c
ex=0.9, 
     xlim=rx, ylim=ry, xaxt="n", 
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     xlab="fold change", ylab="-log10  p-value") 
abline(v=seq(-2,2,1), col="lightgray", lty="dotted") 
abline(h=seq(0,6,1), col="lightgray", lty="dotted") 
axis(1, seq(-2,2,1), paste(c("1/4","1/2","1/1","2/1","4/1"))) 





Chapter 6 Plasma Proteases and Protease 
Inhibitors 
6.1 Introduction 
 As highlighted in Chapter 1 (Section 1.4.1), several strands of evidence 
point to the role of circulating factors within plasma as being pathogenic in non-
genetic SRNS.  Given previous studies suggesting that an increase / decrease in 
circulating proteases or protease inhibitors may be involved in the pathogenesis of 
SRNS [157, 158, 188], this part of the study sought to compare relative levels of 





Patients were selected for investigation from the cohort as described previously in 
Chapter 5. 
 
6.2.2  Human protease/protease inhibitor array 
The Human Protease/Protease Inhibitor Array Kit (R&D Systems, Minneapolis, 
MN, USA; #ARY025) was used following the manufacturer’s instructions.  
Briefly, paired relapse and remission plasma samples were defrosted.  They were 
incubated for 1 hour at room temperature in the supplied buffer with biotinylated 
detection antibody cocktails targeting proteases and separately targeting protease 
inhibitors.  Nitrocellulose membranes were supplied spotted in duplicate with 
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control and capture antibodies against the 35 proteases or 32 protease inhibitors.  
The membranes were incubated in blocking buffer with agitation for 1 hour at 
room temperature.  Following incubation, the plasma/biotinylated antibody 
mixtures were added to the respective membranes and left overnight at 4°C to 
allow binding.  The following day, the membranes were washed 3 × 10 minutes 
with wash buffer and incubated with streptavidin-HRP in array buffer for 30 
minutes at room temperature.  After a further 3 × 10-minute washes, 
chemiluminescence reagents were applied for 1 minute and the membranes 
imaged simultaneously using the Amersham Imager 600 using the automatic 
capture settings.   
 Densitometry of each dot was undertaken with Image J.  The mean 
intensities of the two negative control dots was subtracted from all other 
intensities to account for background.  In the cases where a dot’s intensity was 
lower than the negative control these were given an intensity of 0.  In order to 
compare two membranes, one used for relapse plasma and the other for remission 
plasma, a normalisation factor was calculated: (mean intensity of all positive 
control dots on “relapse” membrane) / (mean intensity of all positive control dots 
on “remission” membrane).  The intensities of all dots on the “remission” 
membrane were multiplied by this factor to account for global differences in the 
processing and imaging.  In order to compare between all patients, a similar 
normalisation factor was calculated: (mean intensity of all positive control dots on 
SRNS1 “relapse” membrane) / (mean intensity of all positive control dots on 
“relapse” membrane for each patient).  The intensities of all dots on the “relapse” 
membrane for each patient were multiplied by their respective normalisation 




6.2.3  Statistical analysis 
Data were analysed using Microsoft Excel 2016 and GraphPad Prism 7.  The 
geometric mean was used to summarise fold change data across multiple patients.  
Statistical analysis was undertaken on the log2 transformed values. The paired t 
test (with two tails) was used to compare protein quantification data at the time of 
relapse and remission.  The Bonferroni correction and Benjamini-Hochberg 
procedures were used to account for multiple comparisons as described 
previously.  The association between variables was determined using Spearman’s 
rank correlation where bivariate normal distributions could not be assumed.  The 
threshold for rejecting the null hypothesis was set at p < 0.05. 
  
6.3 Results 
6.3.1 Patient characteristics 
The following patients, whose samples were used previously for MS analysis, 
were included in this study: SRNS1, SRNS2, SRNS3, 560, 641, 1715.  Other 
patients with SRNS (252, 1291 and 5618) and one patient with SSNS (2704) were 
also tested.  The clinical characteristics and laboratory results at the time of 
sampling are shown in Table 5.5 and Table 5.6.    
 
6.3.2 Protease and Protease inhibitor assays 
The Human Protease/Protease Inhibitor Array Kit (R&D Systems) was used to 
quantify 35 proteases and 32 protease inhibitors in the paired relapse and 
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remission plasma samples for each of the 10 patients.  An example of the dot 
array output generated from the assay is shown in Figure 6.1. 
 
 
Figure 6.1: Dot array output from the Human Protease/Protease Inhibitor 
Array Kit for patient 1291 
Legend: A819, proteases in relapse; A820, proteases in remission; B215, protease 




6.3.2.1 Protease assays 
The log2-transformed relapse/remission quantification ratios for proteases are 
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Figure 6.2: Heat map of log2 (relapse/remission fold change) for proteases in 
plasma from patients with nephrotic syndrome 
Data are shown for 35 proteases assayed in the Human Protease/Protease Inhibitor 
Array Kit (R&D Systems) and 10 patients.  SRNS1-1715 (6 patients) had SRNS 
and were included in the MS proteomics studies.  252-5618 (3 patients) had SRNS 
and 2704 had SSNS.  Proteases which are increased in relapse relative to 
remission are shown in red, those which are decreased are shown in blue.  X 
denotes cases where the protease quantification for either the relapse or remission 






Overall, the heatmap illustrates a lack of a consistent pattern between the 
patients.  For patient 560, for the majority of the proteases there was virtually no 
change between relapse and remission.  This would concord with the available 
clinical data (see Table 5.6), namely that the samples were taken 9 days apart and 
both were, in fact, in remission (the sample labelled as “relapse” was associated 
with the nearest-available uPCR of 8 mg/mmol).  Patient 641 had a particularly 
consistent increase in proteases in relapse compared to remission.  In this case, the 
samples were approximately 1 month apart with plasma albumin and uPCR being 
20 g/L and 7797 mg/mmol respectively at relapse and 35 g/L and 4348 mg/mmol 
at remission.  SRNS2 and 252 both had comparatively more proteases increased 
in relapse relative to remission.  All three of these patients had PSR, and although 
the plasma albumin was > 30 g/L at the time of the “remission” sample, they 
remained significantly proteinuric (uPCR > 500 mg/mmol).  In contrast, in 
SRNS3, 1715 and 5618 the pattern was of proteases generally being decreased in 
relapse compared with remission.  SRNS3 had SSR whereas the other two had 
PSR.  Laboratory data were not available for SRNS3, however, for 1715 and 5618 
the remission samples were obtained at a time of (almost) complete remission 
with uPCR values of 42 mg/mmol and 9.1 mg/mmol respectively. 
 Figure 6.3 illustrates the relationship between the geometric mean of all 
the relapse/remission fold change ratios for all 35 proteases and the 
relapse/remission uPCR ratio for the 7 patients in whom all uPCR values were 
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Figure 6.3: Relationship between the geometric mean of relapse/remission 
fold change ratio for all proteases and the relapse/remission uPCR ratio 
 
There was a statistically significant, very strong negative correlation 
between the log-transformed variables (Spearman r = -0.86, p = 0.024).  That is, 
patients with more severe relative proteinuria in relapse have comparatively lower 
proteases in relapse versus remission.  The most logical explanation would be 
that, as might be expected, proteases are lost in the urine along with many other 
proteins during relapse.  Although this may be the case in general, further 
investigations were undertaken to examine if any of the individual proteases were 
increased or decreased significantly and consistently across all patients. 
 As discussed previously in relation to MS proteomics (Section 5.3.3.1), the 
geometric mean relapse/remission fold change and t-test p values were calculated 
for each of the proteases measured in all 10 patients.  The data are shown in the 
volcano plot (Figure 6.4). 
295 
 






















Ca th e p s in  E
K a llikr e in  5
MMP- 8
 
Figure 6.4: Volcano plot of protease quantification data for relapse/remission 
plasma samples from patients with nephrotic syndrome 
The horizontal line shows the Bonferroni-corrected significance threshold for 35 
proteins with α = 0.05 
 
It can be seen that cathepsin E and kallikrein 5 showed the most 
significant changes (with geometric mean relapse/remission fold changes of 0.58 
and 0.51 respectively).  However, no protease reached the Bonferroni-corrected 
significance threshold for multiple comparisons or were significant after the BH 
procedure with FDR at 10%. 
 An analysis using fold change thresholds of > 1.3 and < 0.77 with the aim 
of maximising consistency across patients is shown in Table 6.1.  Although 
kallikrein 5 was a protein with one of the most significant fold changes, it was not 
in the top 7 proteins, as shown in the table, because it met the threshold (< 0.77) in 




Table 6.1: Proteases consistently increased or decreased in relapse versus remission across 10 patients with nephrotic syndrome 
Target SRNS1 SRNS2 SRNS3 560 641 1715 252 1291 5618 2704 n > 1.3 n < 0.77 
MMP-8 1.10 1.96 1.01 0.91 1.47 1.10 1.10 1.56 0.89 13.62 4 0 
MMP-9 0.92 1.04 1.34 1.01 2.30 1.61 1.80 0.87 0.77 0.82 4 0 
Presenilin 0.72 1.42 0.36 1.11 1.41 N/A 1.66 1.50 0.83 N/A 4 2 
ADAMTS1 1.06 2.67 0.41 1.48 1.50 0.23 0.49 1.71 1.05 0.80 4 3 
Proprotein 
Convertase 9 
1.39 2.15 0.72 0.80 0.70 1.03 0.38 1.35 0.79 1.37 4 3 
MMP-3 3.38 1.30 0.40 0.93 0.43 0.72 1.92 0.37 1.20 1.76 4 4 
Neprilysin/CD10 0.62 1.56 0.32 0.97 2.19 0.73 1.51 2.35 0.39 0.67 4 5 
Cathepsin A 0.56 0.47 0.36 0.68 1.57 0.41 1.84 0.51 0.31 0.92 2 7 
Cathepsin B 0.48 0.73 0.47 1.01 2.20 0.57 2.02 0.73 0.62 0.68 2 7 
Cathepsin E 0.69 0.98 0.68 0.61 1.51 N/A N/A 0.28 0.22 0.45 1 6 
Cathepsin L 0.79 1.26 0.64 0.51 2.33 0.07 N/A 0.57 0.43 0.28 1 6 
Kallikrein 11 0.67 0.64 0.85 0.87 2.66 0.06 2.29 0.69 0.41 0.63 2 6 
Kallikrein 7 0.69 3.09 0.38 0.75 1.70 0.29 0.47 1.80 0.66 0.92 3 6 
Kallikrein 13 0.35 1.31 0.17 0.88 1.61 0.13 0.53 1.90 0.24 0.54 3 6 
Red highlights fold change > 1.3 and blue < 0.77. Patient 2704 had SSNS, all others had SRNS.  The top 7 consistently increased and decreased 




The results for patient 641 appeared inconsistent with others, suggesting it 
may have been an outlier.  Among the proteins which were generally decreased 
during relapse in most patients (with fold change < 0.77, in the lower part of the 
table), in all cases they were increased in relapse in 641.   This may have been 
because there was still heavy proteinuria at the time the (partial) remission sample 
was obtained (uPCR 4348 mg/mmol at remission and 7797 mg/mmol at relapse). 
For the 35 proteases analysed, the median molecular weight was 52 kDa 
(range 27 – 154 kDa).  There was a moderate positive correlation between 
protease molecular weight and log2 geometric mean of the relapse/remission fold 
change (Spearman r = 0.40, p = 0.017).  That is, smaller proteases were relatively 
lower in relapse than remission compared with larger proteases. 
As discussed above, due to general loss of proteins in urine at relapse, it is 
possible that those proteases which are relatively increased in relapse are ones 
which may have potential as biomarkers or provide insight into pathogenesis.  
Taking MMP-8 as an example, however, it was most increased in the SRNS 
patients (SRNS2, 641 and 1291) who had least relative proteinuria in relapse 
(Figure 6.3).  It was particularly increased in 2704 who had SSNS.  In this patient, 
no uPCR was available at the time of remission.  The relapse sample was taken 
approximately 6 months later with plasma albumin 28 g/L and uPCR 704 
mg/mmol. 
 As discussed in Chapter 1, suPAR has been proposed as having a possible 
pathogenic role in SRNS.  The protease array included detection of urokinase-type 
plasminogen activator (uPA).  The relapse/remission ratios for this protease are 




Table 6.2: Relapse/remission ratio of urokinase-type plasminogen activator 
in patients with nephrotic syndrome 
 SRNS1 SRNS2 SRNS3 560 641 1715 252 1291 5618 2704 














Red highlights fold change > 1.3 and blue < 0.77. Patient 2704 had SSNS, all 
others had SRNS.   
 
In most patients, uPA was decreased in relapse but was increased in those 
patients with least relative proteinuria at the time of relapse. 
 
6.3.2.2 Protease inhibitor assays 
The log2-transformed relapse/remission quantification ratios for 32 protease 
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Figure 6.5: Heat map of log2 (relapse/remission fold change) for protease 
inhibitors in plasma from patients with nephrotic syndrome 
Data are shown for 32 protease inhibitors assayed in the Human Protease/Protease 
Inhibitor Array Kit (R&D Systems) and 10 patients.  SRNS1-1715 (6 patients) 
had SRNS and were included in the MS proteomics studies.  252-5618 (3 patients) 
had SRNS and 2704 had SSNS.  Protease inhibitors which are increased in relapse 
relative to remission are shown in red, those which are decreased are shown in 
blue.  X denotes cases where the protease inhibitor quantification for either the 
relapse or remission plasma sample was equivalent to the negative control and a 
fold change could not be calculated. 
 
As for the proteases, overall there was lack of consistent patterns in the 
change in protease inhibitors across all patients.  However, there does not appear 
to be as clear an association between the geometric mean of all relapse/remission 
fold change ratios for all 32 protease inhibitors and the relapse/remission uPCR 
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Figure 6.6: Relationship between the geometric mean of relapse/remission 
fold change ratio for all protease inhibitors and the relapse/remission uPCR 
ratio 
 
The absence of the negative correlation seen previously for proteases, 
suggests that other factors may be influencing the relative quantities of protease 
inhibitors apart from the comparative degree of proteinuria in relapse.  For 
example, patient 5618 had a uPCR 320 times greater in post-transplant relapse 
versus remission (2915 versus 9.1 mg/mmol) and despite this 22 (68.8%) of the 
32 protease inhibitors were increased > 1.3-fold at the time of relapse. 
 A volcano plot summarising the geometric mean relapse/remission fold 
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Figure 6.7: Volcano plot of protease inhibitor quantification data for 
relapse/remission plasma samples from patients with nephrotic syndrome 
The horizontal line shows the Bonferroni-corrected significance threshold for 32 
proteins with α = 0.05 
 
Trappin-2 appeared to be greatly increased in relapse versus remission but 
the geometric mean was distorted by very low quantification in the remission 
sample of patient 252 (relapse/remission of 227.2/0.1 = 2269.1).  Exclusion of this 
value resulted in a geometric mean relapse/remission fold change of 1.15 among 
the other 8 patients for whom the ratio could be calculated.  Cystatin E/M showed 
the most significant change (with geometric mean relapse/remission fold change 
of 0.79).  However, no protease inhibitor reached the Bonferroni-corrected 
significance threshold for multiple comparisons or were significant after the BH 
procedure with FDR at 10%. 
 An analysis using fold change thresholds of > 1.3 and < 0.77 with the aim 
of maximising consistency across patients was performed as previously and is 
shown in Table 6.3.  
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Table 6.3: Protease inhibitors consistently increased or decreased in relapse versus remission across 10 patients with nephrotic 
syndrome 
Target SRNS1 SRNS2 SRNS3 560 641 1715 252 1291 5618 2704 n > 1.3 n < 0.77 
Cystatin A 2.03 1.33 1.99 1.68 1.04 0.66 1.47 0.38 1.40 7.97 7 2 
Lipocalin-1 2.46 1.06 2.69 1.66 1.70 0.46 3.40 0.38 3.85 1.26 6 2 
Cystatin B 1.91 0.95 0.37 1.40 2.74 0.47 3.38 0.60 1.49 1.07 5 3 
HAI-2 1.10 0.99 2.13 1.88 1.60 0.79 1.40 0.83 1.33 1.07 5 0 
Cystatin E/M 0.90 0.82 0.65 1.00 0.75 0.65 0.72 0.65 1.17 0.71 0 6 
RECK 0.64 0.49 0.47 1.14 3.04 0.44 2.97 0.68 1.07 0.87 2 5 
Serpin E1/PAI-1 0.38 0.50 0.11 1.28 7.70 1.08 1.61 0.41 0.38 0.86 2 5 





Cystatin A showed the largest and most consistent increase in relapse 
relative to remission but was reduced below the 0.77-fold change threshold in 2 
patients.  It is a cysteine protease inhibitor and studies have suggested it may act 
as a tumour suppressor in oesophageal cancer and inhibit epithelial to 
mesenchymal transition in lung cancer [368].  There are no published reports 
associating cystatin A with renal disease or NS. 
Cystatin E/M was the most consistently decreased in relapse, below the 
threshold of 0.77 in 60% of patients.  It is a protease inhibitor with tumour 
suppressor function and is most highly expressed in skin epidermis [369, 370].  It 
can bind and inhibit cathepsins L and V which are proteases with a function, 
amongst others, of converting pro-uPA (urinary plasminogen activator) to active 
uPA.  There have been no studies directly linking cystatin E/M with renal disease 
in the published literature. 
For the 32 protease inhibitors analysed, the median molecular weight was 
39 kDa (range 11 – 106 kDa).  There was no significant correlation between 
protease inhibitor molecular weight and log2 geometric mean of the 




6.4.1 Findings of this study 
This study set out to identify proteins which were differentially present in plasma 
of patients with NS at times of relapse and remission and specifically examined 
proteases and protease inhibitors as these may have a direct pathogenic role in NS. 
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 The more-targeted analysis of plasma proteases demonstrated that 
cathepsin E and kallikrein 5 showed the largest and most significant changes 
between relapse and remission (although both below the statistical significance 
threshold after correction of multiple comparisons).  Both were decreased in 
relapse, but given the strong negative correlation between the overall 
relapse/remission ratio and degree of proteinuria (see Figure 6.3), it may be that 
the explanation of the change is that they are being lost in the urine.  In that case, 
they may have no benefit as a biomarker over measurement of plasma albumin 
and uPCR.  Similarly, the protease most increased in relapse was seen in the 
patients with the least relative proteinuria.   
 Regarding protease inhibitors, cystatin A showed the most consistent 
increase in relapse compared with remission and cystatin E/M showed the most 
consistent decrease.  No previous studies have associated these with renal disease 
and the relevance to SRNS is currently unclear. 
As discussed previously in Chapter 5, a longitudinal study with repeated 
samples at multiple time points would allow correlation of the plasma protease or 
protease inhibitor concentrations with uPCR and understanding of whether 
measurement can predict disease relapse or post-transplant recurrence.  If changes 
occurred in protein levels before the onset of relapse it would also warrant further 
investigation to assess whether it may be a pathogenic circulating factor. 
  
6.4.2  Comparison of potential biomarkers from literature with 
protease and protease inhibitor data 
As discussed in Chapter 5, NGAL has been highlighted as a potential biomarker 
and MS showed it was increased > 1.3-fold in relapse versus remission in 7 of 8 
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patients tested (see Table 5.14).  NGAL was also assayed in the current study in 
10 patients (9 with SRNS, 1 with SSNS) using the Human Protease Inhibitor 
Array Kit (Section 6.3.2.2).  This did not show consistent results between the 
subjects (Figure 6.5), with only 2 cases having relapse/remission fold change 
greater than 1.3 and 3 cases having less than 0.77.  A direct comparison of results 
for NGAL using the two techniques is shown in Table 6.4.  There was less 
consistency in the results using the protease inhibitor kit.  However, the direction 
of change was concordant between the techniques for 5 of the patients, with 
discordance only for 1715. 
 
Table 6.4: Relapse/remission ratio of NGAL in patients with SRNS assayed 
using mass spectrometry and human protease array kit 
 SRNS1 SRNS2 SRNS3 560 641 1715 
MS Rel/Rem ratio 2.60 0.85 3.00 1.43 2.38 2.03 
Protease array Rel/Rem ratio 1.27 0.57 1.40 1.22 1.96 0.63 
Red highlights fold change > 1.3 and blue < 0.77. 
Legend: MS, mass spectrometry; Rel, relapse; Rem, remission 
 
 The literature has highlighted the protease hemopexin as a potential 
biomarker or circulating factor in NS [158, 173, 257], however this was not 




This study used the same patient plasma samples as discussed previously in 
Chapter 5, therefore, shares the same limitations including the relatively small 
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number of patients, heterogeneity between them and differences in sample 
handling and processing. 
 
6.4.4 Conclusion 
Due to variability between patients, this study did not identify proteases or 
protease inhibitors which were significantly increased or decreased in plasma 
during NS relapse versus remission.  However, there was some concordance 
between results here and MS data for NGAL, which has previously been 
suggested as potential biomarkers in other studies.  Further analysis of this protein 
in a larger cohort of patients with longitudinal sampling would help to determine 




Chapter 7 Phosphoproteomics of podocytes 
after SRNS plasma treatment 
7.1 Introduction 
As discussed in Chapter 1, several strands of evidence point to the existence of 
pathogenic circulating factors in non-genetic SRNS (Section 1.4.1).  One such 
observation is the recurrence of proteinuria within hours of transplantation of a 
healthy donor kidney.  Biopsy of the transplant, in one published example, 
revealed typical features of podocyte effacement [142].  The search to identify 
one or more of the circulating factors is ongoing.  Despite this, their presence can 
be inferred from the effect of plasma from patients with post-transplant recurrence 
on in vitro podocyte cultures [175]. 
 
7.1.1 Conditionally immortalised human podocytes 
A conditionally-immortalised human podocyte cell line was developed by Bristol 
Renal at the University of Bristol and originally described in 2002 [187].  Primary 
human podocytes were derived from a nephrectomy specimen of a 3-year-old 
child with hydronephrosis.  There were no features of dysplasia or known primary 
glomerular pathology and so the podocytes were considered to be normal.  
Differentiated podocytes in vitro enter terminal growth arrest, therefore, primary 
podocyte cultures were transfected with a retroviral vector carrying the SV40 
large T antigen gene, which promoted ongoing cell division at the permissive 
temperature of 33°C and terminal differentiation at 37°C.  These cells were shown 
to express podocyte-associated proteins including podocin and nephrin.  They 
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have been used to evaluate podocyte structural and functional responses in models 
of diabetes and SRNS.   
As discussed in Chapter 1 (Section 1.4.4), Harris et al. demonstrated that 
VASP in podocytes was consistently phosphorylated in response to FSGS relapse 
plasma [188].  Phosphorylation or dephosphorylation of multiple proteins within 
podocytes, including nephrin, NEPH proteins, focal adhesion kinase (FAK) and 
synaptopodin, are involved in regulation of the actin cytoskeleton and 
maintenance of foot process integrity [371].  Disruption of this is central to the 
pathogenesis of proteinuria in SRNS.   
 
7.1.2 Phosphoproteomics 
Phosphorylation of proteins is one of the commonest post-translational 
modifications and is often key to regulation of their activity and function.  A 
protein may be phosphorylated (or subsequently dephosphorylated) at multiple 
different amino acid residues.  An ability to localise phosphorylation sites as well 
as quantify and compare levels of phosphoproteins in samples can give an insight 
into dynamic regulation of protein function and signalling pathways [372]. 
Chapter 5 described proteomics technologies which enabled quantification of 
multiple proteins in biological samples.  Similar principles apply to 
phosphoproteomics, in the case of this study in relation to proteins extracted from 
podocytes.  Two of the key steps include: 
1. Differential labelling of all the proteins within different samples such that 
they can be mixed and processed in parallel for LC-MS/MS.  Subsequently 




2. Selective enrichment of the phosphopeptide fraction of the samples.  The 
phosphopeptides represent a small proportion of all peptides after 
trypsinisation of a complex mixture of proteins in a cell extract.  
Enrichment of phosphopeptides reduces the complexity and enhances the 
likelihood of accurate peptide identification and quantification by LC-
MS/MS [373]. 
 
Differential labelling of proteins may be achieved in a variety of ways.  In this 
study, 10-plex TMT labelling, as described in Chapter 5 (Figure 5.3), was used 
since this provides the benefit of parallel processing and analysis of 4 
relapse/remission pairs of samples together with two controls. 
 Several methods of phosphoprotein enrichment have been described 
including immobilised metal affinity chromatography and immunoaffinity 
purification [374].  In this study, TiO2 chromatography was employed which is 
based on the very high affinity of the metal oxide for phosphoproteins in an acid 
environment.  After separation of non-bound peptides, the phosphopeptides are 
eluted using an alkaline buffer.  The whole process has a high specificity for 
phosphorylated versus non-phosphorylated peptides and is generally very tolerant 
to the presence of salts and detergents in the protein extraction mixture [375].   
 
7.1.3 Phosphoproteomics of renal cells 
Proteomic analysis of the renal filtration barrier has provided an insight into 
signalling pathways which can be affected in proteinuric disease [376].  The 
potential pathogenic role of disruption of intracellular and extracellular podocyte 
proteases has recently been reviewed [377].  Several studies have examined the 
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phosphoproteome of glomeruli and podocytes in particular.  The most 
comprehensive examined the phosphoproteome of mouse glomeruli and identified 
2449 phosphorylated proteins with 146 phosphorylation sites on proteins 
expressed at high levels in podocytes [378].  Synaptopodin was one with the 
highest number of phosphorylation sites but other phosphorylated proteins 
included podocin, nephrin and CD2AP.   The same research group also examined 
the phosphoproteome of cultured mouse podocytes and identified increased 
phosphorylation of actin-filament associated proteins in fully-differentiated cells 
[379].   
The aim of this study was to compare levels of phosphoproteins in 
podocytes shortly after treatment with plasma from SRNS patients at times of 
disease relapse and remission.  The intention was both to highlight potentially 
novel pathogenic signalling pathways and identify podocyte phosphoproteins 




The same patients were included in this study as previously described in Chapter 
5: C1, SRNS1, SRNS2, SRNS3 and 419.  In the case of patient 419, REL-2 was 
used as the relapse sample as this was associated with more consistent VASP 





7.2.2 Tissue culture of conditionally-immortalised human podocytes 
Tissue culture was performed using podocytes as described previously in Chapter 
5 (Section 5.2.4). 
 
7.2.3 Treatment of podocytes with patient plasma 
On the day of treatment, standard medium was removed and replaced with RMPI 
1640 lacking FBS and ITS.  Podocytes were incubated for 2 hours in serum-free 
(SF) medium before treatment started.  Plasma was diluted in SF RPMI 1640 to a 
final concentration of 10% in a total volume of 4ml.  Paired relapse and remission 
samples were used from the patients with SRNS. After applying the treatment, 
podocytes were returned to 37°C for 30 minutes. 
 
7.2.4 Protein extraction and preparation 
Protein extraction followed the same method as described in Chapter 5 (Section 
5.2.6).  After centrifuging, the supernatant was transferred to fresh Eppendorfs 
and the protein concentration determined using the BCA assay. A total of 100 μg 
protein was sent to the University of Bristol Proteomics Facility for total and 
phosphoproteomic analysis.  Remaining supernatant was stored at -80°C for 
future validation experiments. 
 
7.2.5 Quantitative total and phosphoproteomics 
Quantitative total and phosphoproteomics was performed at the University of 
Bristol Proteomics Facility as previously described [319].  Briefly, 10 samples 
were digested with trypsin overnight, labelled with TMT 10-plex reagents and 
pooled together.  For total proteomics, the pooled samples were fractionated by 
312 
 
high-pH reversed-phase chromatography.  The fractions were analysed by nano-
LC-MS/MS using an Orbitrap Fusion Tribrid mass spectrometer (Thermo 
Scientific).  For phospho-proteomics, samples were processed using TiO2-based 
phosphopeptide enrichment (Pierce) followed by nano-LC-MS/MS.  Data files 
were processed and analysed with Proteome Discoverer software (v1.4, Thermo 
Scientific) and searched against the Uniprot Human database (134169 sequences) 
using the SEQUEST algorithm. The search was performed with full tryptic 
digestion allowing a maximum of one missed cleavage.  The FDR was set at 1% 
for all peptide data using the reverse database search option 
 
7.2.6 Phosphoproteomics data analysis 
Quantification data for peptides from phospho-enriched samples were analysed in 
Proteome Discoverer.  The peptide FDR was set at 1%. The relative fold change 
was calculated as the ratio of quantity in the “relapse” sample to quantity in 
“remission” for the same patient using the Proteome Discoverer Ratio Reporting 
function.  The ratios for each sample to SF control and to C1 control were also 
determined.  The data were then exported to Microsoft Excel for further analysis. 
Only peptides assigned to a single protein group and with complete 
quantification data were included.  Each peptide assigned to a single protein was 
also associated with a UniProt accession number.  However, in many cases 
several proteins each with their own accession number, were a member of a single 
protein group.   Proteome Discoverer assigned the protein group with one 
accession number belonging to the constituent protein with the greatest coverage 
(that is, the one identified with the highest confidence based on the MS data).  In 
order to minimise mismatches when comparing between datasets and using 
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bioinformatics tools, all accession numbers from the protein group together with 
the gene name associated with each peptide were used.   
 In order to identify biological pathways of potential interest, peptides in 
the phospho-enriched samples which changed by > 2 or < 0.5 in podocytes treated 
with relapse versus remission plasma from a single patient were inputted into 
STRING to analyse potential interacting proteins [380].   The following settings 
were adjusted to favour a more stringent analysis:  
• Textmining was deselected as one of the active interaction sources 
• The minimum required interaction score was set at the highest confidence 
(0.900) 
When displaying the protein interaction diagram, disconnected nodes in the 
network were hidden.  The main biological functions of altered proteins were 
summarised using KEGG pathway analysis within STRING [381, 382].  The 
peptide data for each patient relapse/remission pair were inputted separately and 
the affected pathways compared for similarity.   
In order to identify differences in phosphorylation of proteins between 
relapse and remission plasma treatments with a view to more detailed in vitro 
validation, the list of peptides was filtered to those with phospho modifications 
and those with fold changes > 2 or < 0.5 most consistent across four patients.  The 
location of the peptide phospho modification in the parent protein was determined 
using PhosphoSitePlus ® (freely available at www.phosphosite.org) [383].  In the 
initial analysis of the four patients (SRNS1, SRNS2, SRNS3 and 419) only the 
peptide data from the phospho-enriched samples were used and it was assumed 
that the associated total proteins would not change during the 30-minute treatment 
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with relapse or remission plasma.  These findings were used to direct further in 
vitro studies as discussed below. 
 
7.2.7 Western blotting for phosphoproteins 
The antibodies used for Western blotting are shown in Table 7.1. 





Manufacturer Species Dilution 
pBAD (Ser112) 23 9291 CST Rabbit 1:1000 
BAD 23 9292 CST Rabbit 1:1000 





Rosemont, IL, USA 
Rabbit 1:2000 
Phosphoserine - Ab9332 Abcam Rabbit 3 µg/mL 
GAPDH 36 MAB374 Merck Millipore Mouse 1:10000 
 
7.2.8 Immunoprecipitation 
Table 7.2: Solutions used for immunoprecipitation 
IP extraction buffer 
150 mmol/L NaCl 
20 mmol/L Tris base pH 7.5 
10% (v/v) Glycerol 
1% (v/v) Triton® X-100 
Supplements added to IP buffer 
just prior to use 
1% (v/v) Protease inhibitor cocktail (Sigma-
Aldrich; #P8340) 
1% (v/v) Phosphatase inhibitor cocktail 2 
(Sigma-Aldrich, #P5726) 
1% (v/v) Phosphatase inhibitor cocktail 3 
(Sigma-Aldrich; #P0044) 
400 µmol/L Phenylmethane sulfonyl fluoride 
(PMSF) 
TNE buffer 
50 mmol/L Tris HCl pH 7.4 
150 mmol/L NaCl 




Podocytes were cultured, as previously described, in T175 flasks to 
provide sufficient protein for further analysis.  They were treated with plasma for 
30 minutes and proteins extracted using IP extraction buffer with protease and 
phosphatase inhibitor supplements (Table 7.2) before centrifuging and storing the 
supernatant at -80°C for future use. 
Protein A/G Plus agarose beads (10% v/v; Santa-Cruz, #sc-2003) were 
resuspended in TNE buffer (Table 7.2).  Anti-palladin IgG (5 μg) and normal 
rabbit IgG (5 μg) were added to separate aliquots of 200 μL resuspended agarose 
beads in Eppendorf tubes.  These were placed on a rotator overnight at 4°C. 
Podocyte lysates were defrosted for pre-clearing.  10% BSA in TNE was 
added to give a final BSA concentration of 1% followed by 20 μL agarose beads.  
Tubes were rotated at 25 rpm for 1 hour at 4°C before being centrifuged at 1000 × 
g for 1 minute at 4°C.  The supernatants were transferred to fresh tubes and kept 
on ice. 
The Eppendorf tubes containing agarose beads with anti-palladin and 
rabbit IgG were also centrifuged at 1000 × g for 1 minute at 4°C before discarding 
the supernatant.  The beads were washed twice by resuspending in 200 μL TNE 
buffer, centrifuging and discarding the supernatant.  Half the volume of pre-
cleared cell lysate was added to palladin IgG-beads and the rest to normal rabbit 
IgG-beads and the volumes made up to 500 μL.  The mixtures were rotated at 25 
rpm for 3 hours at 4°C and then centrifuged at 1 × g for 1 minute.  The beads were 
washed four times by resuspending in 500 μL and then centrifuging at 1 × g for 1 
minute. 
 Palladin and rabbit IgG immunoprecipitates and whole cell lysate were 
prepared for SDS-PAGE by adding 2 × sample buffer with 2-mercaptoethanol and 
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boiling for 10 minutes at 95°C.  The samples were centrifuged at 1000 × g for 1 
minute to remove bead fragments before proceeding to load on a 10% 
polyacrylamide gel for SDS-PAGE and Western blotting as previously described. 
 
7.3 Results 
7.3.1 Patient characteristics 
The demographic details and data relating to plasma samples were as detailed 
previously in Chapter 5.   
 
7.3.2 Phosphoproteomic analysis of podocytes treated with relapse 
and remission plasma from patients with SRNS 
 
Cell culture extracts from podocytes treated with SF media and plasma from C1, 
SRNS1, SRNS2, SRNS3 and 419 were analysed with LC-MS/MS.  Quantification 
data relating to peptides in the phospho-enriched fraction were extracted and the 
quantification of each plasma sample relative to SF media were examined.  Of 
4217 peptides identified, 5 were not matched to a protein, 245 were assigned to 
more than one protein group and 24 had incomplete quantification data leaving 
3943 peptides with unique protein matches for analysis.  Peptides that were 
increased or decreased in plasma-treated podocytes versus SF media were 




Table 7.3: Number of peptides in phospho-enriched podocyte extracts 
reaching fold-change thresholds after treatment with plasma versus serum-
free media 

























< 0.5 50 84 71 156 91 82 180 40 48 
> 2 297 364 500 292 346 343 190 153 244 
Total   347 448 571 448 437 425 370 193 292 
Total number of peptides with quantification data available = 3943 
Legend: Rel, relapse; Rem, remission, SF, serum-free media 
 
Treatment of podocytes with patient plasma was associated with changes 
in peptide quantities compared with treatment with SF media.  Between 4% (491 
relapse) and 14% (SRNS1 remission) of quantified peptides had a fold change > 
2.  Of note, a similar number of peptides were affected by treatment with plasma 
from the control subject C1 who did not have SRNS.  In order to understand the 
possible effects of plasma on the podocytes, the interactions between proteins 
identified from the peptides were investigated using STRING.   
Peptides that were increased or decreased in response to treatment with 
relapse versus remission plasma were identified and the total numbers used for 
pathway analysis are shown in Table 7.4. 
 
Table 7.4: Number of peptides in phospho-enriched podocyte extracts 
reaching relapse/remission fold-change thresholds and used for STRING 
pathway analysis 
Patient  SRNS1 SRNS2 SRNS3 419 
Relapse/remission fold-
change threshold  
< 0.5 130 116 50 94 
> 2 40 52 311 59 
Total inputted for STRING 
analysis 
 170 168 361 153 
Total recognised and used in 
STRING analysis 
 148 158 290 139 




As described in the Methods, the STRING search used all accession 
numbers from each protein group corresponding to the identified peptides.  
However, in some instances several peptides matched to the same protein hence 
the number used in analysis is fewer that the number inputted due to removal of 
these duplicates.  It was evident that treatment with paired plasma from SRNS3 
was associated with a greater number of peptide changes and in an opposite 
direction (more peptides increased in relapse) compared with the other patients.  
 Figure 7.1 to Figure 7.4 show the networks of protein interactions 
predicted based on peptides increased or decreased by treatment with relapse 
versus remission patient plasma.  In each case the number of interactions (edges) 
was significantly greater than expected by chance based on a set of proteins of 




Figure 7.1: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus remission plasma 
from patient SRNS1 
Legend:  Each circle represents a protein and is annotated with the gene name.  
Only proteins with at least one connection are shown. 
Diagram created using STRING available at https://string-db.org [332] 
 
 
Number of nodes (proteins): 146 
Number of edges (connections): 93 
Expected number of edges: 51 





Figure 7.2: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus remission plasma 
from patient SRNS2 
Legend: See Figure 7.1 
Number of nodes (proteins): 158 
Number of edges (connections): 99 
Expected number of edges: 45 
Protein-protein interaction (PPI) enrichment p value: 2.18 × 10-12 




Figure 7.3: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus remission plasma 
from patient SRNS3 
Legend: See Figure 7.1 
Number of nodes (proteins): 290 
Number of edges (connections): 432 
Expected number of edges: 215 





Figure 7.4: Protein interaction network based on peptide quantification 
ratios > 2 or < 0.5 in podocytes treated with relapse versus remission plasma 
from patient 419 
Legend: See Figure 7.1 
Number of nodes (proteins): 139 
Number of edges (connections): 73 
Expected number of edges: 28 




KEGG pathway analyses for the four relapse/remission plasma samples 
are shown in Table 7.5. 
Table 7.5: Top 5 KEGG pathways most likely affected differentially by 








Regulation of actin cytoskeleton 15 7.30 × 10-9 
Focal adhesion 14 2.94 × 10-8 
Tight junction 11 1.75 × 10-7 
Leukocyte transendothelial migration 9 8.55 × 10-6 
Adherens junction 6 0.00044 
SRNS2 
Focal adhesion 12 1.15 × 10-5 
Regulation of actin cytoskeleton 12 1.15 × 10-5 
Salmonella infection 7 0.000296 
Protein processing in endoplasmic 
reticulum 
9 0.000345 
Viral carcinogenesis 8 0.00481 
SRNS3 
Regulation of actin cytoskeleton 21 6.48 × 10-10 
Focal adhesion 19 1.28 × 10-8 
Bacterial invasion of epithelial cells 12 4.27 × 10-8 
Pathogenic Escherichia coli infection 10 1.88 × 10-7 
Proteoglycans in cancer 17 8.85 × 10-7 
419 
Regulation of actin cytoskeleton 12 5.49 × 10-6 
Thyroid hormone signalling pathway 9 1.30 × 10-5 
Focal adhesion 11 1.32 × 10-5 
Leukocyte transendothelial migration 7 0.000699 
Bacterial invasion of epithelial cells 6 0.000699 
Legend: FDR, false discovery rate 
As evident from the descriptions, proteins in the pathways “regulation of 
actin cytoskeleton”, “focal adhesion” and “adherens junction” all have a role in 
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cellular motility and cell-cell interactions.  The “salmonella infection” pathway 
also includes proteins which induce the rearrangement of the actin cytoskeleton 
and result in membrane ruffles.  In at least three of the top five protein interaction 
pathways for all patients a common theme was cell motility, focal adhesions and 
regulation of the actin cytoskeleton. 
In order to identify individual phosphoproteins for further analysis and in 
vitro validation of potential target pathways, the MS quantification data for 
peptides with phospho modifications from the phospho-enriched samples were 
examined.  A fold-change threshold of > 2 was used to identify phosphopeptides 
increased by treatment with relapse versus remission plasma consistently across 
the four patients.  Three peptides with the greatest fold change and consistency are 
shown in Table 7.6.  The fold change at the level of total proteins is shown in 
Table 7.7.   
 
Table 7.6: Phosphopeptides with relapse/remission fold change > 2 across 













11.14 27.02 11.31 0.76 
cDNA FLJ61193, 
highly similar to 













S3(Phospho) 0.85 2.60 2.63 2.43 






Table 7.7: Relapse/remission fold change at level of total proteins 
corresponding to identified phosphopeptides 




1.01 0.94 1.04 0.96 
cDNA FLJ61193, 
highly similar to 
Bcl2 antagonist of 
cell death 




protein 4 0.95 0.84 1.13 1.08 
 
The three phosphopeptides identified were increased in podocytes treated 
with relapse plasma more than two-fold compared with the treatment with 
remission plasma in three of the four patients.  The difference in the level of 
phosphopeptides was not due to change in the amount of total protein which was 
relatively similar between the two treatments.   
 The size and known functions of the selected proteins are detailed in Table 
7.8.  
 
Table 7.8: Biological characteristics of proteins identified from most 
consistently altered phosphopeptides 




Palladin PALLD 151 
Cytoskeletal protein required for organising actin 
cytoskeleton, component of actin-containing 
microfilaments, role in control of cell shape, adhesion 
and contraction 
Bcl-2 associated 
agonist of cell 
death (BAD) 
BAD 18 
Positive regulator of apoptosis via heterodimers with 
Bcl-xL and Bcl-2 and reversing their death repressor 
activity.  Activity regulated by phosphorylation involving 





Membrane-associated guanylate kinase at post-synaptic 
density in neurones, can interact with potassium 
channels and receptors, may act as an adaptor protein 





A literature review was conduction to understand whether the proteins 
identified from the peptides may be of functional significance in the podocyte 
response to SRNS plasma.  No studies linking DLG-associated protein 4 with 
podocytes were identified.   
Research using cultured podocytes exposed to puromycin 
aminonucleoside showed they underwent apoptosis which appeared to be related 
to increased BAD mRNA and protein expression [384].  Treatment with 
dexamethasone in this setting decreased BAD mRNA and protein levels together 
with reducing apoptosis.  A different study in patients with IgA nephropathy 
found that podocyte Bcl-2 was upregulated in renal biopsies from early-stage 
disease and downregulated in late-stage disease [385]. 
 Palladin has been shown to co-localise with VASP at focal adhesions 
[386].  It is expressed in podocytes, co-localised with F-actin and was found in 
ring-like actin structures and ruffles [387].  Palladin mRNA levels were 
significantly decreased in glomerular tissue from biopsies of patients with FSGS 
compared with controls.  This study did not examine phosphorylation of palladin 
in podocytes, however other research using different in vitro epithelial cell 
cultures, including HEK-293T and human breast cell lines, showed that palladin is 
phosphorylated at serine 77 and 197 in response to the growth factor extracellular 
signal-related kinase (ERK) [388].  Using immunofluorescence with cell lines 
expressing wild-type or mutant palladin, the authors suggested that ERK 
phosphorylation of palladin had an anti-migratory effect. 
 Based on the published research, it was decided to validate the proteomics 
findings of BAD and palladin phosphorylation with further in vitro experiments.  
The localisation of the S3 phospho modification in the BAD peptide was 
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determined using PhosphoSitePlus® as serine 75.  Phosphorylation of BAD at this 
site has been shown to promote binding to 14-3-3 proteins which prevents 
interaction of BAD with Bcl-2 and Bcl-xL and, therefore, has an anti-apoptotic 
effect [389].  An antibody targeting phospho-BAD (Ser75) was commercially 
available and used in Western blotting experiments. 
 The localisation of the S3 phospho modification in the palladin peptide 
was determined as serine 893.  Other than MS, no confirmatory or functional 
studies relating to phospho (Ser893)-palladin exist.  A commercially-available 
antibody targeting this for use in Western blotting was not available, therefore a 
different approach to validation was planned, namely immunoprecipitation to pull 
down total palladin followed by blotting and detection using an anti-
phosphoserine antibody. 
 
7.3.3  Validation of phospho-BAD findings using Western blotting 
Proteins extracted from podocytes after treatment with control and patient 
plasma were separated by SDS-PAGE and detected by Western blotting and 
results shown in Figure 7.5. 
 There was minimal BAD (Ser75) phosphorylation in podocytes in SF 
media.  There was evidence of phosphorylation after 30 minutes’ treatment with 
all of the plasma samples from patients with SRNS and to a lesser extent with 
control plasma.  Although MS proteomics had suggested that the phosphopeptide 
was increased > 1.3-fold (> 0.38 after log2 transformation, Figure 7.5B) after 
treatment with relapse plasma from three patients, these findings were not 
confirmed by Western blotting.  Based on Western blotting quantification, the 
relapse/remission fold change of phospho-BAD normalised to total BAD was not 
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significantly different from 1 for each of the patients (one-sample t test on log-

































W e s te rn  b lo t




Patient SRNS1 SRNS2 SRNS3 419 
Western blotting Rel/Rem fold change 
(geometric mean) 
1.15 0.83 1.30 0.93 
Proteomics Rel/Rem fold change 
4.47 2.35 2.20 0.24 
 
Figure 7.5: Western blotting and proteomic quantification of phospho-BAD 
in extracts from podocytes treated with paired relapse/remission plasma 
samples 
A: Western blot of podocyte extracts after exposure to serum-free media (SF), 
control (C1) and paired relapse and remission plasma samples. B: Log2 
transformed relapse/remission (normalised phospho-BAD/total BAD) fold change 
quantification from densitometry of blots (n = 4) and MS proteomics. C: 
Relapse/remission (normalised phospho-BAD/total BAD) fold change ratios 







7.3.4 Validation of palladin findings using immunoprecipitation 
Prior to IP experiments, Western blotting was used to confirm that total palladin 
could be detected in podocyte extracts and did not appear to change between 




Product literature accompanying the palladin polyclonal antibody (Proteintech, 
#10853-1-AP) confirmed that bands were expected at 95 kDa and 140 kDa but 
other isoforms at 200 kDa and 65 kDa are also known to exist. 
 
Figure 7.7 shows results from immunoprecipitation using anti-palladin 
antibody with lysates from podocytes treated with SF media and plasma from 
SRNS3 at time of relapse.   
 
Figure 7.6: Western blotting of total palladin in extracts from podocytes 







Figure 7.7: Immunoprecipitation of podocyte extracts with anti-palladin 
antibody and Western blotting for palladin and total phosphoserine 
A: Podocytes treated with serum-free media. B: Podocytes treated with plasma 







Total lysate from podocytes in SF media had a major band at and above 75 
kDa after blotting for palladin, however following palladin IP the predominant 
band was just above 65 kDa (Figure 7.7A).  Blotting for total phosphoserine after 
palladin IP detected a band also just above 65 kDa but this was similar in intensity 
to a band at the same position after IP with normal rabbit IgG control antibody, 
suggesting that this may be non-specific.  When podocytes were treated with 
plasma from patient SRNS3 in relapse, it was expected that phospho-palladin 
levels would be increased based on the previous MS results. However, there was a 
very similar pattern to SF media (Figure 7.7B). 
 There appeared to be little difference in the blots using anti-phosphoserine 
after treatment with SF or SRNS3’s plasma either in total lysate or with palladin 
IP.  Western blotting for phosphoserine in whole cell lysate from podocytes after 
treatment with control, relapse and remission plasma samples showed a consistent 
pattern of multiple bands (Figure 7.8).  There was a prominent band at 75 kDa 
which did not vary between relapse and remission plasma treatments.  It was in a 
similar position as the major band when blotting for palladin but probably 





Figure 7.8: Western blotting of total palladin and anti-phosphoserine in 




7.4.1 Findings of this study and comparison with the literature 
This study focused on changes in the podocyte phosphoproteome at 30 minutes 
after exposure to plasma from patients with SRNS.  It directly compared the 
effects of plasma taken at the time of relapse, when circulating factor activity 
would be expected to be greatest, with plasma at the time of remission.  For the 4 
patients, the phosphoproteins with the greatest differences between relapse and 
remission plasma treatments were consistently within the protein interaction 
pathways involved in focal adhesion and regulation of the actin cytoskeleton.  
This supports the current understanding of early changes in actin dynamics and 
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podocyte motility resulting in proteinuria rapidly after transplant in patients 
considered to have circulating factor disease [390, 391].   
 After analysis of the effects of plasma treatment at the pathway level, the 
study sought to focus on individual phosphoproteins showing the largest 
difference between relapse and remission plasma treatments.  Phosphopeptides 
derived from palladin and BAD both showed > 2-fold increase in podocytes 
treated with relapse plasma compared with remission from 3 of the 4 patients.  
Total protein quantification was almost the same with the two treatments 
suggesting the difference was due to increased phosphorylation rather than 
changes in the absolute amount of protein.  Paired plasma from patient 419 did 
not show the same consistency in the relapse/remission fold change of 
phosphoprotein.  The “relapse” plasma sample taken from this patient was at a 
time when the treating clinical team judged them to be in relapse (419 REL-2 
sample), however the uPCR was 81 mg/mmol and plasma albumin was 37 g/L.  
An alternative explanation may be that the circulating factors in 419 were 
different from the other patients, and so activated distinct intracellular pathways in 
podocytes.    Although these may be reasons for the difference from other 
patients, 419 did show more consistent relapse/remission fold change for other 
phosphoproteins. 
 Attempts were made to validate the phosphoproteomic findings for both 
BAD and palladin but neither could be confirmed using the techniques in this 
study.  Western blotting for phospho (Ser75)-BAD did not show a biologically or 
statistically significant increase in relapse versus remission plasma-treated 
podocytes.   
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 The phosphoproteomic data for palladin, with relapse/remission ratios > 
10 for patients SRNS1, SRNS2 and SRNS3, was particularly striking.  It was 
considered whether these data could be outliers however the consistency across 3 
of the 4 patients warranted further investigation.  An initial literature review and 
knowledge that palladin is expressed in podocytes with a role in organisation of 
the actin cytoskeleton provided further justification for ongoing study.  The 
absence of a commercially-available anti-phospho (Ser893)-palladin antibody 
made direct validation of the phosphoproteomic findings more challenging.  The 
use of palladin IP followed by Western blotting for phosphoserine was hampered 
by non-specific binding and would not have been able to confirm phosphorylation 
specifically at Ser893. 
 Since completion of these laboratory experiments, further research has 
been undertaken by others examining in detail the role of palladin in podocytes 
[392].  Artelt et al. (2018) conducted studies using knock-down of palladin in 
cultured podocytes and mice with podocyte-specific knock-out of palladin.  In 
mouse kidney sections and cultured mouse podocytes, they confirmed that 
palladin and synaptopodin colocalised in dense bodies along actin filaments and 
that palladin is present in focal adhesions.  Knock-down of palladin in cultured 
podocytes was associated with a higher number of small focal adhesions, fewer 
actin fibres and a more migratory phenotype.  Podocyte-specific knock-out in 
mice led to an enlarged sub-podocyte space, reduced expression of nephrin and 
increased proteinuria following injection of nephrotoxic serum compared with 
control mice.  The expression of palladin was reduced in podocytes in renal 
biopsies from patients with diabetic nephropathy and FSGS.  In a separate study, 
the same group also found that in the palladin knock-out mice the filtration slit 
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density was significantly lower than in control mice [393].  Taken together, these 
two studies highlight the importance of palladin for podocyte structure and 
function but neither these nor others in the published literature have examined the 
effects, or control, of palladin phosphorylation in these cells. 
 Other groups have sought to develop podocyte-based assays to quantify 
the effects of circulating factor activity.  Kachurina et al. used ci-hPod treated for 
20 hours with serum from 10 patients with FSGS: 4 had post-transplant recurrence 
and 4 did not; 2 patients had idiopathic, non-genetic FSGS and had not been 
transplanted [394].  By immunofluorescence and computerised image analysis, 
they calculated the number of focal adhesion complexes (FACs) per 1000 µm2 
cell area.   In all patients with post-transplant recurrence and the 2 with idiopathic 
FSGS, the number of FACs decreased significantly compared with control 
whereas there was no difference when treated with serum from the patients with 
no recurrence.  Pre-incubation of podocytes with anti-TNF receptor antibodies 
before addition of sera prevented the reduction in FACs in 2 of the 4 recurrent and 
both idiopathic FSGS cases.  The authors suggested their assay may be able to 
identify patients who would respond to TNF-alpha blockade.  They did not 
compare serial samples from the same patients at times of relapse and remission 
and the timing of serum samples with respect to transplantation was unclear.  
Further study using longitudinally-collected samples, particularly pre-transplant, 
would be important to evaluate the predictive value of this assay. 
 The current study examined the podocyte phosphoproteome after 30 
minutes of treatment and that of Kachurina et al. assessed FACs at 20 hours.  It is 
possible that phosphorylation of palladin and of VASP [188], with which it 
interacts [386, 395], are early steps in the pathway leading to reduction of FACs 
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in podocytes.  In the future, development of an anti-phospho (Ser893)-palladin 
antibody would facilitate validation by Western blotting of the MS findings in this 
study.  Immunofluorescence could also be used to visualise phospho-palladin and 
FACs after treatment of podocytes with relapse and remission plasma. 
 
7.4.2 Limitations 
Although this study has highlighted some important findings which will require 
further investigation, it has several limitations.  The phosphoproteomic analysis 
included a relatively small number of patients and, therefore, results may not be 
reproduced in a larger cohort.  The pathogenic processes and circulating factors 
may have been different between the patients although they were included as all 
had SRNS with post-transplant recurrence of disease.  In this study, proteins were 
extracted from podocytes after 30 minutes of treatment with plasma.  It therefore 
gives only a snapshot of the phosphoproteome and cannot provide information 
about differences in phosphorylation within the first minutes after treatment with 
relapse or remission plasma.   
 
7.4.3 Conclusion 
This study aimed to examine differences in phosphoproteins in podocytes after in 
vitro treatment with SRNS relapse and remission plasma.  It highlighted that 
proteins involved in biochemical pathways related to actin cytoskeleton 
reorganisation and focal adhesion are differentially phosphorylated in podocytes 
exposed to the two treatments.  It also pointed to palladin as a protein which was 
markedly more phosphorylated after treatment with relapse plasma.  This study, 
however, was not able to validate the MS findings with an alternative technique 
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and this was limited by the lack of a specific phospho-palladin antibody.  Given 
the increasing literature suggesting the importance of palladin in podocyte 
structure and function, future studies are required to examine the role of palladin 
phosphorylation in pathogenesis and as a biomarker in SRNS relapse. 
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Chapter 8 Discussion 
 
SRNS is a rare disease affecting predominantly children, but also adults.  
Although absolute numbers are comparatively small, the impact on patients’ lives, 
with the high likelihood of development of ESRF, requirement for dialysis or 
transplantation and associated mortality, is significant.  It is clear that SRNS is not 
a single disease but a common endpoint for a heterogenous group of underlying 
genetic and non-genetic pathogenic processes.  There is variation in the success of 
immunosuppressive treatments after the failure of steroids, and also variable 
outcome following transplantation, with up to 50% of patients suffering post-
transplant disease recurrence [142]. 
 The aim of this study was to investigate the interplay of phenotype, 
genotype and potential biomarkers with respect to treatment and long-term 
outcome.  In particular, the intention was to develop further stratification of 
patients and identify biomarkers which could be used in future trials of treatments.   
 
8.1 Findings of this study 
The main findings of this study were: 
• The pattern of steroid resistance strongly predicted non-genetic disease: no 
patients with secondary steroid resistance had a pathogenic variant found 
by whole exome sequencing. 
• When considering first renal biopsies in SRNS, there was no significant 




• Patients with presumed steroid resistance were significantly more likely to 
progress to ESRF than patients with either primary or secondary steroid 
resistance (there was no significant difference between the latter two). 
• Patients with genetic disease were significantly more likely to progress to 
ESRF, but none suffered post-transplant recurrence. 
• Secondary steroid resistance was a strong predictor of post-transplant 
recurrence supporting previous findings [274]. 
• Pathogenic variants were detected in 21.2% of patients with SRNS by 
clinical genetic testing in a real-world international cohort and in 27.8% of 
children with SRNS by WES in a research cohort. 
• Complete response to first IIS treatment was seen in only approximately 
25% of patients with similar response rates for ciclosporin, tacrolimus and 
MMF. 
• Only rituximab when used to treat patients with SSR had a higher 
complete response rate at 66.7%. 
• Irrespective of the drug used, complete or partial response to the first-line 
IIS treatment was associated with a highly significantly lower risk of 
progression to ESRF compared with no response to first treatment. 
• Plasma proteomics identified uteroglobin as a potential biomarker being 
raised at time of disease relapse versus remission, although further 
validation, and study with longitudinally-collected samples, is required to 
confirm whether it has any predictive value. 
• Hemopexin, NGAL and AHSG, which have been suggested as potential 
biomarkers in other studies, also appeared to be differentially present in 
relapse versus remission plasma in this study. 
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• Phosphorylation of palladin in podocytes may be an important step in 
disease pathogenesis after exposure to relapse plasma based on 
phosphoproteomic studies and knowledge of palladin function from the 
published literature.  This would be worthy of more detailed in vitro, and 
subsequently in vivo, study 
 
Based on the findings from this study, a clinical diagnostic and management 
pathway can be proposed.  Patients with presumed or primary steroid resistance 
could be offered clinical genetic testing using a gene panel approach from the 
point of diagnosis.  From the results reported in Chapter 4 and other studies [44, 
57, 396], a genetic cause is likely to be detected in 25-30%.  Age of onset under 1 
year, consanguinity and family history of NS do appear to be associated with 
greater risk of genetic disease, as would be expected.  However, in this and other 
published studies, absence of these factors does not rule out a genetic basis for 
disease.  This, therefore, supports universal testing in patients with presumed or 
primary SR.  Others have also recommended clinical genetic testing using WES in 
all patients with SRNS with onset under 25 years [281, 396].  The caution against 
more prevalent genetic testing is the existence of variants of uncertain 
significance and incidental discovery of secondary variants in genes other than 
that thought to be primarily pathogenic [397].  These secondary variants may have 
modifier effects that are incompletely understood and are likely to complicate 
genetic counselling. 
In this study, no patients with secondary SR had genetic disease.  
Therefore, in clinical practice, it may be reasonable not to undertake genetic 
testing in this subgroup, although a small number of patients with SSNS have 
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been identified with mutations in EMP2 [108].   In the context of future research, 
particularly using WES or WGS, patients with secondary SR should still be 
included as novel gene associations may be discovered. 
 Following clinical genetic testing, those patients diagnosed with genetic 
disease could receive more specific counselling about prognosis, and it would also 
enable the patient’s family to be informed of the likelihood of disease being 
inherited by future children.  Although the chance of response to IIS treatment is 
lower and the risk of progression to ESRF is higher, as discussed in Chapter 3, 
some patients with genetic disease do respond to ciclosporin or tacrolimus [276, 
277].  Furthermore, there have been published reports of patients with WT1, 
NPHS1 or NPHS2 variants responding to IIS therapy [82, 276].    Patients with 
SRNS and pathogenic variants in genes coding for proteins involved in the 
coenzyme Q10 pathway (such as COQ2, COQ6, PDSS2 and ADCK4) have been 
shown to be successfully treated with coenzyme Q10 supplementation [119, 124, 
301].    
Further research and international sharing of data is required to determine 
if patients with specific variants in specific genes are more responsive to 
immunosuppression.  The non-immunologic mechanisms of action of 
immunosuppressants, as discussed in Chapter 1 (Section 1.5.1), provide a 
rationale for their efficacy in genetic disease.  Greater understanding of the 
pathogenic mechanisms of causative mutations will also open new doors for 
potential treatment such as gene therapy. 
For those patients with genetic disease who do require transplantation, 
findings from the studies reported here support previous research that the 
likelihood of recurrence is close to zero [44].  The main exception, reported by 
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others, has been those patients with NPHS1 variants leading to complete absence 
of nephrin in whom anti-nephrin antibodies are associated with post-transplant 
proteinuria [398].  The PodoNet cohort study also reported 4 patients with NPHS2 
variants who suffered post-transplant recurrence [44].  No anti-podocin antibodies 
have been detected and the mechanism of recurrence in this group of patients is 
unclear [399]. 
Patients with presumed or primary SR with single heterozygous variants in 
causative genes may still have genetic disease.  As discussed in Chapter 4, second 
variants in intronic or promoter regions, or combinatorial effects with variants in 
other known or novel causative genes, may together be pathogenic.  WGS and 
future functional studies will hopefully elucidate these hypotheses. 
In those patients with presumed or primary SR and no genetic cause, IIS 
treatment should be the mainstay of treatment.  This study has shown that 
tacrolimus and ciclosporin seem to have similar efficacy, but in both cases 
complete or partial response was under 50%.  As a retrospective and non-
controlled cohort study, the findings are limited due to potential confounding from 
concomitant treatments.  Prospective randomised controlled trials of novel 
therapies in SRNS are required with better patient stratification [195]. 
Patients with secondary SR did show a higher response rate to rituximab 
(Chapter 3) and previous studies have shown evidence of efficacy in FR-SSNS 
and SDNS [206].  A systematic review of rituximab use in SRNS including 226 
patients reported remission in 40.8% of those with initial SR and 52.8% with late 
SR [273].  Consideration should be given to targeting patients with secondary SR 
to earlier treatment with rituximab, although in many cases it may already have 
been given while the patient was steroid sensitive. 
344 
 
Early post-transplant disease recurrence, which is seen most frequently in 
patients with secondary SR, is an indicator of circulating factor disease.  This 
study sought biomarkers in plasma by conducting proteomic analysis at the time 
of disease relapse and remission in patients who had had post-transplant 
recurrence.  Uteroglobin was highlighted as a protein increased in relapse versus 
remission plasma reasonably consistently across patients (Chapter 5).  However, 
as a steroid-inducible protein it may be confounded by treatment.  The ideal 
biomarker would be a protein, or group of proteins, which can be measured 
longitudinally and has the ability to predict which patients will have post-
transplant recurrence prior to the transplant taking place. 
 
8.2 Limitations of this study 
Specific limitations have been discussed in preceding chapters; however, there are 
several which have implications for the study as a whole.  Given the opportunity 
to repeat the project from the start, there are different approaches which could be 
adopted to improve the quality and reliability of the conclusions. 
 The RaDaR cohort included patients retrospectively, in some cases years 
after the initial diagnosis of SRNS.  It relied on clinicians and research nurses, 
often with many other commitments, inputting details from paper and electronic 
medical records.  These factors probably contributed to missing demographic, 
clinical and follow-up data.  A prospectively-collected cohort, including only 
incident cases, would, most likely, improve the completeness of the data.  This 
would be further enhanced by direct linking of electronic patient records with the 
RaDaR database.  During the course of this study, this link was established for 
some patients at certain hospital trusts which were using Renal Patient View.  Had 
345 
 
this been in place for all patients, complete laboratory results would have been 
available, thus improving the quality of data for analysis of responses to 
treatments. 
 The investigation of potential biomarkers in SRNS in this study was 
dependent on biological samples from patients.  Blood samples were sent to the 
University of Bristol at ambient temperature and in some cases arrived several 
days after leaving the patient.  Haemolysis and protein degradation during this 
time was likely to have altered the plasma proteome.  Furthermore, patients would 
have been receiving different treatments at the times of sampling.  The effects of 
these confounding variables could have been reduced by obtaining samples at the 
time of diagnosis before any steroids, and by establishing local standard operating 
procedures for centrifuging the blood and freezing plasma within 30 minutes of 
sampling. 
 This study used plasma exchange fluid for proteomic analysis by mass 
spectrometry but was limited by the availability of paired samples at times of 
relapse and remission.  The heterogeneity became more apparent during the 
course of the research, particularly relating to the timing of “relapse” and 
“remission” samples with respect to each other and renal transplantation.  Sample 
collection and labelling were undertaken by local clinicians / research nurses and 
could have been improved with more stringent definitions and protocols. 
 The proteomics studies were limited by the heterogeneity of the samples, 
and the small number of patients included in the initial search for potential 
biomarkers.  A future, expanded cohort with paired plasma samples and complete 
clinical and laboratory data would facilitate selection of a larger group of more 




8.3 Future studies 
 As a rare disease, continued expansion of the national cohort with high-quality 
baseline and follow-up data is essential as a basis for future research.  Obtaining 
DNA samples for genetic analysis soon after diagnosis and biological samples 
(urine, blood plasma and, when performed, renal biopsy) longitudinally ideally 
prior to any IIS treatments, at times of relapse and remission, and before and after 
transplant will enhance the ability to identify and validate predictive biomarkers.  
The RaDaR and NephroS studies have continued to expand and Bristol Renal has 
taken a leading role in the development of NURTuRE (National Unified Renal 
Translational Research Enterprise), a biobank for CKD and INS covering 
England, Scotland and Wales [400].  The aim will be to include 800 adults and 
children with INS. 
 Genetic analyses discussed in this study have focussed on WES in a 
research cohort and gene panel testing in the clinical context.  As noted in 
Chapters 2 and 4, there were some patients with early-onset disease or CNS with 
no or single heterozygous recessive variants in known causative genes.  Future 
investigation of these patients, in particular, with WGS will help to identify novel 
genes or variants in intronic regulatory elements which may be pathogenic.  An 
understanding of how these cause disease may offer new opportunities to develop 
targeted treatments.  For example, identification of variants in 6 genes coding for 
proteins involved in RhoA regulation in families with partially treatment-sensitive 
NS suggests the Rho GTPase pathway may be a potential therapeutic target [401]. 
 Given the relatively low complete response rate to older ISS agents, novel 
therapies to treat SRNS are required.  In order to interpret and gain the most 
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benefit from future clinical trials, it will be essential that patients are stratified, 
either using inclusion criteria or by prospectively-defined subgroups, particularly 
on the basis of genetic/non-genetic diagnosis and pattern of steroid resistance.  
Two clinical trials are currently, or will shortly be, recruiting focussing on 
prevention of FSGS recurrence post-transplant.  Both exclude patients with 
known genetic disease.  The PRI-VENT FSGS study will randomise patients to 
receive pre-emptive rituximab versus placebo immediately prior to transplant 
[402].  The other study compares bleselumab (a fully human anti-CD40 
monoclonal antibody) with MMF both alongside standard-of-care renal transplant 
immunosuppression [403]. 
 Further identification and validation of plasma biomarkers to predict post-
transplant disease relapse will be facilitated by NURTuRE.  Samples soon after 
diagnosis, ideally prior to starting IIS treatment, and before transplant will enable 
analysis of the predictive capability of potential biomarkers.  Likewise, additional 
longitudinal samples, taken at times of relapse and remission in patients who 
subsequently suffer post-transplant recurrence, may help to develop podocyte-
derived biomarkers of circulating factor disease. 
 
8.4 Conclusions 
This study has highlighted the heterogeneity between patients with the diagnosis 
of SRNS which makes it a challenge both to study and to manage in clinical 
practice.  The findings indicate that early genetic testing has the potential to 
provide a genetic diagnosis in around 25% of patients with subsequent 
implications for treatment decisions, transplantation and prognosis.  The pattern of 
steroid resistance is an important factor: in particular, secondary SR was not 
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associated with genetic disease but did predict higher post-transplant recurrence in 
the small number of patients who progressed to ESRF.  This group also showed 
better response to rituximab than other patients.  Among patients who received IIS 
treatment, any response (complete or partial) was associated with a significantly 
lower risk of ESRF compared with those who showed no response.  This study 
highlighted uteroglobin as a protein increased in plasma at time of relapse versus 
remission.  Its potential as a biomarker will need to be evaluated in a larger group 
of patients with longitudinal sampling.  Phosphorylation of palladin within 
podocytes, at an early stage after exposure to relapse plasma, may also have a role 
as a biomarker of circulating factors, but further in vitro work is required to 
support initial findings. 
 The next steps will be to develop clinical trials using genetic and 
phenotypic characteristics to stratify patients and enable appropriate subgroup 
analysis.  In addition, longitudinal collection of biological samples should be 
integral to such trials to facilitate further biomarker identification and validation.  
Improving outcomes with targeted treatment, ensuring the right patient receives 
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10.1 Demographic and clinical features of 187 patients who had whole exome sequencing (Chapter 2) 
Table 10.1: Demographic and clinical features of 187 patients who had whole exome sequencing 




























562 No F P F 0.0 Yes presumed ND ND 5HD 0.7 No N/A 
Short bowel syndrome, cardiovascular 
disorder, imperforate anus, short gut 
syndrome, developmental delay 
3.0 
760 No M W F 0.2 No presumed ND ND 1 N/A No N/A No 3.3 
651 No F Mixed S 0.6 No presumed DMS ND 2 N/A No N/A No 14.4 
377 No F P S 1.0 Yes primary Other ND 1 N/A No N/A No 4.7 
286 No F W S 1.1 No primary FSGS ND 1 N/A No N/A No 7.6 
509 No M W S 1.2 No primary Other Other 1 N/A No N/A Atopic Eczema 4.6 
608 No F W S 1.2 No primary FSGS FSGS 1 N/A No N/A No 11.8 
435 No F W S 1.3 No primary FSGS ND 1 N/A No N/A Probable Crohn’s disease 12.2 
356 No M Mixed B F 1.3 No secondary MCD ND 5Tx 8.2 Yes Yes No 15.5 
400 No M P S 1.4 Yes primary DMS DMS 5Tx 0.8 Yes No 
Developmental delay with microcephaly, 
Diabetes  
9.0 
469 No M W S 1.5 No secondary FSGS MCD 1 N/A No N/A No 15.2 
314 No F W S 1.6 No primary MCD FSGS 1 N/A No N/A No 6.6 
412 No M W S 1.7 No primary MHc MHc 1 N/A No N/A No 11.9 
443 No M W S 1.7 Unknown primary MCD FSGS 1 N/A No N/A No 16.3 
502 No F I S 1.7 No primary MCD MCD 1 N/A No N/A No 5.9 




FSGS ND 1 N/A No N/A No 3.4 
361 No M W S 1.8 No primary FSGS MHc 1 N/A No N/A Asthma 8.2 
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730 No M B S 1.8 No primary MCD MCD 5PD 1.1 No N/A No 4.4 
464 No M Ban S 1.9 No secondary FSGS ND 5Tx 9.4 Yes No No 16.5 
713 No M W S 2.0 No secondary FSGS FSGS 1 N/A No N/A No 9.0 
732 No M I S 2.0 No primary FSGS ND 1 N/A No N/A Purpura, haematuria  1.3 
401 No M W S 2.1 No primary Other ND 1 N/A No N/A No 8.2 
490 No F W S 2.1 No primary FSGS FSGS 5Tx 1.4 Yes No No 5.2 
425 No M W S 2.1 No primary ND Other 2 N/A No N/A No 5.4 
680 No F W S 2.2 No primary MCD ND 1 N/A No N/A No 3.0 
329 No M W S 2.2 No primary FSGS FSGS 1 N/A No N/A No 8.0 
444 No M W S 2.2 No primary FSGS ND 5Tx 0.1 Yes No No 12.7 
394 No F W S 2.2 No primary MCD FSGS 5Tx 2.0 Yes Yes No 5.0 
452 No F W S 2.2 No primary FSGS ND 5Tx 0.8 Yes No Motor delay 12.0 
312 No F W S 2.2 No primary FSGS ND 5Tx 2.9 Yes No No 11.4 
508 No M W S 2.3 No primary MCD MCD 1 N/A No N/A No 6.8 
287 No M 
Mixed (W 
and B) 
S 2.3 No primary MCD FSGS 5Tx 2.9 Yes Yes No 9.8 
712 No M Mixed S 2.4 No secondary FSGS ND 1 N/A No N/A No 14.1 
505 No F W S 2.4 No secondary TBMN ND 1 N/A No N/A No 5.2 
703 No M W S 2.4 No primary Other MHc 1 N/A No N/A No 4.7 
533 No M W S 2.4 No primary MCD ND 1 N/A No N/A No 3.1 
351 No M P S 2.4 No primary FSGS 
CNI 
toxicity 
1 N/A No N/A No 10.9 
567 No M As S 2.5 No secondary MCD MCD 1 N/A No N/A No 9.4 
324 No F W S 2.6 No secondary FSGS ND 1 N/A No N/A Seizure activity 7.5 
480 No F B S 2.6 No primary MHc FSGS 1 N/A No N/A No 6.4 
439 No F Other S 2.6 No primary FSGS ND 1 N/A No N/A No 6.5 




448 No M P S 2.7 No primary FSGS ND 5Tx 0.5 Yes Yes No 16.0 
526 No M W S 2.8 No primary MCD ND 1 N/A No N/A 
Ex-34 weeks premature, global 
developmental delay 
3.0 
357 No M I F 3.0 No primary FSGS ND 5Tx 2.0 Yes Yes No 11.8 
532 No M W S 3.0 No primary FSGS ND 5Tx 5.4 Yes No No 16.6 
284 No M W S 3.0 No primary MHc ND 5PD 9.9 No N/A No 10.7 
513 No M P S 3.0 No primary FSGS ND 3 N/A No N/A No 5.4 
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460 No F W S 3.2 No primary FSGS FSGS 1 N/A No N/A No 4.5 
735 No M W S 3.2 No primary Other ND 1 N/A No N/A No 3.4 
393 No F B S 3.3 No primary FSGS MCD 1 N/A No N/A No 10.0 
437 No F W S 3.4 No primary FSGS ND 1 N/A No N/A No 6.7 
420 No M Other S 3.4 No primary FSGS ND 5Tx 0.0 Yes No No 14.6 
450 No F Mixed S 3.5 No primary FSGS FSGS 1 N/A No N/A No 6.4 
403 No F B S 3.5 No secondary FSGS ND 1 N/A No N/A No 5.8 
415 No F W S 3.6 No primary FSGS FSGS 1 N/A No N/A No 8.0 
436 No F B S 3.6 No primary FSGS ND 1 N/A No N/A No 10.7 
451 No F W S 3.7 No secondary FSGS ND 5Tx 2.1 Yes Yes No 13.1 
445 No M B S 3.8 No primary FSGS ND 5Tx 4.5 Yes No No 11.9 
309 No F I S 3.9 No primary MCD ND 1 N/A No N/A No 2.2 
427 No M W S 3.9 No secondary FSGS ND 5PD 3.6 No N/A No 3.8 
413 No M P S 4.0 No secondary MCD FSGS 1 N/A No N/A No 6.2 
449 No F W S 4.0 No primary FSGS ND 5Tx 8.0 Yes No No 14.0 
546 No M W S 4.1 No primary MCD Other 1 N/A No N/A No 12.2 
344 No M Ban S 4.1 Unknown primary MHc MHc 1 N/A No N/A No 15.2 
668 No F W S 4.1 No primary FSGS ND 1 N/A No N/A No 8.0 
552 No M W F 4.2 Yes secondary MCD ND 1 N/A No N/A No 10.2 
402 No M W S 4.3 No secondary MCD ND 1 N/A No N/A No 3.7 
489 No F As F 4.4 Unknown primary FSGS ND 1 N/A No N/A No 4.1 
326 No M W S 4.5 No secondary FSGS ND 1 N/A No N/A No 9.9 
346 No F W S 4.6 No primary FSGS ND 5Tx 4.6 Yes Yes  No 15.5 
363 No F B S 4.7 No secondary MCD FSGS 4 N/A No N/A No 15.9 
528 No F W S 4.7 No primary FSGS ND 1 N/A No N/A No 3.3 
473 No M W S 4.8 No primary MCD ND 5ND 5.1 No N/A No 5.5 
685 No F P S 4.8 No primary FSGS ND 1 N/A No N/A No 3.1 
347 No F W S 4.9 No primary FSGS ND 1 N/A No N/A No 2.1 
534 No F W S 5.0 No primary MHc FSGS 1 N/A No N/A No 10.4 
366 No M W F 5.1 No primary FSGS ND 5Tx 6.7 Yes Yes No 15.2 
488 No M W S 5.2 No primary FSGS FSGS 1 N/A No N/A Hypertension 8.2 
342 No F As S 5.4 No primary FSGS ND 1 N/A No N/A No 5.2 
620 No F Mixed S 5.6 No not tried FSGS ND 1 N/A No N/A No 11.8 
434 No M W S 5.6 No primary MHc MCD 1 N/A No N/A No 6.3 
355 No F W S 5.6 No primary FSGS ND 1 N/A No N/A No 4.0 
349 No M W S 5.9 No primary FSGS ND 2 N/A No N/A No 5.7 
453 No M W S 5.9 No secondary FSGS FSGS 5Tx 9.7 Yes No No 16.2 
411 No M W S 5.9 No primary FSGS ND 5Tx 0.6 Yes No Short stature  15.0 
486 No F W S 6.2 No primary MCD 
CNI 
toxicity 




615 No F W F 6.3 No secondary MCD ND 5HD 2.1 No N/A Cataract, diplopia 4.7 
360 No F W S 6.3 No primary MCD ND 1 N/A No N/A No 9.1 
365 No F W S 6.7 No primary FSGS ND 1 N/A No N/A No 3.4 
728 No M W S 6.7 No primary FSGS ND 1 N/A No N/A No 4.3 
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561 No M W S 7.0 No primary MCD ND 5Tx 2.2 Yes Yes 
Bicuspid aortic valve with mild 
incompetence 
5.7 
457 No F W S 7.2 No secondary MCD ND 1 N/A No N/A No 7.2 
392 No F Mixed B S 7.3 No sensitive MCD FSGS 1 N/A No N/A No 5.7 
641 No F P S 7.8 Unknown primary MCD FSGS 5Tx 1.8 Yes Yes Short stature 4.2 
419 No M W S 8.0 No primary MCD FSGS 5Tx 5.2 Yes Yes No 8.7 
410 No F W S 8.2 No primary FSGS FSGS 1 N/A No N/A No 7.7 
749 No M W Unknown 8.2 Unknown primary FSGS ND 1 N/A No N/A No 1.4 
417 No F Mixed S 8.7 No secondary FSGS ND 1 N/A No N/A No 7.5 
558 No M W S 8.8 No primary MCD MCD 1 N/A No N/A No 4.9 
466 No M W S 8.9 No secondary MCD ND 5Tx 3.0 Yes Yes No 8.9 
432 No M W S 8.9 No secondary FSGS ND 1 N/A No N/A No 3.5 
294 No F W S 8.9 No primary FSGS ND 5Tx 1.9 Yes Yes No 16.2 
276 No M As S 9.2 No primary FSGS FSGS 5Tx 3.6 Yes Yes Dyslexia 7.8 
506 No F W S 9.3 No primary FSGS FSGS 1 N/A No N/A No 4.4 
629 No F W S 9.3 No primary MCD FSGS 1 N/A No N/A No 3.2 
291 No F W S 9.5 No primary FSGS ESRF 5Tx 5.5 Yes Yes No 12.9 
475 No F W S 9.6 No secondary MCD MCD 1 N/A No N/A No 4.1 
754 No M W S 9.8 No primary FSGS ND 1 N/A No N/A No 2.6 
525 No F W S 9.9 No primary ND ND 2 N/A No N/A Asthma 4.3 
556 No M W S 10.0 No primary FSGS ND 1 N/A No N/A No 5.1 
654 No F W S 10.5 No primary FSGS ND 2 N/A No N/A No 4.3 
390 No F Other S 10.5 No secondary MCD ND 1 N/A No N/A No 2.4 
316 No M W S 11.3 No primary FSGS ND 5Tx 2.2 Yes Yes No 9.5 
385 No M W S 11.3 No primary FSGS ND 1 N/A No N/A No 5.0 
441 No M W S 11.4 No primary FSGS ND 1 N/A No N/A Hodgkin’s lymphoma  6.5 
395 No M I S 11.7 No secondary MHc FSGS 5Tx 3.8 Yes Yes No 6.9 
440 No M W S 12.0 No primary Other ND 1 N/A No N/A No 8.2 
389 No F I S 12.1 No secondary FSGS ND 5HD 4.7 No N/A 
Developmental delay, severe learning 
difficulties, coeliac disease 
5.0 
560 No F I S 12.1 No primary FSGS ND 5Tx 1.9 Yes Yes No 5.2 
767 No M W S 12.2 No primary FSGS ND 1 N/A No N/A No 2.6 
298 No M W S 12.4 No primary FSGS ND 5Tx 4.3 Yes No No 5.9 
345 No F W S 12.4 No primary FSGS ND 1 N/A No N/A No 5.8 
689 No F W S 12.7 No primary FSGS ND 1 N/A No N/A No 4.0 
372 No M W S 12.8 No primary FSGS ND 1 N/A No N/A Psoriasis 9.0 
494 No F W S 12.9 No primary FSGS ND 1 N/A No N/A No 8.6 
650 No F 
Mixed (W 
and As) 
S 13.2 No primary MCD ND 1 N/A No N/A No 2.4 
649 No M W S 13.4 No sensitive FSGS ND 1 N/A No N/A No 4.1 
330 No F W S 13.8 No primary MHc ND 4 N/A No N/A No 8.3 
671 No M W S 13.9 No primary MCD FSGS 4 N/A No N/A No 4.6 
507 No M As S 14.6 Yes presumed FSGS FSGS 5HD 2.0 No N/A Asthma 4.3 
605 No F W S 15.1 No primary FSGS ND 5ND 5.1 No N/A No 6.0 
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295 No F W S 15.2 No primary FSGS FSGS 5PD 2.8 No N/A No 3.9 
258 No F W S 15.4 No primary FSGS ND 1 N/A No N/A Asthma 2.4 
630 No F B S 16.1 No primary FSGS ND 5Tx 1.2 Yes No No 4.4 
821 NPHS1 M W S 0.0 No presumed ND ND 5Tx 2.3 Yes No Hypothyroidism 5.7 
478 NPHS1 M W S 0.0 No presumed MCD ND 5Tx 0.5 Yes No Epilepsy, ADHD, short stature,  18.9 
315 NPHS1 M W S 0.0 No presumed Finnish Finnish 5Tx 1.3 Yes No Communicating hydrocephalus 8.5 
302 NPHS1 M I S 0.1 Yes presumed DMS DMS 5Tx 3.3 Yes No No 7.9 
430 WT1 F W S 0.1 No presumed MCD ND 5Tx 0.0 Yes No 
ophthalmic problems, no 
gonadoblastoma, no Wilm's tumour, 
normal 46XX 
21.7 
386 NPHS1 M W S 0.1 No presumed Finnish ND 5Tx 4.7 Yes No No 10.9 
375 NPHS1 F P S 0.1 Yes presumed Other ND 5Tx 1.9 Yes No 
Renal extramedullary haematopoiesis, 
mild pulmonary stenosis and VSD 
11.1 
503 LAMB2 M W S 0.1 No presumed ND ND 5PD 0.0 No N/A Pierson syndrome 5.6 
431 NPHS1 M W S 0.1 No presumed Other ND 5Tx 1.8 Yes No No 7.0 
353 NPHS1 M 
mixed (W 
and B) 




Other ND 1 N/A No N/A No 17.7 
305 NPHS1 M W S 0.1 No presumed MCD ND 5Tx 1.6 Yes No No 15.2 
621 NPHS1 M I S 0.1 No presumed Finnish Finnish 5Tx 4.4 Yes No developmental delay 8.1 
497 NPHS1 M W S 0.2 No primary Finnish ND 5Tx 2.3 Yes No No 13.6 
731 MAGI2 M W S 0.3 No primary MCD ND 1 N/A No N/A 
Pyloric stenosis, Polydactyly, 
Thrombocytosis 
11.7 
704 MAGI2 F W F 0.4 No presumed Finnish Finnish 5Tx 0.5 Yes No No 11.5 
652 COL4A5 M P F 0.5 Yes primary Other ND 5PD 2.2 No N/A No 3.3 
687 CRB2 F W S 0.8 No presumed MCD ND 1 N/A No N/A No 4.0 
442 MYO1E F Other S 1.0 Yes primary ND ND 5PD 4.1 No N/A No 6.0 
297 NPHS2 M W S 1.0 No primary FSGS ND 5Tx 7.6 Yes No No 14.9 
285 WT1 F W S 1.0 No presumed ESRF ND 5Tx 0.0 Yes No 
Klinefelter's syndrome - XXY, 
Gonadoblastoma 
11.0 
311 NPHS2 F W F 1.1 No presumed MHc ND 5ND 11.6 No N/A No 11.7 
352 NPHS1 F W S 1.4 No presumed ESRF ND 5Tx 2.4 Yes No No 16.0 
319 NPHS2 M W S 1.8 No primary FSGS FSGS 5Tx 7.5 Yes No No 10.4 
496 WT1 F W S 1.9 No primary FSGS ND 5Tx 9.0 Yes No Normal 46XX 10.7 
495 NPHS1 F Other S 2.0 No primary MCD MCD 2 N/A No N/A No 17.8 
467 NPHS2 F W S 2.0 No primary MCD FSGS 5Tx 3.3 Yes No No 6.8 
323 NUP107 M P S 2.1 Yes primary FSGS ND 5Tx 0.5 Yes No Developmental delay  5.8 
678 NPHS2 M W S 2.8 No primary ND MCD 5Tx 2.4 Yes No No 15.9 
683 DGKE F W S 3.1 No primary FSGS ND 1 N/A No N/A Dyslexia 14.9 
296 TRPC6 M W S 3.2 No primary MCD ND 1 N/A No N/A No 5.0 
383 NPHS2 F W S 3.7 No primary FSGS ND 5Tx 4.4 Yes No No 14.0 
811 WT1 F W S 3.8 No primary Alport ND 1 N/A No N/A 
Chronic cough and diarrhoea, Frasier 
syndrome, XY** 
1.1 
414 NPHS1 M W F 5.7 Unknown primary MHc MHc 1 N/A No N/A Asthma, eczema 11.3 
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446 NPHS2 F P F 6.1 No primary FSGS ND 5Tx 2.2 Yes No No 10.9 
388 NUP93 F W S 6.1 No primary FSGS ND 5Tx 0.2 Yes No No 8.4 
609 NUP107 M P F 6.1 Yes presumed ND ND 1 N/A No N/A 
Learning difficulties, eczema, 
microcephaly  
6.7 
492 NPHS2 F W F 7.0 No primary ND ND 1 N/A No N/A No 6.7 
317 TRPC6 F W S 7.8 No presumed FSGS ND 5Tx 0.0 Yes No No 7.4 
770 COL4A3 F W S 7.9 No primary FSGS ND 1 N/A No N/A No 2.5 
729 NPHS2 M W S 7.9 No primary Other ND 2 N/A No N/A Asthma 2.8 
370 APOL1 M B S 9.9 No primary FSGS ND 5HD 7.4 No N/A No 8.1 
493 NPHS2 F W F 10.1 No primary FSGS ND 5Tx 2.0 Yes No No 9.4 
387 ADCK4 M W S 10.9 No primary FSGS ND 5Tx 1.8 Yes No No 9.2 
397 ACTN4 M W S 12.3 No primary Other ND 5Tx  1.4 Yes No 
Aarskog Syndrome and Horseshoe 
Kidney 
7.4 
566 NUP107 F P F 12.6 Yes presumed ESRF ND 5HD 0.0 No No Microcephaly 4.3 
399 OCRL M W F 12.6 No primary FSGS ND 3 N/A No N/A Short stature 10.0 
516 LMX1B F W F 13.1 No presumed ND FSGS 1 N/A No N/A 
Craniosynostosis, brachycephaly, fixed 
flexion deformities, short tibia, abnormal 
calf muscles, facial dysmorphism, 
receptive and expressive speech disorder 
5.0 
747 NPHS2 M W S 13.8 No primary FSGS ND 5PD 1.3 No N/A No 3.9 
672 NPHS2 F W F 14.1 No primary MCD ND 1 N/A No N/A Learning disabilities, pulmonary embolus 3.7 
613 NUP107 F P F 14.2 Yes presumed FSGS ND 1 N/A No N/A 
Learning difficulties, eczema, 
microcephaly  
2.2 
900 LMX1B F W F 14.9 No primary FSGS ND 1 N/A No N/A Delayed puberty 1.1 
407 PODXL M W S 15.2 No primary FSGS ND 1 N/A No N/A No 2.3 
 
The table is sorted first by non-genetic / genetic status and then by age of onset. 
 
Legend: ADHD, attention deficit hyperactivity disorder; As, Asian; B, Black African/Caribbean; Ban, Bangladeshi; CKD, chronic kidney 
disease; CNI, calcineurin inhibitor; CNS, Congenital nephrotic syndrome; DMH, Diffuse mesangial hypercellularity; DMS, Diffuse mesangial 
sclerosis; DPGN, Diffuse mesangial proliferative glomerulonephritis; ESRF, End stage renal failure; F, female (gender) / familial; FGGS, Focal 
global glomerulosclerosis; FSGS, Focal segmental glomerulosclerosis; HD, Haemodialysis; I, Indian; M, male; MCD, Minimal Change Disease; 
MHc, Mesangial hypercellularity; N/A, not applicable; ND, not done/no data available; P, Pakistani; PD, Peritoneal dialysis; S, sporadic; 
TBMN, thin basement membrane nephropathy; Tx, transplanted; VSD, ventricular septal defect; W, White; ** - karyotyping not done; NGS data 




10.2 Demographic and clinical features of 63 patients who had clinical genetic testing (Chapter 3) 
Table 10.2: Demographic and clinical features of 63 patients who had clinical genetic testing 
Patient 
# 






















5288 No F Other ND 0.0 ND presumed ND 1 N/A No N/A No 1.6 
2935 No F W F 0.1 No presumed ND 1 N/A No N/A Cardiac abnormality - PFO 3.8 
424 No M W S 0.1 No presumed Other 3 N/A No N/A No 4.4 
2015 No M As F 0.2 Yes 
proteinuria 
+ FH 
ND 1 N/A No N/A No 4.1 
2013 No F As F 0.2 Yes presumed ND 1 N/A No N/A No 0.8 
               
9152 No F ND ND 0.2 ND presumed ND 1 N/A No N/A No 0.2 
2249 No F As S 0.3 No presumed ND 1 N/A No N/A No 0.1 
2014 No F As F 0.6 Yes 
proteinuria 
+ FH 
MHc 1 N/A No N/A No 6.3 
5000 No F ND F 1.2 Yes primary FSGS 5HD 0.5 No N/A No 1.7 
2755 No M W S 1.9 No secondary Other 4 N/A No N/A No 2.9 
5939 No M W S 2.2 No secondary ND ND N/A ND ND No 0.0 
7440 No M ND ND 2.2 ND primary Other ND N/A ND ND No 0.0 
4327 No F W F 2.4 No secondary ND 3 N/A No N/A No 1.6 
1412 No M W S 2.9 No primary FSGS 1 N/A No N/A No 2.5 
2017 No M W ND 3.0 ND primary FGGS 5ND 2.3 No N/A Developmental delay 2.4 
622 No M As S 3.1 No primary FSGS 1 N/A No N/A No 4.6 
11247 No F ND F 3.2 No primary MCD 1 N/A No N/A No 0.4 
7277 No M W ND 3.7 ND presumed ND ND N/A ND ND No 21.0 
5386 No M ND ND 3.7 ND primary FSGS ND N/A ND ND No 0.5 
1191 No F W S 3.8 No primary MCD 5HD 1.4 No N/A No 2.9 
915 No M W S 4.1 No primary FSGS 1 N/A No N/A No 2.6 
2250 No F W S 4.1 No primary FSGS 1 N/A No N/A No 1.7 
2384 No M W S 4.1 No primary FSGS 5Tx 1.3 Yes Yes No 2.9 
2959 No M W S 4.7 Yes primary FSGS 1 N/A No N/A No 2.1 
5912 No F W S 4.7 No primary FSGS 1 N/A No N/A No 1.5 
5792 No M W S 5.0 No primary MCD 1 N/A No N/A No 0.1 




2908 No F As S 6.9 No primary FSGS 5HD 9.1 No N/A No 9.4 
866 No M B S 7.2 No primary MCD 1 N/A No N/A No 0.8 
1108 No F W S 8.7 No primary FSGS 1 N/A No N/A No 1.2 
242 No M W S 10.2 No primary FSGS 5Tx 2.5 Yes Yes Aarskog-Scott Syndrome 12.5 
293 No F W S 10.3 No primary FSGS 1 N/A No N/A No 6.6 
1715 No M W S 11.0 No primary 
Collapsing 
glomerulopathy 
5Tx 0.3 Yes Yes ADHD 2.1 
2772 No F W S 11.6 No primary FSGS 1 N/A No N/A No 0.1 




1291 No F W S 12.4 No primary FSGS 5Tx 1.3 Yes Yes No 3.0 
926 No M As S 13.4 No primary FSGS 3 N/A No N/A No 3.3 
1202 No M W F 13.6 No secondary FSGS 5Tx 0.9 Yes Yes Adrenal insufficiency 5.0 
3242 No F W S 14.0 No primary FSGS 1 N/A No N/A No 0.9 
8071 No M W S 14.0 No primary FSGS 1 N/A No N/A No 0.6 
2107 No F W S 14.3 No primary FSGS 1 N/A No N/A No 1.9 
2388 No M W S 15.7 No primary FSGS 5ND 2.1 No N/A No 2.7 
3604 NPHS1 M ND ND 0.0 ND presumed ND 1 N/A No N/A No 0.7 
3988 NPHS1 M W F 0.0 No presumed ND 1 N/A No N/A No 2.0 
3989 NPHS1 F W ND 0.0 ND presumed ND 5Tx 2.8 Yes No No 5.2 
406 NPHS1 F B F 0.0 Yes presumed MHc 1 N/A No N/A No 10.8 
12156 NPHS1 F W S 0.0 No presumed ND ND N/A ND ND No 0.0 
476 NPHS1 M W ND 0.0 ND presumed ESRF 5Tx 2.1 Yes No No 5.5 
12011 NPHS1 M W ND 0.0 ND presumed ESRF 5Tx 2.3 Yes No No 9.0 
281 NPHS1 F W S 0.0 No presumed ND 5Tx 7.1 Yes No Possible autoimmune disease 10.0 
3434 NPHS1 F ND S 0.1 No presumed ND 1 N/A No N/A No 0.6 
8903 NPHS1 F As S 0.1 Yes presumed ND 5Tx 3.9 Yes No Neutropenia 7.4 
3128 NPHS1 M ND ND 0.1 ND presumed ND 5Tx 12.9 Yes No No 17.4 
1810 NPHS1 M As S 0.1 Yes presumed ND ND N/A ND ND No 1.7 
405 NPHS1 F B F 0.2 Yes presumed MHc 5Tx 13.1 Yes No No 14.4 
5750 PLCE1 F ND S 1.1 Yes presumed FGGS 5PD 0.1 No N/A No 0.9 
374 NPHS1 F W S 1.3 No presumed MHc 5Tx 2.1 Yes No No 4.4 
7656 WT1 M W ND 3.2 ND primary DMS 2 N/A No N/A Denys-Drash syndrome 1.6 
343 NPHS2 F ND F 6.8 Yes primary MCD 1 N/A No N/A No 7.0 
514 SMARCAL1 M W S 7.1 No primary FSGS 1 N/A No N/A No 0.4 
2154 NPHS2 F As F 9.2 No presumed ND 1 N/A No N/A MPS type VI 5.5 
9983 NPHS2 F W ND 11.7 ND primary FSGS 1 N/A No N/A No 2.4 
368 NPHS1 F ND ND 12.8 No primary FSGS 3 N/A No N/A No 2.6 
               
 
The table is sorted first by non-genetic / genetic status and then by age of onset. 
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Legend: FSGS-Focal segmental glomerulosclerosis, MCD-Minimal Change Disease, CNS-Congenital nephrotic syndrome, MHc-Mesangial 
hypercellularity, DMH-Diffuse mesangial hypercellularity, DMS-Diffuse mesangial sclerosis, MPGN-Membranoproliferative 
glomerulonephritis, ESRF-End stage renal failure, C1q-C1q nephropathy, FGGS-Focal global glomerulosclerosis, DPGN-Diffuse mesangial 
proliferative glomerulonephritis, MesPGN - Mesangioproliferative glomerulonephritis, W-White, BA-Black African, BC-Black Caribbean, I-
Indian, P-Pakistani, NMO - non mixed origin, As-Asian, Ban-Bangladeshi, CKD – chronic kidney disease, Tx – transplanted, PD-Peritoneal 




10.3 Genotypes and phenotypes of patients with likely-pathogenic variants detected by clinical genetic 
testing (Chapter 4) 
Table 10.3: Genotypes and phenotypes of patients with likely-pathogenic variants 
Patient 
number 
Sex Age at 
onset 
(years) 
















1 M 6* SRNS ND; ND; ND FSGS ND LP ACTN4 c.776C>A p.(Thr25
9Asn) 
PS Del; 1.00 NL; NL; NL 





[404]    
       LP COL4A3 c.3472G>C p.(Gly11
58Arg) 
[404]   









[404]    
       LP COL4A3 c.1985G>A p.(Gly66
2Glu) 
PS Del; 1.00 NL; NL; NL 






PS Del; 0.999 NL; NL; NL 
5 M 5 Haematuria ND; ND; ND Alport ND LP COL4A3 c.898G>A p.(Gly30
0Arg) 
[405]   
       LP COL4A3 c.898G>A p.(Gly30
0Arg) 
[405]   
6 F 20 Haematuria, 
proteinuria, 
TBMN 




[406, 407]    
389 
 





[408]    
7 M 44* Alport ND; ND; ND ND ND LP COL4A3 c.2452G>A; 
mat; tracks 





[404]    
       VUS COL4A4 c.4760C>G; 
mat; tracks 





[407]    
8 M 17* SRNS S; Y; ND FSGS ND LP COL4A4 c.1598G>A p.(Gly53
3Asp) 
[404]   
       LP COL4A4 c.1598G>A p.(Gly53
3Asp) 
[404]    
9 F 78* Hypertensive 
nephrosclerosis
, ESRF 
ND; Y; ND ND ND LP COL4A4 c.2906C>G p.(Ser96
9*) 
[404]    








PS Del; 1.00 NL; NL; 0.00083% 





[409]    




PS Del, 0.00 NL; NL; NL 
11 F 56* Haematuria, 
deafness, 
Alport 
W; N; N ND ND LP COL4A4 c.4538G>A p.(Cys15
13Tyr)  
[404]    
12 F 25* Haematuria W; Y; ND ND ND LP COL4A5 c.367G>A p.(Gly12
3Arg) 
[410]   





W; N; N Not done ND LP COL4A5 c.546+1G>T p.(?) PS n/a; n/a NL; NL; NL 




14 M 42* Haematuria, 
proteinuria, 
hearing loss 
ND; ND; ND ND ND LP COL4A5 c.556G>A p.(Gly18
6Ser) 
PS Del; 0.999 NL; NL; NL 
15 F 34* Alport ND; Y; ND ND ND LP COL4A5 c.1190G>T p.(Gly39
7Val) 
PS Del; 1.00 NL; NL; NL 






[412, 413]    
17 M 9 Alport BA; Y; N Alport ND LP COL4A5 c.1807G>T p.(Gly60
3Cys) 
PS Del; 1.00 NL; NL; NL 











PS Del; 0.999 NL; NL; NL 
19 F 3 Alport W; N; N Alport Imm not 
started 






p) [414]  
Del; 1.00 NL; NL; NL 
20 F 22* Haematuria, 
proteinuria, 
hearing loss 
ND; N; ND Alport ND LP COL4A5 c.3270C>G p.(Tyr10
90*) 
PS n/a; n/a NL; NL; NL 




[415]    
22 F 11 SRNS W; ND; N FSGS ND LP COL4A5 c.4015+2T>C  p.(?) PS n/a; n/a NL; NL; NL 
23 F 15 Haematuria, 
proteinuria 






PS Del; 0.999 NL; NL; NL 
24 M 0.5 Haematuria, 
hearing loss 





PS n/a; n/a NL; NL; NL 







PS Del; 0.999 NL; NL; NL 
       VUS COL4A4 c.778G>A; 
does not track 
p.(Val26
0Ile) 
PS Del; 0.007 NL; NL; 0.0042% 
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with disease: 5 
affected 















Del; 0.999 NL; NL; NL 








28 M 0.1 CNS, Pierson 
syndrome 
ND; ND; ND Not done Palliative 
care 
LP LAMB2 c.825T>A; mat p.(Tyr27
5*) 
[417]    
       LP LAMB2 c.825T>A; pat p.(Tyr27
5*) 
[417]    









[417, 418]    
       LP LAMB2 c.3523delC; pat p.(Gln11
75Serfs*
37) 
PS n/a; n/a NL; NL; NL 
30 M 0 CNS, died at 1 
week 
Ir; Y; Y Not done ND LP LAMB2 c.1814delG p.(Gly60
5Valfs*2
3) 
PS n/a; n/a NL; NL; NL 
       LP LAMB2 c.1814delG p.(Gly60
5Valfs*2
3) 
PS n/a; n/a NL; NL; NL 












32 F 17 SRNS W; N; N FSGS Imm not 
started 







[67, 420]    




[67, 420]    
34 M 2 SRNS ME; N; N FSGS Cessation 
of Imm 
LP LMX1B c.737G>A p.(Arg24
6Gln) 
[67, 420]    
35 F 13* SRNS, 
thrombocytope








36 F 10* NS, 
thrombocytope
nia, FH of same 




[423, 424]    
















p.(?) [74]    
       LP NPHS1 c.320C>T; pat p.(Ala10
7Val) 
[74]    
38 M 0.1 CNS, 
hypomagnesae
mic seizures 
Ban; N; Y Not done Imm not 
started 
LP NPHS1 c.320C>T; mat p.(Ala10
7Val) 
[74]    
       LP NPHS1 c.320C>T; pat p.(Ala10
7Val) 
[74]    
39 F 0 CNS, IUGR ND; N; ND ND ND LP NPHS1 c.325T>C; mat p.(Tyr10
9His)  
PS Del; 0.993 NL; NL; 0.00087%  
       LP NPHS1 c.1868G>T; pat p.(Cys62
3Phe) 
[425]    
40 M 0.1 CNS, 
psychomotor 
delay 
W; N; N Not done Imm not 
started 
LP NPHS1 c.325T>C; pat p.(Tyr10
9His)  
PS Del; 0.993 NL; NL; 0.00087% 




[426]    
41 M 0 CNS, deafness W; N; N FSGS ND LP NPHS1 c.532C>T; mat p.(Gln17
8*) 
[71]   





PS n/a; n/a NL; NL; NL 











[427]    




43 F 0 CNS W; N; N Not done ND LP NPHS1 c.736G>T p.(Glu24
6*) 
[428]    
       LP NPHS1 c.1868G>T p.(Cys62
3Phe) 
[425]    
44 F 0 CNS W; N; N Not done ND LP 
 
NPHS1 c.866G>A; pat p.(Trp28
9*) 
[74]    
       LP NPHS1 Exon 23-29del; 
mat 
p.(?) PS n/a; n/a NL; NL; NL 
45 F 0.4* CNS ND; ND; ND DMS ND LP NPHS1 c.1235delG p.(Gly41
2Valfs*2
) 
PS n/a; n/a NL; NL; NL 
       LP NPHS1 c.3481+1G>T p.(?) [74]    
46 M 2* SRNS ND; ND; ND ND ND LP NPHS1 c.1868G>T  p.(Cys62
3Phe)  
[425]    
       LP NPHS1 c.2335-1G>A p.(?) [283]    


















PS; [283] Del; 0.824 rs115976159; NL; 
0.0099% 




LP NPHS1 c.2335-1G>A; 
mat 
p.(?) [283]    
       LP NPHS1 c.2335-1G>A; 
pat 
p.(?) [283]    
49 F 11* SRNS W; Y; N ND ND LP NPHS2 c.413G>A p.(Arg13
8Gln) 
[296]    
       LP NPHS2 c.378+1_378+2
delinsTG  
p.(?) PS n/a; n/a NL; NL; NL 
50 M 13 SRNS W; N; N FSGS ND LP NPHS2 c.413G>A p.(Arg13
8Gln) 
[296]    
       LP NPHS2 c.868G>A p.(Val29
0Met) 
[430]    
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51 M 0.1 CNS, ESRF, 
died at 2y 




LP NPHS2 c.419G>A; mat p.(Gly14
0Glu) 
PS Del; 1.00 NL; NL; 0.00082% 
       LP NPHS2 c.419G>A; pat p.(Gly14
0Glu) 
PS Del; 1.00 NL; NL; 0.00082% 




NPHS2 c.562G>T; mat p.(Glu18
8*) 
[431]    
       LP NPHS2 c.562G>T; pat p.(Glu18
8*) 
[431]    




[432]    
       LP NPHS2 c.686G>A p.(Arg22
9Gln) 
[69, 297]    
54 F 11 SRNS W; N; N FSGS Imm not 
started 
LP NPHS2 c.890C>T; pat p.(Ala29
7Val)  
[286, 299]    
       LP NPHS2 c.686G>A; mat p.(Arg22
9Gln) 
[69, 297]    
       VUS COL4A4  c.232C>T  p.(Pro78
Ser)   
PS Del; 0.008 NL; NL; 0.00083% 
55 M 0.9* CNS, severe 
pulmonary 
valve stenosis 
W; N; N ND ND LP NPHS2 c.1032delT; pat p.(Phe34
4Leufs*4
) 
[286]    
       LP NPHS2 Exon 2 del; mat p.(?) PS n/a; n/a NL; NL; NL 










[60, 303]    
       LP PLCe1 c.1477C>T; pat p.(Arg49
3*) 
[60, 303]    
       VUS APOL1 c.558delA; pat p.(Gly18
7Alafs*1
9) 
PS n/a; n/a NL; NL; 0.0041% 
57 F 2.8 SRNS Afg; N; N FSGS ND LP PLCe1 c.1477C>T p.(Arg49
3*) 
[60, 303]    
       LP PLCe1 c.1477C>T p.(Arg49
3*) 
[60, 303]    
       VUS CD2AP  c.1511G>A p.(Arg50
4His) 
PS Tol; 0.952 NL; NL; 0.00249% 













       LP SCARB2 c.704+5G>A  p.(?) [434]    











PS  n/a; n/a NL; 0.01%; 
0.0016% 




[91]    
       VUS ALMS1 c.11449C>T p.(Gln38
17*) 
[435]    




[436]    
60 M 39 SRNS, 
unilateral 
blindness 




s) [437]  
Del; 0.995 NL; NL; NL 










PS Del; 0.991 NL; NL; NL 
62 M 11 SRNS, 
undescended 
testes 
W; N; N FSGS Imm not 
started 
LP WT1 c.1091T>G p.(Phe36
4Cys)  
PS Del; 0.89 NL; NL; NL 
63 F 2 SRNS, seizures 
at 6m 
W; N; ND Not done ND LP WT1 c.1097G>A p.(Arg36
6His) 
[65]    




ND; ND; ND ND ND LP WT1 c.1133C>T; 





[81]    




[404]    
65 F 30 Nephrotic in 
pregnancy 
W; Y; N FSGS No planned 
Imm 







Del; 0.999 NL; NL; NL 
396 
 
       VUS COL4A4 c.4334-3C>T; 
pat 
p.(?) PS n/a; n/a NL; NL; NL 
66 F 0.6 Proteinuria, 
ESRF 








LP WT1 c.1180C>T; 





[65, 438]   




PS Del; 0.99 NL; NL; NL 
67 F 1 SRNS ND; ND; ND ND ND LP WT1 c.1180C>T p.(Arg39
4Trp) 
[65, 438]    
68 M 0.3* CNS ND; ND; ND ND ND LP WT1 c.1181G>A; 





[439, 440]   
69 M 3.3 SRNS, ADHD M; N; Y DMS Imm not 
started 
LP WT1 c.1228+5G>A; 
absent in both 
unaffected 
parents 
p.(?) [81, 441]   
70 F 3 SRNS W; N; N FSGS ND LP 
 
WT1 c.1228+5G>A; 
absent in both 
unaffected 
parents 
p.(?) [81, 441]   
71 F 2.5 SRNS W; N; N FSGS ND LP WT1 c.1228+5G>A; 
absent in both 
unaffected 
parents 
p.(?) [81, 441]   
* Denotes age at genetic testing where age at disease onset was not available.  
Genes in bold type are the main causative gene in that patient. 
Legend: 
AA, amino acid; ADHD, attention-deficit hyperactivity disorder; Afg, Afghanistani;  AMRF, action myoclonus renal failure syndrome; BA, 
Black African; Ban, Bangladeshi; CKD, chronic kidney disease; CMT, Charcot Marie Tooth disease; CNS, congenital nephrotic syndrome; Del, 
deleterious; DMS, diffuse mesangial sclerosis; ESRF, end stage renal failure; FH, family history; FSGS, focal segmental glomerulosclerosis; 
Imm, immunosuppression; In, Indian; Ir, Iranian; IUGR, intra-uterine growth restriction; K, Kurdish; m, months; LP, likely-pathogenic; M, 
Moroccan; mat, maternal; MCD, minimal change disease; ME, Middle Eastern;  N, no; n/a, not available; ND, not done/no data; NL, not listed; 
NNP, non-neutral polymorphism; NS, nephrotic syndrome; Pa, Pakistani; pat, paternal; PS, present study; S, Slovakian; SRNS, steroid resistant 
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